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Abstract 
Background: There is a high cellular turnover in the haematopoietic system 
which necessitates that new cells are continuously produced to replace old and 
senescent ones. The haematopoietic stem cells and its progenitors meet this 
requirement. In adults, haematopoietic stem and progenitor cells (HSPCs) 
generally occupy a unique microenvironment in the bone marrow called the 
niche. However, recent findings have shown that approximately 0.06% of HSPCs 
circulate between bone marrow and periphery in steady state. Evidence shows 
that HSPC express cytokine receptors and pathogen recognition receptors [e.g. 
Toll-like receptors (TLRs)], which suggest that HSPCs may directly respond to 
inflammation and infection. The capacity of HSPCs to directly respond to 
infection is demonstrated in models of bacterial infection using LPS injection 
that significantly increases the number of circulating HSPCs. However, the 
underlying mechanism is not clearly understood. As chemokines orchestrate in 
vivo cellular migration, it was hypothesised that HSPC inducibly express 
inflammatory chemokine receptors that enable them to respond to circulating 
chemokines during infection and inflammation. Methods and results: Here, the 
impact of systemic or peripheral inflammation on HSPC of mice was investigated 
using LPS injection and topical imiquimod cream/TPA treatment respectively. 
Using haematopoietic progenitor colony-forming assays, RT-QPCR on isolated 
progenitors, gene-knockout mice, flow cytometric analysis and in vivo antibody-
mediated neutralisation experiments, data are provided showing that HSPC 
inducibly express chemokine receptors in response to inflammation. Critically, 
the topical imiquimod inflammation model required functional chemokine 
receptor 2 (Ccr2) for HSPC mobilisation in contrast to both systemic LPS and 
topical TPA models, which were Ccr2-independent. Furthermore, dermal 
inflammation was necessary for imiquimod-mediated HSPC mobilization, as 
subcutaneously administered imiquimod did not result in significant HSPC 
mobilization. Conclusion: The data suggest that, in addition to the established 
CXCR4-CXCL12 axis that regulates homeostatic HSPC trafficking, the 
inflammatory chemokine-chemokine receptor axes may also be crucial in 
modulating HSPC functions during infection and inflammation. 
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E  MPP Multipotent Progenitors 
ELISA Enzyme-Linked 
Immunosorbent Assay 
MSC Mesenchymal Stromal Cell 
EPO Erythropoietin   
EPOR Erythropoietin Receptor P  
F  PKC Protein Kinase C 
FDA Food and Drug Administration PreCFU-E Precursor Colony-Forming 
Unit, Erythroid 
FMO Fluorescence-Minus-One PreGM Precursor Granulocyte-
Macrophage cell 
G  PreMegE Precursor Megakaryocyte-
Erythrocyte cell 
GAGs Glycosaminoglycans PRR Pattern Recognition 
Receptor 
G-CSF Granulocyte Colony-
Stimulating Factor 
S  
G-
CSFR 
Granulocyte Colony-
Stimulating Factor Receptor 
S.C. Subcutaneous injection 
GMP Granulocyte-Macrophage 
Progenitor 
Sca-1 Stem Cell Antigen 1 
GRO Growth Related Protein SLAM Signalling Lymphocytic 
Activated Molecule 
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1.1 Introduction 
Trafficking of cells is a fundamental physiological process essential not only for 
proper development during embryogenesis but also for proper function of the 
immune system in organisms. This directed cell migration to specific anatomical 
sites is essential for such processes as cardiogenesis, angiogenesis and 
development of the CNS (Adler et al., 2005, Baggiolini, 1998). Cellular 
trafficking is however, kept under tight control as dysregulation frequently leads 
to pathology. Amongst the key regulators of cellular trafficking are chemotactic 
cytokines called chemokines. The cells of the haematopoietic system are one 
such system whose migratory properties are controlled by these chemokines. It 
is estimated that the haematopoietic system generates 3 x 105 red blood cells 
and 3 x 104 white blood cells per second in a 70-Kg human in steady state. This 
means that haematopoietic system have a high turnover rate and thus constantly 
needs to be replenished to sustain the life of an individual in steady-state 
haematopoiesis (Takizawa et al., 2012, Hirayama et al., 1999). This long-term 
cell production is made possible by the presence of a rare population of cells 
called haematopoietic stem cells (HSCs) that, through symmetric/asymmetric 
division, are able to self-renew and differentiate respectively, to progenitors 
with increasingly refined lineage commitment. In vertebrates, blood stem cells 
are produced in a variety of tissues depending on the developmental stage of the 
organism (Galloway and Zon, 2003). 
1.1.1 Chemokines and their receptors 
Chemokines are small chemoattractant cytokines, 8-12 kDa, secreted by immune 
as well as stromal cells, which are involved in regulating directional cell 
migration in vivo (Rot and von Andrian, 2004). These chemokines signal through 
their cognate G-protein coupled receptors (GPCRs) and, function in concert, 
with adhesion molecules as well as glycosaminoglycans (Springer, 1994, Dwir et 
al., 2004).  Approximately, 50 chemokines and 18 chemokine receptors have 
been discovered in humans suggesting redundancy in the ligand:receptor 
interaction in the chemokine system (Rot and von Andrian, 2004, Charo and 
Ransohoff, 2006). 
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1.1.2 Classification of chemokines 
Traditionally, chemokines have been classified based either on functional, or 
structural, criteria. The functional classification is based on the context in which 
the chemokine is secreted. Specifically, chemokines are described as being 
either homeostatic or inflammatory. Inflammatory chemokines are generally not 
expressed in resting tissues but are inducibly expressed upon leucocyte and 
stromal cell activation in response to pro-inflammatory mediators such as 
tumour necrosis factor, interferon gamma and pathogen associated molecular 
pattern. They are fundamental in directional cell migration to sites of infection, 
trauma and inflammation. Although most inflammatory chemokines are 
regulated at the transcriptional level by pro-inflammatory mediators, some (e.g. 
CXCL1, CXCL4, CXCL8 and CCL5) are also produced by platelets, and stored as 
preformed proteins in their α-granules, but released upon platelet activation 
(Power et al., 1995, Weiss et al., 1979, Brandt et al., 2000). Homeostatic 
chemokines, on the other hand, are continuously expressed in specific tissue 
locale and are vital for such processes as stem cell trafficking during 
embryogenesis, immune surveillance, as well as homing of leukocytes to lymph 
nodes and also HSC to the bone marrow after transplantation (Moser, 2003, 
Moser and Willimann, 2004, Mantovani, 1999). It must be noted however that 
this functional classification is not exclusive as some homeostatic chemokines 
show inducible expression in certain circumstances. 
Structural classification of chemokines is based on the presence of a well-
conserved cysteine (C) motif in the N-terminus of their structure. Under this 
system of classification, the chemokines are grouped into four main sub-families: 
CC chemokines have the first two cysteine groups juxtaposed. The CC 
chemokine subfamily constitutes the most abundant chemokine class and is 
mainly encoded by a multigene cluster on chromosome 17q11.2. CXC 
chemokines have a non-cysteine amino acid separating the first two cysteine 
groups. Based on the presence, or absence, of an ELR (Glu-Leu-Arg) motif just 
prior to the first cysteine residue, the CXC chemokine subfamily may be further 
grouped into angiogenic and angiostatic chemokines respectively. The angiogenic 
CXC chemokines mainly attract neutrophils and are primarily encoded by a gene 
cluster on chromosome 4q12-q13; the angiostatic CXC chemokines mainly attract 
T-lymphocytes and are encoded by a gene cluster on chromosome 4q21.21. The 
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CX3C chemokine has three non-cysteine amino acids that separate the first two 
cysteine groups. The CX3C chemokine is encoded on chromosome 16q13 and 
mainly attracts T-lymphocytes and monocytes. The CX3C chemokine family has 
only one member and exists as a transmembrane protein; proteolytic cleavage 
leads to secretion of soluble CX3C chemokine. The C chemokine has only two 
cysteine residues, selectively attracts T-lymphocytes and is encoded by a gene 
on chromosome 1q23 (Locati et al., 2005, Zlotnik and Yoshie, 2012).  
1.1.3 Classification of chemokine receptors 
Chemokine receptors are seven-transmembrane spanning G-protein coupled 
receptors (GPCRs) with their N-termini exposed outside the cell while their C-
termini are intracellular. The chemokine receptors are classified into four main 
groups based on the structural sub-family of chemokines they bind (see figure 1-
1 for an overview of chemokine-chemokine receptor pairing). Thus, we define 
CXCR (cognate receptors for CXC chemokines), CCR (cognate receptors for CC 
chemokine), CX3CR (cognate receptor for CX3C chemokine) and XCR (cognate 
receptor for XC chemokine) receptors. The N-terminus, and the three 
extracellular loops, of the chemokine receptors have been shown to be 
necessary for ligand binding, whereas the C-terminus and the three intracellular 
loops are required for signal transduction (Mayer and Stone, 2000, Booth et al., 
2002, Govaerts et al., 2003).  
1.1.4 Chemokine receptor signalling 
It is widely accepted that chemokine receptor binding and activation follows a 
two-step process: firstly, the core domains of the chemokine ligand bind to the 
N-terminus and the extracellular loops of the chemokine receptor; and secondly, 
this is followed by penetration of the receptor’s helical structure by the N-
terminus of the ligand (Gupta et al., 2001). Ligand occupancy of the requisite 
chemokine receptor leads to conformational change, receptor dimerization 
(hetero- or homo-dimerization), as well as phosphorylation of the conserved 
serine and threonine residues in the short intracytoplasmic tails of the 
chemokine receptor (Youn et al., 2001, Han et al., 1999). Subsequent to this 
activation, there is dissociation of the hetero-trimeric G-protein (Gαβγ) into the 
GTP-associated Gαi subunit and Gβγ subunit. The Gαi subunit is recruited to the 
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chemokine receptor through one of its intracellular loops, and induces activation 
of Src family proteins and a cascade of signalling events [e.g. mitogen-activated 
protein kinase (MAPK), and phosphoinositide 3-kinase (PI3K) cascades] leading to 
cytoskeletal rearrangement, and degranulation (Arai and Charo, 1996, Mellado 
et al., 1998, Damaj et al., 1996, Myers et al., 1995). The Gβγ subunit also 
activates phospholipase C leading to the formation of inositol triphosphate and 
diacylglycerol (DAG) (Jiang et al., 1996). The inositol triphosphate mobilizes 
calcium ions from intracellular stores in the endoplasmic reticulum whereas DAG 
activates protein kinase C and eventually mediates receptor desensitization 
through receptor internalization (Wu et al., 1998). It must be noted that it is the 
Gβγ subunit that mediate the chemotactic responses associated with chemokine 
receptor signalling (Moratz et al., 2004)   
Other events that are generated downstream of chemokine receptor signalling 
includes trafficking and differentiation of haematopoietic precursors, leukocyte 
activation of multiple integrins for firm endothelial adhesion as well as integrin 
recycling at the leading edge of migrating leukocytes (Vulcano et al., 2003, 
Pribila and Shimizu, 2003, Lawson and Maxfield, 1995). 
There are many cellular processes that regulate chemokine receptor signalling. 
Amongst these are the adaptor proteins called arrestins. These arrestins (e.g. β-
arrestins) regulate chemokine receptor signalling via receptor desensitization in 
one of two ways: (1) binding of the arrestins to the activated receptor may 
stearically hinder receptor-G-protein interaction (Vroon et al., 2006); (2) 
arrestin binding may target the receptor to the endosomal pathway for 
degradation, dephosphorylation or recycling back to the cell membrane (Kelly et 
al., 2008, Wolfe and Trejo, 2007). Other mechanisms that regulate chemokine 
receptor signalling such as ligand-induced receptor internalisation and G-protein 
coupled receptor kinases (Ferguson, 2001).     
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Figure  1-1 An overview of the chemokine-chemokine receptor interaction.  
The intersection of the Venn diagram indicates dual chemokines; chemokine receptors are shown 
in bracket beside the chemokine they interact, whereas question mark in bracket indicates 
chemokines with unknown receptor. Adapted from (Zlotnik and Yoshie, 2012, Locati et al., 2005)   
1.1.5 Chemokine receptor expression on early haematopoietic 
progenitors 
Although the expression of chemokine receptors on terminally differentiated 
haematopoietic cells is well established, data on the expression of chemokine 
receptors on haematopoietic stem and progenitors are only now emerging. 
Interestingly, although certain chemokines like CXCL1 (GROα), CXCL2 (GROβ), 
CXCL8 and CCL3 (MIP-1α) have been demonstrated to be actively haematopoietic 
stem and progenitor (HSPC) mobilizing agents, there has not been conclusive 
evidence about the expression of their respective chemokine receptors on the 
HSPCs. In fact, it has been speculated that the HSPC mobilizing actions of 
CXCL1, CXCL2, and CXCL8 are due to an indirect effect on neutrophils, as 
CXCR2, the cognate receptor for these chemokines, has not been shown to be 
expressed on HSPCs (Pruijt et al., 2002, Pelus et al., 2004). In a thioglycollate 
model of aseptic inflammation, it was recently shown that haematopoietic stem 
and progenitor cells use CCR2 to migrate to sites of inflammation in mice (Si et 
al., 2010). Using flow cytometry as well as other in vitro and in vivo migration 
assays, this paper demonstrated that murine haematopoietic progenitor cells 
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(defined as Lin-Kit+) express functional CCR2. In addition, signals received 
through CCR2 were also previously demonstrated to be critical in limiting 
haematopoietic progenitor cell proliferation as well as haematopoietic 
progenitor cell survival in mice (Reid et al., 1999). However, another study 
detected CCR3, CCR9 and CXCR4 in long-term haematopoietic stem cell (LT-HSC) 
and short-term HSC (ST-HSC) at the mRNA level; although with the exception of 
CXCR4, these progenitor populations did not migrate in response to the 
respective chemokine ligands in in vitro chemotaxis assay (Wright et al., 2002). 
Other chemokine receptors like CCR1, CCR2, CCR4, CCR5 and CXCR2 were 
neither consistently detected nor were the haematopoietic progenitors 
responsive in chemotaxis assay using cognate ligands for these receptors. In 
addition, studies that tracked chemokine receptor expression in human ontogeny 
(i.e., foetal liver, mobilised peripheral blood and adult bone marrow) 
demonstrated that although Lin- progenitors expressed CXCR1, CXCR2, CXCR4, 
and CCR5; only CD34-CD38-Lin- and CD34+CD38-Lin- cells expressed CXCR4 (Rosu-
Myles et al., 2000). Moreover, primitive cord blood haematopoietic progenitors 
defined in that study as CD34-CD38-Lin- and CD34+CD38-Lin- were also shown to 
express CXCR1, CXCR2, CXCR4, CCR5, CCR7 and CCR8.   
Perhaps the only chemokine receptor that has been unequivocally demonstrated 
to be expressed in HSPC (both mouse and human studies), as well as 
differentiated haematopoietic cells, is CXCR4. The CXCR4-CXCL12 axis has been 
demonstrated to be vital in embryogenesis as it is required for proper 
neurogenesis, cardiogenesis, vasculogenesis and haematopoiesis (Nagasawa et 
al., 1996). In addition, seeding of the bone marrow by foetal HSC during foetal 
development is inhibited by disruption of the CXCR4-CXCL12 axis (Zou et al., 
1998, Ma et al., 1998a). Moreover, the CXCR4-CXCL12 axis is vital in adult 
haematopoiesis as it is necessary for homing and retention of haematopoietic 
stem and progenitor cells to the bone marrow as well as maintenance of the 
HSPC pool size and quiescence (Nie et al., 2008, Hundt et al., 2006). As 
discussed below (section 1.13.1, 1.13.4.1.3-5), the indispensable role of the 
CXCR4-CXCL12 axis is exploited to induce HSPC mobilization for clinical stem cell 
transplantation. 
In spite of the apparent discrepancies in data on the expression of chemokine 
receptors on HSPCs, it has been shown that chemokine-mobilised HSPCs have 
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superior repopulation kinetics, and competitive engraftment potential, 
compared to those mobilized by the more traditional HSPC mobilizing agent, 
granulocyte colony-stimulating factor (G-CSF) (Broxmeyer et al., 2005, Pelus and 
Fukuda, 2006, Fukuda et al., 2007). Therefore, proper understanding of this 
chemokine-chemokine receptor axis in HSPC biology may be a key component in 
discovery of new therapeutic targets for improved clinical HSPC mobilization as 
well as for defining the mechanisms involved in HSPC trafficking in health and 
disease. 
1.1.6 Chemokines and diseases  
During the initial phase of injury and infection, innate immune cells, notably 
neutrophils, are recruited to these sites to help resolve the acute inflammatory 
response. In later time points, monocytes are also recruited to the inflamed sites 
as well and subsequently differentiate to macrophages to begin the process of 
tissue repair. However, in cases where this initial cellular response fails to 
resolve the acute inflammation and/or injury, the persistence of macrophages as 
well as recruitment of other cells of the adaptive immune system like 
lymphocytes leads to chronic inflammation (Nathan and Ding, 2010). Since 
chemokines are known to orchestrate recruitment of both innate and adaptive 
immune cells to sites of infection and inflammation, it is not surprising that 
these chemotactic inducers have been implicated in a host of inflammatory 
diseases. Data from both in vitro and transgenic animal models have provided 
evidence to establish chemokines and their receptors as crucial players in a 
number of diseases. The role of chemokine receptors in two specific human 
diseases [HIV (human immunodeficiency virus) infection and rheumatoid 
arthritis] have been reviewed here as an example. Table 1-1 gives a brief 
summary of some transgenic mouse models that have shed light on the role of 
specific chemokine receptors in specific disease or inflammatory contexts as 
well as the human diseases in which these chemokine receptors have been 
shown to play crucial roles. Others have previously published detailed 
explorations concerning the roles of specific chemokine, and chemokine 
receptors, in the pathogenesis of inflammatory, infectious and autoimmune 
diseases (White et al., 2013, Romagnani et al., 2004, Strieter et al., 2007). 
Table  1-1 Chemokine receptors in diseases and disease models 
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Receptor KO Developmental 
defects 
Pathophysiologic roles 
[disease models (mouse 
strain)] 
Human diseases 
where receptor 
plays a role 
CCR1-/- None 1. Increased mortality [A. 
fumigatus infection 
(C57Bl/6 mice)] 
 
2. Reduced granuloma 
formation; excessive Th1 
response [S. mansoni 
infection (C57BL/6 mice)] 
 
3. Less Th2 response; 
failure to clear parasite 
[Leishmania infection 
(Sv129xC57BL/6 mice)] 
 
Rheumatoid 
arthritis, multiple 
sclerosis, 
endometriosis 
associated with 
pelvic pain  
CCR2-/- None 1. Failed bacterial 
clearance [L. 
monocytogenes infection 
(Sv129xICR)] 
 
2. Increased lethality; 
absence of monocytosis 
[West Nile Virus 
(C57BL/6)] 
 
3. Reduced macrophage 
recruitment 
[thioglycollate peritonitis 
(Sv129xC57BL/6] 
 
Multiple sclerosis, 
rheumatoid 
arthritis, 
atherosclerosis, 
bone metastases 
CCR4-/- None 1. Decreased mortality; 
enhanced bacterial 
clearance [polymicrobial 
sepsis (C57Bl/6)] 
 
2. Reduced lethality & 
tissue damage [Dengue 
virus infection (C57BL/6)] 
 
 
Adult T-cell 
leukaemia/lympho
ma 
CCR5-/- None 1. Reduced survival; 
defective Treg recruitment 
(Graft versus host disease 
(Sv129xC57BL/6)] 
 
2. Reduced survival; 
defective leucocyte 
recruitment to the brain 
[Cryptococcus neoformans 
infection 
(Sv129xC57BL/6)]  
HIV infection, 
rheumatoid 
arthritis 
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CXCR4-/- Embryonic 
lethal 
 HIV infection, 
cancer metastasis 
 
1.1.6.1 Human immunodeficiency virus (HIV) infection 
HIV is a retrovirus and can be broadly divided into two tropic forms; M-tropic 
(infects primary macrophages), and T-tropic (primarily infects transformed T-
cells). HIV infection or entry into a given cell occurs through a two-step process: 
firstly, the attachment of the virus glycoprotein 120 (gp120) to the host CD4 
antigen (Sattentau and Weiss, 1988). This is then followed by fusion of the virus 
with host cell surface co-receptors in order to deposit the viral genome into the 
host cytoplasm (Alkhatib et al., 1996, Choe et al., 1996, Doranz et al., 1996). 
The co-receptors have been identified as belonging to the chemokine receptor 
family i.e. CCR5 and CXCR4. The M-tropic virus has been shown to preferentially 
utilise CCR5 as the co-receptor, whereas the T-tropic virus uses CXCR4 as the co-
receptor. Thus, the HIV variants are also either called R5 (virus using CCR5 as co-
receptor) or X4 (virus using CXCR4 as co-receptor) in recognition of which co-
receptor is used for viral entry. The R5 variants generally predominate in earlier 
HIV infection; however, a switch from the R5 to X4 phenotype, later in the 
course of the infection, leads to the progression to acquired immunodeficiency 
syndrome (AIDS) (Connor and Ho, 1994, Schuitemaker et al., 1992). 
Liu et al. provided evidence for the fundamental role of CCR5 in the initiation of 
HIV infection when they demonstrated that individuals with homozygous deletion 
of 32-base pairs (CCR5∆32) in the second extracellular loop of CCR5 gene were 
resistant to HIV infection (Liu et al., 1996). This deletion was subsequently 
shown to prevent functional cell surface expression of CCR5. It is estimated that 
the prevalence of the CCR5∆32 mutation is about 1% in the Caucasian population 
of European origin, although the mutation could be higher in northern European 
populations (Novembre et al., 2005). Not surprisingly, the Food and Drug 
Administration (FDA) recently approved a CCR5 blocker, called Maraviroc, for 
the treatment of HIV (Dorr et al., 2005, Wilkin and Gulick, 2012). 
Although, the CXCR4 antagonist, AMD3100, also strongly prevents HIV infection, 
due to its strong ability to mobilise haematopoietic stem and progenitor cells 
(HSPC) to blood, it is currently used to mobilise HPSC for autologous stem cell 
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transplantation (Devine et al., 2004, Devine et al., 2008). The use of AMD3100 as 
an HSPC mobilising agent is extensively discussed later in this chapter. 
1.1.6.2 Rheumatoid arthritis 
Rheumatoid arthritis is a chronic, autoimmune and inflammatory disease that 
affects about 0.5-1% of people in western countries (Symmons et al., 2002). The 
disease is characterised by persistent inflammation of the lining of synovial 
tissues (synovitis), formation of fibrovascular tissue (pannus formation) in the 
affected joint, and ultimately bone, cartilage and ligament destruction. 
Overproduction of pro-inflammatory cytokines such as TNF, IL-6 and IL-1, from 
fibroblast-like synoviocytes and macrophage-like synoviocytes, seems to be a 
major driver of the chronic inflammation as well as bone destruction observed in 
rheumatoid arthritis (Feldmann et al., 1996, Muller-Ladner et al., 1996, Choy et 
al., 2002). Other research findings also suggest that activation of osteoclasts 
partly accounts for the characteristic bone destruction (Cohen et al., 2008). It 
has also been estimated that more than 50% of rheumatoid arthritis patients 
have the classic autoantibody called rheumatoid factor or autoantibodies 
directed against citrullinated peptides (van der Linden et al., 2009). Moreover, 
other findings showed genetic predisposition as a major risk factor in developing 
rheumatoid arthritis (van der Woude et al., 2009). 
Studies using animal models have helped to shape our understanding of the basic 
mechanisms underlying human rheumatoid arthritis as well as the development 
of new therapeutic strategies. Among these animal models are the adjuvant-
induced arthritis model [e.g. complete Freund’s adjuvant (CFA)], and the 
antigen/proteoglycan immunisation-induced arthritis [e.g. collagen-induced 
arthritis (CIA)] model (Courtenay et al., 1980, Hopkins et al., 1984). 
Many chemokines have been shown to be important in the pathophysiology of 
rheumatoid arthritis. For example, Koch et al. showed that in vitro stimulation 
of synovial fibroblast with TNF-α, or IL-1, or IFNγ (each of which is known to be a 
major driver of rheumatoid arthritis) led to increased CCL2 and CCL3 production. 
In agreement with these in vitro data, they also showed that CCL2 and CCL3 
concentrations were elevated in synovial fluid from rheumatoid arthritis patients 
(Koch et al., 1992, Matsui et al., 2001, Ruth et al., 2003). Other studies in 
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human rheumatoid arthritis patients that profiled the expression of chemokine 
receptors, showed that CCRs1-7 were expressed in leukocytes from peripheral 
blood, synovial fluid and tissues (Szekanecz et al., 2006, Szekanecz et al., 2010, 
Katschke et al., 2001, Ruth et al., 2001). 
In spite of the many studies that have demonstrated fundamental involvement 
the chemokine-chemokine receptor axes in the pathology of rheumatoid 
arthritis, therapeutic interventions aimed at interfering with these axes have not 
been met with much success. For example, Maraviroc (CCR5 antagonist) was 
unable to show clinical efficacy in a recent randomized, double-blind placebo-
controlled, Phase IIa, clinical trial in rheumatoid arthritis patients (Fleishaker et 
al., 2012). Similarly, in another previous clinical trial in rheumatoid arthritis 
patients that involved monoclonal antibody-mediated neutralisation of CCL2 
(CCR2 ligand), patients did not demonstrate any clinical improvement 
(Haringman et al., 2006).  
1.2 Atypical chemokine receptors (ACKRs) 
These are a group of 7-transmembrane receptors that are structurally related to 
the chemokine receptor subfamily but are unable to orchestrate G-protein-
coupled signalling events. Members of the ACKR family include ACKR1 (DARC, 
Duffy antigen receptor for chemokines), ACKR2 (D6), ACKR3 (CXCR7) and ACKR4 
(CCRL1) (Bachelerie et al., 2014). Evidence indicates that one of the 
fundamental differences between the ACKRs and the conventional chemokine 
receptors is the alteration of the DRYLAIV consensus sequence in the second 
intracellular loop of the ACKRs (Galliera et al., 2004, Graham et al., 2012). 
These structural modifications lead to uncoupling of G-proteins from the ACKRs 
and a selective bias towards β-arrestin signalling, in contrast to the combined β-
arrestin and G-protein-coupled signalling, described for the conventional 
chemokine receptors in section 1.1.4. Interestingly, two of the conventional 
chemokine receptors, XCR1 and CXCR6, have been shown to have modifications 
in the DRYLAIV consensus sequence (Chandrasekar et al., 2004, Yoshida et al., 
1998), suggesting that such modifications alone does not account for the lack of 
G-αi-mediated signalling of the ACKRs. Recently, data from crystallographic 
analysis of seven transmembrane receptors suggested that three elements i.e. 
the DRY motif [transmembrane domain 3 (TM3)], the CWXP motif (TM6) and the 
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NPXXY5-6F motif (TM7) are the most crucial elements for a seven transmembrane 
receptor to activate Gαi signalling (Nygaard et al., 2009). Further research on 
the structure-functional relationship of the ACKRs is thus warranted to fully 
elucidate the mechanistic details underlining their inability to activate Gαi 
signalling.  
Functionally, the ACKRs have been shown to modulate the actions of chemokines 
by binding, internalising, and degrading chemokines (ACKR2-4) or by transcytosis 
of chemokine ligands (ACKR1). ACKR1 is expressed by erythrocytes, and vascular 
endothelial cells, and has been proposed to act as a “sink” for inflammatory 
chemokines (Kashiwazaki et al., 2003, Darbonne et al., 1991). ACKR2 selectively 
scavenge inflammatory CC chemokines, and is expressed by the 
syncytiotrophoblastic tissue of the placenta, lymphatic endothelial cells of the 
gut, lungs and skin, as well as by some leukocytes (Nibbs et al., 1997, Nibbs et 
al., 2001, Madigan et al., 2010). ACKR3 (CXCR7) on the other hand, scavenges 
CXCL12 and CXCL11, and is expressed in some haematopoietic, mesenchymal and 
neuronal cells (Balabanian et al., 2005, Su et al., 2002). In addition, studies 
from genetic deletion of ACKR3 in mice have implicated a role for this receptor 
in cardiogenesis (Sierro et al., 2007). ACKR4 selectively scavenges homeostatic 
chemokine ligands, CCL19, CCL21 and CCL25, and has been suggested to have a 
role in regulating chemokine-mediated adaptive immune responses (Townson 
and Nibbs, 2002, Gosling et al., 2000, Graham et al., 2012).  
1.3 Pattern recognition receptors 
The presence of invading pathogens is typically detected through ligation of 
pattern recognition receptors (PRR) by specific conserved pathogen-associated 
molecular patterns (PAMPs) on the invading organism. These PRRs are diverse 
and include Toll-like receptors (TLRs), nucleotide-binding oligomerisation 
protein domains receptors (NLRs), and purinergic receptors. Expression of PRRs 
has been demonstrated not only on innate immune effector cells like dendritic 
cells, monocytes, macrophages and neutrophils, but also on endothelial cells and 
haematopoietic progenitor cells (Nagai et al., 2006, Esplin et al., 2011).  
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1.3.1 Toll-like receptors (TLRs) 
One of the fundamental studies underpinning the biology of toll-like receptors 
came in 1996 when it was demonstrated that Drosophila carrying a mutation in 
the “Toll” gene failed to mount effective anti-fungal immunity (Lemaitre et al., 
1996). Later studies identified the human and mouse homologues of the “Toll” 
receptor and murine loss of function mutational studies established the 
fundamental role of the Toll-like receptors in innate immunity (Medzhitov et al., 
1997, Poltorak et al., 1998, Hoshino et al., 1999). Most of the TLRs (TLR1-9) 
identified thus far are well conserved between human and mouse; TLR10 is 
functional only in humans whereas TLR11-13 are only present in mice (Akira et 
al., 2006). TLR-1, -2, -4, -5, -6, and -11 are expressed as cell surface receptors 
whereas TLR-3, -7, -8, and -9 are expressed in intracellular vesicles and can 
detect nucleic acids.  
Structurally, the cell surface TLRs are type I transmembrane receptors with an 
N-terminal extracellular domain (required for PAMP recognition), a 
transmembrane domain and a leucine-rich repeat intracellular domain (required 
for adaptor protein recruitment and downstream signalling). The cytoplasmic 
domain is also called the TIR [Toll-interleukin-1 (IL-1) receptor] domain in 
recognition of its high homology to the cytoplasmic domain of the IL-1 receptor. 
Signalling through the TLRs can be either myeloid differentiation primary 
response gene 88 (MyD88)-dependent, or MyD88-independent, depending on the 
TLR involved and the adaptor proteins recruited. Ultimately, activation of the 
TLRs leads to induction of expression of cytokines, chemokines and interferons 
depending on the TLR involved.  
1.3.2 MyD88-dependent TLR signalling 
The MyD88 pathway is adopted by all the TLRs identified to date. The C-terminal 
domain of the MyD88 protein has a TIR domain whereas the N-terminal portion 
contains a death domain. This allows the C-terminal domain of MyD88 protein to 
form a homotypic association with the TIR domain of TLRs. Upon ligand binding, 
MyD88 recruits IRAK (IL-1 receptor-associated kinase) through its death domain 
and consequently activates the Janus Kinase (JNK) and nuclear factor kappa B 
(NF-kB) pathways.  
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1.3.3 MyD88-independent TLR signalling 
The MyD88-independent pathway is used in TLR4 signalling as well as TLR3 
signalling pathways (Kawai et al., 2001, Kaisho et al., 2001, Alexopoulou et al., 
2001). Numerous findings indicate that MyD88-independent TLR4 signalling leads 
to the induction of interferon regulatory genes through the interferon regulatory 
factor-3 (IRF-3)-IFN-β-Stat1 pathway (Doyle et al., 2002, Toshchakov et al., 
2002, Hoshino et al., 2002). TLR3 signalling has also been shown to induce NF-kB 
as well as IFN-inducible genes through IRF-3 using two adaptor proteins TANK-
binding kinase 1 (TBK1) and inhibitory kappa kinase (IKKε/IKKι) (Sharma et al., 
2003, Fitzgerald et al., 2003).     
1.3.4 Toll-like receptor 4 (TLR4) 
TLR4 belongs to the class of cell surface TLRs that also includes TLR-1, -2, -4, -5, 
and -6. They detect presented microbial products such as lipids (TLR1), 
lipoprotein (TLR2), lipopolysaccharide (TLR4), flagellin (TLR5) and lipoproteins 
(TLR6). Most of these TLRs have been demonstrated to homodimerise, or 
heterodimerise, upon ligand binding so as to recruit the requisite adaptor 
proteins for subsequent downstream signalling. TLR4 was the first member to be 
discovered as the receptor for lipopolysaccharide (LPS), which precipitated 
septic shock in Gram-negative bacterial infection (Akira et al., 2006). Expression 
of TLR4 has been demonstrated on most leukocytes, platelets, epithelial, 
parenchymal endothelial and other endothelial cells (Visintin et al., 2001, Muzio 
et al., 2000, Menzies-Gow et al., 2002, Sabroe et al., 2002, Abreu et al., 2003). 
TLR4 signalling in response to LPS requires formation of a complex with serum 
LPS-binding protein (LPB), membrane-bound CD14 and MD-2 (Shimazu et al., 
1999, Viriyakosol et al., 2001, da Silva Correia et al., 2001). Downstream TLR4 
signalling may be either MyD88-dependent or MyD88-independent.  
1.3.5 Toll-like receptor 7 (TLR7)      
TLR7, along with TLR-3, -8 and -9 are expressed intracellularly and are therefore 
important for detection of viral nucleic acids that are presented via the 
endosomal pathway. TLR7 is expressed in both mice and humans in the spleen, 
lung and placenta. TLR8, which is structurally similar to TLR7, is however only 
functionally expressed in humans in lungs and monocytes (Jurk et al., 2002). 
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Both TLR7 and TLR8 naturally recognize single stranded RNA (ssRNA) viruses such 
as influenza, Sendai, and Coxsackie B, usually after the virus (either replicating 
or non-replicating viruses) has been internalized into endosomes (Heil et al., 
2004, Diebold et al., 2004, Lund et al., 2004, Triantafilou et al., 2005). 
Interaction of TLR7 and/or TLR8 with ligand generates MyD88-dependent 
signalling leading to either induction of pro-inflammatory cytokines and 
chemokines through the nuclear factor-kB (NF-kB) pathway, or interferons 
through the IRF7 pathway. 
It has also been shown in both TLR7 deficient mice, and HEK 293 cells 
transfected with human TLR7, that TLR7 recognizes the imidazoquinoline 
compounds, imiquimod and resiquimod as well as loxoribine (a guanosine analog) 
(Hemmi et al., 2002, Lee et al., 2003). 
1.4 Pattern recognition receptor (PRR) expression on 
Haematopoietic stem and progenitor cells 
It is an established fact that innate immune cells such as neutrophils, 
monocytes, dendritic cells and macrophages sense the presence of invading 
pathogens through intracellular or extracellular PRRs. The timing for the TLR 
acquisition during haematopoietic stem and progenitor cell differentiation, and 
any effect they may exert on lineage specification, was however not 
investigated until recently. Recent data, from both human and murine models, 
have demonstrated that HSPCs also express TLRs at both gene and protein 
levels. Haematopoietic stem cells (which were defined as Lin-Sca+Kit+Flk-), MPP 
(Lin-Sca+Kit+Flk+) and other progenitors were demonstrated to express 
functional, cell surface TLR2, and TLR4 as well as TLR-related molecules CD14 
and MD-2 by flow cytometry (Nagai et al., 2006). Nagai et al. further 
demonstrated in in vitro cultures that LPS and Pam3CSK4 (ligands for TLR4 and 
TLR1/2 respectively) were able to stimulate MyD88-dependent differentiation of 
haematopoietic progenitors [i.e., common myeloid progenitors (CMPs), common 
lymphoid progenitors (CLPs) and granulocyte-macrophage progenitors (GMPs)] in 
the absence of haematopoietic growth factors. Additionally, in vivo LPS 
administration was demonstrated to bind TLR4 on bone marrow HSPCs. There 
has also been another report showing constitutive expression of functional TLR9 
in human CD34+ haematopoietic progenitors that could mediate MAPK-induced 
Chapter 1: General introduction  32 
 
signalling upon CpG oligodinucleotide ligation (Kim et al., 2005). Moreover, 
another recent report also demonstrated the expression of functional TLR2, 
TLR4 and TLR9 on common dendritic progenitors (CDP) and that TLR9 ligation led 
to down-regulation of CXCR4, but up-regulation of CCR7, resulting in increased 
CDP migration to lymph nodes and subsequent differentiation into dendritic cells 
(Schmid et al., 2011). Another report demonstrated that human HSPCs express 
functional TLR-1, -2, -3, -4 and -6 and further showed that Pam3CSK4 (TLR1/2 
ligand) instructed HSC commitment to myeloid differentiation (while inhibiting 
B-lymphoid fate commitment) through upregulation of the transcription factors 
GATA-1, C/EBPα and PU.1 (De Luca et al., 2009). A more elaborate study 
published recently provided unequivocal evidence that TLRs on HSPCs directly 
sense their respective ligands (Megias et al., 2012). The experimental design 
involved transplantation of WT HSPC cells into TLR2-/-, TLR4-/-, or MyD88-/- mice 
prior to injection of soluble Pam3CSK4, LPS, or ODN respectively. Data from that 
report indicated that TLR ligands stimulated the production of inflammatory 
macrophages from the transplanted cell demonstrating that the TLR receptors 
on the transplanted HSPC directly recognized their injected ligands.  
In addition to TLRs, human bone marrow CD34+ haematopoietic progenitor cells 
were demonstrated to express NOD2 receptors. Subsequently, muramyl 
dipeptide induced the formation of CD11c+ myeloid cells from human CD34+ HPCs 
(Sioud and Floisand, 2009). These and many other findings suggest that, in the 
context of inflammation, TLR ligation may replace and/or act in concert with 
endogenous cytokines in mediating HSPC proliferation and differentiation to 
meet the immediate immunological need by mechanisms that have yet to be 
unravelled. It is also reasonable to hypothesise that HSPC may be directly 
involved in the inflammatory response to infection through their functional 
PRRs. 
1.5 Haematopoiesis during development  
The emergence of the haematopoietic system in vertebrates occurs in two 
distinct waves: primitive haematopoiesis, largely concerned with production of 
erythroid cells to provide oxygen to the developing embryo as well as myeloid 
cells, and definitive haematopoiesis capable of producing all myeloerythroid and 
lymphoid cells of the adult haematopoietic system (Palis, 2008). Though the site 
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of primitive haematopoiesis is well established, the anatomical site of 
emergence of definitive haematopoiesis is very much debated.     
1.5.1 Primitive haematopoiesis  
Primitive haematopoiesis in the mouse begins between embryonic day (E) 7 and 
E7.5 as a result of an ingression of the extra-embryonic mesoderm through the 
posterior primitive streak and ultimately haematopoietic differentiation in the 
yolk sac (Silver and Palis, 1997). Using in vitro assays, it was experimentally 
shown that the yolk sac indeed contained clonogenic myeloid progenitors (colony 
forming units-culture, CFU-C), adult type definitive haematopoietic stem cells 
(dHSC) and colony forming units-splenic (CFU-S) (Moore and Metcalf, 1970). 
However, later work using transplantation of yolk sac derived cells to irradiated 
murine hosts found that yolk sac lacked CFU-S prior to E9.5 and dHSC prior to 
E11.5 (Muller et al., 1994, Medvinsky et al., 1993, Medvinsky et al., 1996).  
1.5.2 Definitive haematopoiesis 
It has been proposed that dHSC originate de novo from an intra-embryonic tissue 
region called the aorta-gonad-mesonephros (AGM) region at E9.5 (Muller et al., 
1994, Medvinsky et al., 1993, Medvinsky et al., 1996). This supposition, that 
adult haematopoiesis has an intra-embryonic origin, is also supported by earlier 
findings in avian models (Dieterlen-Lievre, 1975, Cormier and Dieterlen-Lievre, 
1988). Using in vivo transplantation assays, another study has demonstrated that 
the de novo AGM HSC induction is restricted to the ventral tissues of the AGM 
(Peeters et al., 2009). That study further implicated Hedgehog proteins as being 
critical in this dHSC generation from the AGM. In contrast to the studies cited 
above, one recent report that adopted lineage-tracing through induction of 
stage/tissue specific recombination events questioned the intra-embryonic 
origins of dHSC and suggested yolk sac origins of dHSC (Samokhvalov et al., 
2007). Interestingly, another subsequent report that used the same mutant 
mouse failed to corroborate that finding but suggested shear stress in the AGM, 
caused by heart beat-induced blood flow, as a requirement for the de novo 
generation of dHSC in the AGM (Adamo et al., 2009). The Adamo et al. study 
evaluated the effect of fluid shear stress on the gene expression profile and 
haematopoietic potential of in vitro cultured embryoid body-derived cells. They 
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demonstrated that fluid shear stress increased the expression of Runx1 [essential 
for haematogenic endothelium cell specification towards haematopoietic lineage 
(Lancrin et al., 2009)], Flk1+(indicating the formation of haemangioblast), Myb 
[a marker for haemogenic endothelium (North et al., 2002)], and Klf2 [a 
mechano-activated gene known to stimulate erythropoiesis (Basu et al., 2005)]. 
Subsequent in vitro haematopoietic colony-forming assays substantiated these 
findings that abrogation of fluid shear stress perturbed the haematopoietic 
potential of the AGM. 
There has also been an on-going question regarding the lineage of the cells 
within the AGM from which dHSC are derived. Initially, it was proposed that 
haematopoietic stem cells and endothelial cells both originated from a unique 
bi-potential cell population called the haemangioblast. Several lines of evidence 
from in vitro blast colony assay using ES-cells, which identified haemangioblasts, 
supported this concept (Choi et al., 1998, Kennedy et al., 2007, Keller, 2005). 
Later studies however, led to the proposition of haematogenic endothelium as 
the common ancestral cell for both haematopoietic and endothelial cells. This 
concept proposes that haematopoietic stem cells originate from intra-aortic 
endothelial cells in the embryo. Evidence for this concept came from 
experiments that showed that the first dHSC expressed both haematopoietic and 
endothelial cell surface markers (North et al., 1999, Sanchez et al., 1996, North 
et al., 2002). Studies using live imaging in Zebrafish embryos, and slices of 
mouse AGM, have provided further unequivocal evidence of the haematopoietic 
stem cell emergence from the haematogenic endothelium (Bertrand et al., 
2010a, Boisset et al., Kissa and Herbomel, 2010). Recent publications have 
however reconciled the two concepts, i.e. the haemangioblast and 
haematogenic endothelial origins of haematopoietic stem cells, by 
demonstrating that under the transcriptional influence of the stem cell 
leukaemia (Scl) gene, Flk+ haemangioblasts generate haematogenic endothelial 
cells which subsequently differentiate into haematopoietic stem cells, or 
structural endothelial cells, under the transcriptional regulation of Runx1 and 
HoxA3 respectively (Iacovino et al., 2010, Lancrin et al., 2009).  
Thus, the currently accepted dogma is that dHSC originate de novo in the AGM 
even prior to the establishment of circulation since in vitro cultured E8.0 para-
aortic splanchnopleura (which later forms the AGM) generates multilineage 
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progenitors, although the yolk sacs of both mouse and human generates only 
myeloerythroid progenitors (Tavian et al., 2001, Cumano et al., 1996). In 
addition, transplantation of in vitro cultured E8.0 mouse para-aortic 
splanchnopleura cells into Rag2γC-/- recipients mice generated long-term 
multilineage reconstitution (lymphomyeloid cells), whereas the same 
transplantation assay using cultured yolk sac cells generated only short term 
myeloerythroid cells (Cumano et al., 2001). A summary of the developmental 
pathway leading to specification of adult type HSCs is illustrated in figure 1-2 
below.   
  
Figure  1-2: A schematic representation of the developmental pathway towards the 
emergence of definitive HSC from embryonic stem cells. 
Shown are some of the critical transcription factors and cell surface antigenic expression that mark 
specific stages of haematopoietic stem cell ontogeny. Scl; stem cell leukaemia: ESC; embryonic 
stem cell. [Adapted from: (Medvinsky et al., 2011, Lancrin et al., 2009, Iacovino et al., 2010, North 
et al., 2002)]. 
1.5.3 Sites for embryonic haematopoiesis 
In addition to the yolk sac and the AGM that are haematopoietic in the embryo, 
several other organs have been shown to harbour haematopoietic stem cells and 
to have haematopoietic activity. These include the placenta, umbilical cord, 
liver and the spleen. There is an on-going debate as to whether the placenta and 
the umbilical cord are also sites for de novo dHSC generation. What has been 
established is that dHSC from the AGM (and possibly the placenta and the 
umbilical cord) colonize the foetal liver between E11.5-E12.5 in the mouse 
(Medvinsky et al., 2011). Although foetal liver HSC eventually seed the bone 
marrow at ~E16-17 (Morrison et al., 1995), there are some inherent differences 
between the two HSC populations. Murine foetal liver HSC express distinct cell 
surface markers such as Mac-1 and AA4.1 (Jordan et al., 1995, Morrison et al., 
1995), and generate other unique cell populations such as Ly-1+ B-1a B cells 
(that form most of the B cells in the newborn) and CD4+CD3- lymphotoxin β+ 
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integrin α4β7+ which are most likely follicular dendritic cell precursors (Ikuta et 
al., 1990, Havran and Allison, 1988, Mebius et al., 1997). In addition, unlike 
adult HSCs, foetal HSCs have been shown to be actively dividing, with foetal 
liver providing the microenvironment for these expanding HSCs, and these cells 
show robust reconstitution potential in irradiated hosts compared to bone 
marrow counterparts (Holyoake et al., 1999, Harrison et al., 1997). Moreover, 
whereas seeding of foetal liver with HSC does not require a functional CXCR4-
CXCL12 axis, this axis is a necessity for bone marrow colonization by adult HSC 
(Kawabata et al., 1999).  
In the human foetus, however, the yolk sac forms at about day 13 post gestation 
and haematopoiesis begins in the yolk sac by day 16 (Prindull, 1992). HSPC later 
seed the liver after blood vessel formation and, beginning at 5-6 weeks of 
gestation, undergo an exponential increase in numbers as a result of intense 
proliferation with minimal differentiation in the foetal liver (Migliaccio et al., 
1986, Hann et al., 1983). Beginning from the 6th week of gestation, the liver 
predominantly becomes a site of erythropoiesis, although evidence suggests that 
myelopoiesis, lymphopoiesis and megakaryocyte production are also detectable 
(Prindull, 1992). Between 4-5 months of pregnancy, the foetal bone marrow 
becomes a functional haematopoietic tissue (Golden-Mason and O'Farrelly, 
2002). 
1.5.3.1 Foetal spleen and thymus 
In mice, HSC from the foetal liver colonize the foetal spleen and thymus at 
about E13-14 and initiate haematopoietic activity in these organs until birth 
(Godin et al., 1999). After birth, the spleen maintains minimal haematopoietic 
activity in steady state; however, during conditions of stress, its haematopoietic 
activity can increase considerably. The thymus on the other hand, remains the 
site of T-cell maturation. 
1.5.4 Sites for adult haematopoiesis 
Beginning from birth, and throughout life in vertebrates, the bone marrow 
becomes the main site for haematopoiesis in steady state. Other organs like the 
spleen and the liver retain minimal residual haematopoietic activity in steady 
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state but become extra haematopoietic sites during conditions of stress on the 
bone marrow. The ability of the bone marrow to sustain the life-long 
haematopoietic requirements of organisms is due to a unique class of cells called 
haematopoietic stem cells (HSC) equipped with inherent self-renewal and 
differentiation potential.  
1.6 Haematopoietic stem cells (HSCs). 
 
Figure  1-3: A schematic of the haematopoietic stem and progenitor cell differentiation and 
lineage commitment pathways. 
Shown are the various lineage choices from the LT-HSC to series of multipotent progenitors which 
subsequently differentiate to effector cells. Adapted from (Iwasaki and Akashi, 2007, Nutt and Kee, 
2007, Naito et al., 2011, Socolovsky, 2007, Nagasawa, 2006, Perry and Soreq, 2002, Friedman, 
2007).  
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In adult mice, HSCs have been detected in bone marrow, spleen and liver 
whereas in the adult human, they have been detected in the spleen and bone 
marrow (Wolber et al., 2002, Dor et al., 2006). Functionally, HSC are defined by 
their ability to reconstitute the entire repertoire of haematopoietic cells i.e., 
the myeloerythroid and lymphoid lineages, when transplanted into an irradiated 
host. Symmetric cell division of HSC leads to self-renewal of the HSC. However, 
the HSC can also undergo asymmetric cell division to give one HSC and short-
term haematopoietic stem cells (ST-HSC) and a series of multipotent progenitors 
(MPP) that finally differentiate to functional terminally differentiated 
haematopoietic cells (see figure 1-3 above). Whereas the ST-HSC and MPP can 
sustain haematopoiesis only for a short term (up to 8 weeks), the long term HSC 
sustain life-long haematopoiesis. Although HSC numbers vary with age, sex and 
strain of mice as well as the purification protocol adopted, HSCs generally 
account for about 0.001-0.01% of the nucleated cells in the bone marrow of mice 
(Challen et al., 2009, Kiel et al., 2005). In spite of the inherent ability of HSCs to 
undergo proliferation and differentiation to sustain haematopoiesis, it must be 
emphasized that under homeostatic conditions HSCs are mainly quiescent 
(Wilson and Trumpp, 2006). Moreover, it has been proposed that the dormant 
HSC have a high reconstitution potential and divide every 145 days, or 175-350 
days, in mouse and human respectively, whereas the active HSC have lower 
reconstitution ability and divide every 36 days (Catlin et al., 2011, Wilson et al., 
2008). In fact, studies have shown that haematopoietic stress caused by 
infection, cytokines, or chemical agents, may lead to premature exhaustion of 
HSCs as they push the dormant HSC to exit its quiescent/Go phase of the cell 
cycle (Cheng et al., 2000, Hock et al., 2004).  
What is evident from the literature is that the current immunophenotypic 
protocols for identifying HSCs are inadequate because recent findings have 
demonstrated heterogeneity within the isolated HSC. For example, it was 
recently shown that based on the SLAM (signalling lymphocytic activation 
molecule) phenotype (Lin-Kit+Sca-1+CD34-CD48-CD150+), the population 
previously identified as true HSCs (Kiel et al., 2005) could still be separated 
based on CD150 expression with the CD150high population representing the most 
primitive HSC population (Morita et al., 2010). In addition, two recent 
publications have further demonstrated, through functional repopulation assays, 
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that within the SLAM phenotype, HSCs are still heterogeneous and can be 
separated based on c-Kit expression with the c-Kitlow/int population having the 
true stem cell phenotype (Shin et al., 2014, Grinenko et al., 2014). Therefore, 
more research is needed to fully characterize the HSC phenotype so as to 
identify the unique population with ‘stemness’ potential and provide a better 
understanding of the determinants of the switch from self-renewal to 
differentiation.   
Although, haematopoietic stem and progenitor cells (HSPCs) reside in specialized 
niches in the bone marrow of adults, it has been estimated that physiologically, 
~100-400 HSPCs are in the circulation at any time point in mice (Wright et al., 
2001, Goodman and Hodgson, 1962). These HSPCs egress from the bone marrow 
to blood in response to sphingosine 1-phosphate, circulate to several tissue and 
re-enter the blood through the thoracic duct and subsequently home back to the 
bone marrow (Massberg et al., 2007). It is further suggested that these 
circulating HSPCs upregulate CD47 expression to evade phagocytic activity of 
innate immune cells such as macrophages (Jaiswal et al., 2009). Other reports 
also implicate induced CD274 expression by HSPCs as being important in their 
ability to evade the adaptive arm of the immune system during homeostatic 
HSPC trafficking (Zheng et al., 2011). Moreover, it must be stated that the 
homeostatic trafficking of HSPC is under circadian control by the release of 
noradrenaline, with peak levels being achieved 5 hours after the initiation of 
light and trough levels 5 hours after the onset of darkness (Mendez-Ferrer et al., 
2008). Mendez-Ferrer et al. demonstrated that the fluctuation occurred as a 
result of noradrenaline regulation of CXCL12 protein levels in the bone marrow 
niche; bone marrow CXCL12 secretion decreasing to lowest levels 5 hour after 
light initiation (in anti-phase with noradrenaline levels) and peaking 5 hours post 
darkness initiation. 
1.6.1 Identification of HSPCs  
Haematopoietic stem and progenitor cell identification is increasingly based on a 
variety of cell surface markers, and biochemical features as described briefly 
below. 
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1.6.1.1 Multi-colour flow cytometry 
In the mouse, this typically adopts staining protocols that exclude markers for 
lineage specific cells (CD4, CD5, CD8, B220, Ter119, Mac-1 and Gr-1) but include 
positivity for c-Kit and/ Sca-1 antigens depending on which primitive population 
is of interest. It should be noted however that although most of the cell surface 
markers in mice and human haematopoietic progenitor cell populations are well 
conserved, there are fundamental differences in the markers used for the 
phenotypic isolation of mouse and human HSC (see table 1-2). For example, 
whereas mouse HSCs are CD150+ and CD34- (Kiel et al., 2005), human HSCs are 
CD150-, but CD34+ (Novelli et al., 1998, Goodell et al., 1997). 
 
Table  1-2: Immunophenotypic markers used for identifying haematopoietic stem and 
progenitor cells in mice and humans. 
[Adapted from (Wilson et al., 2007, Doulatov et al., 2012, Adolfsson et al., 2005) 
Marker Cell type 
Mouse  
Lin-Sca-1+Kit+ Haematopoietic stem and progenitor 
cells (LSK) 
Lin-Sca-1+Kit+CD34+CD135+CD150- Multipotent progenitors (MPP) 
Lin-Sca-1+Kit+CD34+CD48+CD135-
CD150+ 
MPP1 
LSK CD34+CD48+CD135-CD150- MPP2 
LSK CD34+CD48+CD135+CD150- MPP3 
LSK CD34-CD41-CD135+CD150+ Short-term haematopoietic stem cells 
LSK IL7rα- Myeloerythroid progenitors 
LSK IL7rα+ Common lymphoid progenitors 
LSK CD34+CD135+ Lymphoid-primed MPP (LMPP) 
LSK IL7rα-CD34+CD16/32- Common myeloid progenitors (CMP) 
LSK IL7rα-CD34-CD16/32- Megakaryocyte-erythrocyte progenitors 
(MEP) 
LSK IL7rα-CD34+CD16/32+ Granulocyte-macrophage progenitors 
(GMP) 
LSK IL7rα-CD48-CD150+ Long-term haematopoietic stem cells 
(HSC) 
LSK CD34-CD48-CD135-CD150+ Dormant HSC 
LSK CD34+CD48-CD135-CD150+ Activated HSC 
 
Human 
 
Lin-CD34+CD38-CD45RA-CD90+CD49f+ Long-term haematopoietic stem cells 
Lin-CD34+CD38-CD45RA-CD90-CD49f+ Multipotent progenitors (MPP) 
Lin-CD34+CD38-CD45RA+CD10+CD7- Immature lymphoid progenitors (MLP) 
Lin-CD34+CD38-CD45RA-CD135+CD10-
CD7- 
Common myeloid progenitors (CMP) 
Lin-CD34+CD38-CD45RA-CD135-CD10-
CD7- 
Megakaryocyte-erythrocyte progenitors 
(MEP) 
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Lin-CD34+CD38-CD45RA+CD135+CD10-
CD7- 
Granulocyte-macrophage progenitors 
(GMP) 
 
1.6.1.2 Dye efflux properties 
This method of HSC identification is based on the unique ability of HSC to efflux 
fluorescent vital dyes such as Hoechst 33342. This high dye effluxing activity has 
been shown to be due to the endowment of the HSCs with higher amount of 
multi-drug resistant ATP binding cassette transporters (Goodell et al., 1996, 
Camargo et al., 2006, Zhou et al., 2001). Thus the haematopoietic progenitor 
population appears as a “side population” i.e., a separate population of cells 
that are negative for the Hoechst 33342 dye. This protocol is combined with 
other strategies to identify the HSC population. Species-specific differences in 
HSPC biology are also manifest concerning the side population protocol since 
HSPCs in humans are devoid of the side population pattern seen in mice (Pearce 
and Bonnet, 2007).  
1.6.1.3 Functional identification of HSC 
In vitro clonal culture assays can be used to assess the presence of 
haematopoietic progenitors in a given cell population as well as their 
differentiation potential. These in vitro assay systems include the liquid and 
semi-liquid-based media containing combinations of cytokines and growth 
factors that allow the growth of the progenitor population of interest. Since the 
permissive conditions allowing the in vitro culture of HSC have not been 
discovered, the many numerous in vitro culture systems only give an indication 
of the presence of haematopoietic progenitors. Some in vivo assays such as 
radioprotection and spleen colony forming unit day-12 (d-12 CFU-S) have also 
been used to assess progenitor cell function and number (Pallavicini et al., 1997, 
Kondo et al., 2003). The gold standard for functional assessment of LT-HSC 
population has been the long-term repopulation assay that assesses the 
haematopoietic system reconstitution potential of a particular test cell 
(Harrison, 1980, Harrison et al., 1993, Bhattacharya et al., 2008, Kondo et al., 
2003). In this assay, the cell population whose functionality is being tested is 
intravenously injected into a conditioned host, and then peripheral blood 
samples are withdrawn at regular intervals to quantify the relative contribution 
of the transplanted HSC to the lympho-myeloid lineages in the reconstituted 
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haematopoietic system. The conditioning is assumed to provide “space” in the 
bone marrow niche for the transplanted HSC (Metcalf, 2007).    
1.7 Haematopoietic niche 
It is generally accepted that HSCs are housed in a unique anatomical 
microenvironment called the stem cell niche that integrates both intrinsic and 
extrinsic signals to regulate such processes as self-renewal, differentiation and 
storage of cycling and quiescent stem cells. The niche concept was proposed by 
Schofield when he observed that contact between prospective haematopoietic 
stem cells and cells within their microenvironment was required to sustain stem 
cell behaviour (Schofield, 1978). Research has substantiated the niche concept 
for all somatic stem cells. Via secretion of soluble factors such as cytokines, 
chemokines and extracellular matrix proteins, the bone marrow stromal 
component of the niche provides the critical microenvironment necessary for 
sustenance of HSC functions.  
Two main niches are proposed for the HSC in the adult bone marrow; the 
endosteal and vascular niches. It must be stated beforehand that the two niches 
are probably not mutually exclusive, as more findings seem to suggest that a 
dynamic interaction takes place in the bone marrow (Kiel and Morrison, 2008). 
The principal difference between the two proposed niches might be the oxygen 
content; higher in the vascular niche hypothesized to house mostly active HSCs 
whereas the endosteal/osteoblastic niche is hypoxic and retains mostly dormant 
HSCs (Parmar et al., 2007, Venezia et al., 2004).     
1.7.1 Endosteal niche 
Morphological evidence supports the notion that the more dormant HSCs localize 
to the endosteum in trabecular regions of long bones, whereas more 
differentiated haematopoietic progenitors are found mainly in the central 
regions of the bone marrow close to vascular sinusoids (Foudi et al., 2009, Zhang 
et al., 2003, Lo Celso et al., 2009, Xie et al., 2009). The high Ca2+ ion 
concentration in the bone marrow endosteal surface has been shown to be 
critical for proper homing and lodging of HSCs to the endosteal niche (Adams et 
al., 2006) as the HSCs were shown to express Calcium ion receptors (CaR). Cells 
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lining the endosteal surface of bone, called osteoblasts, have been implicated as 
an essential component of the HSC niche (Deguchi et al., 1999, Ducy et al., 
2000). Other subsequent studies provided evidence for the direct involvement of 
osteoblasts in maintenance of the HSC niche. For example, in one study, 
increased constitutive synthesis of osteoblasts was achieved by expressing 
parathyroid hormone under the type 1 collagen α1 (Col1α1) promoter (Calvi et 
al., 2003). Since parathyroid hormone is involved in calcium homeostasis, the 
constitutive increase in calcium levels resulted in increased bone formation and 
hence increased osteoblasts with a concomitant increase in HSC numbers 
demonstrating a direct correlation between osteoblasts and HSC numbers. Other 
studies that conditionally depleted osteoblasts reported impairment of bone 
marrow haematopoiesis with apparent extramedullary haematopoiesis in the 
liver and spleen (Visnjic et al., 2004, Zhu et al., 2007). Additional evidence 
implicating the essential role of osteoblasts in supporting HSCs came from in 
vitro studies that identified many haematopoietic supporting cytokines as being 
secreted by osteoblastic cell lines (Taichman, 2005, Taichman and Emerson, 
1998). Moreover, in vivo, osteoblasts express angiopoietin 1 (Ang-1) which 
interacts with the tyrosine receptor kinase, Tie2, expressed on HSC, in a 
mechanism that maintains HSC in a quiescent state in the bone marrow (BM) 
niche (Arai et al., 2004). 
In addition, several receptors known to interact with osteopontin (secreted by 
osteoblasts), like CD44, α4 and α5β1 integrins, have been demonstrated to be 
expressed on HSC (Scott et al., 2003, Schmits et al., 1997). Gain and loss of 
function mutation experiments have established that several transmembrane or 
secreted factors from the osteoblasts such as CXCL12, kit ligand (Zsebo et al., 
1990, Broxmeyer et al., 1991), bone morphogenetic protein-4 (Goldman et al., 
2009), and annexin II (Jung et al., 2007) are important for proper HSC function 
in vivo. The osteoblasts further secrete other essential haematopoietic growth 
factors such as GM-CSF, G-CSF, hepatocyte growth factor and IL-6 (Taichman et 
al., 2001, Taichman et al., 1996). 
Recent findings however cast doubt on the exact identity of the cells of the 
osteogenic lineage involved in HSC niche function. Using conditional deletion of 
the ribonuclease Dicer 1 in both osteoprogenitors and osteocalcin-positive 
mature osteoblasts in mice, it was demonstrated that osteoprogenitors, but not 
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osteocalcin-positive osteoblast, are the main osteogenic niche component 
(Raaijmakers et al., 2010). In addition, other findings implicate other stromal 
cells called CXCL12 abundant reticular (CAR) cells as the principal cell type that 
associate directly with HSC in the niche (Sugiyama et al., 2006). These CAR cells 
were shown to produce high amounts of CXCL12 that interacts with CXCR4 on 
HSPCs to retain them in the niche.  
Further findings also implicate a rare cell population called nestin+ mesenchymal 
stem cells, which were shown to have osteogenic, chondrogenic and adipogenic 
potential as a critical component of the bone marrow niche (Mendez-Ferrer et 
al., 2010). Colocalization experimental data from Mendez-Ferrer et al. indicated 
that within the bone marrow, HSC physically associate with nestin+ MSC and that 
HSC home near these nestin+ MSC upon transplantation. These nestin+ MSC were 
shown to produce high levels of CXCL12, kit ligand, and angiopoietin, all of 
which are known to be required for the retention and maintenance of HSC 
quiescence and self-renewal. Conditional ablation of these nestin+ MSC resulted 
in ~50% reduction in multipotent progenitors and mobilization of HSCs to the 
spleen. Further research is thus needed to clarify the lineage relationship 
between these osteoblasts, CAR, and nestin+ MSC to pinpoint which one(s) is/are 
the key endosteal niche components. 
1.7.2 Vascular niche 
It is well documented that during bone marrow stress, haematopoiesis occurs in 
extramedullary sites, such as liver and spleen, which are rich in vascular 
sinusoids but devoid of osteogenic cells. Numerous experimental findings are 
shedding light on the role of the vascular compartment in haematopoiesis. 
Immunofluorescence techniques based on SLAM markers indicated that HSCs 
(Lin- CD41- CD48- CD150+) localized to sinusoidal endothelial linings in both the 
bone marrow and spleen (Kiel et al., 2005). This provided evidence that at least 
the vascular cell compartment provided a microenvironment that harbours HSC. 
To be recognised as a valid niche, the vascular endothelial cells must 
demonstrate the ability to independently support the long-term self-renewal 
potential of HSC. Using both in vitro culture, and in vivo serial transplantation 
assays, Butler et al. showed that bone marrow endothelial cells elaborate 
angiogenesis-related factors that support the expansion of HSC (defined as Lin-
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Sca-1+Kit+CD34-CD135-), as well as maintenance of its self-renewal potential in a 
mechanism that involved direct HSPC-endothelial cell contact and Notch 
signalling (Butler et al., 2010). Remarkably, inhibition of the angiogenic pathway 
through antibody-mediated blockade of vascular endothelial growth factor 
receptor 2 (anti-VEGFR-2) and vascular endothelial cadherin (anti-VE-cadherin), 
led to defective recovery of haematopoiesis in sublethally irradiated hosts 
(Butler et al., 2010); this series of experiments demonstrated the essential role 
of vascular endothelial cell-induced angiocrine signalling in the maintenance of 
HSPC function. These in vivo antibody neutralisation data from Butler et al. 
corroborated the findings from a prior study that phenotypically characterised 
the bone marrow vascular niche sinusoidal endothelial cells as VE-
cadherin+VEGFR2+VEGFR3+Sca-1- (Hooper et al., 2009). In another seminal work 
in which stem cell factor was deleted in bone marrow endothelial and 
perivascular cells, HSCs were preferentially depleted (Ding et al., 2012). This 
suggested two possible scenarios; that in steady state, these cells may secrete 
SCF that is critical in HSC lodging and/or HSC reside in the perivascular niche.  
In addition, stromal cell lines, which have demonstrable support for HSC 
maintenance, have been isolated from both liver and the spleen (O'Neill et al., 
2004, Wineman et al., 1996, Moore et al., 1997). These stromal cells have been 
shown to have an endothelial phenotype and are used for in vitro cultures. Since 
the liver and the spleen are known to contain HSC and are devoid of osteogenic 
precursors, these findings indicate that the endothelial compartment can also 
provide a microenvironment that supports haematopoiesis.    
1.8 Adult extramedullary haematopoiesis 
Extramedullary haematopoiesis refers to all non-bone marrow haematopoiesis 
and may involve single or multiple lineages. Technically, these include all the 
haematopoietic activities that occur in the yolk sac, AGM, placenta, liver and 
spleen during foetal development. In adults, the main sites for extramedullary 
haematopoiesis are the spleen, lymph nodes and the liver as well as, in some 
exceptional cases, the skin (Corella et al., 2008). It may thus be a safe 
assumption to say that extramedullary haematopoiesis principally involves 
reactivation, in adulthood, of microenvironments that were involved in foetal 
haematopoiesis. Factors mediating extramedullary haematopoiesis are variable 
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and include hypoxia-induced increased liver and/or splenic erythropoiesis as a 
consequence of increased circulating erythropoietin, primary myelofibrosis as 
well as infection-mediated haematopoietic activity in extramedullary sites 
(Bozzini et al., 1970, Thiele et al., 1990). In the broader sense, extramedullary 
haematopoiesis could also refer to processes involved in maturation of 
haematopoietic progenitor cells that migrate from the bone marrow to organs 
such as the thymus, spleen and other lymphoid organs. 
Recent findings are shedding light on the potential mechanisms that may 
underlie extramedullary haematopoiesis. One such experiment using FOXP3-null 
mice implicated GM-CSF and IL-3 from overly activated T-cells as the cause of 
the increased myelopoietic activity in the spleen and liver (Lee et al., 2009). 
This experiment thus established that the functions of Tregs are important in 
controlling extramedullary haematopoiesis in steady state. Others have also 
shown through antibody-based depletion of NK cells, that NK cells may be a 
negative regulator of extramedullary myelopoiesis (Hansson et al., 1988). In 
addition others, using infection models, have also shown that lipopolysaccharide 
(TLR4 ligand) and Pam3CSK4 (TLR2 ligand) can directly signal through their 
cognate receptors to mediate extramedullary haematopoietic activities (Nagai et 
al., 2006). Interestingly, findings from that paper indicated that these TLRs 
could reprogramme lymphoid progenitors to differentiate into myeloid cells.  
1.8.1 Spleen 
Historically, the adult spleen is known to contribute to erythropoiesis, but also 
become fully haematopoietic in conditions of bone marrow stress (Yanai et al., 
1991). The spleen in adult mice has been shown to contain a rare population of 
HSC that are capable of long-term reconstitution potential in lethally irradiated 
host (Tan and O'Neill, 2009, Wolber et al., 2002). Similarly to the medullary 
hypoxic endosteal niche, the splenic sinusoidal endothelium in the red pulp is 
estimated to provide the hypoxic microenvironment that supports HSC expansion 
and proliferation during extramedullary haematopoiesis (Tavassoli and Weiss, 
1973). Recent findings suggest that the endogenous splenic HSPC may 
differentiate to give a distinct tissue specific antigen presenting cell type called 
L-DC (dendritic-like cells) (Tan and O'Neill, 2009) during homeostatic conditions. 
It has further been suggested that interaction of stroma of the spleen with this 
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haematopoietic precursor may be critical in influencing its differentiation 
potential as bone marrow HSCs seeded on splenic stroma in in vitro cultures also 
give rise to L-DC (Tan et al., 2010).   
1.8.2 Liver 
The adult liver harbours HSC (Taniguchi et al., 1996, Watanabe et al., 1996), 
and maintains minimal erythropoietic and myelopoietic activities in steady state. 
Some studies have shown that the quantities of HSC in adult human liver are 
comparable to those of the bone marrow although similar studies in mice found 
murine liver to contain about 50% of murine bone marrow HSC (Crosbie et al., 
1999, Taniguchi et al., 1996). Again, in humans, it has been shown that the 
majority of differentiating bone marrow HSCs (CD34+CD38+ HSC) expresses the 
myeloid marker CD33 in contrast to only about 5% of hepatic HSCs (Golden-
Mason et al., 2000). Thus it is not surprising that the adult liver has been found 
to be the maturation site for some populations of unconventional T-cell such as 
CD4-CD8- double negative cells and γδT cells (Golden-Mason and O'Farrelly, 
2002). Others have also demonstrated that the adult liver is an active 
lymphopoietic organ in both humans and mice (Kawamura et al., 1999, Doherty 
et al., 1999, Norris et al., 1998). Taken together with other findings that the 
adult liver produces IL-7 (Golden-Mason et al., 2001) and IL-15 (Golden-Mason 
and O'Farrelly, 2002); two cytokines which have been demonstrated to be 
indispensable for extra-thymic T-cell development (Ohteki et al., 1997, Laky et 
al., 1998), it is fair to say that the adult liver provides a microenvironment 
capable of sustaining haematopoietic activity.  
1.9 Not all adult haematopoietic cells are from bone 
marrow HSC 
Increasingly, there is evidence showing that some tissue-specific macrophages 
are endowed with stem cell-like self-renewal capabilities and are able to 
proliferate to meet local demands. These tissue macrophages have been shown 
to originate from embryonic progenitors in the yolk sac or foetal liver, have stem 
cell-like quiescence in homeostasis and self-renew independently of bone 
marrow HSC in demand-driven conditions (Schulz et al., 2012, Ginhoux et al., 
2010, Hoeffel et al., 2012). Most of the experimental evidence supporting the 
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alternative developmental origin of these tissue macrophages came from lineage 
tracing experiments where genetic approaches were used to trace the fate of 
progenitors using specific lineage markers. In one such experiment, Cre-
recombinase was expressed under the control of the chemokine receptor, 
CX3CR1, which is expressed in monocytic progenitors, but not most mature 
macrophages, and thus allowed the labelling and subsequent tracking of all such 
progenies. (Yona et al., 2013). It became clear that although some peritoneal 
macrophages were labelled, others like Kuppfer cells, Langerhans, alveolar or 
splenic macrophages were not labelled indicating that these had origins other 
than bone marrow derived monocytic progenitors. In other experiments that 
used pulse-labelling of primitive haematopoietic cells at E7.5 (mainly 
macrophages and erythroid cells) with Runx-Cre also demonstrated that ~30% of 
adult brain microglia cells were labelled, thus indicating their embryonic origin, 
since adult type HSC are established after E8-8.5 in the AGM (Ginhoux et al., 
2010). Other data came from disruption of definitive haematopoiesis through 
genetic inactivation of the transcription factor c-Myb, which although is 
absolutely necessary for definitive haematopoiesis, it is dispensable for primitive 
haematopoiesis (Schulz et al., 2012). It was demonstrated in those experiments 
that besides adult brain microglia, other tissue macrophages emerge despite the 
abrogation of definitive haematopoiesis. 
The consensus from these and many other experiments is that, these tissue 
specific macrophages are derived from the embryonic/primitive haematopoiesis, 
migrate to these tissues where they undergo extensive proliferative expansion 
during embryonic development but switch into quiescence after birth (Chorro et 
al., 2009, Murphy et al., 2008, Merad et al., 2002, Kierdorf et al., 2013).   
1.10 Haematopoietic lineage specification  
As shown in figure 1-4, haematopoietic stem cells undergo differentiation into 
multipotent, and a series of increasingly lineage-restricted, progenitors and 
ultimately terminally differentiated mature cells. This occurs under the 
influence of both extrinsic (growth factors, cytokines and other signalling 
effector molecules) and intrinsic (cell-intrinsic transcriptional, chromatin 
remodelling and other epigenetic regulatory mechanisms) cues that may be 
selectively activated, or de-activated, to favour a specific lineage. It has been 
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shown that HSCs express low levels of key master myeloerythroid transcription 
factors (but not lymphoid-priming factors) which were suggested to induce a 
myeloerythroid priming state in the HSCs and whose enforced expression may 
skew the lineage fate/differentiation pathway adopted (Traver and Akashi, 
2004, Laiosa et al., 2006, Miyamoto et al., 2002). In line with its proposed B, T 
and GM, but not MkE (megakaryocyte erythrocyte progenitors), potential the 
LMPP (lymphoid-primed multipotent progenitor) population has also been shown 
to co-express genes specific for lymphoid lineage (Rag1 and IL-7) as well as GM 
lineage (Mansson et al., 2007, Adolfsson et al., 2005) differentiation. Numerous 
genetic approaches that used loss-of-function, or gain-of-function, mutation 
have increased our appreciation of the unique roles played by specific 
transcription factors. It must be noted however that evidence suggests that even 
committed progenitors still retain some level of lineage plasticity as they can be 
reprogrammed into a different lineage through forced expression of another 
lineage specific transcription factor. In line with this it has been demonstrated 
that enforced C/EBPα, or GATA-1, or GATA-2, expression can reprogramme CLP 
(common lymphoid progenitors) into GM, MkE and mast cell lineage cells 
respectively (Iwasaki et al., 2006, Hsu et al., 2006, Iwasaki et al., 2003). This 
perhaps offers some insight into the molecular mechanisms that skew 
haematopoietic output during inflammatory and diseased states.  
1.10.1 Transcriptional control of lineage specification 
The influence that a transcription factor exerts on lineage fate of HSPCs depends 
on its dosage, quantity (up-regulated or down-regulated) as well as the context 
(i.e. presence and/or absence of antagonistic transcription factors) and timing 
of its production (DeKoter and Singh, 2000, Iwasaki et al., 2005a, Iwasaki et al., 
2006). The LT-HSCs have been shown to express low levels of myeloerythroid 
transcription factors such as PU.1, C/EBPα (CCAAT/enhancer-binding protein α), 
and GATA-2 (Tsai and Orkin, 1997, Miyamoto et al., 2002). These transcription 
factors have been suggested to be important for self-renewal of HSCs since post-
natal disruption of PU.1, or C/EBPα, led to rapid loss, and expansion, of HSCs 
respectively (Zhang et al., 2004a, Iwasaki et al., 2005b). A brief overview of 
some of the major transcription factors regulating aspects of haematopoietic 
stem and progenitor cell differentiation is depicted in figure 1-4 
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Figure  1-4 Haematopoietic stem and progenitor cell differentiation and lineage commitment 
pathway. 
Indicated are some of the transcription factors that prime (in blue), induce (in red) or repress (in 
black) lineage commitment at specific stages in the pathway.  Adapted from (Iwasaki and Akashi, 
2007, Nutt and Kee, 2007, Naito et al., 2011, Socolovsky, 2007, Nagasawa, 2006, Perry and 
Soreq, 2002, Friedman, 2007). 
1.10.1.1 Granulocyte and monocyte transcription factors 
Co-operativity between the transcription factors PU.1 and C/EBPα is necessary 
for inducing CMP specification from the LMPP. Traver et al. demonstrated 
C/EBPα expression in HSC (low priming levels), CMP and GMP but not CLP and 
MEP progenitors (Traver et al., 2001). Conditional deletion of C/EBPα in adult 
mice, as well as gene knockout mice (C/EBPα-/-), both led to a block of CMP to 
GMP transition thus substantiating the importance of C/EBPα for myelopoiesis 
(Zhang et al., 2004a, Heath et al., 2004). The expression of C/EBPα has been 
demonstrated to increase in downstream myeloid progenitors to preferentially 
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specify granulocytic lineage over monocytic lineage differentiation (Radomska et 
al., 1998, Cheng et al., 1996). Interestingly, recent findings suggest that the 
emergency granulopoietic response mounted against infectious and inflammatory 
conditions is under the transcriptional control of CEBP/β (Hirai et al., 2006, 
Satake et al., 2012). Clearly, a model thus emerges in which CEBP/α 
transcriptionally regulates steady state granulopoiesis, whereas CEBP/β 
regulates emergency granulopoiesis (Manz and Boettcher, 2014).  Expression of 
C/EBPε and Gfi-1 (growth factor independent 1) are necessary for terminal 
granulocyte differentiation and development of secondary granules (Yamanaka 
et al., 1997a, Yamanaka et al., 1997b, Lekstrom-Himes et al., 1999). 
PU.1 on the other hand is more broadly expressed in HSC (low priming levels), 
and shows higher levels in MPP, LMPP, granulocytic and monocytic cells. It is also 
expressed in CLP, B- and T-lymphoid progenitors but present at lower levels in 
MEP (Klemsz et al., 1990, Chen et al., 1995). Studies using PU.1 null mice have 
shown that these mice have markedly reduced CLP and GMP but increased MEP 
at the progenitor level as well as lack of B cells and monocytes at the effector 
cell level (Iwasaki et al., 2005b, Scott et al., 1994). Downstream effects of 
increasing PU.1 levels include preferential induction of monopoiesis (over 
granulopoiesis) in cooperation with the Egr-2 transcription factor as well as 
repression of GATA-1 and thus erythroid specification (Dahl et al., 2003, 
Rekhtman et al., 1999, Rekhtman et al., 2003, Stopka et al., 2005).    
In another study, conditional deletion of PU.1 in haematopoietic progenitors 
showed it to be absolutely required for dendritic cell (DC) generation, probably 
through its regulation of Flt3 expression (Carotta et al., 2010). The emergence 
of DC is unique, as it has been shown that DC can be generated from both CMP 
and CLP as shown in figure 1-4. 
1.10.1.2 Megakaryocyte and erythrocyte lineage commitment 
transcription factors  
Increased expression of GATA-2 and its subsequent interaction with Friend of 
GATA-1 (FOG-1) induce repression of PU.1 resulting in emergence of MEP 
(megakaryocyte-erythrocyte progenitors) progenitors from multipotent 
progenitors (Stachura et al., 2006). Up-regulation of GATA-1 expression leads to 
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displacement of GATA-2 from its binding to FOG-1 and differentiation of MEP to 
Burst forming unit, erythroid, (BFU-E) (Welch et al., 2004). The N-terminal 
region of GATA-1 has been shown to be necessary for binding of coactivators 
such as FOG-1 (Trainor et al., 1996, Crispino et al., 1999). The GATA-1:FOG-1 
complex is necessary for the induction of an open chromatin loop, β-globin gene 
synthesis and c-kit downregulation in downstream erythroblast differentiation 
(Welch et al., 2004, Vakoc et al., 2005). GATA-1 has also been shown to induce 
proliferation, and survival, of erythroblasts through up-regulation of the Bcl-xL 
anti-apoptotic gene (Gregory et al., 1999, Weiss et al., 1994).  
In addition, microarray studies have demonstrated a critical role for KLF1 
(Kruppel-like transcription factor 1) in repressing FLI-1 (friend leukaemia 
integration 1) and other critical megakaryocytic lineage genes in MEP and thus 
specifying an erythroid differentiation programme in MEP (Frontelo et al., 2007, 
Siatecka et al., 2007). KLF-1 has been shown to be necessary for both primitive 
and definitive erythropoiesis as well as for regulating genes required for haeme, 
and erythrocyte cytoskeletal protein biosynthesis (Drissen et al., 2004, Hodge et 
al., 2006, Nuez et al., 1995, Nilson et al., 2006). Additionally, KLF-1 has been 
demonstrated to be necessary for γ-(foetal) to β-(adult) haemoglobin switching 
during erythropoietic ontogeny (Donze et al., 1995, Wijgerde et al., 1996). 
Sustained GATA-2 and FOG-1 expression in MEP together with up-regulation of 
FLI-1 (Friend leukaemia integration 1) has been shown to induce megakaryocytic 
lineage fate choice. Gain-of-function and loss-of-function studies have 
demonstrated that KLF-1 and FLI-1 act as mutually antagonistic fate 
determinants for MEP precursors (Bouilloux et al., 2008, Klimchenko et al., 2009, 
Tallack and Perkins, 2009, Starck et al., 2010). FLI-1 is required for the 
expression of critical megakaryocyte genes such as glycoprotein (Gp) 1ba, Gp9, 
Mpl (thrombopoietin receptor) and platelet factor 4 (Wang et al., 2002, Pang et 
al., 2006). It has been shown that GATA-1 is required for downstream 
megakaryoblast terminal differentiation to platelets as GATA-1 null mice, and 
humans with GATA-1 point mutations, have thrombocytopenia and defective 
platelets (Shivdasani et al., 1997, Nichols et al., 2000, Freson et al., 2001). 
In addition, the transcription factor nuclear factor erythroid 2 (NF-E2) has been 
implicated as being necessary for inducing pro-platelet formation and platelet 
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release during megakaryoblast terminal differentiation (Shivdasani et al., 1995, 
Lecine et al., 1998).  
1.10.1.3 Lymphoid transcription factors 
Transcription factors mediating MPP to LMPP transition have yet to be defined. 
However, the emergence of CLP from LMPP has been demonstrated to coincide 
with increased IL7rα expression on the LMPP population (Kang and Der, 2004). 
Evidence from published data suggest that expression of the E2A transcription 
factor and induction of IL7r-STAT5 signalling results in the induction of EBF1 
(early B-cell factor 1) expression in CLP and thus skews its differentiation 
towards the B-lineage precursor (Roessler et al., 2007, Dias et al., 2005, Kikuchi 
et al., 2005, Seet et al., 2004). EBF1 then induces expression of the B-lineage 
commitment factor, Paired box 5 protein (Pax5), leading to the differentiation 
of Pro-pre-B cells to the Pre-B cells (Roessler et al., 2007). Both Pax5 and EBF1 
were shown to establish positive feedback regulatory loops that amplify their 
combined effect to sustain B cell differentiation. Thus, both EBF1, and E2A, act 
synergistically to induce a B-lineage specification programme in CLP, whereas 
Pax5 acts as the B-lineage commitment factor (see figure 1-4). Pax5 is stably 
expressed from the pro-B cell stage until terminal differentiation and is finally 
down-regulated in plasma cells (Fuxa and Busslinger, 2007). Pax5 has been 
demonstrated, through global transcriptional profiling approaches, to promote 
B-lineage commitment by upregulating B-cell differentiation genes such as 
Aiolos, inhibitor of DNA binding 3 (Id3), IRF4, IRF8, CD19 and CD79a, while 
repressing non-B cell promoting genes such as MCSF-R and Notch1 (Delogu et al., 
2006, Cobaleda et al., 2007).  
Whereas the development of all B lymphoid cells occurs mainly in the bone 
marrow, T lymphocyte development occurs in the thymus. Among the most 
prominent transcription factors necessary for the emergence of early T-cell 
progenitors (ETP) from the LMPP are Notch1 and T cell factor 1 (TCF-1). 
Inhibition of Notch signalling, or TCF-1, has been demonstrated to result in loss 
of ETP with no apparent effect on the LMPP population (Sambandam et al., 
2005, Weber et al., 2011). The TCF-1 was demonstrated to be a downstream 
target of Notch signalling. Other transcription factors such as GATA-binding 
protein 3 (GATA-3), E2A, and RUNT-related transcription factor (Runx) have all 
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been demonstrated to be necessary at various stages in T-lymphoid progenitor 
specification as shown in figure 1-4 (Hosoya et al., 2009, Dias et al., 2008, 
Talebian et al., 2007, Bain et al., 1997). However, it has been shown that cells 
at the early DN2 (Double Negative 2, as they express neither CD4 nor CD8 
antigen) stage still retain DC, NK and macrophage potential with T-lineage 
commitment occurring in the late DN2 stage under the influence of the B-cell 
leukaemia 11b (Bcl11b) transcription factor (Masuda et al., 2007, Ikawa et al., 
2010, Li et al., 2010). It has been proposed that Bcl11b induces T-lineage 
commitment at the DN2 to DN3 transition by repressing the essential myeloid 
lineage transcription factor PU.1. 
At the DN3 stage, these αβT-cell precursors undergo β-selection under the 
control of T cell receptor β gene (Tcrb) as well as VDJ (Variable, Diverse and 
Joining) rearrangement to express functional TCRβ chain. Several gene 
knockout, or conditional deletion, studies have demonstrated the essential roles 
played by transcription factors such as E2A, HEB (basic helix-loop helix protein 
related to E2A), Notch1, Myb (myeloblastosis viral oncogene homolog), Runx1 
and GATA-3 in TCRβ chain rearrangement (Wojciechowski et al., 2007, Wolfer et 
al., 2002, Lieu et al., 2004, Pai et al., 2003, Egawa et al., 2007). DN3 
thymocytes that have successfully undergone β-selection develops into double 
positive (DP) cells co-expressing CD4 and CD8 receptors. Due to differential 
affinity of αβTCR of DP cells to MHCI and MHCII self-antigen, DP thymocytes 
undergo positive selection to become one of two mature single positive subsets; 
MHCII-selected CD4+CD8- helper lineage or MHCI-selected CD4-CD8+ cytotoxic 
lineage (Germain, 2002). 
1.11 Microenvironment mediated signalling regulating 
haematopoiesis.  
1.11.1 Notch 
Notch is a single transmembrane receptor that depends on intercellular contact 
for activation. Mammalian cells that are responsive to Notch ligands (Jagged 1-2, 
and Delta 1, 3, 4) usually express one or more Notch receptors (Notch 1-4). The 
Notch receptors 1, -2 and -3 are expressed in haematopoietic cells 
(haematopoietic progenitors, erythroid precursors and monocytes), whereas 
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Notch receptor 4 is expressed in vascular endothelial cells; the Notch ligands are 
however expressed by antigen presenting cells, bone marrow stromal cells and 
thymic epithelial cells (Ohishi et al., 2003, Ohishi et al., 2002, Milner et al., 
1994, Felli et al., 1999). Notch ligands are generally internalized and processed 
in endosomes through the activity of E3-ubiquitin ligases Mindbomb and 
Neuralised before presentation on plasma membrane for efficient receptor 
activation (Le Borgne et al., 2005). This ubiquitin ligase activity has been found 
to be a fundamental regulatory step in Notch activation as Mindbomb deficiency 
has been demonstrated to result in defective Notch activation (Itoh et al., 2003, 
Koo et al., 2005). Notch ligand-Notch receptor interaction leads to ADAM (A 
Disintegrin And Metalloproteinase) mediated cleavage of the intracellular Notch 
domain from the transmembrane subunit that translocates to the nucleus and 
interact with co-activators (e.g. Mastermind) to induce target gene expression 
like HES (Hairy/Enhancer of Split) family of transcription factors. 
A large body of evidence from both mutant mouse and Zebrafish models suggests 
that Notch signalling is dispensable for the emergence of primitive 
haematopoiesis during embryonic development (Bertrand et al., 2010b, Burns et 
al., 2005, Robert-Moreno et al., 2005, Robert-Moreno et al., 2007). However, 
there is growing evidence that Notch1 signalling is required for the emergence of 
definitive haematopoiesis from the AGM. This is not surprising considering that 
Notch1 has unequivocally been shown to be required for establishment of an 
arterial programme in the AGM (Koo et al., 2005, Duarte et al., 2004, Domenga 
et al., 2004). Interestingly, the Notch signalling pathway has been shown not to 
be necessary for homeostatic HSC maintenance in adults. Conditional deletion 
experiments have established a critical role for Notch1 in the generation of T-
cell progenitors that seed the thymus and their subsequent differentiation 
(Mancini et al., 2005, Kim et al., 2008, Radtke et al., 1999). 
Clinically, Notch pathway dysfunction has been implicated in about 50% of 
human T-cell acute lymphoblastic leukaemia (T-ALL) (Weng et al., 2004). 
1.11.2 Wingless (Wnt) signalling pathway 
The Wnt signalling pathway has been categorized into three main pathways: 
canonical Wnt pathway, planar cell polarity pathway and Wnt-Ca2+ (non-
Chapter 1: General introduction  56 
 
canonical Wnt) pathway (Staal et al., 2008). Most of the experiments assessing 
the role of Wnt signalling on haematopoiesis have targeted the canonical Wnt 
pathway which is mediated through β-catenin and T-cell factor 
(Tcf)/Lymphocyte-enhancer binding factor (Lef) transcription factors. There are 
about 19 Wnt proteins that signal through Frizzled (Fz) proteins that serve as 
receptors. Fizzled proteins may function in complex with low-density lipoprotein 
receptor-related protein (LRP). In the absence of Wnt ligand binding to Fz, β-
catenin is phosphorylated at multiple sites by glycogen synthase kinase (GSK)3β 
through its sequestration to the destruction complex composed of axin, 
adenomatous polyposis coli (APC), casein kinase 1 (CK1) and GSK3β. This 
phosphorylation process targets β-catenin for proteasomal degradation through 
the β-Trcp (β-transducin repeat containing protein) ubiquitin protein. However, 
binding of Wnt ligands to Fz/LRP5 complex leads to disassembly of the 
destruction complex, stabilization and accumulation of β-catenin and its 
subsequent translocation into the nucleus to stimulate transcriptional activation 
of Tcf/Lef family of transcription factors (Staal et al., 2002, Li et al., 2007). 
Another level of regulation of the canonical Wnt signalling pathway is the 
existence of naturally occurring soluble decoy receptors such as secreted 
frizzled-related protein (sFRP), Wnt inhibitory factor-1 (WIF-1) and Dickkopf-
related proteins (DKK) that bind and block the LRP5/6 co-receptor (Mao et al., 
2001, Bafico et al., 2001, Hsieh et al., 1999, Bafico et al., 1999). 
There is an ongoing debate on the exact role of the Wnt signalling pathway in 
haematopoiesis as previous studies have given conflicting results. Several in 
vitro studies in both mice and humans have indicated that exposure of 
haematopoietic progenitor cells to Wnt ligands lead to expansion and increased 
colony-forming abilities several fold greater than those of non-treated controls 
(Van Den Berg et al., 1998, Austin et al., 1997). Reports using In vivo models 
have also implicated the canonical Wnt signalling as being necessary for HSC 
function. For example, Fleming et al. used transgenic mice expressing the Wnt 
inhibitor DKK1 in osteoblasts to demonstrate that inhibition of Wnt function in 
the niche led to irreversible loss of HSC repopulating potential as a result of 
reduced p21Cip1 expression and increased cycling (Fleming et al., 2008). Also, 
Luis et al. demonstrated the critical need of Wnt3a in both foetal and adult 
haematopoiesis through the use of Wnt3a-/- mice (Luis et al., 2009). They 
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showed, through in vitro cultures and transplantation assays, that Wnt3a was 
required for HSC fate decisions as Wnt3a-/- mice had intact B-lymphoid but 
impaired myeloid progenitor differentiation potential, impaired thymocyte 
development and impaired HSC long-term repopulation ability.  
However, gain-of-function mutation studies have provided conflicting reports in 
the literature. For example, groups using the same retroviral induced expression 
of constitutively active β-catenin in HSC in transgenic mice have reported 
contrasting findings; some studies reporting an expanded HSC compartment with 
increased repopulation ability as against the finding of multilineage lymphoid 
and myeloid differentiation potential with no attending HSC expansion in other 
studies (Willert et al., 2003, Reya et al., 2003, Baba et al., 2005, Baba et al., 
2006). Others have also excluded the relevance of Wnt signalling in 
haematopoiesis and lymphopoiesis as mice with deletion of β-catenin and γ-
catenin had no demonstrable haematopoietic phenotypes (Jeannet et al., 2008, 
Koch et al., 2008). Perhaps, the exception to the ongoing debate concerning the 
role of Wnt signalling in haematopoiesis is in immature T-cell development in 
the thymus that has been consistently shown to require Notch signalling. 
1.11.3 Thrombopoietin (TPO)/myeloproliferative leukaemia virus 
oncogene (MPL) signalling pathway 
Thrombopoietin (TPO) is an acidic glycoprotein, constitutively produced mainly 
in the liver; bone marrow stromal cells, kidney and spleen are also known to 
produce locally acting TPO (Lok et al., 1994, Qian et al., 1998). It has been 
known to be primarily concerned with megakaryopoiesis by signalling through 
the Mpl receptor. In addition to the expression of Mpl in megakaryocytes, 
platelets, haemangioblasts and HSC in adults, Mpl mRNA has also been detected 
in the yolk sac, AGM and foetal liver in mouse embryos at E10.5 (Debili et al., 
1995, Forsberg et al., 2005, Methia et al., 1993). Interestingly, transplantation 
assays undertaken with E14.5 foetal liver haematopoietic progenitors that were 
enriched using phenotypic Mpl expression (AA4+Sca-1+Mpl+) demonstrated 
superior repopulation ability compared with Mpl- (AA4+Sca-1+Mpl-) counterparts 
(Petit-Cocault et al., 2007, Solar et al., 1998).  
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The main stimulus regulating circulating TPO levels is megakaryocyte and 
platelet mass in the circulation as TPO is removed from the circulation through 
its binding to Mpl receptors on platelets. Higher platelet counts are thus 
associated with lower TPO and hence reduced megakaryopoietic output, as there 
will be a correspondingly higher Mpl to absorb TPO from circulation. Although, 
TPO mRNA in liver and kidneys are unresponsive to thrombocytopenia, the TPO 
mRNA in the bone marrow stromal cells increases in response to 
thrombocytopenia suggesting that different regulatory mechanisms may be at 
play in different organs (Stoffel et al., 1996, Sungaran et al., 2000, McCarty et 
al., 1995). 
Recent elegant studies using gene knockout mice have shown that the TPO/Mpl 
signalling pathway may not be necessary for pre-natal haematopoiesis as TPO-/- 
mice were born normally (Qian et al., 2007). However, it became apparent that 
the TPO/Mpl pathway is critical in maintenance of postnatal HSC quiescence as 
these TPO-/- HSCs demonstrated significant age-related decline with concomitant 
increased cycling and reduction in cyclin-dependent kinase inhibitors p57kip2 and 
p19ink4D. Yoshihara and colleagues have also provided additional data showing 
that bone marrow osteoblasts express TPO and that quiescent long-term 
repopulating HSC expressing Mpl localize preferentially towards TPO+ osteoblasts 
(Yoshihara et al., 2007). Moreover, they showed that whereas TPO treatment 
increased the quiescent HSC fraction, neutralizing anti-Mpl antibody treatment 
mediated entry of HSC into cell cycle and release from their microniches. 
Furthermore, de Laval and colleagues have also demonstrated that TPO/Mpl 
pathway is required for the non-homologous end-joining DNA repair mechanisms 
in HSC (de Laval et al., 2013). These findings demonstrate the unique roles that 
TPO/Mpl pathway has in regulating in vivo HSC quiescence and maintenance of 
its genomic integrity. 
1.11.4 CXCL12-CXCR4 axis 
The unique contribution of the CXCL12-CXCR4 axis in regulating HSPC behaviour 
has been described in section 1.13.1. 
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1.12 Haematopoietic growth factors 
These are glycoproteins that directly, or indirectly, regulate haematopoiesis by 
acting in concert with the niche components to control haematopoietic stem and 
progenitor cell survival, proliferation and differentiation as well as 
haematopoietic progenitor lineage commitment and function of terminally 
differentiated cells. The haematopoietic progenitors, and terminal 
differentiated cells, have been shown to express receptors for one or more of 
these growth factors. 
1.12.1 Granulocyte colony stimulating factor (G-CSF) 
Murine G-CSF was characterised by Nicola et al as a 24Kd or 25Kd hydrophilic 
glycoprotein with a neuraminic acid moiety (Nicola et al., 1983). Later, human 
G-CSF was purified from the human bladder carcinoma cell line 5637 and 
squamous carcinoma cell line (CHU-2) with a molecular weight of 18kDa or 
19kDa. Cloning studies identified cDNAs coding for a human G-CSF protein of 174 
and 177 amino acid residues (Welte et al., 1985, Nomura et al., 1986, Nagata et 
al., 1986, Souza et al., 1986). However, these studies identified the 174 amino 
acid version as having three amino acids deleted at the N-terminus, O-
glycosylated on Thr133, as well as being the most active and abundant form of 
the protein.  
G-CSF is produced by endothelial cells, fibroblasts, stromal cells, mesothelial 
cells, monocytes and macrophages, to mainly regulate neutrophilic 
granulopoiesis (Demetri et al., 1989, Zsebo et al., 1988). Inflammatory 
mediators such as TNF-α, IL-1, IL-6, LPS, 12-O-tetradecanoylphorbol 13-acetate 
(TPA) and IFN-γ may also stimulate G-CSF production from activated immune 
cells like monocytes during infection or inflammation (Zsebo et al., 1988, 
Koeffler et al., 1987, Herrmann et al., 1986, Vellenga et al., 1988, Ernst et al., 
1989). G-CSF exerts its biologic effect mostly through its cognate receptor called 
G-CSFR which is expressed on neutrophils and their precursors (Demetri and 
Griffin, 1991). Expression of G-CSFR on haematopoietic progenitors such as MPP, 
CMP and GMP (McKinstry et al., 1997, Onai et al., 2006, Mansson et al., 2009) 
has also been demonstrated. G-CSFR expression has also been demonstrated on 
human placenta, vascular endothelial cells and activated T-lymphocytes; 
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although the functional relevance of G-CSFRs on these cells is not clear 
(Uzumaki et al., 1989, Bussolino et al., 1989). 
The use of G-CSF as haematopoietic stem and progenitor cell mobilization agent 
is discussed in section 1.13.2.1. Moreover, G-CSF has also been employed with 
chemotherapy to treat and prevent neutropenia (Heuser et al., 2007, Roberts, 
2005, Ozer et al., 2000). 
1.12.2 Granulocyte-macrophage colony stimulating factor (GM-
CSF) 
GM-CSF is generally produced, upon stimulation, by a number of cells including 
mast cells, macrophages, endothelial cells, fibroblasts as well as activated T- 
and B-cells (Cousins et al., 1994, Nimer and Uchida, 1995). Depending on the 
degree of its N- and O-glycosylation, the molecular weight may vary between 18-
30kD. Unlike erythropoietin (EPO) however, the degree of glycosylation is not 
critical for biological activity. 
The effect of GM-CSF is dependent on its concentration; at lower doses, it 
stimulates macrophage progenitors but also stimulates multipotent progenitors 
as well as progenitors of erythrocytes, granulocytes, eosinophils and 
megakaryocytes at higher concentrations (Burgess and Metcalf, 1980). Despite 
the effect of GM-CSF on haematopoietic progenitors, GM-CSF deficient mice 
develop normally with apparently normal homeostatic haematopoiesis. However, 
these mice demonstrated the critical need for GM-CSF in pulmonary resistance 
to infection and inflammation by bacteria and fungi (Stanley et al., 1994, Deepe 
et al., 1999). In addition to its role in inducing differentiation of specific 
haematopoietic progenitors, GM-CSF has been shown to exert immune 
stimulating effects on antigen presenting cells (APCs) by inducing maturation of 
APCs, as well as skewing the Th1/Th2 cytokine balance (Wada et al., 1997, 
Gonzalez-Juarrero et al., 2005). 
GM-CSF exerts its effect by signalling through the cell surface GM-CSF receptor, 
which is composed of α (GM-CSFRα) and βc (GM-CSFRβc) subunits that are 
expressed on haematopoietic cells (monocytes, macrophages, granulocytes, 
lymphocytes and haematopoietic progenitors) as well as non-haematopoietic 
Chapter 1: General introduction  61 
 
cells such as endothelial and alveolar epithelial cells (Griffin et al., 1990, 
Miyajima, 1992). Interestingly, studies in mice homozygous for the GM-CSF gene 
revealed that these mice had normal haematopoiesis, but had features 
characteristic of the human disease called alveolar proteinosis (Stanley et al., 
1994). A later study supported those findings by showing that autoantibodies 
directed against human GM-CSF was the primary cause of human pulmonary 
alveolar proteinosis (Uchida et al., 2007).   
Clinically, GM-CSF has been used for the treatment of neutropenia subsequent to 
bone marrow transplantation, or chemotherapy (Gerhartz et al., 1993, Lieschke 
et al., 1989).  
1.12.3 SCF/KITL 
Stem cell factor is widely expressed constitutively by many cell types in the 
body including endothelial cells, stromal cells, keratinocytes and fibroblasts 
(Heinrich et al., 1993, Longley et al., 1993). In both humans and mice, SCF is 
produced in two biologically active forms; soluble and transmembrane forms, as 
a result of alternative splicing that may, or may not, include the proteolytic 
cleavage site at exon 6 (Anderson et al., 1991, Anderson et al., 1990, Du et al., 
1993, Rolink et al., 1991). Although agents that activate protein kinase C, or 
increase the concentration of cytosolic calcium, have been shown to cleave cell 
surface SCF to produce the soluble form (Huang et al., 1992), evidence suggests 
that the two isoforms of SCF play non-redundant roles as the soluble form is 
unable to completely compensate for deficiency in the transmembrane isoform 
(Russell, 1979). Unlike G-CSF and GM-CSF where inflammatory stimuli like TNF 
profoundly increases their production by bone marrow stromal cells, only modest 
increases in SCF production are detected with these inflammatory stimuli in the 
same cells (Broudy et al., 1987).  
SCF functions by binding, and signalling, through a 145kDa glycoprotein receptor 
called c-kit/CD117 which is a member of the type III receptor tyrosine kinase 
family (Yarden et al., 1987, Qiu et al., 1988, Besmer et al., 1986). The receptor 
is composed of an N-terminal extracellular domain with five Ig-like motifs, a 
single transmembrane domain and a cytoplasmic C-terminal domain with 
tyrosine kinase activity that has both an ATP-binding region and a 
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phosphotransferase region. Evidence suggests that whereas the fourth Ig-like 
motif of the N-terminal domain is required for receptor homodimerisation upon 
SCF binding, the first three Ig-like motifs are required for ligand binding 
(Blechman et al., 1993, Lev et al., 1993, Blechman et al., 1995). Two naturally 
occurring isoforms exist in normal tissues due to alternative splicing at codon 
510 within the extracellular domain, leading to the presence (kit A), or absence 
(kit), of the four amino acids Gly-Asn-Asn-Lys (Reith et al., 1991). The ratio of 
the two isoforms varies between tissues as well as in different physiological or 
pathological states (Piao et al., 1994).  
The c-kit receptor is expressed in several cells and tissues including 
spermatogonia, endothelial cells, cerebellum, as well as being broadly expressed 
within the haematopoietic hierarchy (Yoshinaga et al., 1991, Smith et al., 1994, 
Broudy et al., 1994, Manova et al., 1992). SCF has been shown to have 
pleiotropic effects such as supporting spermatogenesis, as well as melanocyte 
and mast cell development (Vincent et al., 1998, Broudy, 1997). It has also been 
shown that by signalling through its cognate receptor, c-kit, SCF regulates self-
renewal of both foetal and adult HSCs (Sharma et al., 2007, Thoren et al., 2008, 
Waskow et al., 2009). In addition, it induces cell cycle entry and survival of 
haematopoietic progenitor cells possibly through anti-apoptotic effects (Li and 
Johnson, 1994, Carson et al., 1994). Through direct interaction of their cognate 
receptors, SCF has been shown to synergise with EPO to regulate erythroid 
development (Wu et al., 1997). SCF also synergises with other growth factors 
like G-CSF, GM-CSF, thrombopoietin, IL-3, and IL-6 to support the formation of 
colonies from CFU-E, CFU-GEMM, CFU-GM and CFU-Meg in in vitro cultures 
(Bernstein et al., 1991, Nocka et al., 1990, Hendrie et al., 1991, McNiece et al., 
1991, Broudy et al., 1995, Briddell et al., 1991). 
1.12.4 Erythropoietin (EPO) 
EPO is a 30.4kDa glycoprotein that regulates erythropoiesis and tissue protection 
during injury in mammals (Bahlmann et al., 2004, Brines et al., 2000, Junk et 
al., 2002). The in vivo biological activity of EPO is governed by its four 
glycosylation sites; the higher the glycosylation, the longer the half-life and 
hence biological activity (Takeuchi et al., 1990, Lukowsky and Painter, 1972). 
EPO induces erythropoiesis predominantly by its anti-apoptotic effect on late 
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erythroid precursors; Burst forming unit-erythroid (BFU-E), colony forming unit-
erythroid (CFU-E) and erythroblast to stimulate survival, maturation and red 
blood cell production. During foetal development, the liver is the main site for 
EPO production. However, in adulthood, EPO is produced by the liver (Koury et 
al., 1991, Zanjani et al., 1977) and by the peritubular cells of the renal cortex 
(Jacobson et al., 1957, Fisher and Birdwell, 1961, Koury et al., 1988) in response 
to hypoxia. Other organs with detectable EPO mRNA include spleen, lung, and 
testis; however, their ability to produce functional EPO protein is debatable 
since they are not able to compensate for EPO production in cases of renal 
dysfunction. EPO mRNA is also detectable in the brain where it has been 
demonstrated to exert a neuroprotective action in inflammatory- and hypoxia-
induced injury (Sakanaka et al., 1998, Brines et al., 2000). 
Several other growth factors including G-CSF, GM-CSF, SCF, IL-1, IL-3, IL-6, IL-
11, and insulin growth factor-1 (IGF-1) function synergistically with EPO in 
erythropoiesis by acting on upstream haematopoietic progenitor cells to induce 
lineage commitment to the erythroid lineage. EPO exerts its effect by signalling 
through its cognate receptor, EPOR, which is expressed on erythroid precursors. 
EPOR expression begins on BFU-E and increases as these progenitors 
differentiate towards CFU-E. The receptor expression subsequently decreases as 
these progenitors undergo further differentiation leading to the lack of EPOR on 
reticulocytes and erythrocytes (Sawada et al., 1990, Wickrema et al., 1992). 
Figure 5 shows some of the cytokines that act during the differentiation of HSC 
to erythrocytes and the specific precursor stages at which EPO is crucially 
required. 
EPO binding to EPOR induces conformational changes that result in dimerization 
of two EPORs and subsequently, phosphorylation of its cytoplasmic Janus Kinase-
2 (JAK2) (Remy et al., 1999, Witthuhn et al., 1993). In addition, the tyrosine 
kinase residues on the intracellular domains of the EPOR also becomes 
phosphorylated and serve as docking sites for SRC homology 2 containing 
domains (Tauchi et al., 1995, Barber et al., 2001), thus leading to the activation 
of several signalling pathways including PI-3K/Akt, STAT5, protein kinase C (PKC) 
and MAP kinase (Constantinescu et al., 2001, Klingmuller, 1997). However, 
others have shown the Jak2/STAT5 pathway to be the principal signalling 
transducer for EPOR (Klingmuller et al., 1996, Socolovsky et al., 1999). In fact, 
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the enhanced survival of erythroid progenitors was shown to be due to 
Jak2/STAT5 signalling in which activated STAT5 translocated into the nucleus to 
induce the expression of the anti-apoptotic gene BclXL (Socolovsky et al., 1999, 
Socolovsky et al., 2001). Inhibition of the effects of EPO may occur through the 
suppressor of cytokine signaling-3 (SOCS3) that acts as a negative feedback to 
inhibit EPO action, or by de-phosphorylation of JAK-2 by haematopoietic cell 
phosphatase, to terminate the action of EPO (Sasaki et al., 2000, Yi et al., 
1995). 
At the transcriptional level, the production of EPO is under the regulation of 
hypoxia inducible factor 2α (HIF-2α) (Warnecke et al., 2004). During normoxic 
conditions, the EPO promoter is suppressed by GATA-2; however, in hypoxic 
conditions, GATA-2 levels decrease with an increase in GATA-1 activity (Tsuchiya 
et al., 1997, Imagawa et al., 2003). At the same time, there is stabilization of 
HIF-2α, which interacts with the hypoxia response element in the promoter 
region of EPO to induce EPO synthesis. Generally, the level of EPO is low in 
steady state, thus ensuring that most erythroid progenitors undergo apoptosis 
with only a few developing into the terminal erythrocytic stage. However, in 
conditions of hypoxia, or anaemia, EPO production increases significantly 
resulting in survival of erythroid committed progenitors and ultimately an 
increase in erythrocyte production (Lacombe et al., 1988, Koury et al., 1989).  
 
Figure  1-5 Murine erythrocyte differentiation pathway from haematopoietic stem cell (HSC) 
showing the stages responsive to erythropoietin (EPO).  
Shown are some of the antigens expressed at different stages of the differentiation pathway and 
some common cytokines that play critical roles at various stages. Gray indicates low expression, 
and dark indicate high expression of antigens. MPP, multipotent progenitors; CMP, common 
myeloid progenitors; MEP, Megakaryocyte-erythroid progenitor; BFU-E, burst forming unit, 
erythroid; CFU-E, colony forming unit, erythroid; EPO, erythropoietin; EPOR, erythropoietin 
receptor.  Adapted from (Sawada et al., 1990, Socolovsky, 2007). 
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1.12.5 The interleukins (ILs). 
Although there are several interleukins that affect haematopoiesis either 
directly or indirectly, most of them are not clinically employed as 
haematopoietic growth factors because of their adverse effects. These include 
IL-1 which is produced in two isoforms (α and β) mostly from cells of the 
monocytes/macrophage lineage and acts on early haematopoietic progenitors. 
1.12.6 Interleukin 3 (IL-3) 
IL-3 (also called multi-lineage CSF) is a 20-26kD, pleiotropic and monomeric 
haematopoietic growth factor that stimulates HSC self-renewal as well as acting 
synergistically with other growth factors to support differentiation of 
downstream haematopoietic progenitors. The major sources of IL-3 include 
activated eosinophils, CD4+ T cells, NK cells and mast cells (Ihle et al., 1983, 
Metcalf, 1989, Pierce, 1989). Signalling by IL-3 is induced in responsive cells 
through the IL-3 receptor (IL-3R) composed of α (IL-Rα/CD123) and β (IL-3Rβ) 
subunits (Miyajima et al., 1992). IL-3R is expressed on HSPCs, haematopoietic 
effector cells, testis, placenta and brain (Morikawa et al., 1996). IL-3 binding 
induces hetero-dimerisation of the α and β subunits through disulphide bonding 
for optimal receptor activation (Orban et al., 1999). This conformational change 
in IL-3R leads to recruitment and activation of Janus Kinase 2 (JAK2) through 
association of the membrane proximal region of IL-3R and the N-terminal region 
of JAK2 and ultimately recruitment of multiple STAT (signal transducer and 
activation of transcription) proteins in haematopoietic cells (Quelle et al., 1994, 
Jaster et al., 1997). One consequence of the JAK2/STAT signalling is MAPK- and 
PI3K/AKT-induced anti-apoptotic effects (mediated through Bcl-2 and Bcl-XL) 
that confer growth and survival advantages in haematopoietic cells (Datta et al., 
1997, Kinoshita et al., 1995, Sakai and Kraft, 1997). 
In a study that used Runx1 haploinsufficient mice, it was demonstrated that IL-3 
may be required for the de novo emergence of HSC from the AGM during 
embryogenesis by acting as a survival and proliferation factor (Robin et al., 
2006).   Another study also found increased expression of CD123 (IL-3Rα) 
expression in various haematopoietic malignancies and postulated that this 
receptor expression could be used as a diagnostic criterion (Munoz et al., 2001). 
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The clinical utility of IL-3 is however limited due to its considerable side effects 
possibly as a consequence of IL-3R expression on many cell types (Eder et al., 
1997, Ottmann et al., 1990). 
1.13 Haematopoietic stem and progenitor cell circulation.  
1.13.1 CXCL12-CXCR4 axis 
CXCL12 is a homeostatic chemokine that is produced in six different isoforms 
(SDF-1α, β, γ, δ, ε and φ) due to alternative splicing of the CXCL12 gene leading 
to differences in the exon 4 (attached to the C-terminus) in the variant isoforms 
(Janowski, 2009, Ho et al., 2012, Yu et al., 2006). This affects the stability in 
blood and hence duration of biological activity as well as tissue distribution of 
CXCL12 isoforms. For example, CXCL12α is ubiquitously expressed by many 
organs but is rapidly degraded in blood, whereas CXCL12β has improved stability 
and is mainly restricted to highly vascularised organs like kidney, liver and 
spleen (Yu et al., 2006, Janowski, 2009). Due to the presence of numerous basic 
amino acids, CXCL12 proteins are positively charged thus endowing them with a 
strong attachment to glycosaminoglycans (GAGs) and increased stability (Rueda 
et al., 2008). Endothelial cells, and bone marrow stromal cells, have been shown 
to constitutively produce CXCL12 (Ponomaryov et al., 2000). The N-terminus of 
CXCL12 is important for receptor binding and signalling which explains why N-
terminal cleavage abrogates chemotactic responses. 
The cognate receptors of CXCL12 are CXCR4 and ACKR3 (CXCR7). Expression of 
functional CXCR4 supports CXCL12 chemotaxis as has been demonstrated on a 
host of stem cells (e.g. haematopoietic stem cells, primordial germ cells, 
satellite cells, neural and endothelial stem cells), haematopoietic cells and 
malignant cells (Aiuti et al., 1997, Ma et al., 1998a, Kucia et al., 2004a, Kucia et 
al., 2005, Ratajczak et al., 2003, Day et al., 2010). ACKR3, on the other hand, 
has been proposed as a decoy receptor and is expressed in organs such as the 
heart, brain, testes and placenta (Singh et al., 2012, Sun et al., 2010, Nibbs and 
Graham, 2013).  
CXCL12, and its receptor CXCR4, have been demonstrated to be fundamentally 
required during embryogenesis as targeted disruption of CXCL12 in mutant mice 
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was shown to result in embryonic lethality (Nagasawa et al., 1996, Nagasawa, 
2000). CXCL12 has also been found to be required for trafficking of several 
organ-type progenitor cells during foetal development as well as migration of 
foetal liver HSC to colonize bone marrow (Nagasawa et al., 1996, Kucia et al., 
2004a, Kucia et al., 2004b). Proper development of the heart, cerebellum, and 
the gastrointestinal tract, has all been shown to require the presence of CXCL12 
(Zou et al., 1998, Nagasawa, 2001). In the adult haematopoietic system, the 
CXCL12/CXCR4 axis has been shown to be critical for HSPC retention, quiescence 
and homing to the bone marrow (Lapidot et al., 2005). CXCR4 has been found to 
be co-receptor for T-tropic HIV infection, important for metastases of various 
cancer types as well a marker for poor prognosis in these cancers (Kucia et al., 
2005, Li et al., 2004, Libura et al., 2002, Scala et al., 2005).  
ACKR3 on the other hand appears to bind CXCL11 as a ligand in addition to 
CXCL12. There is still an ongoing debate as to whether ACKR3 signals upon ligand 
binding. In the haematopoietic system, there is still no evidence concerning the 
expression of ACKR3 on HSPC, although its expression on B-cells, neutrophils and 
monocytes has been reported (Infantino et al., 2006, Sierro et al., 2007). With 
the exception of heart defects, CXCR7 KO mice were shown to develop normally 
with no haematopoietic abnormalities (Sierro et al., 2007, Gerrits et al., 2008). 
Although further work needs to be done concerning the role of ACKR3 in HSPC 
biology, it is unlikely that ACKR3 will have profound effects on HSPC functions. 
1.13.2 Haematopoietic stem and progenitor mobilization 
Research has shown that very low numbers of haematopoietic stem and 
progenitor cells circulate in the periphery at any time point under steady state 
(Wright et al., 2001, Lapidot and Petit, 2002). In mice it has been estimated that 
~ 400 HSPCs circulate at any given moment in the peripheral blood (Goodman 
and Hodgson, 1962, Wright et al., 2001, McCredie et al., 1971, Chervenick and 
Boggs, 1971). Moreover, it has been shown that these circulating HSPCs may 
enter tissues and return to the peripheral blood via the lymphatic vasculature 
and thoracic duct (Massberg et al., 2007). Although the process of homeostatic 
HSPC egress from the bone marrow is not completely understood, evidence 
suggests that both humoral (chemokines and sphingosine 1-phosphate) and 
neural (sympathetic) inputs may play a role. Enforced release of HSPC from the 
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bone marrow, called mobilization, was first shown in the 1980s in response to 
myeloablative agents (To et al., 1984, To et al., 1989). Exercise, psychological 
anxiety, bleeding and infection models (lipopolysaccharide) have also been 
shown to mediate increased HSPC egress from the bone marrow (Barrett et al., 
1978, Cline and Golde, 1977, Kollet et al., 2006, Elsenbruch et al., 2006). Many 
other pharmacological agents that generally disrupt the factors that mediate 
HSPC-niche attachments have subsequently been identified as HSPC mobilisers 
and are discussed below. Mobilised peripheral blood haematopoietic stem cells 
(PBHSC) have now become the preferred source of stem cells for 
transplantation. For rapid, and optimal, reconstitution in autologous 
transplantation, a CD34+ cell count of ≥5x106 cells/kg is generally required, 
although a minimum of 2x106 cells/kg body weight may still be used in poor 
mobilisers (Reiffers et al., 1994, Bensinger et al., 1995, Weaver et al., 1995).  
1.13.2.1  Cytokines 
Among the cytokines employed for HSPC mobilization are G-CSF, GM-CSF, SCF 
and IL-1. However, G-CSF remains the prototypical agent employed for HSPC 
mobilization in the clinic. G-CSF is generally administered at a dose of 5-10µgKg-
1day-1 S.C. over 4-6 consecutive days. Interestingly, it has been demonstrated 
that G-CSF preferentially mobilizes quiescent haematopoietic stem cells into the 
circulation (Roberts and Metcalf, 1995). Several mechanisms have been proposed 
to contribute to the ability of G-CSF to mobilize HSPC to the periphery. 
Accumulating evidence shows that the haematopoietic stem cell mobilization 
effect of G-CSF is indirect, as HSCs do not express the G-CSF receptor. Some 
have postulated that G-CSF induces activation of neutrophils that release matrix 
metalloproteinase-9, cathepsin G and elastases, which cause proteolytic 
cleavage of niche retention factors like CXCL12. In addition, other reports found 
that G-CSF-induced haematopoietic progenitor cell mobilization occurred in 
response to neutrophil elastase-mediated degradation of bone marrow CXCL12 
and upregulation of CXCR4 expression on immature human CD34+ and CD38-/low 
cells (Petit et al., 2002). Others have used genetic approaches, involving G-
CSFR-deficient mice, to underscore the critical need for functional neutrophils in 
orchestrating the G-CSF-mediated HSPC release (Liu et al., 1997, Liu et al., 
2000). Compared to bone marrow derived HSPC, G-CSF-mobilised HSPC have 
enhanced engraftment potential and this has been attributed partly to their 
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lower expression of the CXCL12-degrading enzyme, CD26, and their consequent 
enhanced migration towards CXCL12 (Bonig et al., 2007). Others have implicated 
down-regulation of CXCL12 at the mRNA level in both osteoblast and bone 
marrow stromal cells as being important in HSPC-induced mobilization by G-CSF 
(Semerad et al., 2005). 
Although G-CSF mobilized haematopoietic progenitors offer numerous 
advantages over bone marrow derived counterparts, it has been observed that 
25% of patients with lymphoma or multiple myeloma, as well as those with 
Fanconi anaemia, or previous chemotherapy, fail to mobilize with G-CSF 
(Moskowitz et al., 1998, Bensinger et al., 1994, Croop et al., 2001). In addition, 
recent findings suggest that the 10-20% (Anderlini et al., 1997, Holm, 1998) of 
healthy volunteers who fail to mobilize with G-CSF may be the result of 
polymorphism in the G-CSF receptor (Bogunia-Kubik et al., 2012). For these 
reasons, G-CSF is generally used mostly in combination with chemotherapy in 
these poor mobilizers; a protocol that increases the subsequent dose of G-CSF 
required with its consequent toxicity as well as increased incidence of post-
treatment malignancies (Dreger et al., 1995, Anderlini et al., 1996, Pusic et al., 
2008). Among the side effects observed with G-CSF administration are sickle cell 
crises in individuals with Haemoglobin S or C genotype, bone pain (probably 
resulting from granulocytic marrow hyperplasia), splenic rupture, myocardial 
infarction, anaphylactoid reaction, intracranial haemorrhage and flare-up in 
rheumatoid arthritis (Bensinger et al., 1996, Adler et al., 2001, Fortanier et al., 
2002, Nuamah et al., 2006).  
1.13.2.2  Chemokines ligands/agonists 
In contrast to cytokines like G-CSF that require multiple dosing over several days 
to mobilize HPCs to optimal levels, chemokine-based mobilizing agents rapidly 
mobilize haematopoietic progenitors within minutes to hours per single dose 
(Pelus and Fukuda, 2008). In addition, when compared to G-CSF-mobilised HSPC, 
there are indications of a superior engraftment of chemokine-mobilised HSPC, 
judged by contribution to donor chimerism, in both primary and secondary 
transplantation assays (King et al., 2001, Pelus and Fukuda, 2006, Fukuda et al., 
2007). Both CC- and CXC-chemokines have been shown to be haematopoietic 
stem cell mobilizing agents as discussed below. 
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1.13.2.2.1 CXC-chemokine mobilization agents  
Among the CXC-chemokines employed for haematopoietic progenitor cell 
mobilization are the CXCR2 ligands [CXCL2 (GROβ), or CXCL8∆4 (GROβ_4)], CXCL8, 
as well as CXCL12 peptide analogs (CTCE-0021 and CTCE-0214).  
1.13.2.2.2 Growth-regulated (GRO) proteins (GROβ/CXCL2 and 
GROβ∆4/CXCL2∆4) 
The GRO proteins (CXCL2 or CXCL2_4) have been the most studied agents and are 
employed at 2.5mgKg-1 S.C. (Pelus and Fukuda, 2006, Fukuda et al., 2007). This 
induces rapid mobilization that peaks at 15 minutes post injection and returns to 
baseline in 60 minutes. In trying to unravel the mechanistic details in mouse 
models, it has been suggested that the rapid mobilization occurs as a result of 
indirect effects on bone marrow neutrophils as CXCR2 expression was absent on 
HSPCs (Pruijt et al., 2002, Pelus et al., 2004). However, in studies that profiled 
the chemokine receptor expression on lineage depleted haematopoietic 
progenitors during ontogeny in humans, CXCR2 (together with CXCR1, CXCR4, 
and CXCR5) was detected on bone marrow, mobilized blood, cord blood and 
foetal blood by flow cytometry (Rosu-Myles et al., 2000). That study further 
revealed that whereas the most primitive adult progenitors (defined in the study 
as Lin-CD34+CD38-) did not express CXCR2, the most primitive cord blood cell 
expressed higher levels of CXCR2. Further work thus needs to be done to 
reconcile the discrepancy between the human and mouse data.  
The experience with CXCR2 ligands has shown that a single dose of CXCL2 or 
CXCL2∆4 mobilizes HSPC to similar levels as the multiple daily dosing of G-CSF 
and indeed, is more predictable in its mobilization action, causes less apoptosis 
and a more primitive phenotype of the mobilised cells compared to G-CSF. 
Although either agent could be used as stand-alone mobiliser, a strong synergy 
has been demonstrated between G-CSF (50µgKg-1 twice daily S.C. for 4 days) and 
CXCL2_4 (2.5mgKg
-1 S.C. given on the last dose of G-CSF), as combined therapy 
showed a 7-10-fold increase in long-term haematopoietic progenitor colony-
forming potential compared to G-CSF given alone (Pelus et al., 2002). 
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1.13.2.2.3 CXCL8 (IL-8) 
Pro-inflammatory cytokines such as TNFα, IL-1, IL-3 and GM-CSF induce the 
production of CXCL8 from such cells as monocytes, neutrophils, keratinocytes, 
endothelial cells and mast cells (Strieter et al., 1989, Matsushima and 
Oppenheim, 1989). CXCL8 signals through both CXCR1 and CXCR2 which are 
highly expressed on neutrophils (Holmes et al., 1991, Murphy and Tiffany, 1991). 
Not surprisingly, CXCL8 induces chemotaxis of neutrophils, release of 
metalloproteinases (e.g. MMP-9), shedding of L-selectin as well as up-regulation 
of leukocyte function antigen-1 expression (LFA-1). Single injection of CXCL8 has 
been shown to mediate a rapid haematopoietic progenitor cell mobilization in 
both mice (30µg I.P. per mouse) and rhesus monkeys (10-100µgKg-1 I.V.) 
(Laterveer et al., 1995, Laterveer et al., 1996). The number of mobilized 
haematopoietic progenitors peaked in 15-30 minutes and offered radioprotection 
as well as long-term lymphomyeloid reconstitution in lethally ablated hosts. 
Mechanistically, evidence has been provided demonstrating that the CXCL8-
induced haematopoietic progenitor cell mobilization is critically dependent on 
neutrophils as antibody-mediated depletion of neutrophils inhibited HPC 
mobilization (Hestdal et al., 1991). Other evidence points to roles of LFA-1 and 
metalloproteinase-9, probably from activated neutrophils, as being critical as 
blocking of either substantially ablates the mobilization observed in mice and 
rhesus monkeys (Pruijt et al., 1999, Czuprynski et al., 1994). 
1.13.2.2.4 CXCL12 (SDF-1α) peptide 
In studies that investigated the potential of exogenously administered CXCL12 to 
mobilize HSPC, an Adenoviral delivery system (AdCXCL12) was adopted to sustain 
adequate plasma levels of CXCL12 since the native CXCL12 was rapidly degraded 
in blood (Hattori et al., 2001). In that report, I.V. AdCXCL12, but not 
recombinant CXCL12, significantly mobilized leukocytes, platelets and 
haematopoietic progenitor cells to the circulation in severe combined 
immunodeficient mice. The mobilized haematopoietic progenitor cells 
demonstrated repopulating potential in lethally irradiated recipients, indicating 
the presence of long-term stem cells in this population. Others using the same 
AdCXCL12 model have also shown that endothelial progenitor cells are mobilized 
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in addition to the HSPC as endothelial cells express CXCR4 (Moore et al., 2001, 
Molino et al., 2000). 
Other studies that investigated the CXCL12-CXCR4 axis in HSPC mobilization used 
the CXCL12 peptide analogues, CTCE-0021 and CTCE-0214 (Pelus et al., 2005, 
Zhong et al., 2004). CTCE-0021 was administered intravenously at 25mg/Kg in a 
single dose and demonstrated a dose-dependent effect on haematopoietic 
progenitor mobilization within 60 minutes post injection. When given in 
combined therapy with G-CSF (50µg/kg/day b.i.d x 4 days S.C.), CTCE-0021 
(given at 25mg/kg 16 hours after last G-CSF dose) exhibited synergistic HSPC 
mobilization activity. Interestingly, it was observed that although multi-dosing 
sustained an increased peripheral blood polymorphonuclear count, HPC 
mobilization could not be re-stimulated after the first dose. Mechanistically, it 
was demonstrated that CTCE-0021-induced down-regulation of CXCR4 expression 
on haematopoietic progenitors with concomitant alteration in the CXCL12 
gradient but had no effect on proteases such as MMP-9, neutrophil elastase and 
cathepsin G.  
The other CXCL12 analog, CTCE-0214, has been employed at a similar dose with 
similar HSPC mobilization activity as CTCE-0021 (Zhong et al., 2004).  
1.13.2.2.5 CXCR4 agonist (ATI-2341)  
ATI-2341, is a pepducin derived from the first intracellular loop of human CXCR4 
and has been shown to have CXCR4 agonist properties (Tchernychev et al., 
2010). In both mouse and non-human primate models, ATI-2341 was given 
intravenously at a dose of 0.2-0.66µmol/Kg and demonstrated time-dependent 
HSPC mobilisation potential comparable to the CXCR4 antagonist, AMD3100. 
Interestingly, unlike AMD3100 that mobilises lymphomyeloid progenitors, ATF-
2341 was shown to have a unique ability to mobilize granulocytes and myeloid-
biased HSPCs, but not lymphocytes. This may be particularly important as a 
means to prevent Graft-versus-host reactions. A recent study has proposed that 
the functional selectivity of ATI-2341, compared to CXCL12, may be due to its 
preferential activation of Gαi (but not β-arrestins) leading to biased CXCR4 
agonist effects (Quoyer et al., 2013).  
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1.13.2.2.6 Chemokine receptor antagonist- AMD3100 
The bicyclam molecule 1,1’- [1,4-phenylene-bis(methylene)]-bis-1,4,8,11-
tetraazacyclotetradecane also known as AMD3100 is a selective, competitive 
CXCL12 receptor (CXCR4) inhibitor which was initially investigated for its ability 
to block T-tropic HIV infection (Schols et al., 1997a, Schols et al., 1997b, 
Donzella et al., 1998, Hendrix et al., 2004). Noticeably, significant leucocytosis, 
and increased CD34+ cell numbers, were observed in peripheral blood harvest. 
These observations, coupled with the importance of the CXCL12/CXCR4 axis in 
HSPC homing, prompted investigation geared towards HSPC mobilization. 
AMD3100 is rapidly absorbed after subcutaneous administration with 87% 
bioavailability and a t1/2 of 3.6 hours. Subsequent murine models demonstrated a 
40-fold increase in circulating haematopoietic progenitor cells with 
subcutaneous AMD3100 given at 5mg/kg as a single dose (Broxmeyer et al., 
2005). In addition to inducing significant haematopoietic progenitor cell 
mobilisation in healthy volunteers (Liles et al., 2003), AMD3100 was also able to 
orchestrate mobilization in patients suffering from multiple myeloma, or non-
Hodgkin lymphoma, when combined with G-CSF (Devine et al., 2004, Flomenberg 
et al., 2005). Other studies also suggested that the level of CD34+ 
haematopoietic progenitor cell mobilisation peaked at about 10-14 hours (Liles 
et al., 2003). More importantly, AMD3100 mobilised HSPC had a more quiescent 
and primitive phenotype, higher cell surface CXCR4 and very late antigen-4 
(VLA-4) expression translating into better and faster engraftment with fewer 
doses compared to G-CSF mobilized products (Fruehauf et al., 2009, Donahue et 
al., 2009). Unlike the many side effects associated with G-CSF, only minor side 
effects like mild gastrointestinal tract disturbance, headache and injection site 
erythema have been reported with AMD3100 (Devine et al., 2004, Liles et al., 
2003). Clinically, AMD3100 is used at a dose of 240µg/kg S.C. per single dose as 
an HSPC mobiliser with or without G-CSF (Stewart et al., 2009). 
1.13.2.2.7 CC-chemokine mobilizing agents  
Of the CC-chemokines, only recombinant human CCL3 (macrophage 
inflammatory protein-1, MIP-1α) has been demonstrated to have HSPC mobilizing 
effects. Due to its inhibitory action on cell cycling, CCL3 has been shown to 
protect multipotent haematopoietic progenitors from chemotherapy-induced 
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myelosuppression (Dunlop et al., 1992, Lord et al., 1992). However, due to the 
tendency of human CCL3 to form high molecular weight polymers, a genetic 
variant of the native CCL3 molecule, called BB-10010, has been evaluated for its 
HSPC mobilising properties (Hunter et al., 1995). BB-10010 was produced by a 
single amino acid substitution (Asp26>Ala) and has a reduced tendency to form 
aggregates at physiological pH. Just like the native CCL3, BB-10010 was 
demonstrated to inhibit bone marrow haematopoietic progenitor cell cycling, 
and mobilise HSPC into the peripheral circulation (Lord et al., 1995). However, 
for additive HSPC mobilisation effect, BB-10010 may be used in combination with 
G-CSF, or AMD3100, to achieve optimal haematopoietic progenitor harvest for 
transplantation (Broxmeyer et al., 2007). Although CCL3 signals through both 
CCR1 and CCR5, the HPC mobilization response is presumed to be due to CCR1 
(Broxmeyer et al., 1999, Hunter et al., 1995, Lord et al., 1995).  
1.13.2.3  VLA-4 antagonist 
In humans, research findings indicate that VLA-4 (α4β1) is expressed on CD34+ 
HSPC and is upregulated by IL-3 and SCF, but downregulated by G-CSF (Prosper 
et al., 1998, Bellucci et al., 1999, Lichterfeld et al., 2000, Yamaguchi et al., 
1998). In fact, G-CSF-induced HSPC mobilization was associated with decreased 
VLA-4 expression. Further studies using chimeric, or conditional genetic 
ablation, of α4- or β1-integrin in mice have shed more light on the role of VLA-4 
in the haematopoietic system during ontogeny. β1-/- HSPCs failed to support 
haematopoiesis as there was defective HSPC colonization of foetal liver and also 
spleen, as well as liver and bone marrow in adult mice (Fassler and Meyer, 1995, 
Hirsch et al., 1996, Potocnik et al., 2000). However, α4 integrin was only 
absolutely necessary to support myeloerythroid and lymphoid differentiation in 
adult mice (Arroyo et al., 1996, Arroyo et al., 1999). Conditional deletion of α4 
integrin resulted in HSPC mobilization and sequestration in the spleen and an 
inability to home and competitively repopulate a lethally irradiated host when 
the α4-/- HSPC were transplanted to wild type recipients (Scott et al., 2003, 
Priestley et al., 2006, Priestley et al., 2007). Antibody-mediated inhibition 
experiments provided additional evidence for the role of the VLA-4/VCAM-1 axis 
in HSPC homing to haematopoietic sites. For example, pre-treatment of lethally 
ablated hosts with anti-VCAM-1 antibody prevented wild type HSPC from homing 
to the bone marrow whereas treatment of HSPC with anti-VLA-4 antibody prior 
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to transplantation had the same inhibitory effect on homing (Papayannopoulou 
et al., 1995, Vermeulen et al., 1998).    
Other studies also adopted the use of a small molecule antagonist of VLA-4, 
BIO5192, to evaluate its HSPC mobilizing effect in mice. It was demonstrated 
that BIO5192 administered intravenously at 1mg/kg mobilized HSPC 30-fold over 
baseline levels within 60 minutes. Interestingly, BIO5192 exhibited additive 
effects with either AMD3100 (three fold above AMD3100 alone), or G-CSF (five-
fold over G-CSF alone), as well as when used with both in combined therapy (17-
fold compared with G-CSF alone) (Ramirez et al., 2009). It is interesting to note 
that the HSPC mobilization induced by the VLA-4 antagonist occurs 
independently of the CXCL12/CXCR4 axis, as it was unaffected in CXCR4-/- 
chimeras (Christopher et al., 2009). It will be interesting to see how poor 
mobilisers will respond to HSPC mobilization using either VLA-4 antagonist alone, 
or in a combined therapy with AMD3100 and/or G-CSF.  
1.13.2.4  Elements of Innate immunity 
Innate immunity is naturally present and non-specifically functions to protect an 
organism from infection. It develops with the organism during embryogenesis 
and may thus form a closely-knit unit with components in the niche harbouring 
various stem cells. Not surprisingly, signalling through receptors, or disruption of 
the function of several elements of the immune system, have been implicated in 
the retention and mobilization of HSPC from the bone marrow (Nagai et al., 
2006). These include components of the complement cascade, bioactive lipids, 
neutrophils, macrophages and Toll-like receptors as briefly reviewed below. 
1.13.2.4.1 Components of the complement system 
Evidence for the implication of the complement system in HSPC retention and 
subsequent mobilization came from studies on C3a- and C5a-deficient mice. 
Whereas C3a deficient mice showed enhanced mobilisation with G-CSF, C5a 
deficient mice were poor mobilisers with G-CSF. These series of experiments 
established that the C3a complement product is required for HSPC retention in 
the bone marrow whereas C5a may induce HSPC trafficking from the bone 
marrow (Molendijk et al., 1986, Ratajczak et al., 2004a, Reca et al., 2007). It 
has been suggested that complement activation via the classical pathway, due to 
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naturally occurring antibodies (NAs) that become activated as a consequence of 
G-CSF-induced tissue damage, may be the major mechanism underlying the HSPC 
modulatory effect. This hypothesis is supported by the findings that 
immunodeficient humans (Sekhsaria et al., 1996) and immunodeficient mice 
(Reca et al., 2007) are poor mobilisers due to lack of NAs since supplementation 
of wild-type immunoglobulins in mice significantly improved HSPC mobilization 
(Reca et al., 2007). Critically important findings on the C3a pro-homing effect on 
HSPC were provided by co-localisation experiments that established that C3a 
increases incorporation of CXCR4 and Rac-1 in lipid rafts and hence increases 
HSPC binding affinity to CXCL12 (Ratajczak et al., 2004b, Ratajczak et al., 
2006). Others have also suggested that G-CSF-induced activation of the 
coagulation cascade, and thrombin production, may also have roles in HSPC 
mobilization (Huber-Lang et al., 2006, Bonig et al., 2001, Canales et al., 2002, 
Markiewski and Lambris, 2007).    
1.13.2.4.2 Granulocytes 
Several lines of experimental evidence have implicated granulocytes as playing 
major roles in HSPC mobilization although the exact mechanism(s) underlying 
such roles are still being elucidated. It has been proposed that G-CSF induces 
enhanced granulopoiesis and activation of granulocytes leading to release of 
proteolytic enzymes (e.g. MMP-9, cathepsin G and elastase) that cleave the 
HSPC niche adhesive factors such as VLA-4, CXCL12, and kit ligand in the bone 
marrow (Levesque et al., 2003b, Levesque et al., 2003a, Levesque et al., 2004). 
The proteolytic environment induced by activated granulocytes has also been 
suggested as being vital in generation of activated complement product C5a. 
Granulocytes have been proposed to “pave the way” for subsequent HSPC 
release as they have been demonstrated to be the first group of cells to egress 
from the bone marrow in most HSPC mobilization protocols (King et al., 2001, 
Sato et al., 1994, Glaspy et al., 1997).  
It is interesting to note that other models that used mice genetically deficient in 
several proteases demonstrated normal mobilization with G-CSF, thus suggesting 
that the role of granulocytes may not be an absolute requirement for HSPC 
mobilization (Levesque et al., 2004, Cramer et al., 2008). 
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1.13.2.4.3 Macrophages 
Recent findings have strongly suggested a role for macrophages in the retention 
of HSPC in the bone marrow niche. Two groups of recent publications, adopting 
depletion of specific macrophage populations, particularly stand out. In the first 
publication, bone marrow Gr-1-F4/80+CD169+ macrophages were depleted using 
clodronate-loaded liposomes, or an inducible c-fms macrophage Fas-induced 
apoptosis model in mice (MAFIA model) or transgenic mice in which DTR is under 
the control of the CD169 promoter. In all cases, depletion of bone marrow 
CD169+ macrophages was associated with reduced CXCL12 protein in bone 
marrow extracellular fluid (~40% decrease) as well as HSPC mobilization to blood 
and spleen (Chow et al., 2011). The authors further demonstrated that the 
reduction in CXCL12 protein secretion occurred preferentially in Nestin+ MSC 
instead of osteoblasts, although the factor(s) that mediate the Nestin+ MSC-
CD169 macrophage interaction were not identified. The second set of 
publications also used clodronate-loaded liposomes or the MAFIA model to 
demonstrate that depletion of bone marrow F4/80+ osteomacs (Chang et al., 
2008b, Winkler et al., 2010b) was associated with mobilization of HSPC with 
lympho-myeloid reconstitution potential in lethally ablated host. Further work 
still needs to be done to evaluate whether osteomac and CD169+ macrophage 
populations are the same or different populations as well as the exact effects 
these populations exert on niche retention factors in homeostatic conditions. 
1.13.2.4.4 TLR ligands 
LPS has been shown to induce HSPC mobilization to the periphery in murine 
models of endotoxaemia (Zhang et al., 2005, Vos et al., 1972, Quesenberry et 
al., 1973). It was also observed that CFU-GM counts were significantly increased 
in the bone marrow, blood, and spleen, 48 hours post I.V. LPS injection. In 
addition, in vivo E. coli-induced bacteraemia stimulated haematopoietic 
progenitor cell mobilization into the blood as well as phenotypic inversion of Lin-
Sca-Kit+ to Lin-Sca+Kit+ (Zhang et al., 2008). It is increasingly becoming clear that 
inflammatory responses affect phenotypic expression of antigens in the HSPC 
compartment. For example, it was recently shown that the rate of 
haematopoietic progenitor cell differentiation towards the pro-erythroid lineage 
was inversely correlated to Sca-1 expression (Chang et al., 2008a). 
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1.14 Aims and Objectives 
To investigate the modulation in the HSPC expression of inflammatory 
chemokine receptors in steady states and inflammatory states. 
To investigate the role that inflammatory chemokine-chemokine receptor axes 
play in the mobilization and/or migration of HSPC during inflammation. 
To further explore the molecular mechanisms underlying the inflammation-
induced HSPC mobilisation. 
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2.1 General solutions and consumables 
Plastics: All plastics used were purchased from either Corning laboratories 
(Loughborough, UK) or Gibco (Invitrogen, Paisley, UK). Plates for quantitative 
polymerase chain reaction (QPCR) and filter tips were purchased from StarLab 
(Milton, Keynes, UK). 
1% Acid Alcohol: 990mL of 70% ethanol plus 10 mL of concentrated HCL per litre 
of solution  
Complete medium: 500mL IMDM [Iscove’s Modified Dulbecco’s Medium, 
(Invitrogen, Paisley, UK)] containing 4%v/v foetal calf serum (FCS), penicillin (100 
units/mL), streptomycin (100µg/mL), and 2mM L-Glutamate.  
Dulbecco’s Phosphate Buffered Saline, 1x (1x DPBS) without CaCl2 & MgCl2: 1x 
DPBS was purchased from Life Technologies (Paisley, UK).    
Eosin Y solution: Putts eosin stain was purchased from CellPath (Newtown, 
Powys, UK) and diluted 1:2 with distilled water before being used. 
Fluorescence activated cell sorting (FACS) buffer: 500ml of 1x DPBS containing 
4%v/v FCS, 2mM EDTA and 0.09%
w/v Sodium Azide. 
FACS sorting buffer: 500ml 1x DPBS containing 1%v/v FCS.  
Chemokine receptor FACS staining buffer: 500ml 1x DPBS containing 4%v/v FCS, 
2mM EDTA and 0.2%w/v Sodium Azide  
Chemotaxis buffer: 0.5%w/v Bovine Serum Albumin (BSA) in IMDM 
Haematoxylin Z solution: Haematoxylin ‘Z’ solution was purchased from 
CellPath (Newtown, Powys, UK) and filtered before being used. 
Hanks’ Balanced Salt Solution 1x with CaCl2 and MgCl2 (1x HBSS): 1x HBSS was 
purchased from Life Technologies (Paisley, UK). 
0.2X Primer mix: 0.8µL each of 20X Taqman probe + TE buffer up to 80µL 
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2X Reverse Transcriptase Specific Target Amplification mix per reaction: 1.4 
µL of 0.2X primers mix, 2.8 µL of CellsDirectTM 2X reaction mix (Invitrogen, 
Paisley, UK), 0.056 µL of SUPERase-In (Ambion, Paisley, UK), 0.112 µL of 
Superscript® III RT/Platinium® Taq Mix (Invitrogen, Paisley, UK), and 0.672 µL of 
Resuspension buffer (Invitrogen, Paisley, UK).  
PureLink DNase digestion cocktail (per 80µL): 8µL DNase digestion buffer (Life 
Technologies, Paisley, UK), 10µL of 3U/µL DNase (Life Technologies, Paisley, 
UK), and 64µL RNase-free water. 
Lipopolysaccharide (LPS) 
Ultra-pure LPS from E. coli 0111:B4 strain was purchased from InvivoGen 
(Toulouse, France), reconstituted at 1mg/mL in 1x DPBS (endotoxin-free) and 
kept frozen at -20C until used. 
12-O-tetradecanoylphorbol-13-acatate (TPA) 
TPA was purchased from Sigma-Aldrich (Irvine, UK), reconstituted to a 
concentration of 100µM in acetone and kept at -20°C in the dark until used. 
100µL of this reconstituted TPA was used per treatment in the TPA peripheral 
inflammation model. 
AldaraTM (imiquimod) 5% cream 
AldaraTM 5% cream was purchased from Meda AB (Solna, Sweden). Each sachet of 
the imiquimod cream contains 250mg cream equivalent to 12.5mg active 
imiquimod. 
Collagenase IV 
Collagenase from Clostridium histolyticum (sterile-filtered, Type IA-S, 0.5-
5.0 FALGPA units/mg solid, >125 CDU/mg solid) was purchased from Sigma-
Aldrich (Irvine, UK) and reconstituted in 1X HBSS to a concentration of 
10mg/mL. 300µL of the reconstituted collagenase IV was used per 1mL of bone 
digestion to achieve a final concentration of 3mg/mL. 
2.2 Mice 
All wild type (WT) mice used for the studies were 8-12 week old, female 
C57BL/6 and were purchased from Harlan laboratories (Bichester, UK). CCR2 null 
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mice were 8-12 week old females, on a C57BL/6 background, and were originally 
purchased from Jackson’s laboratory (Maine, U.S.A). Mice used were kept under 
specific pathogen free conditions at the Central Research Facility, CRF 
(University of Glasgow, UK). All procedures were carried out in accordance with 
the United Kingdom Home Office License regulations.  
2.2.1 Topical imiquimod cream or topical TPA-induced peripheral 
inflammation model. 
The dorsal skin of 8-12 week old, female mice was shaved at least a day prior to 
application of inflammatory agents to prevent direct systemic access of the 
topically applied agent through any skin abrasions. For TPA application, acetone 
was used as a control as the TPA was reconstituted in acetone; for topical 
imiquimod cream application, aqueous cream application was used as a control. 
100µL of 100µM TPA, or 62.5mg AldaraTM cream (equivalent to 3.125mg 
imiquimod active ingredient), was daily applied to the shaved dorsal skin for 3 
consecutive days, after which tissues were harvested for the various 
experimental procedures described below. In all cases, other groups of mice 
received 62.5mg aqueous cream, or 100µl acetone, treatment to the shaved 
dorsal skin as controls for the imiquimod cream and TPA treatments 
respectively.  
2.2.2 Intraperitoneal LPS injection model 
In order to ensure that effects detected in the model were due specifically to 
TLR4 signalling and not due to contaminating TLR2 that occurs with other LPS 
products, Ultra-pure LPS was purchased from InvivoGen (Toulouse, France). This 
was reconstituted to a concentration of 1mg/mL in endotoxin-free DPBS. In all 
the LPS injection models, mice (WT or CCR2 KO mice) were each given a single 
dose of intraperitoneal (I.P.) 100µg LPS (in 100µL PBS), or 100µL I.P. PBS 
injection as a control. 18-24 hours after the injection, the mice were culled by 
CO2 asphyxiation and tissues were harvested and used for subsequent 
experiments as described in the relevant sections below. 
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2.3 Tissue processing, embedding and sectioning 
2.3.1 Tissue processing 
WT or CCR2 null mice received the topical imiquimod cream/TPA treatment 
model exactly as described in section 2.2.1, after which mice were euthanized 
in a CO2 chamber, and perfused with 20mL of 1x DPBS (Invitrogen, Paisley, UK). 
The dorsal skins that had directly received the inflammatory agent were 
subsequently harvested and fixed in 10% neutral buffered formalin for 24 hours. 
The fixed skin tissues were then dehydrated through a series of dehydrating 
conditions using an automated tissue processor (Shandon Citadel 1000, Thermo 
Scientific, Loughborough, UK) with a programming condition as detailed below. 
These processing conditions ensured the complete dehydration of the tissues to 
enable paraffin infiltration (embedding) as described in section 2.3.1.1 
70% Alcohol 1 hour 
90% Alcohol 1 hour 
95% Alcohol 1 hour 
100% Alcohol 1x1 hour, 1x 2 hours, 1x 2.5 hours 
Xylene 2x 1 hour, 1x 1.5 hours 
Molten paraffin wax  2x 4 hours at 60-65°C 
2.3.1.1 Embedding 
After the skin had been processed as described above, it was then placed in 
plastic moulds and embedded in paraffin wax blocks (Histocentre 3, Thermo 
Scientific). The embedded tissues were then cooled for several hours on the 
integral cold plate. When the block was set, it was stored at room temperature 
until sectioning. 
2.3.1.2 Tissue sectioning 
Prior to sectioning, the paraffin blocks were placed on crushed ice to harden the 
wax as well as to equilibrate the densities across the surface of the block. Skin 
tissues were cut to 6-8µm and floated in a water bath set to a temperature of 
40°C to smoothen out any creases in the sections. Next, the sections were lifted 
out onto SuperfrostR plus slide (Thermo Scientific), and placed on a histology hot 
plate (Raymond A Lamb Hotplate, Thermo Scientific) set at 55ºC to dry the 
Chapter 2: Materials and Methods  84 
 
sections. The slides were then filed and kept at room temperature until required 
for staining. 
2.4 Haematoxylin and Eosin (H&E) staining of skin 
sections. 
The H&E staining was employed to examine the tissue morphology. 
Haematoxylin is a dark purplish dye that, by its basic nature, stains the 
acidophilic/negatively charged components like nuclear chromatin of cells and 
tissues. Eosin on the other hand, is a reddish-acidophilic dye that preferentially 
stains the basophilic cytoplasmic components. Therefore, the use of these two 
dyes with contrasting properties and staining characteristics enabled a better 
examination of tissue morphology. As described below, the regressive H&E 
staining technique in which sections are initially stained in stronger 
haematoxylin solution and subsequently differentiated in acid-alcohol solution 
was employed. 
2.4.1 H&E staining procedure 
The slides were de-waxed in Xylene 1 for 10 minutes and then re-hydrated 
through decreasing alcohol concentrations; i.e. absolute Alcohol, 95% alcohol, 
and 70% alcohol respectively (10 dips each). Next, the slides were washed in 
running water for a minute, and then stained in haematoxylin Z for 7 minutes. 
After this the slides were washed in running water (until water ran clear), and 
taken through 12 dips in 1% Acid Alcohol to allow differentiation of the staining 
reaction. Next, the slides were washed in running water for 60 seconds and 
incubated in Scotts Tap Water for 2 minutes, washed in running water again, and 
then stained for 4 minutes in Eosin Y that had been diluted 1:2. After washing in 
running water for 2 minutes the slides were taken through 70% Alcohol, 95% 
alcohol and absolute alcohol (10 dips each). The sections were then taken 
through three changes of Xylene i.e. Xylene 2, 3 and 4 (1 minute each), mounted 
in dibutyl phthalate xylene (DPX) and a coverslip (using 0.13-0.17mm cover 
glass) was then applied. The mounted slides were allowed to dry at room 
temperature before visualization by bright-field microscopy. 
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2.5 Fluorescent activated cell sorting (FACS) 
Details of the monoclonal antibodies used for flow cytometry are listed in table 
2-1 below. The antibodies were directly conjugated to one of the following: 
Allophycocyanin (APC), APC conjugated to Cyanine (APC-Cy7), R-Phycoerythrin 
(PE), PE conjugated to Cyanine 7 (PE-Cy7), PE-Cy5, Pacific Blue, Peridinin-
Chlorophyll-Protein (PerCP), PerCP conjugated to Cyanine 5.5 (PerCP-Cy5.5), PE 
conjugated to CF594 (PECF594), AlexaFluor 488 or Fluorescein (FITC). Antibodies 
for staining of CXC-chemokine receptor 4, CXCR4, as well as differentiated 
haematopoietic lineage markers cocktail (CD4, CD5, CD8a, CD11b, CD45R/B220, 
Gr-1 and Ter119) were biotin conjugated. Therefore, an indirect staining 
procedure that required secondary staining with Streptavidin conjugated to a 
flourochrome was employed. Also, the antibody for staining mouse CCR2 was 
derived in goat; this therefore required secondary staining using anti-goat 
antibody. All antibody-staining reactions were done in 1.5mL Eppendorf tubes 
and on ice unless indicated otherwise. All samples were re-suspended in FACS 
buffer and filtered through a 70µm cell strainer into 12 x 75 mm polystyrene 
tubes (Beckman Coulter Inc., High Wycombe, UK) for flow cytometric data 
acquisition on CyAnTM ADP Analyzer (Beckman Coulter Inc., High Wycombe, UK).      
Table  2-1 List of antibodies used for flow cytometry 
Mouse antibody Fluorochrome Clone Supplier Concentration 
CD16/CD32 (Fc 
Block 
  Miltenyi Biotech 1/100 
CD4 Biotin H129.19 BD Biosciences 1/1600 
CD5 Biotin 53-7.3 BD Biosciences 1/800 
CD8a Biotin 53-6.7 BD Biosciences 1/800 
CD11b Biotin M1/70 BD Biosciences 1/200 
CD45R/B220 Biotin RA3-6B2 BD Biosciences 1/200 
Ter119 Biotin, rat 
anti-mouse 
 BD Biosciences 1/50 
Gr-1/Ly-6G/C Biotin RB6-8C5 BD Biosciences 1/200 
Streptavidin Pacific Blue  Molecular Probes 1/100 
CD117/c-Kit APC-Cy7 2B8 BioLegend 1/200 
CD117/c-Kit APC  Miltenyi Biotec 1/200 
Sca-1/Ly6-A/E PE-Cy7 E13-161.7 BioLegend 1/200 
CD135 PE Cy5 A2F10 BioLegend 1/25 
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CD48 FITC HM48-1 eBioscience 1/600 
CD150 SLAM APC TC15-
12F12.2 
BioLegend 1/200 
CD150 SLAM PE TC15-
12F12.2 
BioLegend 1/200 
CD127/IL7rα PE-Cy7 A7R34 BioLegend 1/100 
CD127/IL7rα PE A7R34 BioLegend 1/100 
CD16/32 APC-Cy7 93 BioLegend 1/25 
CD16/32 PerCP Cy5.5 93 eBioscience 1/25 
CD105 PE-CF594 MJ7/18 BD Bioscience 1/100 
CD34 FITC RAM34 BD Biosciences 1/25 
Ter119 FITC TER-119 BioLegend 1/25 
CD41 APC MWReg30 BioLegend 1/100 
CD41 FITC MWReg30 BioLegend 1/100 
CD71 PE Cy7 R17217 BioLegend 1/25 
Goat anti-mouse 
CCR2 
anti-Goat 
AlexaFluor488 
 Abcam 1/100 
CXCR4 Biotin 2B11 eBioscience 1/100 
Rat IgG2bκ Iso 
control 
Biotin eB149/10H5 eBioscience 1/100 
CD31 APC MEC13.3 BioLegend 1/100 
CD51 PE RMV-7 BioLegend 1/100 
CD115 APC AFS98 BioLegend 1/50 
F4/80 FITC BM8 BioLegend 1/25 
Gr-1 Brilliant violet RB6-8C5 BioLegend 1/25 
CD11b PE Cy5.5 M1/70 BioLegend 1/25 
CD169 PE 3D6.112 BioLegend 1/100 
Live/Dead Aqua   Molecular Probes 1/100 
CD45 FITC 30-F11 BioLegend 1/50 
Streptavidin APC  BioLegend 1/100 
     
2.5.1 Bone marrow and peripheral blood HSPC flow cytometry 
procedure 
Mice received the topical imiquimod cream/TPA treatment or I.P. LPS injection 
model exactly as described in sections 2.2.1 & 2.2.2 respectively. After the 
treatment, the mice were euthanized by CO2 asphyxiation and peripheral blood 
was taken from the aorta into EDTA microtainer tubes (BD Biosciences, Oxford, 
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UK). Full haematology profiles were obtained from these blood samples using 
HEMAVET 950FS automated blood counter (DREW Scientific Inc., Dallas, U.S.A).  
The bones [2x (femur + tibia +hip bones)] were also harvested from these same 
mice, and cleared of muscle. Following this, the bones were crushed in a mortar 
and pestle to isolate the bone marrow. Next, the crushed bone/bone marrow 
samples were re-suspended in FACS buffer, filtered through a 70µm cell strainer 
and spun down at 300xg (4°C) for 5 minutes. After discarding the supernatant, 
the cell sediments were re-suspended at 107 cells/mL in Ammonium Chloride 
solution (StemCell Technologies, Vancouver, Canada), to lyse the red cells. 
Next, the cells were washed in FACS buffer and then enriched for 
haematopoietic stem and progenitor cells using the CD117/c-Kit Microbeads and 
the LS columns according to manufacturer’s instructions (Miltenyi Biotec, GmbH, 
Germany); see section 2.5.2 below for details.  
2.5.2 c-Kit enrichment and HSPC staining protocols 
As haematopoietic stem and progenitor cells all express the c-Kit antigen, the c-
Kit-enrichment protocol allowed for substantial depletion of differentiated 
haematopoietic cells. For the c-Kit enrichment, 2.5µL of c-Kit Microbeads was 
added per 107 cells (peripheral blood or bone marrow cells) per 100µL FACS 
buffer and incubated for 20 minutes on a rotating platform at 4°C (in the dark). 
The samples were then washed and run through the LS column fitted to its 
magnetic stand to passively select for c-Kit+ cells. After washing the columns 
with about 10mL of FACS buffer, the columns were taken out of the magnetic 
stand and the positively selected cells (positive fraction) were eluted with 8mL 
of FACS buffer. Next, the positive fractions were then centrifuged at 300xg (4°C) 
for 5 minutes and stained for flow cytometric analysis according to one of the 
following: 
(A) For SLAM staining, the c-kit enriched cells were initially stained with anti-
mouse FcR blocker (Miltenyi Biotec, GmbH, Germany) for 5 minutes, and then 
washed in 1mL of FACS buffer at 300xg (for 5 minutes at 4ºC). Next, the cells 
were stained with c-Kit-APC-Cy7, Sca-1-PE Cy7, CD48-FITC, CD150-APC/PE and a 
cocktail of biotinylated lineage markers (CD4, CD5, CD8a, CD11b, Ter119, 
CD45R/B220 and Gr-1) anti-mouse antibodies for 15 minutes on ice (in the dark). 
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The cells were washed in 1mL ice-cold FACS buffer and subsequently stained 
with Streptavidin Pacific Blue on ice for 15 minutes in the dark. 
(B). For myeloerythroid progenitor cell staining, the enriched cells were stained 
with biotin lineage cocktail, c-Kit-APC-Cy7, IL7Rα-PE Cy7, CD41-FITC, CD150-PE, 
CD105 PECF594, and CD16/32 PerCP Cy5.5 anti-mouse antibodies for 15 minutes 
on ice. After washing the cells in FACS buffer, the cells were next stained with 
Streptavidin Pacific Blue as described in protocol A above.  
(C). For chemokine receptor (CXCR4 or CCR2) staining, the c-Kit enriched cells 
were stained according to protocols A or B above, and then followed by staining 
for the chemokine receptor in chemokine receptor FACS staining buffer. The 
primary chemokine receptor antibody was added (see table for staining 
concentrations) and incubated on ice for 30 minutes. The cells were then 
washed in ice-cold chemokine receptor FACS staining buffer, spun at 300g (4°C), 
cell pellets then re-suspended in chemokine receptor FACS staining buffer and 
secondary antibody was added and subsequently incubated on ice for another 20 
minutes. After the final staining step, the cells were washed in 1mL chemokine 
receptor staining buffer, and then re-suspended in chemokine receptor FACS 
staining buffer for FACS data acquisition on CyAn ADP (Beckman Coulter Inc., 
High Wycombe, UK). 
In all staining protocols, unstained cells, single colour-stained samples and 
fluorescence-minus-one (FMO) samples were included as controls for gating and 
compensation settings. Moreover, dead cells were excluded by staining with 
Live/Dead Aqua fixable dye (Life Technologies, Paisley, UK) for 30 minutes on 
ice as the final staining step. All flow cytometric data were acquired on CyAnTM 
ADP Analyzer (Beckman Coulter Inc., High Wycombe, UK) and the data were 
subsequently analysed using FlowJo (Tree Star Inc., Ashland, USA) 
2.5.2.1 Bone marrow macrophage (Mφ) staining 
In order to understand how each of the systemic (i.e. by LPS injection) and 
peripheral inflammation models affected the medullary mononuclear phagocytic 
cells, the bone marrow cells were immunophenotypically stained to delineate 
monocytes and the macrophage populations. The protocol is essentially as 
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previously published (Chow et al., 2011). WT mice were treated with either 
topical imiquimod cream/TPA, or the I.P. LPS injection exactly as described in 
sections 2.2.1 and 2.2.2 respectively. Following this, the femur and tibia were 
harvested and crushed in a mortar and pestle to isolate the marrow cells. The 
bone marrow/bone fragments were next filtered through a 70µm cell strainer 
and the filtrate was spun at 300xg (4°C) for 5 minutes. The cell pellets were re-
suspended in 500µL ice-cold Ammonium Chloride solution per 106 cells for 60 
seconds, to lyse red blood cells. Next, the cells were washed in 1mL of FACS 
buffer and spun at 300g for 5 minutes. The cells were then treated with FcR 
blocking antibody at a concentration of 1µl per 106 cells at 4°C for 10 minutes, 
and then washed in 1mL of FACS buffer at 300xg (4°C) for 5 minutes. Following 
this, the cells were stained with a cocktail antibody consisting of CD11b, CD169, 
F4/80, CD115, and Gr-1 antibodies, at 4°C for 20 minutes in the dark. The cells 
were next washed in 1mL FACS buffer and spun down at 300xg (4°C) for 5 
minutes. After discarding the supernatants, the cells were next stained with 
Live/Dead Aqua (1µl per 106 cells) at room temperature for 20 minutes. 
Following this, the cells were washed in 1mL of FACS buffer at 300xg (4°C) for 5 
minutes, and re-suspended in FACS buffer for flow cytometric data acquisition 
on CyAnTM ADP flow cytometer (Beckman Coulter, High Wycombe, UK). 
2.5.2.2 Bone marrow stromal cell staining 
The femora, tibiae and hipbones of mice that had been taken through the LPS 
injection model (section 2.2.2) or imiquimod/TPA treatment model (section 
2.2.1) were flushed several times with 1X DPBS to remove the marrow. The 
resulting bones were minced with a scalpel, and then incubated in 3mg/mL 
collagenase IV (Sigma-Aldrich, Irvine, UK) at 37°C on a shaking platform for 40 
minutes (Semerad et al., 2005). Next, the bone fragments were crushed in a 
mortar and pestle and then depleted of residual haematopoietic cells using the 
lineage using the mouse lineage cell depletion kit (Miltenyi Biotec, GmbH, 
Germany) according to manufacturer’s instructions. Firstly, the cells were re-
suspended in 40µL FACS buffer per 107 total cells, and then stained with 10µL 
biotin-antibody cocktail for 10 minutes at 4°C (in the dark). Next, 30µL of FACS 
buffer and 20µL anti-biotin Microbeads were added and incubated at 4°C for an 
additional 20 minutes. After washing the cells in 1mL FACS buffer, the non-
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haematopoietic cells were sorted through negative selection using LS columns 
(Miltenyi Biotech, GmbH, Germany). The resultant negative fraction was spun 
down at 300xg for 5 minutes and stained for 20 minutes at 4°C with a cocktail of 
lineage antibodies (CD4, CD5, CD8a, CD11b, Ter119, B220, Gr-1), CD31, CD45, 
Sca-1 and CD51 antibodies as well as Live/Dead Aqua for dead cell exclusion. 
The staining protocol is essentially as described previously (Winkler et al., 
2010a, Semerad et al., 2005). The cells were then washed and flow cytometric 
data acquired using CyAnTM ADP Analyzer (Beckman Coulter Inc., High Wycombe, 
UK). 
2.6 Primers for quantitative polymerase chain reaction 
(QPCR) 
Primers used for QPCR were purchased from Applied Biosystems (Paisley, UK), 
and their respective catalogue numbers and names are as published in table 2-2. 
Table 2-3 also details the primers used for the TLDA assay. 
 Table  2-2 Taqman probes used for RT-QPCR 
Gene Probe Catalogue number 
Ccr1 FAM Mm01216147_m1 
Ccr2 FAM Mm00438270_m1 
Ccr3 FAM Mm01216172_m1 
Ccr4 FAM Mm04207878_m1 
Ccr5 FAM Mm01216171_m1 
Ccr6 FAM Mm01700298_m1 
Ccr7 FAM Mm01301785_m1 
Ccr8 FAM Mm01351703_m1 
Ccr9 FAM Mm02528165_s1 
Ccr10 FAM Mm01292449_m1 
Cxcr1 FAM Mm00731329_s1 
Cxcr2 FAM Mm00438258_m1 
Cxcr3 FAM Mm00438259_m1 
Cxcr4 FAM Mm01292123_m1 
Cxcr5 FAM Mm00432086_m1 
Cxcr6 FAM Mm00472858_m1 
Cxcr7 FAM Mm00432610_m1 
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Cx3cr1 FAM Mm01301785_m1 
Ccrl1 FAM Mm01232441_m1 
Actb (Beta-actin) FAM Mm01205647_g1 
B2M (beta 2-microglobulin) FAM Mm00437762_m1 
DARC FAM Mm04207950_g1 
Foxo3 FAM Mm01185722_m1 
Hprt FAM Mm01545399_m1 
Itga4 FAM Mm01277951_m1 
c-Kit FAM Mm00445212_m1 
Vwf FAM Mm00550376_m1 
 
Table  2-3 Genes used for Taqman Low Density Array 
Gene Probe Catalogue number 
Il1b FAM Mm00434228_m1 
Il4 FAM Mm00445259_m1 
Il10 FAM Mm00439616_m1 
Il12b FAM Mm01288990_m1 
Il13 FAM Mm00434204_m1 
Il17a FAM Mm00439619_m1 
Il22 FAM Mm00444241_m1 
Tnfa FAM Mm00443258_m1 
Ifng FAM Mm00801778_m1 
Tgfb1 FAM Mm00441724_m1 
18S FAM Hs99999901_s1 
Tbp FAM Mm00446971_m1 
Ccl2 FAM Mm00441242_m1 
Ccl3 FAM Mm00441258_m1 
Ccl4 FAM Mm00443111_m1 
Ccl5 FAM Mm01302427_m1 
Ccl6 FAM Mm01302419_m1 
Ccl7 FAM Mm00443113_m1 
Ccl17 FAM Mm00516136_m1 
Ccl19 FAM Mm00839967_g1 
Ccl20 FAM Mm00444228_m1 
Ccl21 FAM Mm03646971_gH 
Ccl22 FAM Mm00436439_m1 
Ccl27a FAM Mm01215829_m1 
Cxcl2 FAM Mm00436450_m1 
Cxcl5 FAM Mm00436451_g1 
Cxcl10 FAM Mm00445235_m1 
Cxcl11 FAM Mm00444662_m1 
Cxcl12 FAM Mm00445553_m1 
Cxcl13 FAM Mm00444534_m1 
Cxcl14 FAM Mm00444699_m1 
Cx3cl1 FAM Mm00436454_m1 
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2.7 RNA extraction from tissues 
WT mice received topical imiquimod cream or TPA treatment exactly as 
described in section 2.2.1, after which mice were culled by CO2 asphyxiation. 
The shaved dorsal skin tissues (that directly received the treatment) were 
harvested into RNAlater (Qiagen) and kept overnight at 4°C. From these same 
mice, spleen and bones [2x (tibia +femur + hip bone)] were also harvested into 
RNAlater (Qiagen) and kept overnight at 4°C. On the next day, skin tissue was 
each placed in a 2mL microcentrifuge tube, and 1mL of TRIzol reagent 
(Ambion) was added to each tube. Two 5mm stainless steel beads (Qiagen) were 
added to each tube and then placed in TissueLyser LT machine (Qiagen) set at 
500Hz, to homogenize the tissues, for 10 minutes. The TRIzol/tissue lysate 
mixture was then incubated at room temperature for 5 minutes to allow 
complete dissociation of nucleoprotein complexes. 200µL of chloroform was next 
added to each tube and shaken vigorously (by hand) for 15 seconds followed by 3 
minutes incubation at room temperature. Following this, each sample was 
centrifuged for 15 minutes at 12000xg (4°C). After the centrifugation, the upper 
phase containing the RNA (~600µL) was transferred to a fresh 1.5mL 
microcentrifuge tube. Next, an equal volume of 70% ethanol was added to each 
sample, and then thoroughly mixed by vortexing. Next, the RNA samples were 
added to the PureLinkTM RNA mini kit Spin cartridge columns, washed and eluted 
in accordance with manufacturer’s instructions (Ambion, Paisley, UK) so as to 
purify the RNA. Genomic DNA contamination was removed by incubating each 
column with 80µL of PureLink DNase digestion cocktail for 15 minutes at room 
temperature. Afterwards, the columns were washed respectively with 500µL of 
Buffer I and II and then eluted with 50µL of RNase free water. The RNA 
concentrations were subsequently measured with a NanoDrop 2000 
spectrophotometer (Thermo Scientific, Loughborough, UK). The stock RNA 
samples were kept at -80ºC until required for downstream processing such as 
RNA quality verification and cDNA synthesis. 
2.7.1 Measurement of RNA quality and degradation 
Although the NanoDrop 2000 spectrophotometric technique was able to give the 
RNA concentration of the skin samples, it was deemed necessary to verify the 
quality of the RNA before using it for downstream gene profiling assay. This was 
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to ensure that the samples were devoid of contaminants or degraded products 
that could inadvertently affect the gene expression data. Therefore, the Agilent 
2100 Bioanalyzer (Agilent Technologies) was employed to determine the quality 
and integrity of RNA samples. The advantages of the Agilent 2100 Bioanalyzer 
technology include not only the ability to accurately measure the RNA 
concentration of these samples from low cell numbers, but also the RNA 
Integrity Number (RIN) that gives an indication of low molecular weight 
impurities/contaminants. The RIN is a classification system that assigns a 
number 1 (most degraded) through to 10 (non-degraded) to total eukaryotic RNA 
based on a software algorithm, and thereby removing all forms of user-
dependent bias. The output results from the Agilent 2100 Bioanalyzer technology 
also include an electropherogram plot and gel images that enables one to 
identify the cause of a poor RIN, i.e. contaminants and/or degradation. For skin 
RNA samples used for TLDA gene analysis, the RNA Nano LabChip kit (Agilent 
technology, Edinburgh, UK) was used to determine the RIN and also validate the 
NanoDrop 2000 spectrophotometric RNA concentration. 
2.7.2 Complementary DNA (cDNA) synthesis for RNA isolated 
from LK cells 
The high capacity RNA-to-DNA kit (Applied Biosystems, Paisley, UK) was used for 
the cDNA synthesis in accordance with manufacturers’ protocol. A volume of 
RNA isolate equivalent to 30ng was added to 1µL of 20X enzyme mix [contains 
MultiScribe MuLV (Moloney murine leukaemia virus) reverse transcriptase enzyme 
and RNase inhibitor protein], 10µL of 2x reverse transcriptase buffer (contains 
dNTPs, random octamers and Oligo dt-16) and made up to a total of volume of 
20µL with Nuclease-free water for the cDNA synthesis. The resultant mixture 
was spun down at 300xg for 1 minute and incubated on a Veriti® thermocycler 2 
(Applied Biosystems, Paisley, UK) with the following cycling condition:  
37°C 60 minutes 
95°C 5 minutes 
4°C ∞, hold 
  Each cDNA sample was diluted 1:5 with nuclease-free water and kept at -80°C 
until required for QPCR. 
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2.7.3 cDNA synthesis from LSK cells 
WT mice subjected to topical imiquimod cream/TPA treatment exactly as 
described in section 2.2.1. 200 bone marrow LSK (lineage marker negative, c-
Kit+ and Sca-1+), or 100 peripheral blood LSK cells, were sorted into respective 
wells of a 96-well plate containing 5µL of 2X Reverse Transcriptase Specific 
Target Amplification (RTSTA) master mix reaction buffer to enrich samples for 
genes of interest. The plate was vortexed to facilitate the cell lysis process, 
centrifuged at 300xg for 60 seconds and then pre-amplified on a Veriti® 
thermocycler 2 (Applied Biosystems, Paisley, UK) according to the following 
cycling conditions: 
              50ºC         15 minutes 
              96ºC          2 minutes 
 
              95ºC          15 seconds    
              65ºC           4 minutes       22 cycles 
 
 Next, the plate was centrifuged at 300xg for 60 seconds, the samples were 
diluted 1:5 with DNA re-suspension buffer (Invitrogen, Paisley, UK) and kept at -
20°C until required for QPCR. To check for genomic DNA contamination, other 
reaction mixes were also set up exactly as above, but with Taq polymerase 
replacing the Superscript III RT/Platinium Taqmix in the 2X RTSTA buffer so as to 
obtain reverse transcriptase (RT) controls. The QPCR reactions were undertaken 
using the Fluidigm 48.48 Dynamic array platform as described in section 2.7.6. 
 
2.7.4 cDNA synthesis from LT-HSC, MPP1, MPP2, and MPP3 
populations 
To profile the HSPC for chemokine receptor gene expression in mice were 
treated with I.P. LPS or I.P. PBS injection exactly as described in section 2.2.2. 
The cells were next stained for differential expression of Lin, Live/Dead Aqua, c-
Kit, Sca-1, CD48 and CD150 antigens in accordance with the signalling 
lymphocyte antigen molecule (SLAM) staining protocol described in section 2.5.3 
(Kiel et al., 2005). The LT-HSC, MPP1, MPP2 and MPP3 populations were 
immunophenotypically defined as Lin-Sca-1+c-Kit+CD48-CD150+, Lin-Sca-1+c-
Kit+CD48+CD150+, Lin-Sca-1+c-Kit+CD48+CD150-, and Lin-Sca-1+c-Kit+CD48-CD150-
respectively. 200 cells from each of the LT-HSC, MPP1, MPP2 and MPP3 
Chapter 2: Materials and Methods  95 
 
populations were FACS sorted on FACSAria II (BD Biosciences, Oxford, UK) into 
96-well plate containing 5µL of 2X Reverse Transcriptase Specific Target 
Amplification (RTSTA) master mix reaction buffer. The cDNA syntheses were 
undertaken essentially as described in section 2.7.4 above. The QPCR was 
undertaken using the Fluidigm 48.48 Dynamic array as described in section 2.7.6 
below. 
2.7.5 Fluidigm 48.48 Dynamic Array IFC chip run 
The Fluidigm 48.48 Dynamic Array Integrated Fluidic Circuit (IFC) was primed for 
use in accordance with manufacturers’ instructions (Fluidigm BioMarkTM HD 
System). The QPCR was performed in accordance with the protocol for the 
BioMark System. The cycling conditions were as follows: 50°C for 2 minutes, 95°C 
for 10 minutes (Hot start), and then 40 cycles of 95°C (denaturation) and 60°C 
for 60 seconds (annealing). Data were then processed using the BioMark Real-
time PCR analysis software (version 3.0.4). The RT-QPCR data were next 
analysed using Microsoft Office Excel (2011). The data were first normalised to 
Hprt gene expression to obtain the comparative Ct values, and subsequently 
relative to their respective calibrator sample to obtain the 2-∆∆CT.  
2.7.6 Complementary DNA (cDNA) synthesis for Taqman Low 
Density Array (TLDA) 
All cDNA for downstream TLDA assay were synthesised according to the Precision 
nanoScript Reverse Transcriptase kit protocol (PrimerDesign Ltd.). A total 
volume of 20µl cDNA was synthesised per each sample in separate reaction tubes 
as per reaction cocktails below: 
Reaction cocktail 1 
 
Component 1 Reaction 
RNA template 1µg-1.5µg 
Random nanomer primer 1µL 
Oligo-dT primer 1µL 
Nuclease-free water Up to 10µL 
 
Reaction cocktail 2 
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Component 1 Reaction 
NanoScript 10X buffer 2µL 
dNTP Mix 10nM of each 1µL 
DTT 100nM 2µL 
NanoScript enzyme 1µL 
Nuclease-free water 4µL 
Final volume 10µL 
 
Approximately 1.5µg RNA was added to reaction cocktail 1 (see above) and 
heated to 65°C for 5 minutes and then cooled immediately on ice. Following 
this, 10µL of reaction cocktail 2 was added per reaction tube, spun down and 
subjected to the following cycling conditions: 
25°C 5 minutes 
55°C 20 minutes 
75°C 15 minutes 
4°C ∞, hold 
Each reaction tube was spun down at 300xg for 1 minute and diluted 1:5 with 
nuclease-free water and kept at -80°C until required for TLDA gene profiling. 
2.7.7 Taqman QPCR 
Component Volume per reaction 
2X Taqman Universal Master Mix 5.0µL 
cDNA template 1.5µL 
Nuclease-free water 3.5µL 
To avoid intra-sample variability, a master-mix consisting of all the components 
listed above was prepared, vortexed and spun down to ensure thorough mixing 
of all components. 9µL of the master-mix was pipetted into each well and 1µL 
Taqman primer probe was added per well to make a 10µL total reaction volume. 
Each sample reaction was carried out in triplicate to validate the reproducibility 
of results. The QPCR reactions were carried out in a 384-well plate on the 
7900HT Fast Real-time PCR system (Applied Biosystems) programmed according 
to the following cycling conditions: 
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                               95ºC     2 minutes 
 
                               95ºC     15 seconds 
                               65ºC      60 seconds    40 cycles 
 
Data were analysed by RQ-manager version 1.2.2 (Applied Biosystems, Paisley, 
UK). 
Non-amplification in the RT and water controls indicated the absence of genomic 
DNA contamination and contamination from the reagents respectively.  
To allow for plate-to-plate comparison, the same automatically generated 
threshold fluorescence number (Ct) was used to compensate for background 
fluorescence signals. This Ct values represent the amplification cycle number at 
which the recorded fluorescence values is significantly above this pre-set 
background fluorescence in each sample. The recordings of the Ct values always 
occur during the exponential phase of the PCR amplification. For relative RT-
QPCR assays, the Ct values of a gene of interest in experimental samples was 
compared directly to the Ct values of that same gene in the relevant control 
samples (calibrator) to generate the relative quantities; the results were then 
normalized to that of the relative quantities of a reference gene to normalize 
for differences in RNA templates and efficiencies of the reverse transcription 
reactions. These results were then reported as fold changes that gives an 
indication of how more or less a gene is expressed in experimental groups as 
compared to its expression in the calibrator (control) sample. 
2.7.8 Normalisation of QPCR data 
In quantifying the gene expression levels in different samples, variation between 
the gene expression levels between experimental and calibrator groups could be 
due to actual biological differences or variations introduced as a result of 
experimental techniques. Several measures were thus taken to compensate for 
any variations introduced as a result of variability in experimental techniques. 
For the LSK relative RT-QPCR, equal cell numbers were used as the starting 
template material. In all other RT-QPCR reactions, equal amounts of starting 
RNA templates were used. In addition to the above measures, a 
normalizer/reference gene was selected to compensate for any other sources of 
variations such as varying PCR amplification efficiencies. Preliminary 
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experiments showed that TATA Binding Protein (TBP) and HPRT (hypoxanthine-
guanine phosphoribosyltransferase) were more robust to the experimental 
conditions and were thus selected. 
2.8 Mouse in vitro methylcellulose colony-forming 
assays 
As discussed in the general introductory chapter, the gold standard for assessing 
the functionality of HSC is the competitive repopulation assay in lethally ablated 
hosts. However, the haematopoietic colony-forming assay offers the opportunity 
to test the presence of haematopoietic progenitor cell (HPC) population in a 
given sample as it provides the necessary growth nutrients that permit the in 
vitro multiplication of these progenitor cells. The choice of the media selected 
determines which progenitor cell population could be detected as a single media 
that permits the growth of all lymphomyeloid progenitors was yet to be 
manufactured.  
2.8.1 In vitro mouse HPC colony-forming assay. 
2.8.1.1 Introduction 
All haematopoietic colony-forming assays involving tissues from mice were 
undertaken using myeloerythroid growth supporting media, MethocultTM GF 
M3434 (StemCell Technologies, Vancouver, Canada). This is a semi-solid 
methylcellulose-based media containing supplements of recombinant human (rh) 
insulin, rhErythropoietin, fetal bovine serum, β-mercaptoethanol, recombinant 
murine (rm) stem cell factor, rmIL-3 and rmIL-6, thereby allowing the 
identification and enumeration of myeloerythroid colonies. 1x 105 leucocytes 
from peripheral blood or spleen (see below) were seeded into 1.1mL of 
MethocultTM GF M3434 and incubated for 7-10 days at 37°C in a humidified 
chamber in the presence of 5% CO2. After the incubation period, haematopoietic 
progenitor cell-derived colonies were enumerated using an inverted microscope. 
2.8.1.2 Inflammation-induced HPC mobilisation assay 
To investigate the potential of peripheral inflammation inducing the mobilisation 
of haematopoietic stem and progenitor cells from the bone marrow to the 
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circulation, WT mice received topical imiquimod cream/TPA treatment exactly 
as described in section 2.2.1. Other groups of mice were given I.P. LPS injection 
as described in section 2.2.2 to investigate the ability of systemic inflammation 
to mobilise HSPC to the circulation. At the end of each model, mice were culled 
by CO2 asphyxiation and peripheral blood harvested into EDTA anti-coagulated 
tubes. Next, the red blood cells were lysed with ice-cold Ammonium Chloride 
solution at a ratio of 10 parts Ammonium chloride solution: 1 part of blood. 
Next, 1x105 leucocytes were seeded into MethocultTM GF and incubated exactly 
as described in section 2.8.1.1.  
In other experiments, CCR2 KO mice were used instead of WT mice; however, 
the experimental details were essentially the same as described above.  
2.8.1.3 Ligand-induced haematopoietic stem and progenitor cell 
mobilisation assay 
Table  2-4 Dosage of ligands used for HPC mobilisation assay 
Ligand Dosage & route Duration 
rmCCL2 50µg/kg or 75µg/kg body weight 
S.C. 
30-60 minutes 
rmCCL4 50µg/kg or 75µg/kg body weight 
S.C. 
30-60 minutes 
rmCCL11 50µg/kg or 75µg/kg body weight 
S.C. 
30-60 minutes 
rhCCL3 75µg/kg body weight S.C. 30 minutes 
rhCCL7 75µg/kg body weight S.C. 30 minutes 
AMD3100 5mg/kg body weight 60 minutes 
Soluble imiquimod S.C 100µg soluble imiquimod per 
mouse per day  
3 days 
  
Recombinant murine (rm) CCl2, rmCCL4, rmCCL11, rhCCL3, and rhCCL7 were 
purchased from Peprotech (London, UK). These chemokine ligands were initially 
dissolved in minimal volume of sterile water and made up to 1mg/mL final 
concentration with 0.1%w/v BSA (Bovine Serum Albumin) to prevent adsorption of 
the chemokines onto the tubes. Imiquimod was purchased from 
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InvivoGen(Toulouse, France) and reconstituted in 1X DPBS at 1mg/mL. AMD3100 
was purchased from Sigma-Aldrich (Irvine, UK) and reconstituted in 1X DPBS at 
1mg/mL. WT mice were given doses of one of the ligands for duration indicated 
in table 2-4 above. For the chemokine ligand mobilisation assay, equivalent 
volume of 0.1%w/v BSA was used as a control, whereas in AMD3100 or soluble 
imiquimod injections, equivalent volumes of 1X DPBS were injected into mice as 
controls. At the end of the specific treatment protocol, the mice were culled by 
CO2 asphyxiation and peripheral blood samples were taken into EDTA microtainer 
tubes (BD Biosciences, Oxford, UK). After lysing RBCs with 10x volumes of 
Ammonium chloride solution (StemCell Technologies, Vancouver, Canada), 1x105 
leucocytes were plated in 1.1mL MethocultTM GF M3434 (StemCell Technologies, 
Vancouver, Canada), incubated and HPC subsequently enumerated exactly as 
described in section 2.8.1.1.  
In other experiments, CCR2 KO mice were used instead of WT mice; however, 
the details of the experimental protocols were exactly as described above. 
2.8.1.4 In vivo Ccl2 neutralisation assay 
A schematic of the in vivo Ccl2 neutralisation experimental procedure is shown 
below: 
 
 
For Ccl2 in vivo neutralisation experiment, anti-mouse CCL2 affinity purified 
polyclonal antibody (catalogue no: AF-479-NA) was purchased from R&D systems 
(Abingdon, UK) and reconstituted in 1X DPBS to 1µg/mL. Normal goat IgG control 
antibody (catalogue no.: AB-108-C) was also purchased from R&D systems 
(Abingdon, UK) as a negative control. Three groups of WT mice labelled A, B and 
C, were set up for these experiments. Mice in groups A and B each received 
62.5mg imiquimod cream application on shaved dorsal skin for three consecutive 
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days. However, mice in group A each received a single intravenous dose of 15µg 
anti-mouse CCL2 affinity purified polyclonal antibody on day 1, and day 3; on 
the other hand, mice in group B, each received 15µg normal goat IgG control 
antibody also on day 1 and day 3. Mice in group C received topical aqueous 
cream treatment for three consecutive days. Mice in all three groups i.e. A, B 
and C were euthanized in a CO2 chamber on day 4 and peripheral blood taken for 
haematopoietic colony-forming assay as described in section 2.8.1.1. 
2.9 Enzyme-linked immunosorbent assay (ELISA) 
2.9.1 Plasma samples 
WT mice were given either the topical imiquimod cream/TPA treatment or the 
I.P. LPS injection exactly as described in section 2.2.1 and 2.2.2 respectively. 
After the duration of the treatment elapsed, mice were culled by CO2 
asphyxiation and blood taken into EDTA anti-coagulated tubes. Blood was spun 
at >8000g and plasma was taken and kept at -80ºC until required for ELISA. 
2.9.2 Extraction of bone and bone marrow extracellular fluid 
proteins 
WT mice were treated with either topical imiquimod cream/TPA or I.P. LPS 
injection exactly as described in sections 2.2.1 & 2.2.2 respectively. The mice 
were culled by CO2 asphyxiation and femur and tibia were harvested from these 
mice and cleared of muscle tissue. After cutting the ends of each bone, 1mL of 
PBS was used to repeatedly flush out the marrow. The marrow washout was then 
pipetted up and down several times to loosen the cell aggregates and then spun 
at 400xg for 10 minutes. The bone marrow supernatant, henceforth called bone 
marrow extracellular fluid was kept frozen at -80ºC until needed for CXCL12 
ELISA. Next, the hollow cortical bones were homogenised in 400µL of mammalian 
protein extraction reagent (M-PER, Thermo-Scientific, Pearce, UK) using a 
TissueLyser LT machine (Qiagen, Manchester, UK) set at 500Hz (for 10 minutes). 
Afterwards, the cortical bone homogenates were centrifuged at >10,000xg for 10 
minutes. The supernatants were kept frozen at -80ºC until needed for CXCL12 
ELISA. 
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In some experiments, whole bone marrow proteins (i.e. bone marrow + bone 
tissue proteins) were extracted by homogenising whole tibia and femur bones in 
400µL mammalian protein extraction reagent (M-PER, Thermo-Scientific, Pearce, 
UK) using the TissueLyser LT machine (Qiagen) set at 500Hz (for 10 minutes). 
The whole bone marrow homogenates were spun at 10,000 xg for 10 minutes and 
the supernatants were kept frozen at -80ºC until required for CXCL12 ELISA.      
2.9.2.1 CCL2 ELISA experimental procedure 
For quantitative estimation of mouse peripheral blood CCl2, mouse CCL2 (MCP-1) 
ELISA Ready-SET-Go (Catalogue no. 88-7391) was purchased from eBiosciences 
(Hatfield, UK) and used in accordance with manufacturers’ protocol. A Corning 
Costar 9018 ELISA plate was coated with 100µL/well of capture antibody 
(reconstituted in coating buffer) and the plate was sealed and incubated 
overnight at 4°C. On the next day, each well was washed 5x with 300µL washing 
buffer (0.05%v/v Tween 20 in 1x DPBS; pH 7.2-7.4). After blotting the plate with 
absorbent paper, each well was blocked with 200µL of 1X assay diluent and 
incubated at room temperature for 1 hour. Next, each well was washed (3x) 
with ~300µL washing buffer, blotted with absorbent paper, and 100µL of the top 
standard and serial dilutions of the standards were added to the respective wells 
in duplicates. 100µL of neat, as well as 1:5 and 1:10 dilutions of samples 
(dilutions made with 1X ELISA diluent), were next added to their respective 
wells and incubated at room temperature for 2 hours. After washing each well 5 
times and blotting with absorbent paper, 100µL of detection antibody was added 
to each well and incubated for 1 hour at room temperature. Afterwards, each 
well was washed 5x with washing buffer, and blotted thoroughly, 100µL of 
Avidin-HRP was added to each well, sealed and incubated at room temperature 
for 30 minutes. Each well was next washed 7x with washing buffer and blotted 
with absorbent paper, 100µL of 1X TMB substrate solution was added to each 
well and then incubated at room temperature for another 15 minutes. 50µL of 
stop solution (2N H2SO4) was then added to each well and the optical densities of 
each well in the plate was immediately read firstly, at 450nm, and then at 
550nm, on a Tecan SunriseTM microplate reader (Tecan, Maennedorf, 
Switzerland). Subtracting optical density readings at 550nm from each result 
corrected for background optical density interferences. The corrected optical 
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densities of the top standard and its serial dilutions were used to generate a 
standard curve and the data analysed by MagellanTM software (Tecan).  
2.9.2.2 Mouse CXCL12 ELISA 
The mouse Quantikine CXCL12/SDF-1α ELISA kit (catalogue no. MCX120; R & D 
Systems) was used to determine the quantities of Cxcl12 in plasma, bone and 
bone marrow extracellular fluid in accordance with manufacturer’s instruction. 
0.1mg of total protein from whole bone marrow or bone marrow extracellular 
fluid or bone protein extract was used for the assay. Sufficient volume of Assay 
Diluent was added to volumes of samples equivalent to 0.1mg to make up to 
50µL and subsequently transferred to wells of a 96-well microplate. 50µL of 
serially diluted mouse CXCL12 standard, or mouse CXCL12 control were also 
added to the relevant wells. The plate was then sealed with an adhesive strip 
and incubated for 2 hours at room temperature on a horizontal orbital 
microplate shaker set at 500 ± 50 rpm. The subsequent washing of the plate and 
further processing were essentially as stated in the manufacturer’s protocol. The 
optical density of each well of the plate was determined using a Tecan SunriseTM 
microplate reader (Tecan, Maennedorf, Switzerland) set to 450 nm wavelength, 
with wavelength correction set at 570 nm. 
2.10 Mouse Bone marrow and plasma proteome array 
2.10.1 Sample preparation 
Plasma and whole bone marrow protein was harvested from mice (WT or CCR2 
KO mice) treated with topical imiquimod cream/TPA (see section 2.2.1) exactly 
as described in sections 2.9.1 and 2.9.2. In order to obtain representative data, 
plasma was pooled from three mice per treatment and 150µL was used for each 
array. Also, bone marrow protein extracts were pooled from three mice per 
treatment and ~300µg used for the proteome profile array described below. 
2.10.2 Bone marrow and plasma angiogenesis proteome 
array  
The plasma and bone marrow angiogenesis proteome profiling was done in 
accordance with manufacturer’s instructions using the mouse angiogenesis array 
Chapter 2: Materials and Methods  104 
 
kit (Cat. No. ARY015; R&D Systems, Abingdon, UK). The 4 array membranes were 
each placed in separate wells containing 2.0mL of Array Buffer 6 to block the 
membrane against non-specific binding. Next, the membranes were incubated at 
room temperature on a rocking platform shaker for 60 minutes. Simultaneously, 
sample/antibody mixture was constituted by adding the requisite volumes of 
samples (bone marrow homogenate or plasma protein) to 500µL of array buffer 4 
in separate tubes. After adjusting the sample:array buffer 4 volume to 1.5mL 
with array buffer 6, 15µL of detection antibody cocktail was added and 
incubated for 60 minutes at room temperature. When the incubation period 
elapsed, the blocking buffer (array buffer 6) was aspirated from each well, the 
respective sample/antibody mixture was added to the wells, covered and 
incubated overnight at 4°C on a rocking platform. The next day, each membrane 
was washed three times in 20mL of 1X wash buffer on a rocking platform for 10 
minutes each. Afterwards, each membrane was incubated in Streptavidin-HRP on 
a shaking platform for 30 minutes at room temperature. Each membrane was 
then washed 3X in 20mL of 1X wash buffer on a rocking platform for 10 minutes 
each. Next, each membrane was completely blotted on absorbent paper, placed 
on a plastic sheet protector with the identification number facing up. One 
millilitre of Chemi-Reagent Mix was added to each membrane, covered with a 
plastic sheet protector and subsequently smoothed out to ensure uniform 
distribution to all corners of the blot. Next, the membranes were incubated for 
1 minute and then thoroughly blotted with absorbent paper. Afterwards, the 
membranes were placed in an autoradiography film cassette with their 
identification numbers facing up, exposed to X-ray film for 1-10 minutes and the 
film developed. Developed films were scanned with Epson Perfection 3490 Photo 
and signal intensities of developed films were analysed with ImageJ version 
1.46r (National Institute of Health, USA). 
2.10.3 Plasma cytokine proteome array 
The cytokine proteome array kit (catalogue no: ARY006) was purchased from R & 
D Systems (Abingdon, UK). The procedure for the array was essentially as 
described for the angiogenesis array described in section 2.10.2 above, except 
that plasma as well as antibody cocktail detecting cytokine/chemokines were 
used.  
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2.11 CCL2 chemokine transmigration assay 
To investigate the functional relevance of Ccr2 expressed on haematopoietic 
stem and progenitor cells, an in vitro chemotaxis assay utilising CCl2 was 
employed. Recombinant murine CCL2 was purchased from PeproTech (London, 
UK), reconstituted in sterile water and made up to 1ng/mL in chemotaxis buffer. 
24-well transwell plates (6.5mm diameter inserts, 5.0µm pore size) were 
purchased from Corning Incorporated (Radnor, USA). Bone marrow cells from 
mice given topical Imiquimod cream/TPA treatment or LPS injection (as 
described in sections 2.2.1 and 2.2.2 respectively) were processed for FACS (as 
described in section 1.5.1) and stained with biotinylated lineage antibody 
cocktail, c-Kit-APC-Cy7 and Live/Dead Aqua exactly as described in section 
1.5.2. 2x105 LK cells (Lin-, c-Kit+ haematopoietic progenitor cells) were sorted 
on FACS Aria II (BD Biosciences) into FACS sorting buffer, and then washed in 
1mL of chemotaxis buffer. The cell were spun down at 300xg (for 5 minutes at 
4ºC) and re-suspended in 100µl of chemotaxis buffer. 50ng of CCL2 was added to 
600uL chemotaxis buffer in the lower well chamber. The inserts were placed 
back into each well with chemokine-chemotaxis buffer and incubated at 37°C 
for 10 minutes to allow equilibration. The 100ul cell suspension (2x105) was then 
added to the inserts and incubated for 4-5 hours at 37°C, in the presence of 5% 
CO2. After the incubation period, the inserts were carefully removed with 
forceps and transferred into a 24-well plate. 400µL of chemotaxis buffer in the 
lower chamber containing migrated cells were cultured in MethocultTM GF M3434 
for 7-10 days, and colonies were visualised and enumerated using an inverted 
bright-field microscope. 
2.12 Statistical analyses 
Data analyses were undertaken using Prism 5 software (GraphPad, San Diego, 
USA). Unless otherwise indicated, results are presented as mean ± standard error 
of mean (SEM). Prior to analysis, all data were first tested for normality using 
the D’Agostino and Pearson omnibus normality test and Kolmogorov-Smirnov test 
to verify if they were normally distributed. For samples that passed the 
normality test, a 2-tailed unpaired t-test was used to compare each treatment 
group with its respective control; for samples not passing the normality test, two 
groups were compared using the 2-tailed Mann-Whitney U test. Data comparing 
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more than two groups were analysed using 2-tailed Kruskal-Wallis test with 
Dunn’s post-test, unless the data passed the normality test in which case they 
were compared using One-Way ANOVA with Tukey’s post-test. Statistical 
significance were defined as *p<0.05, **p< 0.01, ***p< 0.0001.  
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3.1 Aims and introduction 
Lipopolysaccharide (LPS) is one of the conserved molecular patterns in Gram-
negative bacteria that are recognized by the mammalian TLR4. Accordingly, LPS 
has been used as a model of Gram-negative bacterial infection (Haziot et al., 
1996, Rietschel et al., 1994). In the context of haematopoietic stem and 
progenitor cell (HSPC) biology, LPS has been shown to induce a significant 
mobilisation of HSPC to the circulation when administered through intra-
peritoneal or intravenous routes (Vos et al., 1972, Quesenberry et al., 1973). 
Although it was shown recently that HSPC express TLR4 (Nagai et al., 2006), the 
mechanisms that orchestrate this LPS-induced HSPC mobilisation are still 
unclear. Chemokines are small chemotactic cytokines, and one of these 
chemokines, CXCL12, orchestrates migration of stem cells to specific anatomical 
sites during embryonic development. In addition, other chemokines also play 
fundamental roles in orchestrating the migration of leucocytes to sites of 
infection and inflammation in adult organisms. Due to the crucial roles played by 
chemokines in orchestrating in vivo cellular migration, I hypothesised that HSPC 
inducibly express chemokine receptors in response to LPS injection and that 
manipulation of the chemokine-chemokine receptor axis was crucial in the LPS-
induced HSPC mobilisation and subsequent migration to inflamed sites. 
Additionally, as the retention of HSPC in the bone marrow niche is aided by 
specific HSPC-niche cell interactions, and/or HSPC interactions with soluble 
factors elaborated by these niche cells, I further hypothesised that the HSPC 
mobilisation induced by systemic LPS injection is also related to modulation of 
these niche cells and/or their secreted soluble factors. To test these 
hypotheses, I aimed to address the following questions: 
1. Does TLR4 ligation/LPS injection orchestrate HSPC mobilisation? 
2. Does systemic LPS injection alter the HSPC compartment in the bone marrow? 
3. Does systemic LPS injection alter the HSPC niche in the bone marrow?  
4. What cytokines and chemokines are induced in response to systemic LPS 
injection?  
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By addressing these questions, I sought to obtain a comprehensive understanding 
of the roles for the chemokine-chemokine receptor axis, and bone marrow 
niche, in HSPC biology during LPS mobilisation. 
3.2 Does TLR4 ligation induce HSPC mobilisation? 
3.2.1 Introduction 
To address this question, the intraperitoneal (I.P.) LPS injection was employed 
to investigate how in vivo TLR4 ligation impacted HSPC migration or localisation 
in C57BL/6 mice. LPS is a product of Gram-negative bacteria and is a known 
TLR4 ligand. To ensure that any subsequent observations made were purely due 
to TLR4 signalling, Ultra-pure LPS, which is devoid of contaminating TLR2 
ligands, was purchased from InvivoGen. The in vitro haematopoietic progenitor 
cell (HPC) growth-supporting medium selected to enumerate circulating HPC was 
MethocultTM GF M3434. This M3434 medium is a cytokine-enriched, 
methylcellulose-based medium that supports the in vitro growth of 
myeloerythroid progenitor cells. Although this assay does not allow the 
estimation of haematopoietic stem cells (HSC) and lymphoid progenitors, it 
allows the enumeration of other multipotent haematopoietic progenitors (HPC) 
such as CFU-GEMM (colony forming unit (CFU)- with granulocyte, erythrocyte, 
megakaryocyte and macrophage potential), CFU-GM (CFU with granulocyte-
macrophage potential), and BFU-E (Burst-forming unit, erythroid), which are 
downstream of the HSC in the haematopoietic hierarchy. 
Mice were given a single dose of either I.P. LPS (100µg in 100µL PBS) or 100µL 
I.P. PBS as a control. 18-24 hours after the injection, mice were culled by CO2 
asphyxiation and peripheral blood was taken through cardiac puncture. After 
lysing red blood cells with Ammonium Chloride solution, 1x105 cells were seeded 
into 1.1mL of MethocultTM GF M3434 (StemCell Technologies) and incubated at 
37°C in 5% CO2 to enumerate haematopoietic progenitor cells mobilised to the 
circulation. After 7-10 days of incubation, HPC colonies were visualised and 
counted using an inverted microscope.  
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3.2.2 Intraperitoneal LPS injection induces HSPC mobilisation. 
As summarised in the scatter plot in figure 3-1A, I.P. LPS significantly induced 
HPC mobilisation to the peripheral circulation in mice compared to PBS treated 
controls (***p=0.0001; 2-tailed unpaired T-test). On average, LPS injection 
induced approximately, a 4-fold (22.85/5.6) increase in total circulating 
progenitor cell numbers compared to PBS treated controls. Further analysis of 
the colony morphology showed that LPS injection induced increased circulating 
levels of CFU-GEMM, CFU-GM and BFU-E compared to PBS controls; although the 
majority of the progenitors were CFU-GM (figure 3-1B). 
 
Figure 3-1 LPS induces haematopoietic progenitor cell mobilisation to peripheral blood. 
C57BL/6 mice were either given a single dose of intraperitoneal LPS (100µg in 100µL PBS), or 
100µL I.P. PBS injection as a control. 18-24 hours after the injection, mice were euthanized by CO2 
asphyxiation and peripheral blood taken for haematopoietic colony-forming assay. After lysing red 
blood cells with Ammonium chloride, 1x105 leucocytes were seeded into 1.1mL of MethocultTM GF 
M3434 medium (StemCell Technologies) in duplicates, and incubated for 7-10 days in a 5% CO2 
humidified chamber. Colonies representing haematopoietic progenitor cell were then enumerated 
using an inverted microscope. In A, the total colonies formed were compared for the LPS treated 
groups and PBS treated controls. In B, the different myeloerythroid progenitor colonies were 
compared. [***p=0.0001; 2-tailed, unpaired t-test, n=5-7 mice in each experiment (5 independent 
experiments); data points are a representation of two independent experiments pooled together; 
Data were plotted as mean ±SEM]. 
Taken together, the data presented in this section indicate that LPS injection 
induces HPC mobilisation to peripheral blood. 
3.3 Does systemic LPS injection alter the HSPC 
compartment in the bone marrow? 
3.3.1 LPS injection significantly reduces bone marrow cellularity. 
After establishing that LPS injection mobilised HPC to the circulation, the wider 
effects of systemic LPS injection on the HSPC compartment (including HSC), was 
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further explored through fluorescence associated cell sorting (FACS). Mice were 
given a single dose of 100µg I.P. LPS (or 100µL I.P. PBS as a control) and were 
culled 24 hours after the injection. Bones [2x (tibia + femur + hip bones) were 
harvested from each mouse, cleared of muscle and crushed in a mortar and 
pestle. Red blood cells were lysed with Ammonium chloride solution and total 
bone marrow cellularity was calculated using a haemocytometer with Trypan 
Blue dead cell exclusion. As shown in figure 3-2, LPS injection significantly 
reduced the total bone marrow cellularity compared to PBS treated controls 
(**p= 0.0014; 2-tailed Mann-Whitney U test). On average, LPS injection reduced 
the total bone marrow cellularity by approximately 33% compared to PBS treated 
control [(111.8-75.24)/111.8]*100%. 
 
Figure 3-2 Intraperitoneal LPS injection significantly reduces bone marrow cellularity. 
C57BL/6 mice were either given a single dose of I.P. LPS (100µg in 100µL PBS) or 100µL I.P. PBS 
as a control. 18-24 hours after the injection, mice were euthanized by CO2 asphyxiation and bones 
[2x (tibia + femur + hip bones)] were taken for cell count. Total bone marrow cellularity was 
estimated using haemocytometer and trypan blue dead cell exclusion. Data were plotted as 
mean±SEM [**p=0.0014, 2-tailed Mann-Whitney U test; n=7-8 (3 independent experiments)]. 
3.3.2 LPS injection causes an apparent increase in bone marrow 
HSPC frequency. 
In terms of abundance, HSC have been estimated to account for about 0.001-
0.01% of total nucleated bone marrow cells in mice (Challen et al., 2009, Kiel et 
al., 2005). Therefore, to increase the chances of detecting measurable HSC 
numbers through flow cytometric analysis, the bone marrow cells were c-Kit 
enriched using the CD117 Microbeads and LS columns (Miltenyi Biotec, Surrey, 
UK) according to manufacturer’s instructions. All HSPC have been shown to 
express the c-Kit antigen (Zhao et al., 2000) and therefore this enrichment 
technique allowed for a substantial depletion of cells not expressing this 
antigen. c-Kit enriched bone marrow cells were subsequently stained for 
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differential expression of haematopoietic lineage-specific markers (CD4, CD5, 
CD8a, CD11b, B220, Ter119 and Gr-1), as well as Sca-1, c-Kit, CD150 and CD48 
antigens to analyse the HSPC compartment in accordance with the CD150+ SLAM 
(signalling lymphocyte activation molecule) antibody staining protocol (Kiel et 
al., 2005). A representative gating strategy used to analyse the HSPC 
compartment is shown in figure 3-3. Dead cells were excluded using a 
combination of singlet selection and then Live/dead Aqua fixable dye retention 
to gate out dead cells. Previous reports have established that HSPC are negative 
for antigens that identify terminally differentiated haematopoietic cells (Lin-), 
but are positive for both the stem cell antigen (Sca-1+) and CD117 (c-Kit+) 
antigens, i.e. the LSK gate in figure 3-3 (Zhao et al., 2000, van de Rijn et al., 
1989, Spangrude and Brooks, 1993). Therefore the cells in the LSK gate 
represent most of the HSPC; these LSK cells were thus selected for subsequent 
analysis. 
 
Figure 3-3 Gating strategy used for haematopoietic stem and progenitor (LSK) cell 
identification 
C57BL/6 mice were either given a single dose of I.P. LPS (100µg in 100µL PBS) or 100µL I.P. PBS 
as a control. 18-24 hours after the injection, mice were euthanized by CO2 asphyxiation and bone 
marrow [2x (tibia + femur + hip bones)] harvested, and enriched for haematopoietic progenitor cells 
using the CD117 (c-Kit) Microbeads and LS magnetic columns according to manufacturer 
instructions (Miltenyi Biotec). The c-Kit-enriched cells were then stained with lineage antibody 
cocktail (CD4, CD5, CD8a, Mac-1, B220, Ter119 and Gr-1), c-Kit, Sca-1, CD48 and CD150 to 
evaluate the HSPC compartment. After excluding dead cells through doublet exclusion and 
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Live/Dead Aqua fixable dye retention, cells positive for markers of terminal differentiation were also 
gated out. Next, cells co-expressing the c-Kit antigen and Sca-1 antigens were selected as the 
haematopoietic stem and progenitor cells (LSK gate). 
A comparison of the proportion of cells in the LSK gate between the LPS and PBS 
treated mice revealed an apparent expansion of the LSK compartment in 
response to LPS injection (compare figures 3-4 A & B). Consistent with this 
apparent increase in the proportion of bone marrow LSK cells, there was a 
statistically significant increase in the frequency of the LSK cells in the bone 
marrow of LPS treated mice compared to PBS treated controls (figure 3-4C: 
p=0.0001; 2-tailed, unpaired t test). The apparent increase in the proportion of 
LSK cells also reached statistical significance (figure 3-4D: p=0.0001; 2-tailed, 
unpaired t test). Moreover, on average, the cells in the LSK compartment of the 
bone marrow of LPS-treated mice were ~6-fold more frequent (1.555/0.273) 
when compared to the bone marrow of PBS-treated controls. 
Altogether, the dot plots of the flow cytometric data show that LPS injection 
causes a pseudo re-acquisition of Sca-1 expression by some Kit+Sca-1- cells 
(compare figures 3-4 A & B) resulting in an apparent expansion of the LSK 
compartment.   
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Figure 3-4 LPS injection causes an apparent expansion of the bone marrow LSK 
compartment. 
Figures A & B are representative plots of the LSK compartment in the I.P. LPS (100µg in 100µL 
PBS) or 100µL I.P. PBS injected mice based on the gating strategy shown in figure 3-3. Figure C is 
a scatter plot comparing the frequency of the cells in the LSK compartment per 1x106 total c-Kit 
enriched bone marrow cells (***p=0.0001; 2-tailed unpaired t-test; n=5 (three independent 
experiments)]. Figure D compares the percentages of the LSK cells in the I.P. LPS or I.P. PBS 
treated mice (***p=0.0001, 2-tailed unpaired t-test; n=5 (three independent experiments)]. 
3.3.3 LPS injection depletes the bone marrow HSPC populations. 
The flow cytometric analysis of the HSPC compartment (LSK cells) presented in 
section 3.3.2 (figure 3-3A-C) showed that LPS injection significantly increased 
Sca-1 expression. This phenomenon of pseudo increase in Sca-1 expression has 
been reported in other inflammation models (Zhang et al., 2008, Melvan et al., 
2011, Shi et al., 2013). Therefore, in order to avoid potential bias introduced by 
pseudo Sca-1 expression, a new gating strategy that excludes the Sca-1 antigen 
was adopted to analyse the HSPC compartment. Previously, Adolfsson et al. 
published a protocol that allowed the immunophenotypic characterisation of the 
HPC compartment into lymphoid-primed multipotent progenitor cells (LMPP) and 
common lymphoid progenitor (CLP) cells based on differential expression of 
CD34 and FLT3 antigens (Adolfsson et al., 2005). This protocol was employed 
with minor modifications: (1) due to the LPS-induced increase in Sca-1 antigen 
expression, Sca-1 was excluded from the gating strategy; (2) CD150 expression 
was included to permit the identification of the LT-HSC population in accordance 
with Kiel et al. who showed that expression of CD150 antigen identified the LT-
HSC population from the haematopoietic progenitor cells (Kiel et al., 2005). 
Therefore, in the staining protocol employed in the studies below, LMPP, CLP, 
ST-HSC and multipotent progenitor populations were defined as Lin-
Kit+CD34+FLT3+, Lin-Kit+CD34-FLT3+, Lin-Kit+CD34+FLT3- and Lin-Kit+CD34-FLT3- 
respectively in accordance with previously published protocols that were 
modified on the basis of pseudo Sca-1 expression (Adolfsson et al., 2005, Yang et 
al., 2005, Osawa et al., 1996). 
Figure 3-5 is a representative plot showing the gating strategy used to select the 
haematopoietic stem and progenitor cells (Lin-Kit+ cells, henceforth called LK) 
for further analysis. After excluding cellular debris through forward-side scatter 
plots, dead cells were excluded using a combination of doublet exclusion and 
retention of the Live/Dead Aqua fixable dye. After excluding terminally 
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differentiated haematopoietic cell i.e. Lin+ cells, c-Kithigh expressing cells were 
selected as the haematopoietic progenitor cells, i.e. LK cells. 
 
Figure 3-5 Gating strategy used for haematopoietic progenitor (LK) cell identification 
C57BL/6 mice were either given a single dose of I.P. LPS (100µg in 100µL PBS) or 100µL I.P. PBS 
as a control. 18-24 hours after the injection, mice were euthanized by CO2 asphyxiation and bone 
marrow [2x (tibia + femur + hip bones)] harvested, and enriched for haematopoietic progenitor cells 
using the CD117 (c-Kit) Microbeads and LS magnetic columns according to manufacturer 
instructions (Miltenyi Biotec). The c-Kit-enriched cells were then stained with lineage antibody 
cocktail (CD4, CD5, CD8a, Mac-1, B220, Ter119 and Gr-1), as well as c-Kit, Sca-1, CD34, CD150 
and FLT3 antibodies to evaluate the HSPC compartment. After excluding dead cells through 
doublet exclusion and Live/Dead Aqua fixable dye retention, cells positive for markers of terminal 
differentiation of haematopoietic cells were also gated out. Next, cells expressing high levels of c-
Kit antigen were selected as the haematopoietic progenitor cells (LK gate). 
Figures 3-6 A and B are representative respective dot plots showing LK cells from 
PBS or LPS treated mice, re-gated for differential expression of CD34 and FLT3 
antigens. As summarised in the bar graph in figure 3-6 C, LPS injection 
significantly reduced the bone marrow HPC populations. Specifically, LPS 
injection caused significant reduction in the bone marrow CLP population when 
compared to PBS treated controls (figure 3-6C, p<0.0001; 2-tailed unpaired t-
test). In addition, LPS injection significantly reduced the bone marrow LMPP 
population compared to PBS treated controls (figure 3-6C, p<0.0001; 2-tailed 
unpaired t-test). Moreover, LPS injection also reduced the ST-HSC population 
compared to PBS treated controls (figure 3-6C, p<0.0001; 2-tailed unpaired t-
test). 
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Figure 3-6 Intraperitoneal LPS-induced inflammation decreases the proportion of HPC with 
lymphoid potential. 
C57BL/6 mice received a single dose of Ultra-pure I.P. LPS (100µg in 100µL PBS) or 100µL I.P. 
PBS. 18-24 hours after the injection, mice were culled by CO2 asphyxiation and bone marrow cells 
[2x (tibia + femur + hip bones)] were harvested, and enriched for haematopoietic progenitor cells 
using the CD117 (c-Kit) Microbeads and LS magnetic columns according to manufacturer’s 
instructions (Miltenyi Biotec). The c-Kit-enriched cells were then stained with lineage antibody 
cocktail (CD4, CD5, CD8a, Mac-1, B220, Ter119 and Gr-1), as well as c-Kit, CD34, CD150, and 
FLT3 antibodies to evaluate the HSPC compartment. After excluding dead cells (see gating 
strategy in figure 3-5), c-Kit+ cells were re-gated for expression of CD34 and FLT3 antigens to 
delineate CLP, LMPP, ST-HSC and CD34-FLT3- multipotent cells. Figures A & B are respective 
representative dot plots showing the sub-gating of the bone marrow LK cells from PBS and LPS 
treated mice based on CD34 and FLT3 expression. Figure C is a bar graph summarising the 
changes in the proportions of the LMPP, ST-HSC, CLP and LKCD34-FLT3- multipotent progenitors 
in response to the systemic LPS-induced inflammation. Statistical significance was estimated using 
the unpaired t-test (2-tailed) in all cases. (n=5, 2-independent experiments)]. 
3.3.4 LPS injection significantly reduces bone marrow LT-HSC 
population. 
The Lin-Kit+CD34-FLT3- cell population (see gating strategy in section 3.3.3, 
figure 3-6 above) was re-gated for the differential expression of c-Kit and CD150 
expression to examine the effect of systemic LPS injection on the long-term 
haematopoietic stem cell population (LT-HSC). Previously, Kiel et al. published a 
protocol intimating that CD150 antigen expression enriches for LT-HSC 
population within the HSPC cells. Figures 3-7 A & B are representative dot plots 
showing CD150 expression within the Lin-Kit+CD34-FLT3- multipotent progenitor 
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cells in the bone marrow from I.P. PBS or I.P. LPS treated mice respectively. As 
summarised in the scatter plot in figure 3-7 C, LPS injection caused significant 
reduction in the proportion of the LT-HSC cells (defined as Lin-Kit+CD34-FLT3-
CD150high cells) in the bone marrow of C57BL/6 mice compared to PBS treated 
controls (figure 3-7C, p=0.0005; 2-tailed unpaired t-test). 
 
Figure 3-7 LPS injection significantly reduces the bone marrow LT-HSC population in 
C57BL/6 mice. 
The CD34-FLT3- cells (see gating strategy in figure 3-6 above) from I.P. PBS treated mice (A) or 
I.P. LPS treated mice (B), were re-gated for the expression of c-Kit and CD150 antigens to 
characterise the LT-HSC population. Figure C is a representative scatter plot summarising the 
effect of the I.P. LPS injection on the LT-HSC population in the bone marrow of C57BL/6 mice. 
Statistical significance was calculated using the 2-tailed unpaired t-test. [N=6; 2 independent 
experiments]. 
In summary, the data presented in this section show that LPS injection altered 
the HSPC compartment by significantly reducing the bone marrow cellularity 
that was reflected in significant reductions in the CLP, LMPP, ST-HSC and LT-HSC 
populations. 
3.4 Does systemic LPS injection alter the HSPC niche in 
the bone marrow? 
As reviewed extensively in the general introductory chapter, and elsewhere 
(Ehninger and Trumpp, 2011), the bone marrow niche comprises cellular 
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components and their secreted soluble products that interact with HSPC to 
retain them in the bone marrow. Thus, disruption of one or more of these 
interactions has been shown to be fundamental in influencing HSPC localisation 
and migration. To obtain a comprehensive picture of how LPS-induced systemic 
inflammation impacted the HSPC niche, this section of the study sought to 
address: 
1. How LPS injection affected the CXCR4/CXCL12 axis 
2. How LPS injection affected the bone marrow stromal cell compartment 
3. How LPS injection affected the mononuclear phagocytic cells of the bone 
marrow. 
In this way, I sought to obtain a comprehensive understanding of how LPS 
injection affected the bone marrow HSPC niche. Ultimately, the main objective 
was to begin the process of elucidating the basic mechanisms underpinning the 
HSPC mobilisation seen in the LPS injection model. 
3.4.1 LPS-induced systemic inflammation modulates the CXCR4-
CXCL12 axis in HSPC 
3.4.1.1 Introduction 
In line with the crucial roles played by the CXCR4/CXCL12 axis in the retention 
of HSPC in the bone marrow niche (Lapidot et al., 2005, Lapidot and Kollet, 
2002, Lapidot and Petit, 2002), many reports have shown that perturbation of 
the CXCR4/CXCL12 signalling axis is one of the fundamental mechanisms 
underpinning the ability of agents like G-CSF and AMD3100 to mobilise HSPC to 
the circulation (Christopher et al., 2009, Semerad et al., 2005). As I.P. LPS 
injection induced haematopoietic progenitor cell mobilisation [as demonstrated 
in haematopoietic colony forming assay (figure 3-1, section 3.2.2)], I sought to 
understand how the LPS-induced systemic inflammation modulated Cxcr4 
expression in the haematopoietic progenitor cells as well as CXCL12 protein 
concentration in the bone marrow and peripheral blood. 
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3.4.1.2 LPS injection decreases haematopoietic progenitor cell surface 
CXCR4 expression. 
Flow cytometry was employed to determine cell surface Cxcr4 expression in the 
haematopoietic progenitor cell population. As shown in section 3.3 of this study, 
and by others (Shi et al., 2013, Zhang et al., 2008), the inflammation models 
altered Sca-1 expression in the haematopoietic progenitor cells. Therefore, to 
obtain unbiased CXCR4 expression data in the HSPC of C57BL/6 mice, the LK 
(Lin-Kit+ cells) that encompasses the entire lymphomyeloid progenitor HSPC 
compartment was investigated for CXCR4 expression in the LPS injection model. 
Mice received a single I.P. LPS/PBS injection exactly as described in section 
3.3.1. The gating strategy for LK cells was essentially as described in section 
3.3.3. The dot plots in figures 3-8 A & B show the LK cell gating of the bone 
marrow of mice treated with either I.P. PBS or I.P. LPS respectively. Figure 3-8 C 
shows the histogram overlay plots for CXCR4 expression in LK cells from mice 
treated with I.P. PBS or LPS. The CXCR4 specific isotype-control staining pattern 
(figure 3-8C) shows the specificity of the CXCR4 antibody staining. As the 
histogram plots showed two distinct peaks for CXCR4 expression in the 
haematopoietic progenitor cells, only the CXCR4high expressing cells were further 
analysed in figure 3-8D. As summarised in the scatter plot in figure 3-8D, LPS-
induced systemic inflammation significantly reduced the LK CXCR4 cell surface 
expression compared to PBS treated controls (figure 3-8 D, p< 0.0001; 2-tailed 
unpaired t-test). 
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Figure 3-8 LPS induced systemic inflammation reduces CXCR4 expression on HSPC. 
C57BL/6 mice were either given a single dose of I.P. LPS (100µg in 100µL PBS) or 100µL I.P. PBS 
as a control. 18-24 hours after the injection, mice were euthanized by CO2 asphyxiation and bone 
marrow cells [2x (tibia + femur + hip bones)] were harvested, and enriched for haematopoietic 
progenitor cells using the CD117 (c-Kit) Microbeads and LS magnetic columns according to 
manufacturer’s instructions (Miltenyi Biotec). The c-Kit-enriched cells were then stained with 
lineage antibody cocktail (CD4, CD5, CD8a, Mac-1, B220, Ter119 and Gr-1), as well as c-Kit, 
CXCR4, and Live/Dead Aqua fixable dye to analyse the HSPC (LK) compartment for cell surface 
CXCR4 receptor expression. After gating on live cells through dead cell exclusion using the 
Live/Dead Aqua fixable dye, Lin- cells were selected for further analysis (see section 3.3.3 for 
example of gating strategy). Figures A & B are representative dot plots showing the LK (HSPC) 
gate for PBS and LPS treated bone marrow cells respectively. Figure C is a representative 
histogram plot showing the overlay of LK CXCR4 receptor expression for LPS and PBS treated 
mice (showing two distinct peaks representing CXCR4low and CXCR4high cells) as well as CXCR4 
isotype-matched control. Figure D is a scatter plot summarising the MFI of the surface CXCR4 
expression of the LK compartment for LPS and PBS treated controls. Statistical significance was 
calculated using the 2-tailed, unpaired t-test [N=5-6 (2 independent experiments)]. 
Taken together, the reduced CXCR4 receptor expression of the HSPC population, 
observed with LPS-induced inflammation, possibly play a contributory role to the 
increased numbers of HSPC released in response to the LPS injection. 
3.4.1.3 LPS-induced systemic inflammation significantly reduces bone 
marrow CXCL12 concentration. 
Having examined surface Cxcr4 expression in the LK population, I next sought to 
understand how LPS-induced systemic inflammation also affected the production 
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of CXCL12, which is the ligand for CXCR4. An enzyme-linked immunosorbent 
assay (ELISA) was employed to measure concentrations of CXCL12 in the plasma, 
bone marrow, bone marrow extracellular fluid, and bone protein extract. As 
discussed in the general introductory chapter, exogenously administered CXCL12 
mobilises HSPC from the bone marrow as it induces a sustained peripheral blood 
CXCL12 level, thus creating a CXCL12 gradient between the blood and bone 
marrow. Circulating CXCL12 levels were estimated by measuring the CXCL12 
concentration in the plasma. The aim was to determine whether LPS-induced 
systemic inflammation was able to create a similar CXCL12 concentration 
gradient that favoured the exit of HSPC from the bone marrow. Figure 3-9A 
shows the calibration curve used to establish the limit of detection of the assay 
with reliability (R2=0.997) between the CXCL12 concentration and the optical 
density of the measurements. The results from the plasma CXCL12 measurement 
showed comparable CXCL12 levels in PBS-treated and LPS-injected groups (figure 
3-9B). This suggests that LPS-induced systemic inflammation did not increase 
plasma CXCL12 concentration that might have led to the HSPC mobilisation.  
 
Figure 3-9 LPS induced systemic inflammation does not significantly change plasma 
CXCL12 concentration.  
C57BL/6 mice were either given a single dose of I.P. LPS (100µg in 100µL PBS), or 100µL I.P. 
PBS as a control. 18-24 hours after the injection, mice were euthanized by CO2 asphyxiation, 
peripheral blood was taken into EDTA anti-coagulation tubes, spun at >10,000xg for 10 minutes 
and plasma taken for CXCL12 ELISA. Figure A is the calibration curve showing a good fit 
(R2=0.997) for the concentration of CXCL12 and optical density and the detection limit of the assay. 
Figure B summarises the measured CXCL12 concentration in the plasma of PBS and LPS treated 
mice. (n=5). 
To measure the total bone marrow CXCL12 concentration, whole bones [2x 
(femur + tibia)] were homogenised in 400µL of mammalian protein extraction 
reagent (M-PER, Thermo Scientific) to extract the total bone marrow protein. 
Also, to examine the separate contribution from the bone tissue and the bone 
marrow extracellular fluid towards the measured total bone marrow CXCL12, 
bone marrow extracellular fluid, and bone protein extract, CXCL12 levels were 
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also measured. Extracellular bone marrow proteins were extracted in 
accordance with previously published protocols (Semerad et al., 2005, Levesque 
et al., 2001). Measurement of total bone marrow CXCL12 concentration revealed 
that the LPS-induced systemic inflammation significantly decreased the total 
bone marrow CXCL12 concentration (figure 3-10A, p= 0.0286; 2-tailed, Mann-
Whitney U test). In addition, the LPS-induced inflammation also significantly 
reduced the bone marrow extracellular fluid CXCL12 concentration (figure 3-
10B, p= 0.0286; 2-tailed, Mann-Whitney U test). However, the CXCL12 
concentration in the bone protein extract, showed no difference between LPS- 
and PBS-treated groups (figure 3-10C). 
 
Figure 3-10 Systemic LPS-induced inflammation significantly reduces bone marrow CXCL12 
levels. 
C57BL/6 mice were either given a single dose of I.P. LPS (100µg in 100µL PBS) or 100µL I.P. PBS 
as a control. 18-24 hours after the injection, mice were euthanized by CO2 asphyxiation and bones 
[2x (tibia +femur)] were harvested for further processing. In some cases (figure A), whole bone 
were homogenised in 400µL of mammalian protein extraction reagents (MPER, Thermo Scientific) 
to obtain total bone marrow protein. In other cases (figure B), the marrow was flushed repeatedly 
with 1mL of PBS, and the resulting PBS-bone marrow suspension was spun at >10,000xg to 
harvest the bone marrow extracellular fluid protein. The hollow bone tissues were also 
homogenised in 400µL of mammalian protein extraction reagent, spun at 10,000xg and 
supernatants harvested to obtain bone protein extract (figure C). About 0.1mg of the respective 
proteins (from LPS, or PBS, treated mice) was used for CXCL12 quantification using the 
Quantikine mouse CXCL12 ELISA kit (R&D Systems). Figures A, B and C show the respective 
plots of CXCL12 measured in total bone marrow protein, bone marrow extracellular fluid, and bone 
proteins respectively for LPS and PBS treated groups. [*p=0.0286; 2-tailed Mann-Whitney U test, 
(n=5)]. 
Altogether, the results from the ELISA data suggest that LPS-induced systemic 
inflammation could have created a perturbation of the CXCL12 gradient 
favouring the egress of CXCR4-expressing cells, including HSPCs, from the bone 
marrow. This argument is supported by the findings that although circulating 
CXCL12 levels [as estimated by the plasma CXCL12 (figure 3-9B)] remained 
unchanged between LPS and PBS treated mice, the extracellular bone marrow 
CXCL12 concentration was significantly reduced [(reduced to ~half the level in 
PBS treated control (see figure 3-10B)] by LPS-induced systemic inflammation. 
Therefore, perturbation of the CXCL12 gradient may be another significant 
component of the mechanism underpinning the LPS-induced HSPC mobilisation. 
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3.4.2 The impact of LPS-induced inflammation on the bone 
marrow stromal cells. 
3.4.2.1 Introduction. 
The role of the bone marrow microenvironment, or niche, in regulating 
haematopoietic stem and progenitor cell behaviour has been discussed at length 
in the general introductory chapter. Previous reports have shown that the 
cellular components of the bone marrow stroma that include endothelial cells, 
nestin+ mesenchymal stromal cells, CXCL12-abundant reticular cells, and 
osteoblasts, as well as their elaborated soluble factors such as CXCL12, stem cell 
factor, angiopoietin-1 and osteopontin, interact with HSPC to mediate their 
retention in the bone marrow. Not surprisingly, many previous findings have 
shown that most HSPC mobilising agents modulate the functions of these cellular 
niche components (Chow et al., 2011, Christopher et al., 2009). For example, G-
CSF has been shown to reduce Cxcl12 secretion in the bone marrow by inhibiting 
osteoblast activity (Semerad et al., 2005). 
In order to begin evaluating the role of the bone marrow stromal cells in LPS-
induced haematopoietic progenitor cell mobilisation, flow cytometry was 
employed to assess the endothelial cell, mesenchymal stromal cell and 
osteoblast populations in the endosteal bone surface. Mice were given I.P. 
LPS/PBS injection exactly as described in section 3.3.1, and bones were 
harvested as described in section 3.3.3. After flushing out the marrow, the 
bones were incubated in digestion buffer consisting of 3mg/mL collagenase IV 
(Sigma-Aldrich, Irvine, UK) in 1xHBSS at 37°C for 45 minutes (Semerad et al., 
2005). The bones were then crushed in a mortar and pestle, and filtered through 
a 70µm cell strainer (BD Biosciences, Oxford, UK) to remove bone fragments. 
The resulting suspension was spun at 300xg and the bone stromal cells were 
depleted of haematopoietic cells using the mouse lineage cell depletion kit and 
LS magnetic columns in accordance with manufacturer’s protocol (Miltenyi 
Biotec, Surrey, UK). The resulting cells were next stained for differential 
expression of lineage antibody cocktail (Lin), CD45, CD31, CD51, and Sca-1 
antigens in accordance with previously published protocol (Winkler et al., 
2010a). Dead cells were excluded using Live/Dead Aqua (Life Technologies). To 
ensure the exclusion of haematopoietic cells, cells staining positive for either 
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CD45 and/or the cocktail of haematopoietic lineage detection antibody (Lin) 
were excluded as shown in the gating strategy (figure 3-11). Bone marrow 
endothelial cells, mesenchymal stromal cells and osteoblasts were defined as 
Lin-CD45-Sca-1+CD31+, Lin-CD45-CD31-Sca-1+CD51+ and Lin-CD45-CD31-Sca-1-CD51+ 
respectively (Winkler et al., 2010a). 
 
Figure 3-11 Gating strategy used to select the bone marrow stromal cells. 
C57BL/6 mice were either given a single dose of I.P. LPS (100µg in 100µL PBS) or 100µL I.P. PBS 
as a control. 18-24 hours after the injection, mice were euthanized by CO2 asphyxiation, and bones 
[2x (tibia + femur + hip bones)] were harvested, and the marrow was subsequently flushed with 
PBS. The remaining bone tissue was incubated in 3mg/mL collagenase IV in 1xHBSS buffer at 
37°C for 45 minutes. The bones were then crushed using a mortar and pestle, filtered to exclude 
bone fragment and then depleted of haematopoietic cells using biotinylated lineage antibody 
cocktail, anti-biotin Microbeads and LS magnetic columns (Miltenyi Biotec). The resultant cells 
were stained for differential expression of haematopoietic lineage markers [Lin cocktail antibody 
(CD4, CD5, CD8a, CD11b, CD45R, Ter119 and Gr-1)], CD45, CD31, Sca-1 and CD51. The gating 
strategy used to exclude both dead cells and cells of the haematopoietic lineages from the 
subsequent analysis of the bone marrow stromal cell compartment is shown. 
3.4.2.2 LPS-induced systemic inflammation increases bone marrow 
endothelial cells 
The CD45-Lin- cell gate (shown in the gating strategy in section 3.4.2.1 above; 
figure 3-11) was sub-gated for differential expression of Sca-1 and CD31 
antigens. The Lin-CD45-Sca-1+CD31- population was further analysed as discussed 
in section 3.4.2.3 below. The Lin-CD45-Sca-1+CD31+ population was referred to as 
endothelial cells in agreement with previously published reports (Winkler et al., 
2010a, Winkler et al., 2010b). As shown in figure 3-12 (compare figures A & B), 
LPS-induced systemic inflammation caused an expansion in the proportion of the 
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bone marrow endothelial cell compartment. This increase in the endothelial cell 
proportion reached statistical significance (figure 3-12 C; **p=0.001; 2-tailed, 
Unpaired t-test). 
 
Figure 3-12 LPS injection increases the proportion of bone marrow endothelial cells. 
The CD45-Lin- non-haematopoietic cells (see figure 3-11 for gating strategy), from bone stromal 
cells of either PBS, or LPS, treated mice, were re-gated for differential expression of CD31 and 
Sca-1 antigens to identify endothelial cells (CD45-Lin-CD31+Sca-1+) and non-endothelial cells 
(CD45-Lin-CD31-Sca-1-/+) for further analysis. Figures A and B are representative dot plots for the 
re-gating of the CD45-Lin- non-haematopoietic cells from PBS and LPS treated mice respectively. 
C is a scatter plot summarising the effects of the LPS injection on the bone marrow endothelial cell 
compartment as compared to PBS treated controls. Data presented in the scatter plots are 
mean±SEM [**p=0.001; 2-tailed, unpaired t-test; n=5 (2 independent experiments)] 
3.4.2.3 LPS injection significantly increases MSC but reduces bone marrow 
osteoblast population. 
The Lin-CD45-Sca-1-/+CD31- cells (indicated as non-endothelial cells in figure 3-12 
A & B), were next re-gated for the differential expression of CD51 and Sca-1 
antigens. Cells that co-expressed CD51 and Sca-1 (i.e. Lin-CD45-Sca-1+CD31-
CD51+) were subsequently referred to as mesenchymal stromal cells (MSC), 
whereas cells that expressed the CD51, but not Sca-1 antigens, (i.e. Lin-CD45-
Sca-1-CD31-CD51+) were referred to as osteoblasts in agreement with previous 
reports (Semerad et al., 2005, Short et al., 2009, Winkler et al., 2010b). As 
shown in figures 3-13 A & B, and summarised in figure 3-13C, I.P. LPS-induced 
systemic inflammation orchestrated a statistically significant increase in the 
proportion of MSC in the total bone marrow stromal population (figure 3-13C, 
Chapter 3: Systemic inflammation model  126 
 
p<0.0001; 2-tailed, Unpaired t-test). In addition, systemic LPS led to a 
statistically significant reduction in the osteoblast population (figure 3-13C, 
p=0.0017; 2-tailed, unpaired t-test).  
 
Figure 3-13 LPS injection significantly alters the osteoblasts and MSC of the HSPC niche.  
The non-endothelial cells (CD45-Lin-CD31-Sca-1-/+) (see figure 3-12 A & B for gating strategy), from 
bone stromal cells of either I.P. PBS, or I.P. LPS, treated mice, were re-gated for differential 
expression of CD51 and Sca-1 antigen to identify osteoblasts (CD45-Lin-CD31-Sca-1-CD51+) and 
mesenchymal stromal cells [MSC, CD45-Lin-CD31-Sca-1+CD51+). Figures A & B are representative 
plots from the re-gating of the CD45-Lin-CD31-Sca-1-/+ non-endothelial cells from PBS and LPS 
treated mice respectively. C is a scatter plot comparing the proportion of MSC cells in PBS and 
LPS treated mice. D is a scatter plot comparing the proportions of osteoblasts in PBS and LPS 
treated mice. [***p<0.0001; **p=0.0017; 2-tailed Unpaired t-test, n=4 (2 independent experiments)]. 
Taken together, systemic LPS-induced inflammation led to significant 
modulation of the bone marrow stromal cell population that has established 
roles as critical components of the bone marrow niche. 
3.4.3 The effects of LPS-induced inflammation on bone marrow 
mononuclear phagocytic cells. 
Previous studies have indicated that cellular components of the innate immune 
system are important in the retention of haematopoietic stem and progenitor 
cells in the bone marrow (Chow et al., 2011, Winkler et al., 2010b). To begin to 
address how these cells were impacted by systemic LPS injection, bone marrow 
cells from I.P. LPS, or PBS, injected mice were analysed by flow cytometry in 
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accordance with a previously published protocol (Chow et al., 2011). Figure 3-14 
shows the gating strategy used to sub-set the mononuclear phagocytic cells. 
After excluding dead cells through positive staining for Live/Dead Aqua fixable 
dye, the live cells were gated for differential expression of the granulocytic 
marker, Gr-1, and the monocytic marker, CD115. This enabled the exclusion of 
Gr-1highCD115+ cells (mainly neutrophils and monocytes), to allow for the Gr-
1lowCD115+/- cells to be further analysed (see sections 3.4.3.1 & 3.4.3.2 below). 
 
Figure 3-14 Gating strategy used to characterise the bone marrow mononuclear phagocytic 
cells. 
C57BL/6 mice were either given a single intraperitoneal injection of Ultra-pure LPS (100µg in 
100µL PBS) or 100µL PBS as a control. 18-24 hours after the injection, mice were euthanized by 
CO2 asphyxiation, and bones [2x (tibia + femur)] were harvested and the marrow flushed with 
FACS buffer. After lysing red blood cells with Ammonium chloride, the cells were stained with 
Live/Dead Aqua fixable dye, F4/80, CD115, Gr-1, CD11b and CD169 antibodies to evaluate the 
mononuclear phagocytic cells of the bone marrow. Figure 3-14 is a representative plot illustrating 
the gating strategy used to exclude dead cells through doublet exclusion and retention of 
Live/Dead Aqua fixable dye. The live cells were then sub-gated for differential expression of Gr-1 
and CD115 antigen to select Gr-1-/lowCD115-/+ mononuclear cells. These Gr-1-/lowCD115-/+ 
mononuclear cells were then re-gated for the differential expression of F4/80 and CD115 antigens 
to identify the Gr-1lowCD115+ monocytic cells and Gr-1-/lowCD115int mononuclear cells. 
3.4.3.1 LPS injection reduces the bone marrow Gr-1lowCD115+ monocytic 
population. 
The Gr-1lowCD115+/- cells were subsequently re-gated for differential expression 
of CD115 and F4/80 antigens to delineate two cellular populations: F4/80+ but 
CD115int (CD115 intermediate expressing cells), and F4/80+ but CD115high 
Chapter 3: Systemic inflammation model  128 
 
monocytic cells. When these Gr-1lowF4/80+CD115high monocytic cell populations 
from bone marrow of LPS and PBS treated mice were compared, it was apparent 
that systemic LPS injection significantly reduced this population (figure 3-15, p = 
0.0289; 2-tailed, Mann-Whitney U test).  
 
Figure 3-15 LPS injection reduces the bone marrow Gr-1lowCD115high monocytic population. 
A & B are the respective representative plots comparing the bone marrow mononuclear cells (Gr-
1lowCD115high monocytic) of PBS and LPS injected mice (see figure 3-14 for gating strategy). C is a 
scatter plot summarising the changes in the Gr-1lowCD115high monocytic cells in response to either 
PBS or LPS intraperitoneal injection. [p=0.0289; 2-tailed, Mann-Whitney U test, n=4 (three 
independent experiments). 
3.4.3.2 LPS injection significantly reduces the bone marrow macrophage 
population. 
The Gr-1lowF4/80+CD115int population (see gating strategy from section 3.4.3.1) 
was sub-gated for differential expression of CD169 and CD11b expression to 
delineate the macrophage population (Gr-1-/lowF4/80+CD115intCD169+CD11blow) as 
defined by Chow et al. (Chow et al., 2011). Chow et al. demonstrated that 
clodronate liposome depletion of this CD169+ macrophage population led to 
mobilisation of HSPC to the circulation. The aim was therefore to try to 
understand whether systemic LPS-induced inflammation affected this 
macrophage population. As shown in figures 3-16 A &B, and summarised in figure 
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3-16C, systemic LPS-induced inflammation led to a marginal, but significant, 
reduction of this bone marrow CD169+ macrophage population when compared to 
PBS treated control (p = 0.046; 2-tailed Unpaired t-test). 
Taken together, the data presented suggest that LPS induced systemic 
inflammation led to significant reductions in the bone marrow monocytic and 
macrophage populations. 
 
Figure 3-16 Intraperitoneal LPS injection reduces the bone marrow CD169+ macrophage 
population. 
The F4/80+CD115int mononuclear cells (see figure 3-15 gating strategy) were then re-gated for the 
differential expression of F4/80 and CD11b antigens to identify the CD169+ macrophage population 
(Gr-1-CD115intCD169+CD11blow mononuclear cells) and Gr-1-CD115intCD169+CD11b+ mononuclear 
cells. [p=0.046; 2-tailed unpaired t-test (n=4; 2 independent experiments pooled together). 
In summary, data presented in this section suggest that LPS injection altered the 
HSPC niche by: 
A. Significantly altering the CXCR4/CXCL12 axis in the HSPC niche by reducing 
the HSPC surface expression of CXCR4 and reducing bone marrow CXCL12 
concentration. 
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B. Significantly reducing the bone marrow stromal osteoblast population while 
significantly increasing the MSC and endothelial cell populations. 
C. Significantly altering the bone marrow mononuclear phagocytic cells by 
significantly reducing the Gr-1lowCD115+ monocytic cell and CD169+ macrophage 
populations. 
3.5 What chemokines and cytokines are produced in 
response to systemic LPS injection?  
3.5.1 Introduction 
The data presented thus far provide evidence that LPS-induced systemic 
inflammation resulted in a significant mobilisation of haematopoietic progenitor 
cells into the circulation. As cellular migration in multicellular organisms occurs 
in response to molecular cues such as chemokines and cytokines, it was 
interesting to understand how the LPS-induced systemic inflammation 
comprehensively affected chemokine and cytokine production as well as 
chemokine receptor expression in the HSPC. This section thus set out to address 
the following questions: 
A. What chemokines and cytokines are expressed in the bone marrow in response 
to LPS injection? 
B. What chemokines and cytokines are expressed in the plasma in response to 
LPS injection? 
C. What chemokine receptors are expressed in HSPC in response to LPS 
injection? 
In order to obtain a comprehensive picture of the inflammatory chemokines and 
cytokines that are expressed in the bone marrow and the peripheral blood in 
response to LPS injection, proteome arrays were employed (see sections 3.5.1-
3.5.2 below). These arrays are basically nitrocellulose membranes that have 
been pre-spotted with specific capture antibodies by the manufacturer (R&D 
Systems). Prior to adding samples to the membranes, the samples are pre-mixed 
with a cocktail of biotinylated antibodies, and the resultant antibody/cytokine 
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complexes are then incubated with the membranes to allow binding to cognate 
antibodies immobilised on the membranes. Following this, the membranes are 
washed and Streptavidin-HRP, as well as chemiluminescent detection reagents, 
are added sequentially to enable detection of bound cytokines (see materials 
and methods for details). Images are then acquired with X-ray films, the images 
are scanned and then analysed using ImageJ software (NIH, USA) to determine 
pixel intensity of each spot. 
Moreover, in order to determine what chemokine receptors are expressed in the 
HSPC in response to LPS injection, RT-QPCR was employed as explained in 
section 3.5.3 below.  
3.5.2 Profiling of the bone marrow proteome in response to LPS 
injection. 
As the bone marrow provides the niche for the retention of HSPC, and its 
perturbation generally leads to HSPC release to the circulation, the bone marrow 
cytokine milieu was firstly evaluated to assess what cytokines are expressed in 
the bone marrow niche in response to LPS-induced systemic inflammation. The 
proteome array kit (ARY015; R&D Systems) was used for this purpose. As shown 
in figure 3-17 and table 3-1, this proteome array kit detects 53 different 
proteins, some of which are chemokines, cytokines, growth factors, and other 
angiogenesis related proteins. 
 
Figure 3-17 A schematic of the Mouse Angiogenesis Array overlay 
Shown is the Mouse Angiogenesis Array overlay indicating the design of the array and how 
analytes are pre-spotted on the membranes. 
Table 3-1 Enumeration of the array coordinates and the analytes they represent on the 
mouse angiogenesis proteome array 
Coordinate Analyte Coordinate Analyte Coordinate Analyte 
A1, A2 Reference 
spots 
C5, C6 CX3CL1 E3, E4 Osteopontin 
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A5, A6 ADAMTS1 C7, C8 GM-CSF E5, E6 PD-ECGF 
A7, A8 Amphiregulin C9, C10 HB-EGF E7, E8 PDGF-AA 
A9, A10 Angiogenin C11, C12 HGF E9, E10 PDGF-AB/ PDGF-
BB 
A11, A12 Angiopoietin-
1 
C13, C14 IGFBP-1 E11, E12 Pentraxin-3 
A13, A14 Angiopoietin-
3 
C15, C16 IGFBP-2 E13, E14 Platelet factor 4 
A15, A16 Coagulation 
factor III 
C17, C18 IGFBP-3 E15, E16 PIGF-2 
A17, A18 CXCL16 C19, C20 IL-1α E17, E18 Prolactin 
A21, A22 Reference 
spots 
C21, C22 IL-1β E19, E20 Proliferin 
B3, B4 Cyr61 D3, D4 IL-10 F1, F2 Reference spots 
B5, B6 DLL4 D5, D6 CXCL10 F3, F4 CXCL12 
B7, B8 CD26 D7, D8 CXCL1 F5, F6 Serpin E1 
B9, B10 EGF D9, D10 Leptin F7, F8 Serpin F1 
B11, B12 Endoglin D11, D12 CCL2 F9, F10 Thrombospondin-
2 
B13, B14 Endostatin D13, D14 CCL3 F11, F12 TIMP-1 
B15, B16 Endothelin-1 D15, D16 MMP-3 F13, F14 TIMP-4 
B17, B18 FGF acidic D17, D18 MMP-8 
(pro 
form) 
F15, F16 VEGF 
B19, B20 FGF basic D19, D20 MMp-9 
(pro & 
active) 
F17, F18 VEGF-B 
C3, C4 FGF-7 D21, D22 IGFBP-9 F19, F20 Negative control 
 
To evaluate the bone marrow inflammatory proteome milieu, C57BL/6 mice 
received a single I.P. injection of either Ultra-pure LPS or PBS as described in 
section 3.3.1, and bones harvested exactly as described in section 3.3.3. The 
bones were cleared of muscle, and then homogenised in mammalian protein 
extraction reagent (M-PER, Thermo Scientific). As they were expensive, the 
arrays were run only once; however, to obtain representative data, bone marrow 
homogenates from three mice were pooled and 300µg of the resultant whole 
bone marrow homogenates used for the subsequent proteome array. A scanned 
image of the membranes with the signal intensities representing analytes on a 
developed X-ray film (after 4 minutes exposure) is shown in figure 3-18.  
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Figure 3-18 Representative bone marrow angiogenesis array blots showing developed 
signal intensities of spots. 
C57BL/6 mice were either given a single dose of intraperitoneal LPS (100µg in 100µL PBS) or 
100µL PBS as a control. 18-24 hours after the injection, mice were euthanized by CO2 
asphyxiation, bones [2x (tibia + femur+ hip bones)] were harvested and homogenised in 400µL of 
mammalian protein extraction reagent. The total bone marrow homogenates were spun at 
>10,000xg for 10 minutes and supernatants taken for proteome array profiling. In order to obtain a 
representative proteome profile for each treatment group, protein lysates from three mice were 
pooled together for each treatment group (LPS or PBS treated controls). After estimating the 
pooled lysate protein concentration using the BCA method, ~300µg was used for the proteome 
profiling using the Mouse angiogenesis proteome array (R&D systems). A & B are the respective 
scanned images of the blots from PBS and LPS treated mice, after developing on X-ray films. 
The signal intensities were measured with ImageJ 1.48 (NIH, USA) software. As 
each analyte is represented in duplicate, the signal intensities of the duplicate 
spots were then averaged to get the mean signal intensities. Next, the mean 
signal intensity of the spots for negative controls was subtracted from that of 
the calculated mean signal intensity of each analyte to correct for background 
signals. Fold change in mean signal intensity for each analyte was calculated by 
dividing the mean signal intensity of the LPS treated group by the mean signal 
intensity of the respective analyte in the PBS treated group. To increase the 
stringency of the assay, only analytes demonstrating a ≥2-fold modulation were 
further analysed.  
Chapter 3: Systemic inflammation model  134 
 
3.5.2.1 LPS injection modulates bone marrow chemokine expression 
The bar graph in figure 3-19 shows the CC- and CXC-chemokines that 
demonstrated >2-fold change in expression levels in response to the I.P. LPS 
injection.  
For the inflammatory CC-chemokines, there was increased expression of bone 
marrow CCL2 (8-fold increase) and CCL3 (~4-fold increase) in response to the 
I.P. LPS injection. In addition, the expression of CXC-chemokines was also 
modulated. Specifically, there were >8-fold increases in the expression of bone 
marrow CXCL10 and CXCL16 in response to systemic LPS injection compared to 
PBS treated controls.  
 
Figure 3-19 I.P. LPS injection modulates the expression of chemokines in the bone marrow. 
The signal intensity of each spot on the developed array blots (see figure 3-18) was estimated with 
ImageJ 1.42 software (NIH, USA). As duplicate spots represented each cytokine, the mean of the 
signal intensity of each chemokine was calculated, and the corrected signal intensities were next 
calculated by subtracting the mean signal intensity of the spots for the negative control from the 
mean signal intensity of each chemokine. Next, the fold change in the corrected mean signal 
intensities were estimated for each analyte by dividing the corrected mean signal intensity of that 
analyte in the LPS treated group by the corrected mean signal intensity of that same analyte in the 
PBS treated group. Figure 3-19 is a bar graph showing the fold change in chemokines in the bone 
marrow of C57BL/6 mice in response to the LPS injection. Fold change >1, means increased 
production of the analyte in response to LPS. 
3.5.2.2 Other inflammatory mediators produced in the bone marrow in 
response to I.P. LPS injection. 
The other protein changes detected in the proteome array profiler are 
summarized in the bar graph in figure 3-20. As stated in the previous section, 
only analytes meeting the cut-off threshold of ≥2-fold modulation are presented 
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in figure 3-20. The systemic LPS-induced inflammation led to >3-fold increase in 
the expression of coagulation factor III in the bone marrow. As sepsis is known to 
induce a pro-coagulant phenotype, LPS-induced increase in coagulation factor III 
was not a surprising finding. Interestingly, although endoglin and endostatin 
have opposing roles in angiogenesis, i.e. angiogenic and angiostatic respectively, 
the expression of both proteins was increased by >2-fold.  
Matrix metalloproteinases (MMP) are known to degrade extracellular tissue 
matrix, and have been shown to promote angiogenesis, cancer metastasis and 
cellular migration. Generally, they are secreted in latent (inactive/pro) forms 
that require proteolytic cleavage to become the active forms that have 
functional activity. The proteome array data showed that LPS-induced 
inflammation led to ~2-fold increase in the expression MMP-8 in the bone 
marrow. In contrast, LPS-induced inflammation led to a 32-fold reduction in the 
bone marrow MMP-9 (pro- and active forms). This profound reduction in bone 
marrow MMP-9 activity is interestingly considering that previous reports have 
implicated increased MMP-9 activity as being crucial for HSPC mobilisation 
(Heissig et al., 2002, Jalili et al., 2010).  
The pentraxin family consists of pro-inflammatory proteins including C-reactive 
proteins and pentraxin-3. Increased production of pentraxin-3 is seen in various 
cells such as endothelial cells, fibroblast, monocytes and macrophages in 
response to inflammatory mediators (Han et al., 2005, Introna et al., 1996). In 
addition, pre-formed pentraxin-3 is also known to be stored in the specific 
granules of neutrophils and is released upon neutrophil activation (Jaillon et al., 
2007). As shown in figure 3-20, LPS systemic injection led to >3-fold increase in 
the bone marrow secretion of pentraxin-3 suggesting an inflammatory bone 
marrow milieu. 
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Figure 3-20 LPS injection modulates bone marrow cytokine expression. 
The signal intensities of each spot on the developed array blots (see figure 3-18) were estimated 
with ImageJ 1.42 software (NIH, USA). As duplicate spots represent each cytokine, the mean of 
the signal intensity of each cytokine was calculated, and the corrected signal intensities were next 
calculated by subtracting the mean signal intensity of the spots for the negative control from the 
mean signal intensity of each cytokine. Next, the fold change in the corrected mean signal 
intensities were estimated for each analyte by dividing the corrected mean signal intensity of that 
analyte in the LPS treated sample by the corrected mean signal intensity of that same analyte in 
the PBS treated group. Figure 3-20 is a bar graph showing the fold change in the analytes in 
response to the LPS injection. 
3.5.3 Profiling of the circulating plasma cytokines and 
chemokines in response to I.P. LPS injection. 
The proteome array, presented in section 3.5.1-3.5.2 above, profiled the 
inflammatory context in the bone marrow. As I.P. LPS injection resulted in 
increased circulating haematopoietic progenitors, it was also deemed important 
to analyse the proteome profile in peripheral blood. As cellular migration is not 
stochastic, but an instructive process in response to specific cues, the aim was 
to define the repertoire of cytokines and chemokines in the plasma (post LPS-
induced inflammation) and then compare these data to the bone marrow 
proteome (presented in section 3.5.1) to identify possible differences that could 
reveal potential candidates involved in orchestrating the increased numbers of 
mobilised haematopoietic progenitors seen in the systemic LPS-induced 
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inflammation model. To begin to do this, the mouse cytokine array panel A 
(ARY006; R&D Systems) was employed. This proteome array allowed the parallel 
detection of the relative levels of a total of 40 proteins (cytokines and 
chemokines). It consists of nitrocellulose membranes on which capture 
antibodies for specific proteins are pre-spotted (duplicate for each analyte). The 
principle underlying the assay is essentially as described for the proteome array 
ARY015 in section 3.5.1 above. Figure 3-21 and table 3-2, respectively, show the 
cytokine array overlay and the coordinates corresponding to the analytes in the 
mouse cytokine array panel A. 
 
Figure 3-21 Mouse Cytokine Array Panel A coordinates 
Shown is the Mouse Cytokine Array Panel A overlay indicating the design of the array and how 
analytes are pre-spotted on the membranes. 
Table 3-2 Enumeration of the array coordinates and the analytes they represent on the 
Mouse Cytokine Array Panel A 
Coordinate Target Coordinate Target Coordinate Target 
A1, A2 Reference 
spot 
C3, C4 IL-4 D9, D10 CCL2 
A23, A24 Reference 
spot 
C5, C6 IL-5 D11, D12 CCL12 
B1, B2 CXCL13 C7, C8 IL-6 D13, D14 CXCL9 
B3, B4 C5/C5a C9, C10 IL-7 D15, D16 CCL3 
B5, B6 G-CSF C11, C12 IL-10 D17, D18 CCL4 
B7, B8 GM-CSF C13, C14 IL-13 D19, D20 CXCL2 
B9, B10 CCL1 C15, C16 IL-12p70 D21, D22 CCL5 
B11, B12 CCL11 C17, C18 IL-16 D23, D24 CXCL12 
B13, B14 sICAM-1 C19, C20 IL-17 E1, E2 CCL17 
B15, B16 IFN-γ C21, C22 IL-23 E3, E4 TIMP-1 
B17, B18 IL-1α C23, C24 IL-27 E5, E6 TNF-α 
B19, B20 IL-1β D1, D2 CXCL10 E7, E8 TREM-1 
B21, B22 IL-1rα D3, D4 CXCL11 F1, F2 Reference 
spot 
B23, B24 IL-2 D5, D6 CXCL1 F23, F24 Negative 
control 
C1, C2 IL-3 D7, D8 M-CSF   
 
To evaluate the circulating inflammatory proteome milieu, mice were treated 
with I.P. injection of either Ultra-pure LPS or PBS exactly as described in section 
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3.3.1. Peripheral blood was taken from these mice into EDTA microtainer tubes 
(BD Biosciences, Oxford, UK). The blood was centrifuged at 8000xg for 10 
minutes and plasma was harvested for the subsequent proteome array. Plasma 
from three mice was pooled together and 150µL of the resultant pooled plasma 
was used for the subsequent proteome array in order to obtain representative 
data. As platelets are known to contain chemokines that are released upon 
activation, the rational for using plasma, instead of serum, was to avoid the 
possibility of activated platelets artificially increasing the amounts of cytokines 
detected in each sample. Figure 3-22 shows scanned images of the blots with 
spot intensity representing analytes on a developed X-ray film (after 8 minutes 
exposure). 
 
 
Figure 3-22 Array blots showing cytokines detected in the plasma I.P. PBS or I.P. LPS 
treated mice.  
C57BL/6 mice were either given a single dose of intraperitoneal LPS (100µg in 100µL PBS) or 
100µL PBS as a control. 18-24 hours after the injection, mice were euthanized by CO2 
asphyxiation, peripheral blood was taken into EDTA anti-coagulated tube, spun at >10,000xg for 10 
minutes and plasma taken for cytokine proteome array. 150µL of plasma from either LPS, or PBS, 
injected mice was used for the cytokine proteome profiling using the Mouse Cytokine Array panel A 
(ARY006; R&D Systems). A & B are the respective scanned images of the blots from PBS and LPS 
treated mice, after developing on X-ray films. In each case plasma was pooled from three mice and 
150µL of the resultant plasma was used to obtain a representative proteome profile for each 
treatment. 
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The signal intensity of each spot was quantified using ImageJ 1.42 software (NIH, 
USA). Mean spot intensity was next calculated from respective duplicate spots 
(representing each cytokine). The mean signal of the spots corresponding to the 
negative control was then subtracted from the calculated mean signal of each 
analyte to obtain the corrected mean signal intensities. As some cytokines were 
inducibly expressed in response to systemic LPS injection, but not in PBS treated 
plasma, the mean signal intensities (corrected for background) of the LPS- and 
PBS-treated samples were plotted side-by-side for comparison, rather than fold 
changes as presented in figure 3-19 & 3-20. 
3.5.3.1 Intraperitoneal LPS injection mediates increased circulating plasma 
chemokine levels. 
The bar graph in figure 3-23 shows the differentially expressed CC and CXC 
chemokines detected in the plasma of I.P. PBS or I.P. LPS treated mice plotted 
side by side. For CC chemokines, whereas CCL2 was highly expressed in the 
plasma of LPS treated mice, it was barely detectable in plasma of PBS treated 
mice. In addition, both CCL5 and CCL12 were highly expressed in the plasma of 
LPS treated mice; however, the levels of these chemokines (i.e. CCL5 and 
CCL12) in the plasma of PBS treated mice were below the limit of detection of 
this assay. For CXC chemokines, CXCL1, CXCL9, CXCL10 and CXCL13 were all 
highly expressed in the plasma of LPS treated mice, although they were not 
detectable in the plasma of PBS controls. Considering that LPS injection is a 
model of Gram-negative bacterial infection, the increased inflammatory 
chemokine levels detected in the plasma of LPS treated mice is not a surprising 
finding. 
Taken together with the bone marrow proteome array, it is interesting to point 
out that both CCL2 and CXCL10 were highly expressed both in the bone marrow, 
and the circulation, in response to I.P. LPS injection. However, some chemokines 
such as CCL3, CCL5, CXCL9 were differentially expressed between the bone 
marrow and the plasma. 
Chapter 3: Systemic inflammation model  140 
 
 
Figure 3-23 LPS injection induces inflammatory & homeostatic chemokine expression in the 
plasma 
The signal intensities of each spot on the developed array blots (see figure 3-22) were estimated 
with ImageJ 1.42 software (NIH, USA). As duplicate spots represent each cytokine, the mean of 
the signal intensity of each cytokine was calculated, and the corrected signal intensities were 
calculated by subtracting the mean signal intensity of the spots for the negative control from the 
mean signal intensity of each cytokine. Figure 3-23 is a bar graph showing the corrected mean 
signal intensities of the chemokines in the plasma of LPS and PBS treated mice plotted side-by-
side. 
3.5.3.2 Cytokines and growth factors produced in response to I.P. LPS 
injection. 
The bar graph in figure 3-24 summarises the comparison of the cytokines and 
growth factors that were differentially detected in the plasma of LPS and PBS 
treated mice. The expression of G-CSF (granulocyte-colony stimulating factor) 
was highly increased in response to LPS injection, in contrast to PBS controls 
where the level of G-CSF was below the detection limit of the cytokine array. 
Considering that I.P. LPS injection models Gram-negative bacterial infection, the 
increased expression of plasma G-CSF is not a surprising finding as emergency 
granulopoiesis generally occurs in response to most bacterial infections (Selig 
and Nothdurft, 1995, Watari et al., 1989). In addition, recognition of LPS by the 
TLR4 receptor involves CD14 on myelomonocytic cells that ultimately leads to 
the activation of these cells (Nioche et al., 1988). Thus, the increased G-CSF 
could be considered as a physiological response as G-CSF is produced from 
activated mononuclear cells (see the general introductory chapter). However, as 
G-CSF is a known HSPC mobilising agent, the LPS injection-induced increase in 
its plasma levels could also partly account for the HSPC mobilisation observed in 
the I.P. LPS injection model. 
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The immunodulatory and antiviral cytokine, interferon-gamma (IFN-γ) was 
approximately 3-fold more highly expressed in the plasma of LPS treated mice 
compared to controls. Not surprisingly LPS, which is a component of the cell wall 
of Gram-negative bacteria, induced increased expression of the pro-
inflammatory cytokine, IL-1α (interleukin-1 alpha), compared to PBS treated 
controls. As the proper balance between IL-1α and IL-1rα (IL-1 receptor 
antagonist) has been shown to be important in the pathophysiology of many 
diseases (Ma et al., 1998b, Piguet et al., 1993), it is also not surprising that I.P. 
LPS injection also induced increased expression of IL-1rα (~1500 fold), in 
contrast to PBS treated controls where the level of IL-1rα was below the limit of 
detection of the cytokine array. This is in agreement with a previous study that 
found approximately 100 fold greater IL-1rα, in comparison with IL-1α, in the 
plasma during an experimental endotoxaemia (Granowitz et al., 1991). 
Moreover, IL-16, which is also a pro-inflammatory cytokine, was highly expressed 
in the plasma of LPS treated mice, even though IL-16 was not detectable in the 
plasma of PBS mice. 
Tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) was approximately 2-fold 
more highly expressed in the plasma of LPS treated mice when compared to 
controls. Another pro-inflammatory cytokine that was ~2-fold more expressed in 
the plasma of LPS treated mice compared to PBS treated controls was tumour 
necrosis factor-alpha (TNF-α). Taken together, systemic LPS inflammation 
induced an inflammatory milieu in the plasma. 
 
Figure 3-24 LPS injection modulates the plasma cytokine expression 
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The signal intensities of each spot on the developed array blots (see figure 3-20) were estimated 
with ImageJ 1.42 software (NIH, USA). As duplicate spots represent each chemokine, the mean of 
the signal intensity of each chemokine was calculated, and the corrected signal intensities were 
calculated by subtracting the mean signal intensity of the spots for the negative control from the 
mean signal intensity of each cytokine. Figure 3-24 is a bar graph showing the corrected mean 
intensities of the LPS and PBS treated mice plotted side-by-side for the cytokines and growth 
factors expressed in response to the LPS, or PBS, treatment. 
3.5.4 Profiling of bone marrow HSPC for chemokine receptors 
and ACKR expression. 
Having shown that LPS injection induced HPC mobilisation to the circulation in 
mice, and that inflammatory chemokines were elaborated in the bone marrow 
and peripheral blood in response to the LPS injection, it was interesting to 
examine the HSPC to determine whether they inducibly expressed chemokine 
receptors in response to LPS injection. Chemokine-chemokine receptor 
interaction is one of the fundamental axes that mediate cellular migration. 
Therefore, the hypothesis that HSPC alter chemokine receptor expression in 
response to the LPS-induced systemic inflammation model was tested. To do 
this, mice were treated with I.P. LPS/PBS exactly as described in section 3.3.1, 
and bone marrow was harvested and processed exactly as described in section 
3.3.3. The bone marrow cells were stained in accordance with CD150 SLAM 
antibody staining protocol (Kiel et al., 2005) for enumeration of the HSC (Lin-
Sca-1+Kit+CD150+CD48-), and MPP1 (Lin-Sca-1+Kit+CD150+CD48+), MPP2 (Lin-Sca-
1+Kit+CD150-CD48+), and MPP3 (Lin-Sca-1+Kit+CD150-CD48-) cells. 200 cells from 
each of the HSC, MPP1, MPP2, or MPP3, populations were sorted on FACS Aria II 
(BD Biosciences) into 5µL of reverse transcriptase (RT)-specific target 
amplification master-mix (Fluidigm Technologies) and pre-amplified using 
thermal cycling conditions as described in the materials and methods chapter. 
Sorting exactly the same number of cells enabled the normalisation of starting 
material for the downstream gene profiling. Additionally, the pre-amplification 
step enabled the reverse transcription of target genes [chemokine receptors and 
atypical chemokine receptors (ACKR)] to cDNA for quantitative polymerase chain 
reaction (QPCR). The QPCR was undertaken using the Fluidigm 48.48 Dynamic 
Chip array platform in accordance with manufacturer’s protocol (Fluidigm 
Technologies), and target gene expression was normalised to Hprt levels. In all 
cases, the gene expression in the LT-HSC from PBS treated group was used as the 
calibrator (baseline) for subsequent analysis. Additionally, to increase the 
stringency of the gene expression data, a fold change ≥2 (upregulated gene 
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expression), or ≤2 (downregulated gene expression), was set as the threshold for 
assuming the modulation in gene expression to be above background. 
3.5.4.1 HSC express chemokine receptors and ACKRs 
As shown in the bar graph in figure 3-25, the analysis of the chemokine receptor 
gene expression profiling in LT-HSC revealed that in the non-inflamed state, 
both homeostatic and inflammatory chemokine receptors as well as atypical 
chemokine receptors could be detected. More importantly, LPS-induced systemic 
inflammation led to up-regulation of the expression of the inflammatory CC-
chemokine receptors Ccr1 (>7-fold increase), ccr2 (~8-fold increase), Ccr3 (2-
fold increase) and Ccr5 (>2-fold increase) in the LT-HSC (LSK CD48-CD150+) 
population compared to the LT-HSC from PBS treated controls (figure 3-25). In 
addition, of the CXC-chemokine receptors, there was an approximately 4-fold 
increase in the expression of the inflammatory chemokine receptor, Cxcr2.  
Atypical chemokine receptors (ACKR) have been shown to modulate the function 
of chemokines to prevent exaggerated immune responses and modulate cell 
movement. Therefore, in the context of inflammation-induced chemokine gene 
expression, it is possible that expression of these atypical receptors may also be 
modulated. As shown in the bar graph in figure 3-25, the LPS-induced systemic 
inflammation caused up-regulated expression of Ackr3 [Cxcr7 (~4 fold)], and 
ACKR4 [Ccrl1 (>4 fold)] in the LT-HSC population. The expression of the c-kit 
antigen was included as a positive control, to validate the gene expression in the 
fluidigm data, as HSPC are known to express c-kit antigen. In addition, the gene 
for Von Willibrand factor (VWF) was consistently detected in the LT-HSC 
population in basal state (i.e. LT-HSC from PBS treated groups); the expression 
of this gene was also downregulated by approximately 6-fold in response to the 
LPS-induced systemic inflammation. 
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Figure 3-25 Changes in chemokine receptors and ACKRs in LT-HSC in response to LPS  
C57BL/6 mice were either given a single dose of intraperitoneal LPS (100µg in 100µL PBS), or 
100µL I.P. PBS as a control. 18-24 hours after the injection, mice were euthanized by CO2 
asphyxiation and bone marrow [2x (tibia + femur + hip bones)] harvested, and enriched for 
haematopoietic progenitor cells using the CD117 (c-Kit) Microbeads and LS magnetic columns 
according to manufacturer’s instructions (Miltenyi Biotec). The c-kit enriched cells were then 
stained with lineage antibody cocktail (CD4, CD5, CD8a, Mac-1, B220, Ter119 and Gr-1), c-Kit, 
Sca-1, CD48 and CD150 to evaluate HSPC compartment. 200 LT-HSC (defined as Lin-Sca-
1+Kit+CD48-CD150+) cells from either LPS or PBS treated mice were sorted on FACS Aria II for RT-
QPCR using the Fluidigm microfluidic 48.48 Dynamic array platform. Gene expression was 
normalised to Hprt expression levels and fold change in gene expression calculated relative to the 
gene expression in LT-HSC population from PBS treated controls; (N=8). 
3.5.4.2 LPS injection modulates the chemokine receptor and ACKR 
expression in MPP populations. 
LT-HSC sits atop the haematopoietic stem and progenitor cell hierarchy and is 
the cell population from which all downstream cells are derived. Therefore, the 
expression of the chemokine receptors and ACKRs in the LT-HSC of PBS-treated 
mice was next set as the baseline (calibrator population) to allow for the 
comparison of the chemokine receptor and ACKR expression in the 
haematopoietic progenitor cell in the PBS and LPS treated mice. This analysis 
permitted two comparisons to be made: how the gene expression in each 
progenitor population varied from the expression of the same gene in the PBS 
treated LT-HSC population; and also how the LPS-induced inflammation 
modulated the gene expression in the MPP1, MPP2, and MPP3 populations 
compared to the respective PBS treated MPP1, MPP2, and MPP3 populations. As 
stated above (see section 3.5.4), to increases the stringency of the data, a 
threshold of fold change of ≥2 (upregulated gene expression), or ≤2 
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(downregulated gene expression), was set as a criterion for assuming the 
modulation in gene expression to be above background. 
The data from the chemokine receptor and ACKR gene expression profiling of the 
MPP1, MPP2 and MPP3 populations are as summarised in the bar graphs in figures 
3-26 A, B & C respectively. For the CC-chemokine receptors, only CCR1 
demonstrated a consistent >2-fold upregulated expression in response to the I.P. 
LPS injection in MPP1, MPP2, and MPP3 populations. Although CCR2 transcript 
was also consistently detected in all the MPP populations, it was only in the 
MPP1 population that it showed a significant upregulation in response to the I.P. 
LPS injection (figure 3-26A, p=0.0001; 2-tailed unpaired t-test). The expression 
of CCR2 was comparable between the PBS and LPS treated MPP2 and MPP3 
populations (figure 3-26B & C). The expression of CCR3 in the MPP1-3 
populations, were also modulated by I.P. LPS injection; 8-fold downregulation in 
MPP1 population, but a >4-fold increase in MPP3 population. However, it was 
only in the MPP2 population that LPS treatment led to a >4-fold increase in CCR5 
expression.  
For CXC chemokine receptors, CXCR2 was significantly downregulated in the 
MPP1 population in response to LPS injection when compared to the MPP1 
population from PBS treated controls (figure 3-26A, p=0.0238, 2-tailed unpaired 
t-test). However, the expression of the CXCR2 transcript was comparable 
between the PBS treated and LPS treated MPP2 populations (figure 3-26B). For 
the atypical chemokine receptor gene expression, only ACKR4 consistently 
demonstrated a >2-fold upregulated expression in response to LPS injection 
(figure 3-26 A, B & C). Whereas ACKR1 expression was downregulated in both 
MPP1 and MPP2 population in response to LPS injection, ACKR3 was only 
consistently detected in the MPP3 population. Interestingly, vwf gene expression 
was consistently downregulated in all the MPP populations (figure 3-26 A, B & C). 
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Figure 3-26 I.P. LPS injection modulates chemokine receptor and atypical chemokine 
receptor expression in the HSPC compartment. 
C57BL/6 mice were either given a single dose of intraperitoneal LPS (100µg in 100µL PBS) or 
100µL PBS as a control. 18-24 hours after the injection, mice were euthanized by CO2 asphyxiation 
and bone marrow [2x (tibia + femur + hip bones)] harvested, and enriched for haematopoietic 
progenitor cells using the CD117 (c-Kit) Microbeads and LS magnetic columns according to 
manufacturer instructions (Miltenyi Biotec). The c-kit enriched cells were then stained with lineage 
antibody cocktail (CD4, CD5, CD8a, Mac-1, B220, Ter119 and Gr-1), c-Kit, Sca-1, CD48 and 
CD150 to evaluate HSPC compartment. Dead cells were excluded using Live/Dead Aqua. 200 
cells from the MPP1 (A), MPP2 (B) and MPP3 (C) population from either LPS or PBS treated mice 
were sorted on FACS Aria II for QPCR using the Fluidigm microfluidic 48.48 Dynamic array 
platform. Gene expression was firstly normalised to Hprt expression levels, and fold change in 
gene expression calculated relative to the gene expression in the LT-HSC population from PBS 
treated controls. Figure 3-26 A, B, & C summarises the plot of the fold changes in the respective 
gene expression in response to LPS, or PBS, treatment plotted side-by-side. [Statistical 
significance was calculated using 2-tailed unpaired t-test to compare the fold change in the gene 
expression in LPS treated sample to the fold change in the expression of that same gene in PBS 
treated mice; (N=8)]. 
3.6 Discussion of the LPS-induced systemic 
inflammation model 
3.6.1 LPS-induced inflammation significantly reduces the bone 
marrow HSPC. 
In this chapter I sought to obtain a comprehensive understanding of the 
mechanism underlying the increased HSPC mobilisation from bone marrow into 
the circulation caused by I.P. LPS injection. LPS, which is a component of the 
cell wall of Gram-negative bacteria, has been used in models of sepsis. Although 
previous reports have established the ability of systemic LPS injection to 
orchestrate release of HSPC from the bone marrow into the circulation, the 
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mechanistic details still remain to be elucidated. In agreement with previous 
reports, the experiments reported here also found that I.P. LPS injection 
induced significant increases in the numbers of circulating haematopoietic 
progenitor cells as measured by haematopoietic colony-forming assay of 
peripheral blood (Vos et al., 1972, Quesenberry et al., 1973). In accordance with 
LPS-induced mobilisation of bone marrow HSPC to the circulation, the LPS 
injection significantly reduced the bone marrow cellularity by approximately 33% 
when compared to PBS treated controls. Furthermore, this reduced bone marrow 
cellularity was also reflected in significantly reduced CLP, LMPP, ST-HSC and LT-
HSC populations in the bone marrow. As reported in other inflammation models 
(Zhang et al., 2008, Shi et al., 2013), this study also identified an increase in 
expression of the Sca-1 antigen resulting in an apparent expansion of the 
proportion of the HSPC (LSK cells) in the LPS treated mice as revealed by flow 
cytometric analysis. Zhang et al. demonstrated that this apparent expansion of 
the HSPC was the result of a phenotypic inversion of Lin-Sca-1-Kit+ into Lin-Sca-
1+Kit+ as a result of re-expression of Sca-1 antigen in response to LPS (Zhang et 
al., 2008). In the light of these findings, Sca-1 was omitted from subsequent 
antibody staining panels. 
3.6.2 Role of the bone marrow niche in LPS-induced HSPC 
mobilisation  
The interactions of the HSPC and the niche cells, and/or soluble products from 
these cells are crucial in the retention of the HSPC in their native bone marrow 
microenvironment. Many previous studies have established that disruption of this 
HSPC-niche interaction is a critical component of the mechanism underlying 
most HSPC mobilising agents such as G-CSF and AMD3100 (Levesque et al., 
2003a, Levesque et al., 2003b, Liles et al., 2003, Broxmeyer et al., 2005). In 
order to understand how the I.P. LPS-induced systemic inflammation affected 
some of these factors, proteome array, ELISA, and flow cytometric analysis were 
employed to evaluate these factors. Firstly, I wanted to understand how CXCR4 
expression was affected at the protein level as the CXCR4-CXCL12 receptor 
interaction has been established as perhaps the most critical niche component. 
A previous report proposed that constitutive receptor internalisation and 
subsequent recycling, independent of ligand binding, was the mechanism 
regulating homeostatic cell surface CXCR4 expression in human CD34+ 
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haematopoietic progenitors (Zhang et al., 2004b). It is therefore possible that 
the LPS-induced reduction in cell surface Cxcr4 expression may be the result of 
interference in receptor recycling, or increased degradation of the internalised 
Cxcr4 or induction of processes that are inhibitory to effective translation of the 
Cxcr4 transcript. 
The ELISA data presented in this study also showed a significant reduction in 
bone marrow CXCL12 in response to I.P. LPS induced systemic inflammation. This 
reduction in bone marrow CXCL12 levels may not be surprising considering the 
increased circulating/plasma G-CSF as revealed in the proteome array data. 
Previous studies found that reduction in bone marrow CXCL12 was a significant 
component of the exogenously administered G-CSF-mediated HSPC mobilisation 
(Christopher et al., 2009, Semerad et al., 2005). However, as G-CSF-induced 
mobilisation takes a matter of days, in contrast to the 24-hour time point used 
for the I.P. LPS systemic inflammation model, other factors may contribute to 
the significant HSPC mobilisation observed with the systemic LPS inflammation 
model. 
The data presented in this chapter also argue for a role of osteoblasts in the 
HSPC mobilisation observed in the I.P. LPS systemic inflammation model. 
Previous studies have shown that cells of the osteoblastic lineage, mesenchymal 
stromal cells (MSC) and bone marrow endothelial cells are critical components of 
the bone marrow endosteal niche. These cells have been proposed to be the 
major producers of critical soluble niche factors such as CXCL12, angiopoietin-1, 
stem cell factor, and osteopontin (Ducy et al., 2000, Calvi et al., 2003, Arai et 
al., 2004, Mendez-Ferrer et al., 2010). Therefore, a disruption in the function of 
one of these cellular niche components (i.e. MSC, osteoblasts and endothelial 
cells) indirectly leads to perturbation of concentration of one or more of these 
soluble niche products and hence results in HSPC egress from the bone marrow 
into the peripheral blood. The data presented in this chapter revealed a 
significant increase in the proportion of bone marrow MSC and endothelial cell 
populations in response to the I.P. LPS-induced systemic inflammation; in 
contrast, the I.P. LPS-induced systemic inflammation led to a significant 
reduction in the proportion of the bone marrow osteoblast population. 
Interpreting these data in the light of the significant reduction in CXCL12 protein 
in the bone marrow, it is reasonable to suggest that, in the I.P. LPS-induced 
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HSPC mobilisation, the critical cellular niche component responsible for CXCL12 
reduction may be the osteoblastic cell population. 
Interestingly, Heissig et al. previously implicated a role for MMP-9 in HSPC 
mobilisation by showing that myeloablation-induced increase in bone marrow 
CXCL12 levels resulted in a corresponding increase in MMP-9 activity that 
favoured HSPC mobilisation as a consequence of cleavage of c-Kit ligand in the 
bone marrow (Heissig et al., 2002). As shown in section 3.4.1.3 (see figure 3-10), 
LPS injection resulted in reduced bone marrow CXCL12 levels as well as reduced 
MMP-9 levels (see figure 3-20) making it unlikely that the LPS-induced HSPC 
mobilisation depended on increased MMP-9 activity. 
Finally, the phagocytic mononuclear cells of the innate arm of the immune 
system have also been shown to have roles in retention of HSPC in the bone 
marrow niche. In line with this, Chow et al. found that clodronate-mediated 
depletion of bone marrow CD169+ macrophage populations led to significant 
mobilisation of bone marrow HSPC to the circulation (Chow et al., 2011). In 
addition, Winkler et al. also demonstrated that G-CSF-induced HSPC mobilisation 
occurred partly due to a depletion of the bone marrow macrophage population, 
which they called osteomac (Winkler et al., 2010b). Others have also reported 
that depletion of bone marrow granulocytic cell population accounted in part for 
the HSPC mobilisation observed with CXCL2, CXCL8 and G-CSF (Levesque et al., 
2003b, Pruijt et al., 2002). In order to understand the potential roles played by 
these mononuclear phagocytic cells in the I.P. LPS-induced HSPC mobilisation, 
the bone marrow of LPS, or PBS, treated mice was analysed by flow cytometry. 
These analyses revealed two interesting findings concerning the cells of the 
mononuclear phagocytic system: firstly, I.P. LPS significantly reduced the bone 
marrow Gr-1lowF4/80+CD115high monocytic cell population compared to PBS 
treated controls. Secondly, the I.P. LPS induced inflammation reduced the 
CD169+ macrophage population (defined as Gr-1-F4/80+CD115intCD169+CD11blow) 
(Chow et al., 2011). Therefore, the I.P. LPS-induced HSPC mobilisation may also 
have a significant contribution from perturbation of cells of the mononuclear 
phagocytic system in agreement the previously published data described above. 
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3.6.3 Potential role of the inflammatory chemokine/chemokine 
receptor axes in LPS-induced HSPC mobilisation. 
The chemokine expression profiling data showed that many inflammatory 
chemokines i.e. CCL2, CCL5, CXCL1, CXCL9 and CXCL10 were inducibly 
expressed in the plasma of LPS treated mice although these chemokines were 
below the level of detection in PBS treated control mice. This inducible 
expression of inflammatory chemokines in both the plasma and bone marrow is 
not surprising considering that a critical component in LPS-induced inflammation 
comes from activated monocytic cells (Nioche et al., 1988, Wright et al., 1990). 
Thus these elaborated inflammatory mediators could be products released from 
the activated cells. Moreover, the plasma levels of the homeostatic chemokine, 
CXCL13, increased in response to the I.P. LPS injection. Interestingly, the 
chemokine receptor profiling data showed that CCR1, CCR2 and CXCR2 could be 
consistently detected in the bone marrow HSPC. In addition, I.P. LPS injection 
induced upregulated expression of the transcripts of these chemokine receptors, 
suggesting a potential instructive role of the inflammatory milieu. As chemokine-
chemokine receptor interactions are one of the key molecular cues orchestrating 
cellular migration, these findings suggest that these inflammatory chemokine 
receptors may have a role in the I.P. LPS-induced HSPC mobilisation.  
3.7 Chapter summary 
From the data presented in this chapter, the following findings are important: 
1. LPS injection causes significant mobilisation of HSPC to the circulation leading 
to significantly reduced bone marrow cellularity as well as reduced CLP, LMPP, 
ST-HSC and LT-HSC populations in the bone marrow. 
2. The mechanism underlying the I.P. LPS inflammation-induced HSPC 
mobilisation is potentially multi-factorial involving many players i.e. disruption 
of the CXCR4/CXCL12 axis by downregulation of HSPC surface CXCR4 and bone 
marrow CXCL12 protein expression; increased secretion of G-CSF that might be 
involved in cleavage of CXCL12 and decreased osteoblasts population; depletion 
of the bone marrow mononuclear phagocytic cell population i.e. monocytes and 
CD169+ macrophage; and inducible expression of chemokine receptors that may 
enable them to respond to circulating inflammatory chemokines.  
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4.1 Aims and introduction 
Data presented in the previous chapter provides evidence that HPC are mobilised 
to the circulation in response to systemic LPS injection. In addition, the 
chemokine receptor gene expression profiling, and the proteome array data, 
were suggestive of a potential role for the chemokine/chemokine receptor axis 
in systemic inflammation-induced HSPC mobilisation. However there are many 
peripheral pathological processes, like psoriasis and dermatitis, that also have 
inflammatory underpinnings and therefore it was also important to assess the 
effects of peripheral inflammation on the HSPC compartment to see if it could 
indirectly induce HSPC mobilisation via release of inflammatory mediators into 
the circulation. In addition, the data presented in the previous chapter did not 
determine whether the inflamed context alone, or TLR signalling, or both were 
critical in orchestrating HSPC exit from the bone marrow. In order to understand 
whether the inflammatory context alone and/or TLR signalling-induced 
inflammation was critical for inducing HSPC mobilisation, I set out to use sterile 
and TLR driven peripheral inflammation models. These involve cutaneous 12-O-
tetradecanoylphorbol-13-acetate (TPA), and imiquimod cream, application 
respectively. Imiquimod cream contains a TLR7 ligand (Hemmi et al., 2002, Lee 
et al., 2003), whereas TPA is a purely inflammatory agent with no associated 
TLR signal induction (Blumberg et al., 1984a, Blumberg et al., 1984b, Sharkey et 
al., 1984). TPA has been used extensively to induce sterile inflammation (Lee et 
al., 1994, Chiba et al., 1984). It is known to induce inflammation by activating 
protein kinase C through its mimicry of diacylglycerol (Blumberg et al., 1984a, 
Blumberg et al., 1984b). Recently, imiquimod cream application to the dorsal 
skin of mice has also been proposed as a model of human psoriasis (van der Fits 
et al., 2009). The dose of imiquimod cream employed in this study is in 
accordance with the dose used to model human psoriasis as published by van der 
Fits et al. Imiquimod mimics viral infection as it act as a TLR7/8 ligand (in 
humans) and TLR7 ligand (in mouse). The hypothesis that was tested was that 
HSPCs may inducibly express inflammatory chemokine receptors in response to 
peripheral inflammatory mediators, and that the inflammatory 
chemokine/chemokine receptor axis influences the migratory properties of 
HSPC. The fundamental questions I aimed to address in this part of the study 
were: 
Chapter 4: Peripheral inflammation model  154 
 
1. Does peripheral tissue inflammation orchestrate HSPC mobilisation?  
2. Does peripheral tissue inflammation impact the bone marrow HSPC 
compartment? 
3. Does peripheral tissue inflammation alter the HSPC niche? 
4. What chemokines and cytokines are produced in response to peripheral tissue 
inflammation? 
In this way, I sought to obtain a comprehensive understanding of the role of the 
inflammatory chemokine/chemokine receptor axis in HSPC biology in peripheral 
tissue inflammation models associated with infectious components as well as 
purely inflammatory stimuli with no infectious surrogates. 
4.2 Does peripheral inflammation orchestrate HSPC 
mobilisation 
4.2.1 Introduction 
In the previous chapter, the ability of systemic inflammation to orchestrate 
HSPC mobilisation was evaluated using the I.P. LPS injection model. In this 
chapter, the ability of peripheral inflammation to influence HSPC biology was 
also assessed using topical imiquimod cream, or topical TPA application, to the 
shaved dorsal skin of mice. To elicit the peripheral inflammation, mice received 
a single daily application of either ~62.5mg imiquimod cream (equivalent to 
3.125mg active TLR7 ligand), or 100µM TPA, on shaved dorsal skin for three 
consecutive days. Simultaneously, other groups of mice received topical 
application of either aqueous cream or acetone as controls for imiquimod cream 
and TPA treatments respectively. After the treatment, mice were culled by CO2 
asphyxiation and peripheral blood, bone marrow and spleen harvested for 
further analysis (see details described in relevant sections below).  
Histological sections of skin that directly received inflammatory agent 
application were also examined. Also, the cellularity of the bone marrow and 
spleen was assessed to understand how the peripheral inflammation models 
affected haematopoietic activity in each of these organs. Additionally, the 
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ability of the peripheral inflammation models to induce HSPC mobilisation from 
the bone marrow to the circulation and spleen were investigated using HPC 
colony-forming assays. 
4.2.2 Histology 
Before investigating the systemic effects produced by the topical imiquimod 
cream, or TPA, treatment, I sought to examine the morphology of the skin to 
determine the local effects produced by each of these inflammatory agents. The 
dorsal skin that directly received the topical imiquimod cream/TPA treatment 
(see section 4.2.1 for description) was harvested, embedded in paraffin, 
sectioned to 8µm and stained by haematoxylin and eosin. Figures 4-1A-D are the 
representative micrographs of the skin sections of mice treated with aqueous 
cream (A), imiquimod cream (B), acetone (C), and TPA (D). Topical imiquimod 
cream, or TPA, treatment induced a profound inflammatory response in the 
dorsal skin of mice as shown by the epidermal thickening [indicated by the 
arrows in figures 4-1B (imiquimod cream treatment) and 4-1D (TPA treatment)].  
 
Figure  4-1 Topical imiquimod cream, or TPA, treatment causes epidermal thicknening in the 
dorsal skin of mice. 
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The dorsal skin of mice that had directly received aqueous cream (A), or topical imiquimod cream 
(B), or acetone (C), or TPA (D), treatment was harvested, embedded in paraffin, sectioned to 8µm 
and stained with haematoxylin and eosin for morphological examination. Images were acquired 
using 20X magnification on Zeiss Axiostar Plus Microscope fitted with AxioVision software; arrow 
points to epidermal thickening in response to imiquimod cream (B), or TPA (D), treatment. [DE, 
dermis; EP, epidermis; HF, hair follicle; SC, stratum corneum] 
 
4.2.3 Topical imiquimod cream, or TPA, application induces HSPC 
mobilisation 
The number of haematopoietic progenitors in peripheral blood and spleen were 
assessed using colony-forming assays as a measure of how the different 
peripheral inflammatory stimuli affected haematopoietic progenitor cell 
mobilisation. As explained in the previous chapter, the medium employed for 
the haematopoietic colony-forming assay was MethocultTM GF M3434 (StemCell 
Technologies). 1 x105 peripheral blood or splenic leucocytes from the topical 
imiquimod cream or TPA treated mice (or their respective control groups) were 
seeded into 1.1mL of MethocultTM GF M3434 in duplicate, and incubated for 7-10 
days at 37°C in a humidified chamber, after which colonies were identified and 
enumerated using an inverted microscope. 
As shown in the scatter plot in figure 4-2A, both imiquimod cream, and TPA, 
treatment induced statistically significant increases in the numbers of circulating 
myeloerythroid progenitor colonies, predominantly CFU-GM (p<0.0001 in each 
case; 2-tailed unpaired t test in both cases). On average, imiquimod cream 
treatment induced >4-fold increase (19.33/4.444) in circulating myeloerythroid 
progenitors; whereas, TPA-induced inflammation resulted in >5-fold 
(25.56/4.667) increase in the number of circulating myeloerythroid progenitors. 
Figures 4-2 B, C & D are representative pictures of colonies counted as CFU-
GEMM, CFU-GM and CFU-E respectively. 
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Figure  4-2 Topical imiquimod cream or TPA application mobilises HPC to the circulation. 
C57BL/6 mice received a single, daily dose of topical imiquimod cream (62.5mg) or TPA (100µM in 
100µL acetone) application to the shaved dorsal skin for three consecutive days. Simultaneously, 
other groups of mice received equivalent amounts of topical application of either aqueous cream or 
acetone application as controls for topical imiquimod cream and TPA application respectively. On 
day 4, the mice were euthanized by CO2 asphyxiation, and peripheral blood was taken for 
haematopoietic colony-forming assay. After lysing red blood cells with Ammonium chloride, 1x105 
leucocytes were seeded into 1.1mL of MethocultTM GF M3434 medium (StemCell Technologies) in 
duplicate, and incubated for 7-10 days at 37°C, in a 5% CO2 humidified chamber. Colonies 
representing haematopoietic progenitor cells were then identified and enumerated using an 
inverted microscope. In figure 4-2 A, the total colonies formed were compared for each treatment 
group and its respective control i.e. imiquimod cream with aqueous cream and TPA with acetone 
treated controls. [p<0.0001; 2-tailed, unpaired t-test, n=4-5 mice per experiment; (5 independent 
experiments)]. Data were plotted from mean ±SEM]. Figures B, C, and D, are respective 
representative colonies identified as CFU-GEMM, CFU-GM and CFU-E. 
In addition, imiquimod cream, or TPA, induced peripheral inflammation led to 
increased numbers of total myeloerythroid progenitors in the spleen (figure 4-3, 
p<0.0001; 2-tailed unpaired t-test in each case). Topical imiquimod cream-
induced peripheral inflammation resulted in >5-fold (53.38/9.250) increase in 
total splenic myeloerythroid progenitors, whereas TPA-induced peripheral 
inflammation led to >4-fold (44.56/10.44) increase in splenic myeloerythroid 
progenitor cell numbers. 
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Figure  4-3 Topical imiquimod cream or TPA application significantly increases HPC in the 
spleen. 
C57BL/6 mice received a single, daily dose of topical imiquimod cream (62.5mg) or TPA (100µM in 
100µL acetone) application to the shaved dorsal skin for three consecutive days. Simultaneously, 
other groups of mice received equivalent amounts of topical application of either aqueous cream or 
acetone application as controls for topical imiquimod cream and TPA application respectively. On 
day 4, the mice were euthanized by CO2 asphyxiation, and spleens were taken for haematopoietic 
colony-forming assay. After mincing and filtering the spleen through a 70µm cell strainer, red blood 
cells were lysed with Ammonium chloride solution. Next, 1x105 leucocytes were seeded into 1.1mL 
of MethocultTM GF M3434 medium (StemCell Technologies) in duplicate, and incubated for 7-10 
days at 37°C, in a 5% CO2 humidified chamber. Colonies representing haematopoietic progenitor 
cell were then enumerated using an inverted microscope. In figure 4-3, the total colonies formed 
were compared for each treatment group and its respective control i.e. imiquimod cream with 
aqueous cream and TPA with acetone treated controls. [***p<0.0001; 2-tailed, unpaired t-test, n=4-
5 mice per experiment; 5 independent experiments). Data were plotted from mean ±SEM]. 
4.2.4 Topical imiquimod cream, or TPA, treatment significantly 
reduces bone marrow cellularity. 
Bones [2x (tibia + femur + hip bone)] harvested from mice treated with topical 
imiquimod cream, or TPA, as described in section 4.2.1, were crushed in a 
mortar and pestle, re-suspended in FACS buffer and filtered through 70µm cell 
strainer (BD Biosciences) to eliminate bone fragments. After lysing red blood 
cells with Ammonium chloride solution, total cells were counted using a 
haemocytometer with trypan blue dead cell exclusion. As summarised in the 
scatter plot in figure 4-4, peripheral inflammation induced by either imiquimod 
cream or TPA treatment significantly reduced the bone marrow cellularity 
compared to their respective controls (figure 4-4, p = 0.0014; 2-tailed Mann-
Whitney U test). On average, the topical imiquimod cream application reduced 
the total bone marrow cellularity by 47.8% [(111.8-58.41)/111.8*100%], whereas 
the topical TPA treatment reduced the total bone marrow cellularity by 27.1% 
[(110.7-80.68)/110.7*100%]. 
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Figure  4-4 Topical imiquimod cream, or TPA, application significantly reduces the bone 
marrow cellularity. 
A single, daily dose of topical imiquimod cream [IMQ (62.5mg)], or TPA (100µM in 100µL acetone) 
was applied to the shaved dorsal skin of C57BL/6 mice for three consecutive days. Simultaneously, 
other groups of mice received equivalent amounts of topical application of either aqueous cream, 
or acetone, application as controls for topical imiquimod cream and TPA application respectively. 
On day 4, the mice were euthanized by CO2 asphyxiation, and bone marrow [2x (tibia + femur + hip 
bones)] harvested for total bone marrow cellularity estimation. Total bone marrow cells were 
counted using haemocytometer and the trypan blue dead cell exclusion method. Statistical 
significance was calculated by comparing each treatment group with its respective control group. 
[2-tailed Mann-Whitney U test; n=7-8 (3 independent experiments)]. 
4.2.5 Topical imiquimod cream, or TPA, application significantly 
increases spleen cellularity 
Spleen harvested from mice treated with the topical imiquimod cream or TPA 
(see section 4.2.1) was minced to isolate haematopoietic cells (see materials 
and methods for details). Total spleen cellularity was determined using a 
haemocytometer with trypan blue dead cell exclusion. As summarised in the 
scatter plot in figure 4-5, peripheral inflammation following topical imiquimod 
cream, or TPA, application, significantly increased splenic cellularity when 
compared to their respective control groups (figure 4-5, p = 0.0002 (imiquimod 
cream treatment) or p <0.0001 (TPA treatment); 2-tailed Mann-Whitney U test in 
both cases). On average, the topical imiquimod cream treatment increased the 
splenic cellularity by 2.7-fold (213.7/80.62) compared to aqueous cream treated 
controls, whereas topical TPA treatment increased the splenic cellularity by 
~1.9-fold (147.3/78.52) compared to acetone treated controls. 
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Figure  4-5 Topical imiquimod cream, or TPA, application significantly increases the splenic 
cellularity. 
A single, daily dose of topical imiquimod cream [IMQ (62.5mg)] or TPA (100µM in 100µL acetone) 
was applied to the shaved dorsal skin of C57BL/6 mice for three consecutive days. Simultaneously, 
other groups of mice received equivalent amounts of topical application of either aqueous cream or 
acetone application as controls for topical imiquimod cream and TPA application respectively. On 
day 4, the mice were euthanized by CO2 asphyxiation, and spleens harvested for cellularity 
estimation. Total spleen cells were counted using a haemocytometer with the trypan blue dead cell 
exclusion method. Statistical significance was calculated by comparing each treatment group with 
its respective control group. [2-tailed Mann-Whitney U test; n=5 (3 independent experiments)]. 
In summary, data presented in this section suggest that the topical imiquimod 
cream and TPA treatments: 
(A) Significantly mobilised HPC to the circulation, leading to significant 
reductions in bone marrow cellularity. 
(B) Significantly increased the splenic cellularity with an accompanying increase 
in haematopoietic progenitor cells in the spleen, which may be suggestive of 
infiltration of the spleen by mobilised HSPC and/or increased haematopoietic 
activity in the spleen in response to each of these peripheral inflammation-
inducing agents. 
4.3 Does the peripheral inflammation impact the HSPC 
compartment? 
4.3.1 Immunophenotypic characterisation of HSPC 
As stated in the previous chapter, one of the drawbacks with the haematopoietic 
colony-forming assay is its inability to support the growth of LT-HSC. In addition, 
the medium employed in the haematopoietic colony-forming assays, described in 
the previous sections, does not support the growth of lymphoid progenitor cells. 
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In order to obtain a comprehensive understanding of how the different 
peripheral inflammation models impacted subsets of cells in the HSPC 
compartment, flow cytometry was employed to immunophenotypically 
characterised these cells. Mice received topical imiquimod cream, or TPA, 
application as described in section 4.2.1 above. Femur, tibia and hipbones were 
next harvested from these mice and processed exactly as described in section 
4.2.4 to isolate the marrow cells. After enriching the marrow cells for 
haematopoietic stem and progenitor cells (see previous chapter for details), the 
c-Kit enriched cells were subsequently stained using the CD150+ SLAM staining 
protocol as described in the previous chapter (Kiel et al., 2005). 
4.3.2 Topical imiquimod cream, or TPA, treatment causes an 
apparent LSK/HSPC expansion 
The gating strategy used to select the HSPC/LSK was exactly as described in the 
previous chapter (section 3.2). In line with previously published data suggesting 
that Sca-1 expression is modulated by inflammation (Zhang et al., 2008), the 
Sca-1 protein expression was observed to be significantly upregulated by each of 
the peripheral inflammatory stimuli resulting in apparent expansion of the LSK 
compartment (compare figures 4-6 A & B for aqueous cream and imiquimod 
cream treatment respectively; or figures 4-6 C & D for topical acetone and TPA 
application respectively). As summarised in the scatter plot in figure 4-6E, the 
increased Sca-1 expression was reflected in apparently increased frequency of 
the HSPC/LSK cells in the bone marrow of topical imiquimod cream or TPA 
treated mice compared to relevant controls (p<0.001; 2-tailed unpaired t-test in 
each case).  
Altogether, by comparing figures 4-6 A & B, to C & D, it is evident that this 
phenomenon of pseudo Sca-1 re-expression by Kit+Sca-1- cells is a mainly a 
consequence of TLR-driven inflammation (see also chapter 3). 
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Figure  4-6 Topical imiquimod cream (IMQ), or TPA, treatment leads to apparent increase in 
bone marrow LSK cells. 
Figures 4-6 A & B are respective representative dot plots showing the gating of the bone marrow 
LSK cells in mice treated with either topical aqueous cream or imiquimod cream. Similarly, figures 
4-6 C & D are respective representative dot plots showing the gating of the bone marrow LSK cells 
in mice treated with either topical acetone, or TPA. Figure 4-6F compares the frequency of the cells 
in the LSK compartment per 1x106 total c-Kit enriched bone marrow cells between each treatment 
group and its respective control [***p<0.001; 2-tailed unpaired t-test; n=4-5 (two independent 
experiments pooled together)]. 
4.3.3 Topical imiquimod cream, or TPA, application alters the 
cellular composition of the HSPC compartment. 
Although the data presented in section 4.2.2 showed that topical imiquimod 
cream or TPA treatment significantly reduced total bone marrow cellularity, the 
data presented in section 4.3.2 was, paradoxically, suggestive of increased HSPC 
numbers in response to each of the peripheral inflammation inducing agents. 
This was most probably due to the increased Sca-1 expression as shown above 
(and also in the previous chapter). In order to obtain an unbiased 
immunophenotypic characterisation of the HSPC compartment, the method 
published by Adolfsson et al. (modified as explained in the previous chapter) was 
employed to stain bone marrow cells from mice treated with either topical 
imiquimod cream or TPA (Adolfsson et al., 2005). The strategy used for gating 
the LK cells was exactly as explained in the previous chapter. The dot plots in 
figures 4-7 A & B are the respective immunophenotypic characterisation of the 
bone marrow LK cells from mice treated with topical aqueous cream or 
imiquimod cream. Figures 4-7 C & D are also the respective dot plots of the 
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immunophenotypic characterisation of LK cells from mice treated with topical 
acetone or TPA. As summarised in the bar graph in figure 4-7E, whereas topical 
imiquimod cream treatment significantly increased the bone marrow CLP 
population (p=0.004; 2-tailed unpaired t-test), topical TPA treatment 
significantly reduced this population (p=0.0011; 2-tailed unpaired t test). Also, 
each of the peripheral inflammatory agents significantly reduced the LMPP 
population when compared to their respective controls (p=0.0006, or p=0.0027 
for imiquimod cream and TPA treatment respectively; 2-tailed unpaired t-test). 
In addition, topical TPA application significantly reduced the bone marrow ST-
HSC population compared to acetone treated controls (p=0.0197; 2-tailed 
unpaired t test). Although there was a trend towards reduction in the ST-HSC 
population in response to the topical imiquimod cream treatment, this did not 
reach statistical significance. 
 
Figure  4-7 Topical imiquimod cream or TPA treatment modulates cellular composition of the 
HSPC compartment. 
A single, daily dose of topical imiquimod cream [IMQ (62.5mg)] or TPA (100µM in 100µL acetone) 
was applied to the shaved dorsal skin of C57BL/6 mice for three consecutive days. Simultaneously, 
other groups of mice received equivalent amounts of topical application of either aqueous cream or 
acetone application as controls for topical imiquimod cream and TPA application respectively. On 
day 4, the mice were euthanized by CO2 asphyxiation, and bone marrow [2x (tibia + femur + hip 
bones)] harvested, and enriched for haematopoietic progenitor cells using the CD117 (c-Kit) 
Microbeads and LS magnetic columns according to manufacturer instructions (Miltenyi Biotec). The 
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c-Kit-enriched cells were then stained with lineage antibody cocktail (CD4, CD5, CD8a, Mac-1, 
B220, Ter119 and Gr-1), as well as c-Kit, CD34, CD150, and FLT3 antibodies to evaluate the 
HSPC compartment. After excluding dead cells, c-Kit+ cells were re-gated for expression of CD34 
and FLT3 antigens to identify CLP, LMPP, ST-HSC and CD34-FLT3- multipotent cells. Figures A & 
B are respective representative dot plots showing the sub-gating of the bone marrow LK cells from 
topical aqueous cream and imiquimod cream treated mice based on CD34 and FLT3 expressions; 
similarly, figures C & D are respective representative dot plots showing the sub-gating of the bone 
marrow LK cells from acetone and TPA based on CD34 and FLT3 expressions. Figure E is a bar 
graph summarising the changes in the proportions of the LMPP, ST-HSC, CLP and LKCD34-FLT3- 
multipotent progenitors in response to the either topical imiquimod cream or TPA treatment. 
Statistical significance was estimated using the unpaired t-test (2-tailed) in all cases. (n=5, 2-
independent experiments)]. 
 
4.3.4 Topical imiquimod cream application significantly reduces 
bone marrow phenotypic LT-HSC population. 
As explained elsewhere (Kiel et al., 2005) and in the previous chapter, within 
the HSPC population, CD150 antigenic expression enriches for cells with long-
term repopulation potential (LT-HSC). As LT-HSC expresses neither CD34 nor 
FLT3 antigens (Yang et al., 2005, Osawa et al., 1996), the CD34-FLT3- 
multipotent cells (see gating in figure 4-7 above) were re-gated for differential 
expression of c-Kit and CD150 antigens. As shown in figures 4-8 A & B and 
summarised in figure 4-8E, topical imiquimod cream treatment significantly 
reduced the bone marrow Lin-Kit+CD34-FLT3-CD150high population (p<0.0001; 2-
tailed unpaired t-test). However, the topical TPA application did not 
significantly alter the bone marrow LT-HSC population (compare figures 4-8 C & 
D). 
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Figure  4-8 Topical imiquimod cream treatment significantly reduces the bone marrow Lin-
Kit+CD34-FLT3-CD150high population in mice. 
The CD34-FLT3- cells (see gating strategy in figure 4-7 above) from aqueous cream (A) or 
imiquimod cream (B) or acetone (C) or TPA (D) treated mice were re-gated for differential 
expression of c-Kit and CD150 antigens to identify the LT-HSC population (Lin-Kit+CD34-FLT3-
CD150high cells). Figure E is a scatter plot summarising the impact of the topical imiquimod cream 
or TPA treatment on the LT-HSC population in the bone marrow of mice. Statistical significance 
was calculated using the 2-tailed unpaired t-test. [N=6; 2 independent experiments]. 
In summary, data presented in this section suggest that: 
(A) Whereas peripheral inflammation induced by topical imiquimod cream 
treatment causes significantly increased Sca-1 expression in HSPC population, 
TPA-induced peripheral inflammation only caused a moderate increase in Sca-1 
re-expression on HSPC population. 
(B) Whereas topical imiquimod cream treatment significantly increased CLP and 
reduced the LT-HSC and LMPP population, TPA treatment significantly reduced 
the CLP, LMPP, and ST-HSC populations without significantly altering the LT-HSC 
population in the bone marrow of mice.    
4.4 Does the peripheral inflammation alter the bone 
marrow niche? 
As extensively reviewed by others (Ehninger and Trumpp, 2011) and as outlined 
in the general introductory chapter, the haematopoietic stem cell niche has 
cellular component (e.g. macrophages, osteoblasts, endothelial cells, 
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mesenchymal stromal cells) and their elaborated soluble products (e.g. CXCL12, 
stem cell factor, angiopoietin-1, etc.). The interactions between these niche 
cells, or their secreted products, and the HSPC are critical in ensuring HSPC 
retention and proper function in the organism. Therefore, to understand the 
extent to which the peripheral inflammation models impacted the bone marrow 
niche, the following questions were addressed: 
1. How do the peripheral inflammation models affect the CXCR4/CXCL12 axis in 
the bone marrow? 
2. How do the peripheral inflammation models affect the bone marrow stromal 
cell compartment (i.e. MSC, endothelial cells and osteoblasts)? 
3. How do the peripheral inflammation models affect the mononuclear 
phagocytic cells of the bone marrow? 
The overall objective was to begin the process of elucidating the mechanistic 
details that resulted in the egress of bone marrow HSPC to the circulation as 
reported in previous sections of this study. 
4.4.1 How do the peripheral inflammation models affect the 
CXCR4/CXCL12 axis in the bone marrow? 
The essential role of the CXCR4/CXCL12 axis in the retention of HSPC in the 
bone marrow has been extensively reviewed in the general introductory chapter. 
Others have shown that perturbation of this CXCR4/CXCL12 signalling axis is one 
of the fundamental mechanisms used by most HSPC mobilising agents 
(Christopher et al., 2009, Semerad et al., 2005). It has been shown that HSPC 
express CXCR4 that interacts with CXCL12 secreted from bone marrow stromal 
cells such as osteoblasts and MSC (Aiuti et al., 1997, Peled et al., 2000). In this 
section of the study the main objectives were: firstly, to use flow cytometry to 
analyse HSPC for CXCR4 expression in mice treated with topical imiquimod 
cream or TPA; and secondly, to measure the plasma and bone marrow CXCL12 
concentration by ELISA to understand how each of the peripheral inflammation 
models affected the CXCL12 levels. Ultimately, I hoped to understand whether a 
perturbation of the CXCR4/CXCL12 axis contributed to the increased circulating 
HSPC seen in the topical imiquimod cream, or TPA application, models. 
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4.4.1.1 Topical imiquimod cream, or TPA, application does not significantly 
alter HSPC CXCR4 expression. 
Mice received daily topical imiquimod cream, or TPA, application for three 
consecutive days (see section 4.2.1 for details). Bone marrow cells were 
enriched for HSPC by the c-Kit enrichment protocol described in previous 
sections, and stained with Live/Dead aqua fixable dye as well as haematopoietic 
lineage (Lin) cell markers, c-Kit, and CXCR4 antibodies to assess CXCR4 cell 
surface expression in HSPC (LK cells). The gating strategy for the LK cells was 
essentially as described in the previous chapter. Figures 4-9 A & B are the 
respective histogram overlays of the CXCR4 expression in the LK/HSPC 
population from mice treated with either topical imiquimod cream or topical 
TPA. As shown by the two distinct peaks in figures 4-9 A & B, there were two 
patterns of HSPC CXCR4 expression; CXCR4low and CXCR4high cells. The scatter 
plot in figure 4-9C summarises the impact of topical imiquimod cream, or TPA, 
treatment on CXCR4high expressing HSPC, showing that neither treatment 
significantly altered the CXCR4 expression (ns = not significant; 2-tailed unpaired 
t-test). The CXCR4 specific isotype-control staining pattern (figures 4-9 A and B) 
shows the specificity of the CXCR4 staining. 
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Figure  4-9 Neither topical imiquimod cream, nor TPA, application significantly alters HSPC 
surface CXCR4 expression. 
C57BL/6 mice were either given a single daily dose of topical imiquimod cream (62.5mg) or TPA 
(100µM in 100µL acetone) application for three consecutive days. On day four, the mice were 
euthanized by CO2 asphyxiation and bone marrow cells [2x (tibia + femur + hip bones)] were 
harvested, crushed in a mortar and pestle, and enriched for haematopoietic progenitor cells using 
the CD117 (c-Kit) Microbeads and LS magnetic columns according to manufacturer instructions 
(Miltenyi Biotec, UK). The c-Kit-enriched cells were then stained with lineage antibody cocktail 
(CD4, CD5, CD8a, Mac-1, B220, Ter119 and Gr-1), c-Kit, CXCR4, and Live/Dead Aqua fixable dye 
to analyse the HSPC (LK) compartment for cell surface CXCR4 receptor expression. After gating 
on live cells through dead cell exclusion using the Live/Dead Aqua fixable dye, Lin- cells were 
selected for further analysis. Figure A is a histogram plot showing the overlay of the CXCR4 
expression in HSPC from imiquimod cream or aqueous cream treated mice and isotype control. 
Similarly, figure B is a histogram overlay showing the CXCR4 expression in bone marrow HSPC of 
mice treated with either topical acetone or TPA. Figure C is a scatter plot summarising of the 
comparison of the MFI for the impact of imiquimod cream/TPA treatment on HSPC surface 
CXCR4high expressing cells.. Statistical significance was calculated using the 2-tailed unpaired t-
test. (n=5; 2 independent experiments). 
4.4.1.2 Topical imiquimod cream or TPA treatment significantly reduces 
bone marrow CXCL12 concentration. 
Having addressed the effects of the peripheral inflammation on LK/HSPC cell 
surface CXCR4 expression, I next sought to investigate the bone marrow CXCL12 
concentrations. CXCL12 is the ligand for CXCR4, and it is the interaction of this 
ligand with CXCR4 that aids the retention of HSPC in the bone marrow. The 
amount of CXCL12 in the peripheral blood was also quantified. The goal was to 
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firstly investigate whether the bone marrow CXCL12 concentration was affected 
by any of the peripheral inflammation inducing agents. Secondly, by measuring 
the peripheral blood CXCL12 concentration, I also wanted to understand if any 
perturbation in the bone marrow CXCL12 created a CXCL12 gradient that 
favoured the exit of HSPC from the bone marrow. Mice were treated with topical 
imiquimod cream or TPA as described in the previous sections. Peripheral blood 
and total bone marrow proteins were harvested as described in chapter 3. Total 
CXCL12 concentration in plasma, or total bone marrow protein extract, from 
mice treated with topical imiquimod cream (or aqueous cream treated controls), 
or TPA (or acetone treated controls), was estimated using ELISA as described in 
section 3.4.1.3 (see chapter 3). 
The calibration curve used to establish the correlation between the optical 
density and CXCL12 concentration as well as the assay detection range (0-10ng) 
was as described in the previous chapter (section 3.4.1.3, figure 3-9A). As shown 
in figure 4-10A, neither topical imiquimod cream, nor TPA, application 
significantly affected the amount of CXCL12 in the circulation of mice compared 
to their respective controls. However, topical imiquimod cream-, or TPA-
induced, peripheral inflammation significantly reduced the concentration of 
total bone marrow CXCL12 (figure 4-10B: p=0.0286; 2-tailed Mann-Whitney U 
test). 
 
Figure  4-10 Topical imiquimod or TPA application significantly reduce bone marrow CXCL12 
concentration.  
C57BL/6 mice were given a single daily topical application of either 62.5mg imiquimod cream, or 
100µM TPA (in 100µL acetone), for three consecutive days. On day four, mice were euthanized by 
CO2 asphyxiation, peripheral blood was taken into EDTA anti-coagulation tubes, spun at >10,000xg 
for 10 minutes and plasma harvested for ELISA. Simultaneously, bones [2x (tibia + femur + hip 
bones)] were also harvested, and total bone marrow protein extracted for CXCL12 ELISA. Figure A 
summarises the measured CXCL12 concentration in the plasma of imiquimod cream (or aqueous 
cream) or TPA (or acetone) treated mice. Figure B summarises the estimated CXCL12 
concentration in the total bone marrow protein extract of imiquimod cream (or aqueous cream) or 
TPA (or acetone) treated mice. [*p=0.0286; 2-tailed Mann-Whitney U test, (n=5)]. 
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Taken together, data presented in this section suggest that the topical 
imiquimod cream or TPA treatment-induced HSPC mobilisation may have a 
significant contribution from a perturbed CXCR4/CXCL12. This suggestion is 
supported by the findings that although the HSPC CXCR4 expression was not 
significantly altered, there were significant reductions in bone marrow CXCL12 
concentration. As neither the topical imiquimod cream, nor TPA, treatment 
altered the plasma CXCL12 concentration, it is reasonable to suggest that 
maintained plasma CXCL12 levels coupled with a reduced bone marrow CXCL12 
levels, might not only have disrupted the HSPC-niche interaction, but also might 
have created a gradient that favoured HSPC migration towards the plasma 
CXCL12. 
4.4.2 How do the peripheral inflammation models affect the bone 
marrow stromal cell compartment? 
In this section of the study, the aim was to understand how these peripheral 
inflammation models (i.e. topical imiquimod cream, or topical TPA, application) 
affected the bone marrow stromal cell compartment, i.e. endothelial cells, 
osteoblasts, mesenchymal stromal cells (MSC). The critical roles played by these 
bone marrow stromal cellular components have been extensively reviewed in the 
general introductory chapter. Flow cytometry was employed to analyse the bone 
marrow stromal compartment to investigate how the peripheral inflammation 
models affected these bone marrow stromal cells. Mice received topical 
imiquimod cream, or TPA, application as described in section 4.2.1. Bones [2x 
(tibia + femur + hip bones)] were harvested, flushed with PBS to eliminate 
haematopoietic cells and processed exactly as described in section 3.4.2.1 of the 
previous chapter (Semerad et al., 2005). The bone stromal cells were stained for 
differential expression of lineage antibody cocktail (Lin), CD45, CD31, CD51, and 
Sca-1 antigen as previously published (Winkler et al., 2010a). The gating strategy 
used for characterising the bone marrow endothelial cells, MSC and osteoblasts 
is exactly as described in section 3.4.2.1 of the previous chapter. As explained in 
the previous chapter, bone marrow endothelial cells, mesenchymal stromal cells 
and osteoblasts were defined as Lin-CD45-Sca-1+CD31+, Lin-CD45-CD31-Sca-
1+CD51+ and Lin-CD45-CD31-Sca-1-CD51+ respectively (Winkler et al., 2010a). 
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4.4.2.1 Peripheral inflammation models differentially modulate bone marrow 
endothelial cell populations. 
The non-haematopoietic/bone marrow stromal cells (defined as CD45-Lin- cells, 
see previous chapter for gating strategy) were sub-gated for differential 
expressions of Sca-1 and CD31 antigens. Figures 4-11 A & B are the respective 
dot plots showing the re-gating of the stromal cells from the bone marrow of 
mice treated with topical aqueous cream or imiquimod cream. Figure 4-11 C & D 
are also the respective dot plots showing the differential expression of CD31 and 
Sca-1 by the bone stromal cells from mice treated with either topical acetone or 
TPA respectively. The Lin-CD45-Sca-1+CD31+ stromal cell population was referred 
to as endothelial cells in agreement with previously published reports (Winkler 
et al., 2010a, Winkler et al., 2010b). As summarised in figure 4-11 E, whereas 
topical imiquimod cream treatment significantly increased the bone marrow 
endothelial cell population (p=0.0066; 2-tailed unpaired t-test), topical TPA 
treatment modestly, but significantly reduced the bone marrow stromal 
endothelial cell population (p=0.0445; 2-tailed unpaired t-test). 
 
Figure  4-11 Bone marrow stromal endothelial cells are differentially modulated by topical 
imiquimod cream, or TPA, treatment. 
The CD45-Lin- non-haematopoietic cells from bone stromal cells were re-gated for differential 
expression of CD31 and Sca-1 to identify endothelial cells (CD45-Lin-CD31+Sca-1+) and non-
endothelial cells (CD45-Lin-CD31-Sca-1-/+) for further analysis. Figures A and B are the respective 
representative dot plots for the gating of the CD45-Lin- non-haematopoietic cells from topical 
aqueous and imiquimod cream treated mice respectively. Similarly, figures C & D are also the 
respective representative dot plots of non-haematopoietic bone stromal cells from mice treated with 
either topical acetone or TPA. Figure E is a scatter plot summarising the effects of the imiquimod 
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cream or TPA treatment on the bone marrow endothelial cell compartment as compared to 
respective control groups. Statistical significance was calculated using the 2-tailed unpaired t-test. 
Data presented in scatter plot are mean±SEM [n=4 (2 independent experiments)]. 
4.4.2.2 Topical imiquimod cream or TPA treatment modulates bone marrow 
osteoblast and mesenchymal stromal cells. 
The Lin-CD45-Sca-1+CD31- cells (indicated as non-endothelial cells in 4-11 A-D 
above), were next, re-gated for the differential expression of CD51 and Sca-1. 
Cells that co-expressed CD51 and Sca-1 (i.e. Lin-CD45-Sca-1+CD31-CD51+) were 
subsequently referred to as mesenchymal stromal cells (MSC); cells that 
expressed CD51, but not Sca-1, (i.e. Lin-CD45-Sca-1-CD31-CD51+) were referred to 
as osteoblasts in agreement with previous reports (Semerad et al., 2005, Short 
et al., 2009, Winkler et al., 2010b). Figures 4-12 A & B are the respective 
representative dot plots showing the gating strategy for MSC and osteoblasts 
from mice treated with topical aqueous cream or imiquimod cream; figures 4-12 
C & D are similar representative plots from mice treated with topical acetone, 
and TPA respectively. As summarised in the scatter plot in figure 4-12E, although 
topical TPA treatment did not significantly alter the bone marrow MSC 
population, imiquimod cream application significantly increased the bone 
marrow MSC population (p=0.0014; 2-tailed unpaired t-test). In addition, each of 
the topical inflammatory agents significantly reduced the bone marrow 
osteoblast population (figure 4-12F, p=0.0011 or p=0.0273 for imiquimod cream 
and TPA treatment respectively; 2-tailed unpaired t-test in each case). 
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Figure  4-12 Bone stromal osteoblasts and MSC populations are differentially modulated by 
topical imiquimod cream or TPA treatment.  
The non-endothelial cells (CD45-Lin-CD31-Sca-1-/+) (see figures 4-11 for gating strategy), from 
bone stromal cells were re-gated for differential expression of CD51 and Sca-1 antigen to identify 
osteoblasts (CD45-Lin-CD31-Sca-1-CD51+) and mesenchymal stromal cells [MSC, CD45-Lin-CD31-
Sca-1+CD51+). Figures A & B are the respective representative plot for the re-gating of the CD45-
Lin-CD31-Sca-1-/+ non-endothelial cells from aqueous cream and imiquimod cream treated mice; 
figures C & D are similar respective plots of non-endothelial cells from mice treated with topical 
acetone or TPA. Figure E is a scatter plot summarising the impact of the topical imiquimod cream 
or TPA treatment on the bone stromal MSC population. Figure F is also a scatter plot summarising 
the impact of topical imiquimod cream or TPA treatment on the bone stromal osteoblasts. 
Statistical significance was calculated using the 2-tailed unpaired t-test. Data in scatter plots are 
presented as mean ±SEM (n=4; 2 independent experiments)]. 
Taken together, each of the peripheral inflammation models led to significant 
modulation of the bone marrow stromal cell compartment and these may have 
impacted the HSPC-retention ability of the bone marrow niche. 
4.4.3 How do the peripheral inflammation models affect the 
mononuclear phagocytic cells of the bone marrow? 
Numerous cells in the innate arm of the immune system have been demonstrated 
to have essential roles in the retention of HSPC in the bone marrow niche 
(Levesque et al., 2003a, Levesque et al., 2003b, Chow et al., 2011). Various 
reports have shown that not only does depletion of these innate immune cells 
lead to HSPC mobilisation, but also that most HSPC mobilising agents act 
indirectly by activating some of these innate cells to release hydrolytic enzymes 
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that degrade HSPC niche retention factors. In this section of the study, the aim 
was to begin to elucidate the potential roles played by cells of the mononuclear 
phagocytic system in peripheral inflammation-induced HSPC mobilisation. Two 
specific mononuclear cell populations were investigated in the bone marrow of 
mice treated with either topical imiquimod cream, or TPA, namely, Gr-
1lowF4/80+CD115high monocytic cells and CD169+ macrophages. The staining 
protocol used was in accordance with a previously published protocol (Chow et 
al., 2011) and the gating strategy was exactly as described in section 3.4.3 of 
the previous chapter. 
4.4.3.1 Topical imiquimod cream application significantly increases bone 
marrow Gr-1lowCD115high monocytic cell population. 
The bone marrow Gr-1lowCD115+/- cells from either imiquimod cream treated, or 
TPA treated mice, or their respective controls, were re-gated for differential 
expression of CD115 and F4/80 antigens to delineate two cellular populations: 
F4/80+ but CD115int (CD115 intermediate expressing cells), and F4/80+ but 
CD115high monocytic cells. Figures 4-13 A & B are the respective representative 
dot plots of F4/80 and CD115 differential expression by bone marrow Gr-
1lowCD115+/- cells from aqueous cream, or imiquimod cream, treated mice; 
figures 4-13 C & D are similar plots for mice treated with either topical acetone, 
or TPA, respectively. As summarised in figure 4-13E, topical imiquimod cream 
application significantly increased the Gr-1lowF4/80+CD115high monocytic cell 
population compared to aqueous cream treated controls (figure 4-13E, p = 
0.0006; 2-tailed, Unpaired t-test). On the other hand, topical TPA application 
did not significantly alter the bone marrow Gr-1lowF4/80+CD115high monocytic cell 
population. 
Chapter 4: Peripheral inflammation model  175 
 
 
Figure  4-13 Topical imiquimod cream application significantly increases the bone marrow 
Gr-1lowCD115high monocytic population. 
Bone marrow cells were gated for differential expression F4/80 and CD115 antigens to investigate 
the Gr-1lowCD115high monocytic cells. A & B are the respective representative plots showing the 
bone marrow mononuclear cells (Gr-1lowCD115high monocytic) of aqueous cream and imiquimod 
cream treated mice; similarly, C & D are the respective representative dot plots of Gr-1lowCD115high 
monocytic cells from the bone marrow of mice treated with topical acetone or TPA. E is a scatter 
plot summarising the changes in the Gr-1lowCD115high monocytic cells in response to either 
imiquimod cream or TPA treatment. Statistical significance was calculated using the 2-tailed 
unpaired t-test. [Ns; means non-significant, n=4 (two independent experiments pooled together)]. 
4.4.3.2 Topical imiquimod cream or TPA treatment differentially modulates 
the bone marrow CD169+ macrophage population. 
Previously, Chow et al. published a protocol that used differential expression of 
CD169 and CD11b antigens by cells of the Gr-1lowF4/80+CD115int population (see 
section 4.4.3.1 for gating strategy) to identify a macrophage population (defined 
as Gr-1-/lowF4/80+CD115intCD169+CD11blow) that was crucial for the retention of 
HSPC in the bone marrow niche (Chow et al., 2011). They established this by 
demonstrating that clodronate-liposome-induced depletion of this macrophage 
population led to mobilisation of HSPC to the circulation. To understand how 
much of the HSPC mobilisation seen with the peripheral inflammation models 
adopted for this study impacted this macrophage population, the Gr-
1lowF4/80+CD115int from mice treated with either topical imiquimod cream or 
TPA application (or their respective control groups), were re-gated for 
differential expression of CD169 and CD11b. Figures 4-14 A & B are the 
respective representative dot plots showing the CD169 and CD11b differential 
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expression for the Gr-1lowF4/80+CD115int population from the bone marrow of 
mice treated with either topical aqueous cream or imiquimod cream; figures 4-
14 C & D are similar representative plots from mice treated with either topical 
acetone, or TPA. As summarised in figure 4-14E, topical imiquimod cream 
treatment significantly reduced the bone marrow Gr-1-
/lowF4/80+CD115intCD169+CD11blow macrophage population when compared to 
aqueous cream treated control (p<0.0001; 2-tailed Unpaired t-test). In contrast, 
topical TPA treatment modestly, but significantly increased the Gr-1-
/lowF4/80+CD115intCD169+CD11blow macrophage population when compared to 
acetone treated controls (p<0.0001; 2-tailed Unpaired t-test). 
 
Figure  4-14 Bone marrow CD169+ macrophage population is differentially affected by 
topical imiquimod cream or TPA treatment.  
The F4/80+CD115int mononuclear cells (see figure 4-13 for gating strategies) from the bone marrow 
were re-gated for the differential expressions of CD169 and CD11b antigens to identify the Gr-1-
CD115intCD169+CD11blow macrophage population and Gr-1-CD115intCD169+CD11b+ mononuclear 
cells. A & B are the respective representative dot plots of the bone marrow of mice treated with 
either aqueous cream or imiquimod cream, showing the gating of the Gr-1-
CD115intCD169+CD11blow macrophage population and Gr-1-CD115intCD169+CD11b+ mononuclear 
cells; C & D are similar plots from the bone marrow of mice treated with acetone and TPA 
respectively. E is a scatter plot summarising the impact of topical imiquimod cream or TPA 
treatment on the bone marrow Gr-1-CD115intCD169+CD11blow macrophage population. Statistical 
significance was calculated using the 2-tailed unpaired t-test. (n=6; 2 independent experiments). 
In summary, data presented in this section suggest that the peripheral 
inflammation agents altered the HSPC niche by: 
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A. Significantly altering the CXCR4/CXCL12 axis in the HSPC niche by reducing 
the bone marrow CXCL12 concentration in both topical imiquimod cream, and 
TPA, treatment models. 
B. In the bone marrow stromal cell compartment, whereas topical imiquimod 
cream treatment significantly reduced the bone marrow stromal osteoblasts 
population, it also significantly increased the MSC and endothelial cell 
populations. On the other hand, although topical TPA treatment did not 
significantly alter the MSC population, it significantly reduced both osteoblasts 
and endothelial cell populations. 
C. With bone marrow mononuclear phagocytic cells, whereas topical imiquimod 
cream treatment significantly reduced the Gr-1-/lowF4/80+CD115intCD169+CD11blow 
macrophage population, it also significantly increased the Gr-1lowCD115high 
monocytic cells. Topical TPA treatment on the other hand, significantly 
increased the bone marrow Gr-1-/lowF4/80+CD115intCD169+CD11blow macrophage 
population, even though it did not significantly alter the Gr-1lowCD115high 
monocytic cell population. 
4.5 What chemokines and cytokines are produced in 
response to the peripheral inflammation? 
The data presented thus far have shown that topical imiquimod cream, or TPA, 
treatment mobilised HSPC to the circulation. As the topical imiquimod cream or 
TPA was applied directly to shaved dorsal skin of mice, the implication is that 
the inflammatory processes elicited by these peripheral inflammatory stimuli 
were communicated to the bone marrow niche. To obtain an understanding of 
the inflammatory milieu elicited in response to the topical imiquimod cream, or 
TPA, treatment and how this is reflected in the plasma, this section of the study 
sought to answer the following questions: 
1. What cutaneous chemokines and cytokines are produced in response to topical 
imiquimod cream or TPA treatment? 
2. What chemokines and cytokines are released into the plasma in response to 
the topical imiquimod cream or TPA treatment? 
Chapter 4: Peripheral inflammation model  178 
 
3. What chemokines and cytokines are produced in the bone marrow in response 
to the topical imiquimod cream or TPA treatment? 
4. What chemokine receptors are expressed by bone marrow and peripheral 
blood HSPC in response to the topical imiquimod cream, or TPA, treatment? 
As the imiquimod cream, or the TPA, was directly applied to the dorsal skin of 
the mice, the overall objective of this section of the study was to profile the 
skin, peripheral blood, bone marrow and HSPC for inflammatory signatures and 
then determine whether any of these mediators could have orchestrated the 
HSPC mobilisation reported in the previous sections. 
4.5.1 What cutaneous chemokines and cytokines are produced in 
response to the topical imiquimod cream, or TPA, 
treatment? 
Before determining the inflammatory mediators in the circulation and bone 
marrow niche, the level of inflammation in the skin (direct point of stimuli 
application) elicited by imiquimod cream, or TPA, painting was first determined 
by RT-QPCR. Mice received topical imiquimod cream, or TPA, treatment exactly 
as described in section 4.2.1. After the treatment, the mice were euthanized by 
CO2 asphyxiation and dorsal skin harvested and analysed by Taqman Low Density 
Array (TLDA) for chemokine and cytokine gene expression in comparison with 
respective control mice, i.e. aqueous cream or acetone treatment for imiquimod 
cream and TPA respectively. 
4.5.1.1 Assessment of the quality of skin RNA isolates. 
Before proceeding to profile the inflammatory gene signatures in the skin, the 
quality of the RNA isolates from the dorsal skin was assessed with nanochips 
using the Agilent 2100 Bioanalyzer platform. The Bioanalyzer provides an RNA 
integrity number (RIN), ratio of 28s/18s, as well as a graphical output that gives 
information on the degree of noise and low molecular weight contamination, as 
shown in figures 4-15A-D. Only samples with RIN >8.0 were used for downstream 
TLDAs. 
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Figure  4-15 Assessment of the quality of skin RNA isolates used for the inflammatory gene 
signature assay 
62.5mg imiquimod cream (IMQ) or 100µM TPA was applied to the shaved dorsal skin of C57BL/6 
mice for three consecutive days, after which skin was harvested for total RNA isolation. A-D shows 
verification of RNA integrity as assessed by the Agilent Bioanalyser 2100. Figure A shows a 
representative gel image (A), and B-D are the representative electropherogram plots for samples 
(CT= representative plot for control samples). The x-axis represents the amplicon size (nt) whereas 
the y-axis represents fluorescence units (FU) for the electropherogram plots; the distinct 18S and 
28S peaks demonstrate lack of noise. 
Approximately, 1500ng of total RNA was used for complementary DNA (cDNA) 
synthesis and subsequent downstream TLDA plate analysis. The TLDA is a 
customised 384-well microfluidic plate (Applied Biosystems, UK) containing 
primers for pre-selected CCL, CXCL, CX3CL and XCL chemokines as well as other 
inflammatory cytokines. In all, the format selected allowed the profiling of a 
total of 32 genes implicated in inflammatory responses (see materials and 
methods for a list of the genes). All gene expression levels were firstly 
normalised to cutaneous TATA binding protein expression levels, and secondly, 
related to their respective controls (i.e. aqueous cream or acetone for 
imiquimod cream and TPA treatment respectively) to obtain the fold change 
(∆∆Ct). Therefore, a fold change of >1 or <1, means that the topical imiquimod 
cream/TPA application induced upregulation or downregulation, in that gene’s 
expression compared to control samples. To enable a direct comparison of the 
modulation in gene expression in response to each of the peripheral 
inflammatory agents to be made, the fold change of each gene expression, in 
response to imiquimod cream, or TPA, treatment were plotted on the same axis. 
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Statistical significance for differences in the fold change in expression of each 
gene was calculated by using the 2-tailed Mann-Whitney U test. 
4.5.1.2 Cutaneous CC-chemokines expressed in response to topical 
imiquimod cream, or TPA, treatment. 
A representative plot for the cutaneous CC-chemokines expressed in response to 
either topical imiquimod cream, or TPA, treatment is shown in figure 4-16. 
Whereas topical imiquimod cream induced a modest increase in Ccl2 expression, 
TPA treatment induced almost a 32-fold increase in expression. Not surprisingly, 
the fold change in Ccl2 gene expression was significantly different between the 
two treatments (p<0.05; 2-tailed Mann-Whitney U test). For Ccl3 expression in 
the skin, whereas topical imiquimod cream application induced a >32-fold 
increase in expression, topical TPA application induced a >1000-fold increase. 
The fold change in the Ccl3 gene expression was significantly different between 
the two treatments (p<0.05; Mann-Whitney U, 2-tailed test). For Ccl4 
expression, whereas topical imiquimod cream application induced an 
approximately 8-fold increase in expression, topical TPA application induced a 
>1000-fold increase (p<0.001; Mann-Whitney U, 2-tailed test). Also, topical 
imiquimod cream or TPA application induced ~4-fold increase in Ccl5 expression. 
In addition, cutaneous Ccl7 gene expression was significantly increased in TPA 
application (>8-fold increase) compared to imiquimod (~2-fold increase) 
application (p=0.029; 2-tailed Mann-Whitney U test). 
Interestingly, there were significant, but differential modulations of cutaneous 
Ccl6 (p=0.029), Ccl17 (p=0.0002), Ccl19 (p=0.028), Ccl20 (p=0.028), Ccl21 
(p=0.0294) and Ccl22 (p=0.0286) gene expression in response to topical 
imiquimod cream and TPA application (2-tailed Mann-Whitney U test in all 
cases); whereas, topical imiquimod cream application down-regulated the 
expression of these genes, TPA application up-regulated the expression of these 
same genes. On the other hand, cutaneous Ccl27 gene expression was down-
regulated by both topical imiquimod cream and TPA application. The difference 
in the down-regulated Ccl27 expression in response to topical imiquimod cream 
or TPA treatment reached statistical significance (p=0.0286; 2-tailed Mann-
Whitney U test). 
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Figure  4-16 Cutaneous CC-chemokine gene expression is modulated by topical imiquimod 
cream or TPA application. 
A single, daily dose of topical imiquimod cream [IMQ (62.5mg)] or TPA (100µM in 100µL acetone) 
was applied to the shaved dorsal skin of C57BL/6 mice for three consecutive days and skin 
harvested for total RNA isolation. Simultaneously, other groups of mice received equivalent 
amounts of topical application of either aqueous cream or acetone application as controls for 
topical imiquimod cream and TPA application respectively. 1.5µg of total RNA was used for cDNA 
synthesis, diluted 1:5 and then used for chemokine and cytokine gene analysis using Taqman Low 
Density Analysis. Gene expression was firstly, normalised to the cutaneous TBP gene expression, 
and then secondly to the respective gene expression in the relevant controls to obtain the fold 
changes (∆∆Ct) in gene expression. The bar graph in figure 4-16 summarises the modulation of 
CC-chemokine gene expression in the dorsal skin in response to either topical imiquimod cream or 
TPA application. Statistical analysis compared the fold change in gene expression in response to 
topical imiquimod cream application to the fold change in the same gene expression induced by 
topical TPA application using 2-tailed Mann-Whitney U test. [(n=4; 2 independent experiments 
pooled together)]. 
4.5.1.3 Cutaneous CXC- and CX3C-chemokines expressed in response to 
topical imiquimod cream, or TPA, treatment. 
A summary of the topical imiquimod cream and TPA application-induced 
modulation of cutaneous CXC and CX3C gene expression is shown in figure 4-17. 
Imiquimod cream application induced a ≥32-fold increase in cutaneous Cxcl2 and 
Cxcl5 expression; TPA application, on the other hand, induced >1000-fold 
increase in expression of both genes. The differences in the fold changes in the 
expression of Cxcl2 and Cxcl5 in response to either topical imiquimod cream or 
TPA treatments reached statistical significance (p<0.001 or p<0.01 for Cxcl2 and 
Cxcl5 respectively; 2-tailed Mann-Whitney U test in both cases). The expression 
of cutaneous Cxcl11 was significantly, but differentially modulated by topical 
imiquimod cream and TPA (p=0.0079; 2-tailed Mann-Whitney U test); whereas 
topical imiquimod cream treatment caused a >32-fold down-regulation, TPA 
treatment caused ~32-fold increased expression. Also, there was ~32-fold 
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increase in expression of Cxcl13 in response to topical imiquimod cream, in 
contrast to TPA treatment which led to ~4-fold reduction in expression. The fold 
change in expression was significantly different between the two treatment 
groups (p=0.006; 2-tailed Mann-Whitney U test). The cutaneous expression of 
Cxcl10, Cxcl12, Cxcl14 and Cx3cl1 were not significantly different from baseline 
levels (i.e. almost the same as control samples). 
 
Figure  4-17 Cutaneous CXC- and CX3C- chemokine gene expression is modulated by topical 
imiquimod cream or TPA application. 
A single, daily dose of topical imiquimod cream [IMQ (62.5mg)] or TPA (100µM in 100µL acetone) 
was applied to the shaved dorsal skin of C57BL/6 mice for three consecutive days and skin 
harvested for total RNA isolation. Simultaneously, other groups of mice received equivalent 
amounts of topical application of either aqueous cream or acetone application as controls for 
topical imiquimod cream and TPA application respectively. 1.5µg of total RNA was used for cDNA 
synthesis, diluted 1:5 and then used for chemokine and cytokine gene analysis using Taqman Low 
Density gene Analysis. Gene expression was firstly, normalised to the cutaneous TBP gene 
expression, and then secondly to the respective gene expression in the relevant controls to obtain 
the fold changes (∆∆Ct) in gene expression. Figure 4-17 summarises the modulation of CXC-
chemokine gene expression in the dorsal skin in response to either imiquimod cream or TPA 
application. Statistical analysis compared the fold change in gene expression in response to topical 
imiquimod cream application to the fold change in the same gene expression induced by topical 
TPA application using 2-tailed Mann-Whitney U test. [(n=4; 2 independent experiments pooled 
together)]. 
4.5.1.4 Cutaneous cytokines expressed in response to topical imiquimod 
cream or TPA treatment. 
The cytokine signatures also followed the same differential regulation pattern 
shown by the CC and CXC chemokines (see figure 4-18). The only cytokine genes 
that were up-regulated in both models were interferon-gamma (IFN-γ) and 
interleukin-1β (IL-1β), whereas IL-4 was only up-regulated in response to topical 
imiquimod cream treatment. Topical imiquimod cream treatment induced ~4-
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fold down-regulation of TNF-α expression in dorsal skin, but topical TPA 
treatment induced ~32-fold up-regulation of expression. This differential 
modulation of cutaneous TNF-α expression was statistically significant 
(p=0.0286; 2-tailed Mann-Whitney U test). There was a modest up-regulation in 
expression of interferon-γ (IFN-γ) in response to topical imiquimod cream, or the 
topical TPA, treatment. The difference in the increased IFN-γ expression in the 
dorsal skin treated with either topical imiquimod cream or TPA was statistically 
significant (p=0.0286; 2-tailed Mann-Whitney U test). The expression of TGFβ1 
was increased by ~4-fold in response to TPA treatment; the expression of TGFβ1 
was only slightly down-regulated in response to topical imiquimod treatment.  
Although IL-1β expression was increased in dorsal skin in response to each of 
topical imiquimod cream and TPA treatments, the difference in the fold changes 
in IL-1β expression, in response to the two treatments, was statistically 
significant (p=0.0286; 2-tailed Mann-Whitney U test). Interestingly, IL-4 gene 
expression was only up-regulated (32-fold) in response to topical imiquimod 
treatment. In addition, whereas, IL-10 gene expression was slightly down-
regulated in response to the topical imiquimod cream application, there was a 
>8-fold up-regulation in expression in response to topical TPA application. The 
difference in IL-10 expression in response to each of topical imiquimod cream or 
TPA application was statistically significant (p=0.0286; 2-tailed Mann-Whitney U 
test). IL-13 was significantly, but differentially, modulated by the two 
treatments (p=0.0286; 2-tailed Mann-Whitney U test); whereas it was ~16-fold 
up-regulated in response to the topical TPA application, there was ~16-fold 
down-regulation in response to topical imiquimod cream application model. IL-
17a was only moderately expressed in TPA treated skin. In addition, IL-22 
expression was >4-fold down-regulated in response to topical imiquimod cream 
treatment, although its expression was not altered by the topical TPA 
treatment. 
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Figure  4-18 Cutaneous cytokine gene expression is modulated by topical imiquimod cream 
or TPA application. 
A single, daily dose of topical imiquimod cream [IMQ (62.5mg)] or TPA (100µM in 100µL acetone) 
was applied to the shaved dorsal skin of C57BL/6 mice for three consecutive days and skin 
harvested for total RNA isolation. Simultaneously, other groups of mice received equivalent 
amounts of topical application of either aqueous cream or acetone application as controls for 
topical imiquimod cream and TPA application respectively. 1.5µg of total RNA was used for cDNA 
synthesis, diluted 1:5 and then used for chemokine and cytokine gene analysis using Taqman Low 
Density Analysis. Gene expression was firstly, normalised to the cutaneous TBP gene expression, 
and then secondly to the respective gene expression in the relevant controls to obtain the fold 
changes (∆∆Ct) in gene expression. Figure 4-18 summarises the modulation of cytokine gene 
expression in the dorsal skin in response to either cream or TPA application. Statistical analysis 
compared the fold change in gene expression in response to topical imiquimod cream application 
to the fold change in the same gene expression induced by topical TPA application using 2-tailed 
Mann-Whitney U test, [(n=4; 2 independent experiments pooled together)]. 
4.5.2 What chemokines and cytokines are released into the 
plasma in response to the topical imiquimod cream or TPA 
treatment? 
4.5.2.1 Introduction 
The cutaneous gene expression data presented above suggest that the topical 
imiquimod cream or TPA treatment elicited upregulation of inflammatory gene 
expression in the skin. However, for the inflammatory gene signatures to 
effectively reach the bone marrow, and thus induce HSPC mobilisation, it is 
imperative that the genes are effectively translated to functional proteins that 
enter the circulation. In order to examine the inflammatory proteome profile in 
the peripheral blood, the aim in this section of the study was to profile the same 
cytokines studied in the previous chapter and compare the repertoire of 
cytokines and chemokines in the plasma (in the systemic and peripheral 
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inflammation models) for potential candidates that might orchestrate the 
increased numbers of mobilised haematopoietic progenitors. Therefore, the 
same mouse cytokine array panel A (ARY006; R&D Systems), as used for the 
plasma inflammatory proteome profiling in the LPS-induced inflammation model 
was employed. As explained in the previous chapter, this proteome array 
allowed the parallel detection of the relative levels of a total of 40 proteins 
(cytokines and chemokines). It principally consists of nitrocellulose membranes 
on which are pre-spotted capture antibodies for specific proteins (duplicate for 
each analyte). The principle underlying the assay procedure is essentially as 
described for the proteome array ARY015 in section 3.5.1 in the previous 
chapter. 
To evaluate the circulating inflammatory proteome milieu, peripheral blood was 
taken from mice treated with topical imiquimod cream, or TPA, (as described in 
section 4.2.1) into EDTA microtainer tubes (BD Biosciences). The blood was 
centrifuged at 8000xg for 10 minutes and plasma was harvested for the 
subsequent proteome array. As the arrays were expensive, the array was run 
once for each treatment; however, plasma from three mice (for each treatment 
group) was pooled together and 150µL of the resultant pooled plasma was used 
for the subsequent proteome array in order to obtain representative data. 
4.5.2.2 Quantification of plasma proteome analytes 
Figure 4-19 shows scanned images of the blots, with the signal intensities 
representing plasma analytes on a developed X-ray film from aqueous cream (A), 
or imiquimod (IMQ) cream (B), acetone (C), or TPA (D), treated mice (after 8 
minutes exposure). 
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Figure  4-19 Mouse cytokine proteome profiling array blots showing signal intensities of 
analytes for plasma from imiquimod cream or TPA treated mice. 
A single, daily dose of topical imiquimod cream [IMQ (62.5mg)] or TPA (100µM in 100µL acetone) 
was applied to the shaved dorsal skin of C57BL/6 mice for three consecutive days. Simultaneously, 
other groups of mice received equivalent amounts of aqueous cream or acetone as controls for 
imiquimod cream and TPA treatment respectively. On the fourth day, mice were euthanized by CO2 
asphyxiation, and plasma taken from the respective mice for cytokine proteome assay. In order to 
obtain a representative proteome profile for each treatment group, plasma from three mice was 
pooled together for each treatment group (i.e. topical imiquimod cream or aqueous cream). 150µL 
of the respective plasma samples was used for the proteome profiling using the Mouse cytokine 
proteome array kit (R&D systems). A & B are the respective scanned images of the blots from the 
plasma of mice treated with aqueous cream or imiquimod cream; C & D are also the respective 
scanned images of blots from the plasma of mice treated with acetone or TPA. 
The spot coordinates and the analytes they represent are exactly as described in 
section 3.5.2 of the previous chapter. The signal intensities were estimated with 
ImageJ 1.48 (NIH, USA) software. As each analyte is represented by duplicate 
spots, the signal intensities of the duplicate spots were then averaged to get the 
mean signal intensities. Next, the mean signal intensity of the spots for negative 
controls was subtracted from that of the calculated mean signal intensity of 
each analyte to correct for background signals. Then, fold change in mean signal 
intensity for each analyte was calculated by dividing the mean signal intensity of 
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the imiquimod cream/TPA treated group by the mean signal intensity of the 
respective analyte in the aqueous cream/acetone treated group to obtain a fold 
change in that analyte concentration. As explained in the previous sections, the 
objective of this analysis was to set the mean signal intensity of each analyte in 
the aqueous cream (control for imiquimod cream) or acetone (control group for 
TPA treatment) to baseline (i.e. 1 in each case). Therefore, the fold change in 
mean signal intensity plotted for each analyte (see below) gives an indirect 
measure of how much the circulating levels of that particular protein was 
increased (fold change >1), or decreased (fold change <1), in response to the 
topical imiquimod cream/TPA-induced peripheral inflammation compared to 
respective controls. To increase the stringency of the assay, only analytes 
demonstrating a >2-fold change in expression were considered to merit further 
consideration. 
4.5.2.3 Imiquimod cream or TPA treatment modulates chemokine levels in 
the circulation. 
Figure 4-20 summarises the fold changes seen in the expression of CC- and CXC-
chemokines in the plasma of mice treated with either topical imiquimod cream 
or TPA. Topical imiquimod cream treatment caused increased circulating CC-
chemokines; CCL2 (>7-fold increase), CCL3 (>2-fold increase), CCL4 (>4-fold 
increase), CCL5 (~7-fold increase), CCL11 (~6-fold increase), CCL12 (~8-fold 
increase) and CCL17 (>2fold increase). However, the only CC chemokine that 
showed a >2-fold increased expression in response to topical TPA treatment was 
CCL2. 
For CXC-chemokines, whereas topical imiquimod cream application caused 
reduced expression of circulating CXCL2 (>4-fold reduction), and CXCL11 (>2-fold 
reduction), it also caused approximately 4-fold increase in CXCL13 levels. In the 
plasma of TPA treated mice, none of the CXC-chemokines was expressed above 
the background, i.e. all were below the cut-off threshold fold change of 2. 
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Figure  4-20 Topical imiquimod cream application modulates chemokine expression in the 
plasma. 
The pixel intensity of each spot on the developed array blots (see figure 4-19) was estimated with 
ImageJ 1.42 software (NIH, USA). As duplicate spots represent each chemokine, the mean of the 
signal intensity of each chemokine was calculated, and the corrected signal intensities were next 
calculated by subtracting the mean signal intensity of the spots for the negative control, from the 
mean signal intensity of each chemokine. Next, the fold change in the corrected mean signal 
intensities were estimated for each analyte by dividing the corrected mean signal intensity of that 
analyte in the imiquimod cream/TPA treated sample by the corrected mean signal intensity of that 
same analyte in the aqueous cream/acetone treated group. Figure 4-20 is a bar graph showing the 
fold change in the plasma chemokines in response to topical imiquimod cream or TPA application. 
Fold change >1, means increased production of the chemokine in response to the treatment; fold 
change <1, indicates reduced chemokine levels in response to the treatment. 
4.5.2.4 Topical imiquimod cream or TPA treatment modulates circulating 
cytokine expression. 
Figure 4-21 summarises the expression of various growth factors and cytokines in 
response to the topical imiquimod cream/TPA-induced peripheral inflammation. 
Topical imiquimod cream application led to a 4-fold increase in the level of the 
myelopoietic cytokine G-CSF in the plasma. Topical imiquimod cream treatment 
also caused increased circulating levels of a host of pro-inflammatory cytokines, 
namely, TNF-α (>2-fold increase), IL-16 (>2-fold increase), IL-17 (>4-fold 
increase), IL-23 (~6-fold increase) and IL-27 (~4-fold increase). It is interesting 
to note that topical imiquimod cream treatment also led to approximately a 4-
fold increase in circulating levels of IL-1α antagonist, IL-1rα, even though the 
fold change in IL-1α itself was not altered. In addition, the topical imiquimod 
cream application led to ~32-fold increase in the expression of the anti-
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inflammatory cytokine, IL-10, in the plasma compared to aqueous cream treated 
controls.  
Unlike the topical imiquimod cream treatment that elicited increases in many 
inflammatory mediators, the only analyte that showed a >2-fold increase in 
circulating levels in response to TPA treatment was tissue inhibitor of matrix 
metalloproteinase 1 (TIMP-1). 
 
Figure  4-21 Topical imiquimod cream application modulates cytokine expression in the 
plasma. 
The pixel intensity of each spot on the developed array blots (see figure 4-19) were estimated with 
ImageJ 1.42 software (NIH, USA). As duplicate spots represent each cytokine, the mean of the 
signal intensity of each cytokine was calculated, and the corrected signal intensities were next 
calculated by subtracting the mean signal intensity of the spots for the negative control, from the 
mean signal intensity of each cytokine. Next, the fold change in the corrected mean signal 
intensities were estimated for each analyte by dividing the corrected mean signal intensity of that 
analyte in the imiquimod cream/TPA treated sample by the corrected mean signal intensity of that 
same analyte in the respective control group. Figure 4-21 is a bar graph showing the fold change in 
the plasma cytokines in response to the topical imiquimod cream or TPA application. Fold change 
>1, means increased production of the cytokine in response to the treatment. 
Taken together, it is reasonable to state that compared to topical TPA 
application, the topical imiquimod cream application induced a strong pro-
inflammatory milieu in the plasma. The strong IL-10 production in the imiquimod 
cream treated mice could therefore be a negative feedback mechanism to 
prevent exaggerated/deregulated immune response. It is possible that the TPA 
treatment induces production of inflammatory mediators that peaked at an 
earlier time point than the 72 hours used for the plasma proteome profiling. The 
only inflammatory chemokine that was consistently highly expressed in the 
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plasma of both imiquimod cream and TPA treated mice was CCL2 suggesting a 
potential role for CCL2 in the observed effects (this is explored further in the 
next chapter).  
4.5.3 What chemokines and cytokines are produced in the bone 
marrow in response to the topical imiquimod cream or TPA 
application? 
4.5.3.1 Introduction 
The overall objective of this thesis was to try to obtain a comprehensive 
understanding of how different inflammatory contexts affected HSPC migratory 
properties. The cutaneous gene expression data presented in section 4.5.1 
suggested that topical imiquimod (TLR7 ligand) and TPA (inflammatory agent 
acting through PKC) application elicited different inflammatory signatures. In 
addition, the plasma proteome profiling data presented above (see section 
4.5.2) also suggested that, at least in the imiquimod cream application model, 
many inflammatory chemokines and cytokines were released into the 
circulation. To understand how these cutaneous inflammatory gene signatures, 
and the circulating inflammatory milieu, reflected in the bone marrow niche, 
proteome arrays were again employed to profile for differences and/or 
similarities in bone marrow proteins between imiquimod cream- and TPA-treated 
mice. Through these arrays, I hoped to identify differences in proteome factors 
between the bone marrow and the circulation that may offer possible 
explanation(s) for the increased HSPC egress from the bone marrow in response 
to each treatment. The mouse angiogenesis array kit (ARY015) was selected for 
this purpose (see previous chapter for details). As the arrays are expensive, each 
array was run once; however, to make it representative, bone marrow protein 
extracts from three mice were pulled together and used for the array. 
Approximately 300µg of whole bone marrow protein extract was used for each 
array. The experimental details are exactly as described in section 3.5.4 in 
the previous chapter. Figures 4-22 shows the array blots from total bone 
marrow protein extract of aqueous cream (A), or imiquimod (B), or acetone (C), 
or TPA (D) treated mice. 
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Figure  4-22 Array blots for bone marrow proteome profiling using the mouse angiogenesis 
proteome array kit. 
A single, daily dose of topical imiquimod cream [IMQ (62.5mg)] or TPA (100µM 100µL acetone), 
was applied to the shaved dorsal skin of C57BL/6 mice for three consecutive days. Simultaneously, 
other groups of mice received equivalent amounts of aqueous cream or acetone as controls for 
imiquimod cream and TPA treatment respectively. On the fourth day, mice were euthanized by CO2 
asphyxiation, bones [2x (tibia + femur+ hip bones)] were harvested, and homogenised in 400µL of 
mammalian protein extraction reagent (MPER, Thermo Scientific). The total bone marrow 
homogenates were spun at >10,000xg for 10 minutes and supernatants taken for proteome array 
profiling. In order to obtain a representative proteome profile for each treatment group, bone 
marrow protein lysates from three mice were pooled together for each treatment group. After 
estimating the pooled lysate protein concentration using the BCA method, ~300µg of the respective 
samples was used for the proteome profiling using the Mouse angiogenesis proteome array kit 
(R&D systems). A & B are the respective scanned images of the blots of the bone marrow 
proteome from aqueous cream (aq. cream) and imiquimod cream; C & D are the respective 
scanned image of the blots of the protein extracts from the bone marrow of acetone and TPA 
treatment. 
After estimating the signal intensity of each spot using ImageJ 1.48 (NIH, USA), 
similar assumptions, as explained in section 4.5.2, were used to calculate the 
fold change in signal intensities. To increase the stringency of the assay, only 
analytes demonstrating >2-fold modulation were considered to merit further 
discussion. 
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4.5.3.2 Chemokines and cytokines produced in the bone marrow in 
response to topical imiquimod cream or TPA treatment. 
As summarised in the bar graph in figure 4-23, topical imiquimod cream 
application led to a >2-fold reduction in the level of bone marrow osteopontin 
(OSPN), and CX3CL1 compared to aqueous cream treated controls. In addition, 
topical imiquimod cream treatment led to increases in the bone marrow IL-1α 
(2-fold increase) and IL-1β (>4-fold increase) when compared to aqueous cream 
treated controls. 
Interestingly, the only chemokine that showed a >2-fold reduced expression in 
the bone marrow of TPA treated mice was CXCL16. No other cytokines or 
chemokines were detected in this proteome analysis. 
It is also interesting to note that no significant alteration in bone marrow 
CXCL12 was found in spite of the significant reductions as determined by ELISA 
in section 4.4.1.2, thus highlighting the limitations of the proteome arrays. 
 
Figure  4-23 Topical imiquimod cream application modulates chemokine and cytokine 
expression in the bone marrow. 
The signal intensities of each spot on the developed array blot (see figure 4-22) was estimated with 
ImageJ 1.42 software (NIH, USA). As duplicate spots represent each cytokine, the mean of the 
signal intensity of each cytokine/chemokine was calculated, and the corrected signal intensities 
were next calculated by subtracting the mean signal intensity of the spots for the negative control, 
from the mean signal intensity of each cytokine. Next, the fold change in the corrected mean signal 
intensities were estimated for each analyte by dividing the corrected mean signal intensity of that 
analyte in the imiquimod cream/TPA treated sample by the corrected mean signal intensity of that 
same analyte in the respective control groups. Figure 4-23 is a bar graph showing the fold change 
in the bone marrow analytes in response to the topical imiquimod cream or TPA treatment. Fold 
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change >1, means increased production of the analyte in response to the treatment; fold change 
<1, indicates reduced analyte concentration in response to the treatment.  
4.5.3.3 Other angiogenesis related proteins released in response to topical 
imiquimod cream or TPA treatment. 
The other analytes also detected by the angiogenesis array are presented in 
figure 4-24 below. Topical imiquimod cream application induced a 2-fold or >4-
fold increased bone marrow secretion of platelet-derived growth factor-AA 
(PDGF-AA) and PDGF-AB respectively. However, topical TPA treatment led to >2-
fold reduction in the bone marrow PDGF-AB levels. Also, topical imiquimod 
cream application induced an ~8-fold increase in pentraxin-3 secretion in the 
bone marrow and a >2-fold increased expression of insulin-like growth factor 
binding protein-3 (IGFBP-3) compared to aqueous cream treated controls. 
Topical TPA treatment on the other hand led to a >2-fold increase in the 
expression of MMP-8 in the bone marrow. However, whereas TPA treatment 
caused a >2-fold reduction in the TIMP-1 levels in the bone marrow, it caused a 
>2-fold increase in the bone marrow TIMP-4 levels.  
 
Figure  4-24 Topical imiquimod cream or TPA treatment modulates the expression of 
angiogenesis-related factors in the bone marrow. 
The signal intensities of each spot on the developed array blot (see figure 4-22) was estimated with 
ImageJ 1.42 software (NIH, USA). As duplicate spots represent each cytokine, the mean of the 
signal intensity of each cytokine was calculated, and the corrected signal intensities were next 
calculated by subtracting the mean signal intensity of the spots for the negative control, from the 
mean signal intensity of each cytokine. Next, the fold change in the corrected mean signal 
intensities were estimated for each analyte by dividing the corrected mean density of that analyte in 
the imiquimod cream/TPA treated sample by the corrected mean signal intensity of that same 
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analyte in the respective control groups. Figure 4-24 is a bar graph showing the fold change in the 
bone marrow analytes in response to the topical imiquimod cream or TPA treatment. Fold change 
>1, means increased production of the analyte in response to the treatment; fold change <1, 
indicates reduced analyte concentration in response to the treatment.  
In summary, the data presented in this section suggest that at the 72 hour time 
point where samples were taken, topical imiquimod cream, or TPA, treatment 
affected the chemokine and cytokine expression by: 
(A) Induction of strong inflammatory chemokine and cytokine gene expressions in 
the skin in response to each of topical imiquimod cream or TPA. 
(B) Topical imiquimod cream treatment comparatively induced the expression of 
inflammatory chemokines in the plasma with a corresponding strong IL-10 
response. Most of the circulating inflammatory mediators were not altered in the 
bone marrow milieu. 
(C) Interestingly, although TPA treatment induced a strong inflammatory gene 
expression in the dorsal skin at the 72 hour time point employed for the gene 
and proteome array assays, there were no corresponding increases in 
inflammatory mediators in the circulation in these mice. 
(D). Altogether, the only inflammatory chemokine that was highly expressed in 
the plasma of both imiquimod cream and TPA treated mice was CCL2. This is 
further explored in the next chapter. 
4.5.4  What chemokine receptors are produced by bone marrow 
and peripheral blood HSPC population in response to the 
topical imiquimod cream, or TPA, application? 
4.5.4.1 Introduction 
Having established that topical imiquimod cream or TPA application induced 
mobilisation of haematopoietic progenitor cells into the circulation (section 
4.2.4) and that these peripheral inflammation models orchestrated increased 
elaboration of inflammatory chemokines in the plasma, with CCL2 the common 
chemokine expressed in both imiquimod cream and TPA treatments (section 
4.5.3), it was deemed important to assess how these changes impacted 
chemokine receptor expression in HSPC. As chemokines are amongst the key 
players involved in cellular migration, I hypothesised that HSPC inducibly express 
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inflammatory chemokine receptors in response to these peripheral inflammatory 
agents (i.e. topical imiquimod cream or TPA application), that enabled them to 
migrate in response to the increased circulating inflammatory chemokines 
especially CCL2.  
To do this, mice received topical imiquimod cream or TPA treatment exactly as 
described in section 4.2.1. Bone marrow from these mice was harvested and 
processed for flow cytometry exactly as described in section 4.3.1. In order to 
obtain an overview of the entire repertoire of chemokine receptors expressed in 
the HSPC in response to each of the topical imiquimod cream or TPA treatment, 
LSK cells from both the peripheral blood and bone marrow were sorted by flow 
cytometry for RT-QPCR. 200 bone marrow or 100 peripheral blood LSK cells were 
sorted into respective wells of 96-well plates and then pre-amplified using the 
specific target pre-amplification protocol in accordance with manufacturer’s 
instructions (Fluidigm Technologies; see materials and methods for details). The 
QPCR was undertaken using the Fluidigm 48.48 Dynamic Chip array platform in 
accordance with the manufacturer’s protocol (see materials and methods for 
details). 
The assumptions made in the analyses of the Fluidigm data to calculate the fold 
change in gene expression were as described in the previous chapter. Only genes 
showing fold change of 2 or more were considered to merit further discussion.  
4.5.4.2 Bone marrow HSPC (LSK) expresses chemokine receptors 
The bar graph in figure 4-25 summarises the fold changes in bone marrow HSPC 
chemokine receptor gene expressions in response to either topical imiquimod 
cream or TPA treatment. For CC-chemokine receptor expression, CCR2, CCR3, 
CCR5, and CCR9 genes were expressed and modulated by the two topical 
inflammatory agents. Specifically, whereas imiquimod cream treatment induced 
a >32-fold increase in CCR2 expression, TPA treatment caused a 16-fold increase 
in expression in the bone marrow HSPC. The difference in the inducible CCR2 
expression in the bone marrow HSPC was significant between the two treatments 
(p=0.01; 2-tailed Mann-Whitney U test). Topical imiquimod cream treatment also 
led to ~16-fold reduction in CCR3 expression. However, the fold change in CCR3 
expression in response to TPA treatment was below the cut-off threshold of 2. 
Chapter 4: Peripheral inflammation model  196 
 
Topical imiquimod cream or TPA application induced up-regulation in the 
expression of CCR5; both topical imiquimod cream application and topical TPA 
application induced >8-fold increase in CCR5 gene expression. Also, whereas 
topical imiquimod cream application induced ~8-fold down-regulation of CCR7 
expression, the fold change in CCR7 expression in response to topical TPA 
treatment was below the cut-off used to screen out background noise. Moreover, 
there was a >2-fold down-regulated expression of CCR9 in response to the 
topical imiquimod cream treatment. 
The two topical inflammation models also modulated the expression of CXC-
chemokine genes in bone marrow HSPC, i.e., CXCR2, CXCR3, and CXCR5, as well 
as the gene for CX3CR1. Specifically, for CXCR2 expression, topical imiquimod 
cream or topical TPA application induced ~8-fold up-regulation in CXCR2 
expression. The expression of the CXCR3 was >2-fold down-regulated in response 
to topical imiquimod cream treatment; the expression of CXCR3 in response to 
TPA treatment was however below the cut-off threshold established to screen 
against background noise. In addition, topical imiquimod cream application 
induced ~2-fold up-regulation in CXCR4 expression. Furthermore, whereas 
topical TPA application induced an ~4-fold down-regulation in CXCR5 expression, 
the expression of CXCR5 in response to topical imiquimod cream application was 
not above background. There was also inducible up-regulation in the CX3CR1 
gene in response to the topical imiquimod cream application (16-fold increase) 
or topical TPA application (>6-fold increase). The difference in the fold change 
in CX3CR1 expression in response to topical imiquimod cream and TPA treatment 
was statistically significant (p=0.0003; 2-tailed Mann-Whitney U test).  
Finally, the c-kit and cited-2 genes were included in the assay as positive 
controls to validate the data as these two genes have demonstrable expression 
in cells of the HSPC compartment. Interestingly, both transcripts were 
consistently detected in the bone marrow HSPC, but neither topical imiquimod 
cream nor TPA treatment modulated their expression. 
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Figure  4-25 Topical imiquimod cream or TPA application modulates chemokine receptor 
gene expression in the bone marrow HSPC 
C57BL/6 mice received a single, daily dose of topical imiquimod cream (62.5mg) or TPA (100µM in 
100µL acetone) application to the shaved dorsal skin for three consecutive days. Simultaneously, 
other groups of mice received equivalent amounts of topical application of either aqueous cream or 
acetone application as controls for topical imiquimod cream and TPA application respectively. On 
day 4, the mice were euthanized by CO2 asphyxiation, and bone marrow [2x (tibia + femur + hip 
bones)] harvested, and enriched for haematopoietic progenitor cells using the CD117 (c-Kit) 
Microbeads and LS magnetic columns according to manufacturer instructions (Miltenyi Biotec). The 
c-kit-enriched cells were then stained with lineage antibody cocktail (CD4, CD5, CD8a, Mac-1, 
B220, Ter119 and Gr-1), as well as c-Kit, and Sca-1, to evaluate HSPC compartment. After 
excluding dead cells through Live/Dead Aqua fixable dye retention, cells positive for markers for 
terminal differentiation of haematopoietic cells were also gated out. Next, 200 bone marrow 
HSPC/LSK cells were sorted on FACSAria II for RT-QPCR using the Fluidigm 48.48 Dynamic array 
platform (Fluidigm Technologies). Gene expression was firstly normalised to Hprt levels and then 
secondly, to the respective control treated sample i.e. aqueous cream or acetone for imiquimod 
cream and TPA treatment respectively to obtain the fold change in expression (∆∆Ct). The fold 
changes in the bone marrow HSPC chemokine receptor expression induced by either topical 
imiquimod cream application or topical TPA application were plotted on the same axis to enable 
direct comparison. Statistical analyses were all computed using the 2-tailed, Mann-Whitney U test. 
(N=8). 
4.5.4.3 Peripheral blood LSK/HSPC express chemokine receptors 
The calculations for the fold change (∆∆Ct) in the gene expression in blood HSPC 
(LSK), was done using similar assumptions as explained for the ∆∆Ct calculations 
for bone marrow HSPC (see section 4.5.4.1 above). The results of the analyses of 
peripheral blood HSPC chemokine receptor expression are summarised in the bar 
graph in figure 4-26. For CC-chemokines, the expression of CCR2, CCR5, CCR7 
and CCR9, were modulated in response to the topical imiquimod cream or TPA 
application. Specifically, although topical TPA treatment caused ~16 fold down-
regulation of CCR2 expression, the fold change in CCR2 expression in response to 
imiquimod cream treatment was below the cut-off threshold. The expression of 
CCR5 was also differentially, but significantly, modulated in response to topical 
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imiquimod cream or TPA application (p=0.004, 2-tailed Mann-Whitney U test). 
Specifically, whereas topical imiquimod cream induced ~6-fold up-regulation of 
CCR5 expression, topical TPA application induced ~2-fold down-regulation. In 
addition, the topical imiquimod cream, or topical TPA, application induced 
down-regulation of CCR7 expression in the peripheral blood HSPC population; a 
>2-fold or a >32-fold down-regulation in CCR7 gene expression in response to 
topical imiquimod cream and TPA application respectively. The difference in the 
CCR7 down-regulation was statistically significant between the two treatment 
groups (p=0.0007; 2-tailed Mann-Whitney U test). Moreover, topical imiquimod 
cream, or TPA, application induced CCR9 gene down-regulation; topical 
imiquimod cream application induced a >16-fold down-regulation, whereas 
topical TPA application induced ~2-fold reduction. The difference in the induced 
CCR9 gene down-regulation between the two treatment groups reached 
statistical significance (p=0.0001; 2-tailed, Mann-Whitney U test). 
CXC-chemokine receptor gene expression in peripheral blood HSPC, i.e. CXCR1, 
CXCR2, CXCR4 and CXCR5 was also modulated in response to each of the two 
peripheral inflammation models. The expression of CXCR1 was differentially, but 
significantly, modulated in response to the topical imiquimod or TPA application 
(p=0.004; 2-tailed Mann-Whitney U test). Specifically, whereas topical 
imiquimod cream induced a >2-fold down-regulation in expression, the topical 
TPA treatment induced ~4-fold upregulation. Also, each of the peripheral 
inflammation models induced up-regulation of CXCR2. Specifically, whereas 
topical imiquimod cream application caused ~8-fold up-regulation, topical TPA 
application induced >32-fold up-regulation. The difference in the induced CXCR2 
gene expression in response to the topical imiquimod cream and TPA application 
reached statistical significance (p=0.0007; 2-tailed Mann-Whitney U test). 
Interestingly, topical imiquimod cream treatment caused ~2-fold up-regulation 
in CXCR4 gene expression; although the fold change in CXCR4 expression in 
response to topical TPA treatment was below the cut-off threshold. Moreover, 
the two peripheral inflammation models significantly, but differentially, 
modulated the expression of the CXCR5 gene in peripheral blood HSPC (p=0.004; 
2-tailed, Mann-Whitney U test). Whereas topical imiquimod cream application 
caused a 4-fold up-regulation in CXCR5 expression, topical TPA application 
induced a >2-fold downregulation. 
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As stated in the previous section, the Cited-2 and c-Kit genes were included as 
positive controls to validate the gene expression data. However, it is interesting 
to note that TPA treatment caused ~4-fold increase in expression of both c-Kit 
and cited-2 transcripts in peripheral blood HSPC. 
 
Figure  4-26 Topical imiquimod cream or TPA application modulates chemokine receptor 
gene expression in the peripheral blood HSPC 
C57BL/6 mice received a single, daily dose of topical imiquimod cream (62.5mg) or TPA (100µM in 
100µL acetone) application to the shaved dorsal skin for three consecutive days. Simultaneously, 
other groups of mice received equivalent amounts of topical application of either aqueous cream or 
acetone application as controls for topical imiquimod cream or TPA application respectively. On 
day 4, the mice were euthanized by CO2 asphyxiation, peripheral blood was harvested into EDTA 
anticoagulation tubes. After lysing red blood cells, the cells were enriched for haematopoietic 
progenitor cells using the CD117 (c-Kit) Microbeads and LS magnetic columns according to 
manufacturer instructions (Miltenyi Biotech, UK). The c-kit-enriched cells were next stained with 
lineage antibody cocktail (CD4, CD5, CD8a, Mac-1, B220, Ter119 and Gr-1), as well as c-Kit, and 
Sca-1, to evaluate HSPC compartment. After excluding dead cells through Live/Dead Aqua fixable 
dye retention, HSPC/LSK cells were sorted on FACSAria II for RT-QPCR using the Fluidigm 48.48 
Dynamic array platform. Gene expression was firstly, normalised to Hprt levels, and secondly, to 
the respective control treated sample i.e. aqueous cream or acetone for imiquimod cream or TPA 
treatment respectively to obtain the fold change in gene expression (∆∆Ct). The fold changes in the 
peripheral blood HSPC chemokine receptor expression induced by either topical imiquimod cream 
application or topical TPA application were plotted on the same axis to enable direct comparison. 
Statistical analyses were all computed using the 2-tailed, Mann-Whitney U test. (N=8). 
4.6 Discussion of the data from the peripheral 
inflammation model 
4.6.1 Topical imiquimod cream or TPA treatment induced 
peripheral inflammation mobilises HSPC to the periphery. 
In the previous chapter, evidence was provided showing that systemic 
inflammation induced by LPS injection caused significant alterations in the bone 
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marrow niche leading to HSPC mobilisation to the circulation. This chapter 
sought to broaden this understanding by investigating the effects of peripheral 
inflammation on HSPC mobilisation and localisation in mice. Topical imiquimod 
cream and TPA treatment models of peripheral inflammation were employed to 
elucidate whether inflammatory signals alone and/or TLR ligation were crucial in 
inflammation-induced HSPC mobilisation. In this chapter, evidence is provided 
showing that topical imiquimod cream, or TPA, treatment mobilised significant 
numbers of HSPC from the bone marrow to the circulation (see figure 4-2). This 
demonstrates that TLR ligation was not obligatory in the inflammation-induced 
HSPC mobilisation as TPA does not act through TLRs. The HSPC mobilisation in 
response to topical imiquimod cream treatment resulted in ~48% reduction in 
bone marrow cellularity compared to aqueous cream treated controls (see figure 
4-4). This reduction in bone marrow cellularity was further reflected in the 
reductions in LMPP, ST-HSC and LT-HSC populations (figures 4-7 & 4-8). 
Similarly, topical TPA treatment also led to ~27% reduction in bone marrow 
cellularity that was reflected in significant reductions in bone marrow CLP, 
LMPP, and ST-HSC populations (figures 4-4, 4-7 & 4-8). As reported elsewhere 
(Shi et al., 2013, Zhang et al., 2008), and in the previous chapter, topical 
imiquimod cream treatment also led to apparent expansion of the HSPC 
compartment as a result of re-expression of Sca-1 on Kit+Sca-1- HSPC. TPA-
induced inflammation, on the other hand, only caused a slight increase in this 
pseudo Sca-1 re-expression, suggesting a TLR-driven effect as the underlying 
cause of this Sca-1 phenotypic inversion i.e. the re-acquisition of Sca-1 antigens 
by previously Sca-1 negative cells. 
Interestingly, each of the peripheral inflammatory agents caused a significant 
increase in spleen cellularity, i.e., 2.7-fold or 1.9-fold increased cellularity in 
response to topical imiquimod cream, and TPA, treatment respectively. This was 
suggestive of either increased extramedullary haematopoietic activity in the 
spleen and/or increased sequestration of haematopoietic cells into the spleen.     
4.6.2 Role of the bone marrow niche in the peripheral 
inflammation induced HSPC mobilisation 
The interactions of the HSPC and the niche cells, and/or soluble products from 
these cells are crucial in the retention of the HSPC in their native bone marrow 
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microenvironment. Many previous studies have established that disruption of 
these HSPC-niche interactions are a critical component of the mechanism 
underlying most HSPC mobilising agents such as G-CSF, and AMD3100 (Levesque 
et al., 2003a, Levesque et al., 2003b, Liles et al., 2003, Broxmeyer et al., 2005). 
The data presented herein suggest that peripheral inflammation, induced by 
either topical imiquimod cream, or topical TPA, application perturbed the 
CXCR4/CXCL12 axis in the bone marrow niche. Each of the peripheral 
inflammation-inducing agents (topical imiquimod cream or TPA) caused 
significant reduction in the bone marrow CXCL12 concentration (as measured by 
ELISA). In contrast, neither topical imiquimod cream nor TPA treatment 
significantly altered the HSPC CXCR4 expression. It is interesting to note that 
neither of the peripheral inflammation models significantly altered the 
peripheral blood CXCL12 concentration. Therefore, it is reasonable to suggest 
that the sustained plasma CXCL12 concentration, with a concomitant reduced 
bone marrow CXCL12, could have created a CXCL12 gradient that favoured HSPC 
egress to the circulation. 
The data presented in this chapter also argue strongly for a role for osteoblasts 
in the HSPC mobilisation observed with each of the peripheral inflammation 
models. The bone marrow stromal cell compartment, i.e. osteoblastic lineage 
cells, mesenchymal stromal cells (MSC) and bone marrow endothelial cells, has 
been demonstrated to be a critical component of the bone marrow endosteal 
niche. These cells have been proposed to be the major producers of critical 
soluble niche factors such as CXCL12, angiopoietin-1, stem cell factor, and 
osteopontin (Ducy et al., 2000, Calvi et al., 2003, Arai et al., 2004, Mendez-
Ferrer et al., 2010). Interfering with the function of these stromal niche cells 
will therefore potentially lead to increased egress of HSPC from the bone 
marrow niche. The data presented in this chapter showed that topical imiquimod 
cream application led to significant increases in the bone marrow endothelial 
cell and MSC populations. In contrast, the topical TPA application led to 
significant reduction in the bone marrow endothelial cell population, although 
the MSC population was not significantly altered. It is reasonable to speculate 
that these increases in MSC and endothelial cells in response to topical 
imiquimod cream treatment, but not TPA treatment, could have resulted in the 
release of inflammatory mediators in the bone marrow of topical imiquimod 
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treated mice (in contrast to the few inflammatory mediators detected in the 
bone marrow of topical TPA treated mice). In addition, both peripheral 
inflammatory agents led to significant reduction in the proportion of the bone 
marrow osteoblast populations. Interpreting these data in the light of the 
significant reduction in bone marrow CXCL12 concentration, it is reasonable to 
suggest that, in both peripheral inflammation models, the most probable critical 
cellular niche component involved in the secretion of CXCL12 might have been 
the osteoblast cell population as it was the only stromal niche cellular 
component that was significantly reduced in the bone marrow of both topical 
imiquimod cream and TPA treated mice (see figures 4-11 & 4-12) (Christopher et 
al., 2009, Semerad et al., 2005, Christopher and Link, 2008). 
Finally, the phagocytic mononuclear cells of the innate arm of the immune 
system have also been shown to have roles in the retention of HSPC in the bone 
marrow niche. Many previous reports have used depletion experiments to 
provide evidence for specific cell populations such as CD169+ macrophages 
(Chow et al., 2011), osteomacs (Winkler et al., 2010b) and granulocytic cells 
(Levesque et al., 2003b, Pruijt et al., 2002) as being crucial in HSPC retention in 
the bone marrow. Interestingly, whereas topical imiquimod cream treatment led 
to a significant increase in the bone marrow monocytic cell population (in 
agreement with the findings reported in the systemic inflammation model in the 
previous chapter), topical TPA application did not significantly alter this cell 
population. Moreover, and in agreement with data published by Chow et al., 
topical imiquimod cream treatment led to significant reduction in the Gr-1-
F4/80+CD115intCD169+CD11blow macrophage population (Chow et al., 2011). In 
stark contrast, the topical TPA application significantly increased the Gr-1-
F4/80+CD115intCD169+CD11blow macrophage population in the bone marrow. 
Therefore, whereas the topical imiquimod cream-induced HSPC mobilisation may 
have a significant contribution from a perturbation of the cells of the 
mononuclear phagocytic system (in agreement the previously published 
macrophage depletion data), the topical TPA application model rather increased 
the macrophage population, suggesting that there may be fundamental 
differences in the mechanisms involved. 
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4.6.3 Inflammatory mediators may play a role in the inflammation-
induced HSPC mobilisation. 
Chemokine ligand/chemokine receptor interactions are fundamental in cellular 
migration in multicellular organisms. The HSPC chemokine receptor transcript 
data presented in this chapter showed that topical imiquimod cream or TPA 
treatment upregulated the expression of CCR2, CCR5, CXCR2 and CX3CR1 in 
bone marrow HSPC. In addition, topical imiquimod cream treatment also caused 
increased expression of CCL2, CCL3, CCL4, CCL5, and CCL11 in the circulation, 
thus raising the possibility that chemokine/chemokine receptor interaction may 
have a role in the HSPC mobilisation to the circulation in response to topical 
imiquimod cream treatment. Interestingly, the only chemokine that was 
increased in the circulation of TPA treated mice was CCL2, which perhaps may 
be suggestive of a role of CCR2/CCL2 axis in the observed HSPC egress from the 
bone marrow in response to topical imiquimod cream or TPA treatment (see next 
chapter). Surprisingly, the only chemokine receptor gene that was upregulated 
in peripheral blood HSPC in response to each of the two peripheral inflammation 
models was CXCR2. It is also interesting to note that although expression of 
many inflammatory cytokine and chemokine genes was upregulated in the dorsal 
skin of TPA treated mice, the corresponding protein products of these same 
genes could not be detected in the plasma of the mice. This may suggest that 
either the genes were not efficiently translated or that their protein products 
did not enter the circulation.  
Also, the topical imiquimod cream application induced a strong increase in the 
expression of pro-inflammatory cytokines such as, TNF-1α, IL-16, IL-17, IL-23 and 
IL-27. This agrees with a previous publication that established the topical 
imiquimod cream application as a model of human psoriasis (van der Fits et al., 
2009). In that paper, Van der Fits et al. implicated the IL-23/IL-17 axis as the 
critical determinant of the psoriasis phenotype. Moreover, others have found 
that in topical imiquimod cream treated mice, as well as in human psoriasis 
patients, neutrophils and pDCs infiltrated the skin lesions and that IL-17, IL-22, 
and IL-23 were important for the observed disease pathology (Cai et al., 2011, 
Stanley, 2002, Van Belle et al., 2012). It is therefore possible that cells that 
infiltrated the lesion sites produced some of the circulating cytokines detected 
in the cytokine array. However, the higher IL-10 (~32-fold increase) levels 
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detected in the plasma of mice treated with topical imiquimod cream suggest 
that feedback mechanisms were invoked to modulate the inflammatory response 
in these mice. Previous reports have suggested that direct TLR ligation on 
immune cells such as macrophages and myeloid derived dendritic cells led to 
increased IL-10 secretion (Agrawal et al., 2003, Dillon et al., 2004, Boonstra et 
al., 2006). Thus, it is possible that the increased IL-10 concentration detected in 
the plasma may be the result of a direct TLR7 ligation on some of these 
recruited and resident skin immune cells. However, none of these inflammatory 
cytokines were detectable in the plasma of the mice treated with the topical 
TPA. Therefore, it is reasonable to suggest that because the TPA application has 
no inherent TLR signalling properties, the inflammation is probably more 
localised. In contrast, due to the expression of TLR7 in some leucocytes (Renn et 
al., 2006, Kadowaki et al., 2001, Jarrossay et al., 2001), the initial inflammatory 
stimulus elicited by the topical imiquimod cream application might have been 
amplified by the subsequent TLR7 signalling in the recruited leucocyte 
populations. This, therefore, sets up an enhanced inflammatory context that 
requires a negative feedback response (in this case a strong IL-10 induction) to 
prevent an exaggerated inflammatory response. Since most of these leucocyte 
populations are motile, it is reasonable to speculate that this skin-induced 
inflammation, in the topical imiquimod cream model, is likely to be 
communicated to other organs in the body. 
As an alternative explanation, one can argue that as the vehicle for the TPA 
treatment, i.e. acetone, is volatile, it evaporated quickly and therefore did not 
allow sufficient time for the TPA to penetrate the epidermal skin layer. In 
contrast, as the imiquimod was in the form of a cream that remained on the skin 
surface for longer period of time, imiquimod could have had sufficient time to 
penetrate the epidermal and dermal skin layers and ultimately entered the 
systemic circulation to initiate a comparatively stronger inflammatory response. 
Therefore, the differences in the durations for which the topical imiquimod 
cream and TPA remained in contact with the dorsal skin might have been a 
contributory factor as to why TPA produced a more localised inflammatory 
response whereas topical imiquimod cream produced a more generalised and 
systemic effect.         
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4.7 Chapter summary 
Both topical imiquimod cream and TPA application modulate inflammatory 
chemokine receptor gene expression in the HSPC. These modulations of the 
chemokine receptor gene expression may have a role in the observed increased 
numbers of HSPC in the circulating blood as increased levels of inflammatory 
mediators were released into the circulation. In addition, both treatments 
caused significantly increased splenic cellularity and haematopoietic progenitor 
cell numbers in the spleen suggesting increased haematopoietic activity in the 
spleen. The following should also be noted: 
1. The topical imiquimod cream application-induced peripheral inflammation 
orchestrated HSPC mobilisation through a multi-faceted mechanism that 
probably involves one or more of the following: significant reduction in the bone 
marrow CXCL12 concentration without altering peripheral blood CXCL12 levels, 
and thus generating a CXCL12 gradient that favours the exit of HSPC from the 
bone marrow; depletion of the CD169+ macrophage population, as well as 
depletion of the stromal bone osteoblast population, leading to decreased bone 
marrow CXCL12. All these might have combined to favour HSPC egress from the 
bone marrow to the circulation. 
2. Topical TPA application induced inflammation also orchestrated HSPC 
mobilisation that may involve: reduction in the bone marrow CXCL12 
concentration that favours a positive gradient towards the peripheral blood 
CXCL12; significant reduction in the stromal bone osteoblast population that 
might have contributed to the reduction in the bone marrow CXCL12 as 
osteoblasts are a major source of CXCL12. 
3. The only inflammatory chemokine that was highly expressed in the plasma in 
both topical imiquimod cream, and TPA, treatment models was CCL2, suggesting 
that if a common chemokine was responsible for the HSPC egress, then the 
CCL2/CCR2 axis was worth consideration (this is explored further in chapter 5).  
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Chapter 5: Role of CCR2 in the topical imiquimod 
cream-induced HPC mobilisation. 
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5.1 Introduction and aims 
In the previous two chapters, evidence was provided that both LPS-induced 
systemic inflammation and peripheral inflammation (due to either topical 
imiquimod cream or TPA application) resulted in the mobilisation of increased 
numbers of haematopoietic progenitor cells to the circulation. Efforts were 
made to provide some insights into the basic mechanisms underpinning the 
increased egress of the HSPC from the bone marrow. Among these, it was found 
that inflammatory chemokine receptor expression by HSPC was modulated in 
both the systemic and the peripheral inflammation models. As a matter of fact, 
CCR2 was highly upregulated in bone marrow HSPC during the systemic 
inflammation model; in the peripheral inflammation models too, CCR2 was the 
most highly upregulated (>16-fold increase over baseline) chemokine receptor. 
In addition, although the CCR2 ligand, CCL2, was highly expressed in both the 
bone marrow and peripheral blood during LPS-induced systemic inflammation, 
CCL2 was consistently highly expressed in the peripheral blood in the peripheral 
inflammation models (i.e. topical imiquimod cream or TPA application). In this 
chapter, I hypothesised that the CCR2/CCL2 axis may have a role in the observed 
HSPC mobilisation during the LPS-induced systemic inflammation model and/or 
the peripheral inflammation model. In order to test this hypothesis, I aimed to 
address the following questions: 
1. Does the inflammation-induced CCR2 gene expression in bone marrow HSPC 
translate to functional cell surface CCR2 protein expression? 
2. How does disruption of the CCR2/CCL2 axis (i.e. CCR2 knock out or CCL2 
neutralisation) impact the observed HSPC mobilisation during the inflammation? 
3. How does the peripheral inflammation model in WT compare to CCR2 KO 
mice? 
4. How do exogenously administered chemokine ligands affect the numbers of 
HSPC in peripheral blood? 
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In this way I sought to begin a detailed exploration of the role of the 
inflammatory chemokine-chemokine receptor axis in HSPC biology during 
inflammation.  
5.2 Does the inflammation-induced CCR2 gene 
expression in HSPC translate to functional cell 
surface protein? 
5.2.1 Introduction 
In the previous chapters, data were provided that both the LPS-induced systemic 
inflammation, and peripheral inflammation models (i.e. topical imiquimod 
cream or topical TPA application) inducibly modulated the expression of some 
inflammatory chemokine receptors in HSPC. In addition, it was also shown that 
the most highly upregulated inflammatory chemokine receptor transcript, 
particularly in the bone marrow HSPC during the peripheral inflammation 
models, was CCR2. Previous reports have indicated that mRNA abundance does 
not necessarily translate into functional cellular protein abundance as many 
post-transcriptional regulatory processes could affect the downstream 
translational processes (de Sousa Abreu et al., 2009, Maier et al., 2009). Thus it 
was necessary to establish that the upregulated Ccr2 mRNA in the bone marrow 
HSPC was translated into functional, cell surface protein in the haematopoietic 
progenitors. Flow cytometric analysis was employed for this purpose. More 
importantly, as CCR2 was the most highly upregulated inflammatory chemokine 
receptor in the bone marrow HSPC, I aimed to address the following questions: 
(A) Do HSPC express cell surface CCR2 in response to inflammation? 
(B) Does such CCR2 expression affect migration of HSPC towards an in vitro 
gradient of CCL2? 
By addressing these questions, I hoped to understand whether during 
inflammation the CCR2/CCL2 axis influenced HSPC biology and thus played a role 
in the observed increased numbers of HSPC exiting the bone marrow in response 
to any of the inflammation models used in this study. 
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5.2.2 Do the HSPCs express cell surface CCR2 in response to 
inflammation? 
As stated in previous chapters, the haematopoietic colony-forming assay 
employed in this study i.e. the MethocultTM GF 3434 medium, allowed the 
detection of myeloerythroid progenitors. Therefore, the objective in this part of 
the study was to characterise the surface CCR2 expression in these 
myeloerythroid progenitors in order to build upon the data reported in the 
previous chapters. Previously, Pronk et al. published a protocol that used 
differential cell staining for CD41, CD105, CD150, Sca-1, c-Kit, and CD16/32 
(FcgRII/III) antigens, to characterise the hierarchy of myeloerythroid progenitors 
(Pronk et al., 2007). This protocol was employed, but with a slight modification. 
As shown in the previous chapters and by others (Zhang et al., 2008), the 
inflammatory context affected the expression of the Sca-1 antigen and therefore 
had the potential to inadvertently bias subsequent analysis. Therefore, IL-7Rα 
antigen expression was used, instead of Sca-1 antibody, to exclude lymphoid-
biased progenitors from the subsequent downstream analysis of the 
myeloerythroid progenitors. Thus, the various myeloerythroid progenitor cells 
were defined as: MkP, megakaryocyte progenitors (Lin-c-Kit+IL-7Rα-
CD41+CD150+); GMP, granulocyte-macrophage progenitors (Lin-c-Kit+IL-7Rα-CD41-
CD150-CD16/32+); PreGM, precursors of granulocyte-macrophage progenitors 
(Lin-c-Kit+IL-7Rα-CD41-CD150-CD16/32-CD105-); CFU-E, colony-forming unit-
erythroid (Lin-c-Kit+IL-7Rα-CD41-CD150-CD16/32-CD105+); preCFU-E, precursors of 
CFU-E (Lin-c-Kit+IL-7Rα-CD41-CD150+CD16/32-CD105+); PreMegE, precursors of 
megakaryocyte-erythroid progenitors (Lin-c-Kit+IL-7Rα-CD41-CD150+CD16/32-
CD105-). 
5.2.2.1 Gating strategy used for the CCR2 receptor staining in 
myeloerythroid progenitors. 
WT mice were treated with either systemic LPS injection, or with topical 
imiquimod cream or TPA application, exactly as described in the previous 
chapters. Femur, tibia as well as hipbones were harvested from these mice and 
processed for FACS by enriching the bone marrow cell isolates for HSPC using the 
c-Kit Microbeads and LS magnetic columns (see previous chapters for details). 
The cells were then stained for lineage (Lin) marker cocktail (CD4, CD5, CD8a, 
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CD11b, B220, Ter119 and Gr-1), c-Kit and Live/dead aqua, CD41, CD105, CD150 
CD16/32 and IL7Rα antibodies to analyse the myeloerythroid progenitor 
compartment. To ensure the specificity of the CCR2 antibody staining, FMO 
(fluorescent minus-one) controls in which all the antibodies in the staining 
cocktail were used except the CCR2 antibody were included in all experiments. 
To further increase the stringency of the assay, bone marrow cells from CCR2 KO 
mice were also stained for CCR2, and compared with the WT mice samples to 
further check for non-specific staining. 
The dot plots in figure 5-1 show representative plots illustrating the gating 
strategy used to firstly, exclude debris, dead cells and terminally differentiated 
haematopoietic cells (Lin+ cells) from further analysis. The myeloerythroid 
progenitors, defined herein as Lin-c-Kit+IL7Rα-CD41-CD150+/- cells, were then 
selected and re-gated in subsequent analysis to characterise the GMP, PreGM, 
CFU-E, PreCFU-E and PreMegE populations (see sections 5.2.2.2-5.3.2.7 
below). 
 
Figure  5-1 Gating strategy used to characterise bone marrow myeloerythroid progenitor cell 
populations. 
C57BL/6 mice received a single, daily dose of topical imiquimod cream (62.5mg) or TPA (100µM in 
100µL acetone) application to the shaved dorsal skin for three consecutive days. Simultaneously, 
other groups of mice received equivalent amounts of topical application of either aqueous cream or 
acetone application as controls for topical imiquimod cream and TPA application respectively. On 
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day three of the model, other groups of mice received a single I.P. injection of 100µL LPS or 100µL 
I.P. PBS injection as a control. On day 4, the mice were euthanized by CO2 asphyxiation, and bone 
marrow [2x (tibia + femur + hip bones)] harvested, and enriched for haematopoietic progenitor cells 
using the CD117 (c-Kit) Microbeads and LS magnetic columns according to manufacturer 
instructions (Miltenyi Biotec). The c-kit-enriched cells were then stained with lineage antibody 
cocktail (CD4, CD5, CD8a, Mac-1, B220, Ter119 and Gr-1), c-Kit, IL-7Rα, CD41, CD150, CD16/32, 
CD105, and Live/Dead Aqua antibodies to evaluate myeloerythroid compartment of the bone 
marrow. Debris and dead cells were excluded using forward-side scatter characteristics, doublet 
exclusion, and Live/Dead Aqua fixable cell retention. Next, cells positive for markers of terminal 
differentiation of haematopoietic cells were also gated out. Next, cells expressing the c-Kit antigen, 
but negative for the IL-7Rα antigens were selected so as to exclude the lymphoid-biased 
progenitors from the subsequent analysis. Re-gating on this population for the differential 
expression of CD41 and CD150 enabled the selection of the myeloerythroid progenitors, i.e. Lin-
Kit+IL-7Rα-CD41-CD150-/+ cells, that were re-analysed as described below. 
5.2.2.2 LPS-induced inflammation significantly upregulates CCR2 
expression in GMP cells 
The Lin-c-Kit+IL7Rα-CD41-CD150+/- cells i.e. the myeloerythroid progenitor cells, 
(see section 5.3.2.1 and figure 5-1 for gating strategy) were next re-gated for 
differential expression of CD150 and CD16/32 antigens to define the GMP cells 
(CD16/32+CD150- cells), and non-GMP cells (CD150+CD16/32- cells). Figures 5-2 A 
& B show representative plots for the GMP cell delineation from bone marrow of 
mice treated with I.P. PBS and I.P. LPS respectively. The histogram overlay in 
figure 5-2 C shows expression of CCR2 on GMP cells from mice treated with 
either LPS or PBS injection. As summarised by the scatter plot in figure 5-2D, I.P. 
LPS injection led to significantly increased CCR2 expression on the bone marrow 
GMP cells when compared to I.P. PBS treated controls (figure 5-2 D; p=0.0286, 2-
tailed Mann-Whitney U test). 
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Figure  5-2 LPS-induced systemic inflammation increases CCR2 expression on GMP cells. 
The myeloerythroid progenitor cell, i.e. Lin-Kit+IL-7Rα-CD41-CD150-/+ population from I.P. PBS (A) 
or I.P. LPS (B), were re-gated for differential expression of CD16/32 and CD150 antigens to identify 
the GMP cells (i.e. Lin-Kit+IL-7Rα-CD41-CD150-CD16/32+ cells) and non-GMP cells (i.e. Lin-Kit+IL-
7Rα-CD41-CD150-/+CD16/32- cells). C shows the histogram overlay of the CCR2 expression in the 
GMP cells from the bone marrow of PBS (in green) or LPS (in blue) or CCR2 KO mice or 
fluorescent-minus-CCR2 antibody controls. D is a scatter plot summarising the comparison of the 
MFI of the CCR2 expression in the GMP from the bone marrow of I.P. PBS or I.P. LPS treated WT 
C57BL/6 mice. Statistical significance was calculated by using the 2-tailed, Mann-Whitney U test to 
compare the MFI of CCR2 expression on bone marrow GMP cells from I.P. PBS and I.P. LPS 
treated mice. (N=4). 
5.2.2.3 LPS-induced inflammation significantly upregulates CCR2 
expression on PreGM cells. 
The non-GMP cells i.e. CD150+CD16/32- cells, (see section 5.3.2.2) were re-gated 
for the differential expression of the CD105 and CD150 antigens to delineate the 
PreGM, CFU-E, PreCFU-E, and PreMegE populations. Figures 5-3 A & B are the 
respective representative plots showing the characterisation of these 
myeloerythroid progenitor population from the bone marrow of WT mice treated 
with either I.P. PBS or I.P. LPS injection. Each of these myeloerythroid sub-
populations was then re-gated for the expression of surface CCR2. Figure 5-3 C is 
a representative histogram overlay plot for the expression of surface CCR2 in the 
PreGM cells. This analysis showed that the PreGM cells also express CCR2 that 
was upregulated by the I.P. LPS injection. This I.P. LPS-induced increase in CCR2 
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expression was statistically significant when compared to I.P. PBS treated 
controls (figure 5-3 D, p=0.0286; 2-tailed, Mann-Whitney U test). 
 
Figure  5-3 LPS-induced systemic inflammation significantly increases CCR2 expression on 
PreGM cells. 
The non-GMP cells i.e. Lin-Kit+IL-7Rα-CD41-CD150-/+CD16/32- cells from I.P. PBS or I.P. LPS 
treated WT C57BL/6 mice were re-gated for differential expression of the CD105 and CD150 
antigens to characterise the PreGM, CFU-E, PreCFU-E, and PreMegE populations. A and B are 
representative plots showing the PreGM, CFU-E, PreCFU-E, and PreMegE subsets from bone 
marrow of I.P. PBS or I.P. LPS treated mice respectively. C shows the histogram overlay of the 
CCR2 expression in the PreGM cells from the bone marrow of I.P. PBS (in blue) or I.P. LPS (in 
green) or CCR2 KO mice or fluorescent-minus-CCR2 antibody controls. D is a scatter plot 
summarising the comparison of the MFI of the CCR2 expression in the PreGM cells from the bone 
marrow of I.P. PBS and I.P. LPS treated WT mice. Statistical significance was calculated by using 
the 2-tailed, Mann-Whitney U test to compare the MFI of PreGM CCR2 expression from I.P. PBS 
and I.P. LPS treated mice. (N=4). 
5.2.2.4 CCR2 expression on CFU-E and PreCFU-E are not significantly 
modulated by LPS-induced inflammation. 
Erythroid-biased progenitors were also analysed for CCR2 expression. However, 
as shown in figures 5-4 A & B, although the expression of CCR2 could be 
detected in the CFU-E and PreCFU-E populations, the I.P. LPS injection did not 
significantly alter CCR2 expression in these populations. 
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Figure  5-4 LPS-induced systemic inflammation does not significantly alter CCR2 expression 
on CFU-E or PreCFU-E. 
The CFU-E and PreCFU-E were also re-analysed for CCR2 expression. A is the representative 
histogram overlay for the CCR2 expression in PreCFU-E from the bone marrow of WT mice treated 
with I.P. PBS injection (in green), or I.P. LPS injection (in blue). B is the representative histogram 
overlay for the CCR2 expression in CFU-E from the bone marrow of WT mice treated with either 
I.P. PBS injection (in red), or I.P. LPS injection (in blue) application. 
5.2.2.5 Topical imiquimod cream or TPA treatment significantly increases 
CCR2 expression on GMPs. 
A similar gating strategy described in section 5.2.2.1 was used to select the 
myeloerythroid progenitor cell population, i.e. Lin-c-Kit+IL7Rα-CD41-CD150+/-
cells, from mice treated with topical imiquimod cream or TPA. The 
representative dot plots in figure 5-5 A shows a histogram overlay illustrating 
CCR2 expression in bone marrow GMP cells of mice treated with either topical 
aqueous cream or imiquimod cream; similarly, figure 5-5B is a representative 
histogram overlay for CCR2 expression in bone marrow GMP cells of mice treated 
with either acetone or TPA. As summarised in the scatter plot in figure 5-5C, 
topical imiquimod cream or TPA treatment significantly increased CCR2 
expression on GMP cells (p=0.0286, 2-tailed Mann-Whitney U test in both cases). 
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Figure  5-5 Topical imiquimod cream or TPA treatment significantly increases CCR2 
expression on bone marrow GMP cells. 
The myeloerythroid progenitor cells, i.e. Lin-Kit+IL-7Rα-CD41-CD150-/+ population from topical 
aqueous cream treated mice or topical imiquimod cream treated mice (or their respective controls), 
were re-gated for differential expression of CD16/32 and CD150 antigens to identify the GMP cells 
(i.e. Lin-Kit+IL-7Rα-CD41-CD150-CD16/32+ cells) and non-GMP cells (i.e. Lin-Kit+IL-7Rα-CD41-
CD150-/+CD16/32- cells). A shows the histogram overlay of the CCR2 expression on GMP cells 
from the bone marrow of topical aqueous cream (in blue) or topical imiquimod cream (in red) 
treated WT mice, or CCR2 KO mice, or cells from WT mice stained with fluorescent-minus-CCR2 
antibody control; similarly, figure B is the histogram overlay showing the expression of CCR2 on 
the GMP cells of mice treated with either acetone or TPA. As summarised in the scatter plot in 
figure C, both topical imiquimod cream and TPA treatment significantly increase the expression of 
CCR2 on bone marrow GMP cells [2-tailed, Mann-Whitney U test (N=4)]. 
5.2.2.6 Topical imiquimod cream or TPA treatment significantly increases 
CCR2 expression on PreGM cells. 
The characterisation of bone marrow PreGM, CFU-E, PreCFU-E, and PreMegE 
populations of mice treated with topical imiquimod cream or TPA (and their 
respective controls) was exactly as described in section 5.2.2.3. Figure 5-6A is a 
representative histogram overlay showing the effect of topical imiquimod cream 
treatment on CCR2 expression in the PreGM population; similarly, figure 5-6B is 
a representative histogram overlay showing the impact of TPA treatment on 
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CCR2 expression in the PreGM cells. As summarised in the scatter plot in figure 
5-6C, topical imiquimod cream, or TPA, treatment significantly increased the 
CCR2 expression on the PreGM cells (p=0.0286; 2-tailed Mann-Whitney U test in 
both cases). 
 
Figure  5-6 Topical imiquimod cream- or TPA-induced inflammation significantly increases 
CCR2 expression on PreGM cells. 
The non-GMP cells i.e. Lin-Kit+IL-7Rα-CD41-CD150-/+CD16/32- cells (see section 5.2.2.3 for gating 
strategy) from topical imiquimod cream/TPA treated WT mice, were re-gated for differential 
expression of the CD105 and CD150 antigens to delineate the PreGM, CFU-E, PreCFU-E, and 
PreMegE populations. A shows the histogram overlay illustrating CCR2 expression in the PreGM 
cells of the bone marrow of topical aqueous cream treated (in blue) or topical imiquimod cream (in 
red) treated WT mice, or CCR2 KO mice or bone marrow cells from WT mice stained with 
fluorescent-minus-CCR2 antibody control. Similarly, B is also a histogram overlay showing CCR2 
expression on PreGM cells of mice treated with either acetone (in blue) or TPA (in red). C is a 
scatter plot summarising the impact of topical imiquimod cream or TPA treatment on CCR2 
expression in PreGM cells [2-tailed, Mann-Whitney U test in each (N=4)]. 
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5.2.2.7 Topical imiquimod cream or TPA treatment does not significantly 
alter the CCR2 expression in CFU-E or PreCFU-E cells.  
The scatter plots in figures 5-7 A & B respectively summarise CCR2 expression in 
PreCFU-E and CFU-E in response to either topical imiquimod cream or TPA 
treatment. Both populations expressed CCR2, although neither imiquimod cream 
nor TPA treatment significantly altered the receptor expression in these 
populations. 
 
Figure  5-7 Topical imiquimod cream-induced inflammation does not alter CCR2 expression 
in CFU-E or PreCFU-E. 
The CFU-E and PreCFU-E of mice treated with either topical imiquimod cream, or TPA, were also 
re-analysed for CCR2 expression. A is a scatter plot summarising the impact of topical imiquimod 
cream or TPA treatment on CCR2 expression in PreCFU-E cells. B also summarises the impacts of 
topical imiquimod cream or TPA treatment on CCR2 expression on CFU-E cells. All statistical 
significances were calculated using the 2-tailed Mann-Whitney U test (n=4).  
Taken together, these data suggest that GMP and PreGM cells significantly 
increase their expression of CCR2 in response to inflammation. 
5.2.3 Does increased CCR2 expression affect migration of HSPC 
towards an in vitro gradient of CCL2? 
5.2.3.1 Introduction  
After establishing that the HSPC, particularly the GMP and the preGMP 
populations, inducibly express increased surface CCR2 in response to peripheral 
or systemic inflammation, I next sought to understand the functional relevance 
of CCR2 in the HSPC. To do this, I employed in vitro chemotaxis assays, using the 
5.0µm pore size polycarbonate membrane Transwell chamber (Corning 
Incorporated, USA), to test the ability of the HSPC to migrate towards CCL2. 
Mice received systemic LPS injection or topical imiquimod cream/TPA treatment 
exactly as described in the previous chapters. Femur, tibia as well as hipbones 
were harvested from these mice, crushed in a mortar and pestle to isolate the 
bone marrow cells, which were then enriched for HSPC using the c-Kit 
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Microbeads and LS magnetic columns (see previous chapters for details). The 
cells were then stained for lineage marker cocktail (CD4, CD5, CD8a, CD11b, 
B220, Ter119 and Gr-1), c-Kit and Live/dead aqua antibodies. After excluding 
dead cells and debris, cells negative for markers for differentiated 
haematopoietic lineage cells (Lin-), but positive for the c-Kit antigen (Kit+), 
henceforth called LK cells, were FACS sorted on a FACSAria II into chemotaxis 
buffer (IMDM containing 1% BSA). The LK cells were sorted, instead of the LSK 
cells, because of the sensitivity of Sca-1 expression to TLR-driven inflammation 
as reported in the previous chapters. 
5.2.3.2 Set up of the CCL2 chemotaxis assay 
All the chambers that included CCL2 are henceforth, called +CCL2 chamber, 
whereas the chambers that excluded CCL2 are called –CCL2 chamber. The 
concentration of CCL2 (20ng/mL) used for the chemotaxis assay, i.e. in the 
lower Transwell chamber, was in accordance with a previous publication (Si et 
al., 2010) who also used LK cells for their chemotaxis assay to study the 
functional relevance of CCR2 in HSPC. 2 x 105 LK cells were added to the upper 
Transwell chamber, and incubated for 3-5 hours at 37°C in a humidified 
incubator in the presence of 5% CO2 plus CCL2 in the lower chamber (i.e. +CCL2 
chamber). For each treatment group, other chambers were also set up with 
2x105 LK cells in the upper chamber but with no CCL2 in the lower chamber (i.e. 
-CCL2 chamber) to account for spontaneous cellular migration. After the 
incubation period, 400µL of the medium in the lower chamber, containing LK 
cells that had migrated in response to the CCL2, were seeded into 3mL of 
MethocultTM GF M3434 medium for duplicate 1.1mL cultures in 35mm plates. The 
plates were incubated and haematopoietic progenitor colonies enumerated 
exactly as described in the previous chapters. 
5.2.3.3 Haematopoietic progenitor cells from I.P. LPS or topical 
imiquimod/TPA treated mice have enhanced in vitro migration 
towards CCL2. 
As summarised in figure 5-8, LK cells from naïve WT mice (i.e. no treatment) 
migrated towards CCL2 suggesting the presence of functional CCR2 on these cells 
(p<0.0001; 2-tailed paired t-test). LK cells from LPS treated mice also migrated 
in significant numbers in response to CCL2 compared to the –CCL2 control 
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(p=0.0015; 2-tailed t-test). In addition, significantly higher numbers of LK cells 
from topical imiquimod cream treated mice migrated towards CCL2 (p<0.0001; 
2-tailed paired t-test). Moreover, significantly higher numbers of haematopoietic 
progenitors from topical TPA treated mice also migrated in response to the CCL2 
(p=0.0001; 2-tailed paired t-test). Furthermore, when topical imiquimod cream 
and TPA treatment groups were compared,  significantly higher numbers of LK 
cells from TPA treated mice migrated towards CCL2 than LK cells from 
imiquimod cream treated mice (p<0.0001; 2-tailed unpaired t-test). 
Taken together, these data argue strongly that the CCR2 expression in the HSPC 
has functional relevance. 
 
Figure  5-8 Enhanced in vitro chemotaxis of haematopoietic progenitors, from I.P. LPS or 
topical imiquimod cream/TPA treated mice, towards CCL2. 
C57BL/6 mice received a single, daily dose of topical imiquimod cream (62.5mg) or TPA (100µM in 
100µL acetone) application to the shaved dorsal skin for three consecutive days. Simultaneously, 
other groups of mice received equivalent amounts of topical application of either aqueous cream or 
acetone application as controls for topical imiquimod cream and TPA application respectively. On 
day three of the model, other groups of mice received a single I.P. injection of 100µg LPS or 100µL 
I.P. PBS as a control. On day 4, the mice were euthanized by CO2 asphyxiation, and bone marrow 
[2x (tibia + femur + hip bones)] harvested, and enriched for haematopoietic progenitor cells using 
the CD117 (c-Kit) Microbeads and LS magnetic columns according to manufacturer instructions 
(Miltenyi Biotec, UK). The HSPC-enriched cells were then stained with lineage antibody cocktail 
(CD4, CD5, CD8a, Mac-1, B220, Ter119 and Gr-1), c-Kit, and Live/Dead Aqua antibodies. Debris 
and dead cells were excluded using forward-side scatter characteristics, doublet exclusion, and 
Live/Dead Aqua fixable dye retention. Next, cells positive for markers of terminal differentiation of 
haematopoietic cells were also gated out, and 2x105 LK cells were FACS sorted into chemotaxis 
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buffer. The LK cells were washed once, and were subsequently seeded to the upper Transwell 
chamber of 5µm pore size, with 20ng/mL CCL2 in the lower chamber and incubated for 3-5 hours. 
After the incubation period, 400µL of the chemotaxis buffer in the lower Transwell chamber was 
subsequently seeded into 3mL of MethocultTM GF M3434 for duplicate 1.1mL culture for 7-10 days 
at 37°C in a 5% CO2 incubator. Total colonies were counted using an inverted microscope, and 
statistical significance calculated using the 2-tailed paired t-test in all cases except the comparison 
between topical imiquimod cream and TPA LK cells where 2-tailed unpaired t-test was used. (N=3-
4; 2-independent experiments pooled together). 
In summary, the following findings should be noted from the data presented in 
this section: 
(A) Myeloerythroid progenitors express functional CCR2. 
(B) CCR2 expression particularly on GMP and PreGM cells is upregulated in 
response to inflammatory stimuli. 
5.3 Does disruption of the CCR2/CCL2 axis disturb the 
inflammation-induced HSPC mobilisation? 
5.3.1 Introduction 
The data presented thus far show that myeloerythroid progenitors express CCR2 
that is increased in response to inflammation. Having demonstrated the function 
of the increased CCR2 expression in in vitro chemotaxis assays, it was deemed 
important to also confirm the functional relevance of the CCR2/CCL2 axis in in 
vivo settings. In this section of the study, I hypothesised that the CCR2/CCL2 
axis was critical in the inflammation-induced HSPC mobilisation and therefore its 
disruption would abrogate the inflammation-orchestrated HSPC mobilisation. To 
test this hypothesis, I sought to address the following questions: 
(1) How does systemic or peripheral inflammation affect plasma CCL2 
concentration? 
(2) Does the disruption of the CCR2/CCL2 axis, i.e. in CCR2 KO mice, or by CCL2 
neutralisation in WT mice, abrogate the systemic or peripheral inflammation-
induced HSPC mobilisation? 
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5.3.2 How does LPS injection or topical imiquimod cream/TPA-
induced peripheral inflammation affect plasma CCL2 
concentration? 
The proteome array data presented in the previous chapters suggested that the 
systemic or peripheral inflammation models led to an increase in the plasma 
CCL2 levels when compared to their respective controls. However, the nature of 
the array data precluded quantitative protein measurements. In line with the 
hypothesis that the CCR2/CCL2 axis might play a role in the inflammation 
orchestrated HSPC mobilisation, I sought to further validate the CCL2 array data 
by quantitatively measuring the plasma CCL2 concentration using ELISA. A mouse 
CCL2 ELISA kit was purchased from EBiosciences (Hatfield, UK) and used to 
measure the plasma CCL2 concentration in accordance with the manufacturer’s 
specifications. WT mice received systemic LPS injection, or imiquimod 
cream/TPA treatment, exactly as described in the previous chapters. Peripheral 
blood was harvested from these mice into EDTA microtainer tubes (BD 
Biosciences). The blood was spun at 10,000xg for 10 minutes, after which the 
plasma was harvested and used for the CCL2 ELISA measurements. The results of 
the plasma CCL2 quantification by ELISA are shown in figure 5-9. 
The CCL2 calibration curve (figure 5-9 A) established a good fit (R2=0.995) for 
the relationship between the CCL2 concentration and the absorbance or optical 
density of analytes. In addition, it also helped establish the detection limits of 
the ELISA assay. In agreement with the proteome array data presented in the 
previous chapters (see chapters 3 & 4), topical imiquimod cream or topical TPA 
application-induced peripheral inflammation each caused a statistically 
significant increase in the concentration of CCL2 in the plasma (figure 5-9B; 
p=0.0079, 2-tailed, Mann-Whitney U test in each case). In addition, LPS-induced 
systemic inflammation also significantly increased the concentration of 
circulating CCL2 (figure 5-9B; p=0.0079; 2-tailed Mann-Whitney U test). 
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Figure  5-9 Peripheral and systemic inflammations significantly increased plasma CCL2 
concentration. 
C57BL/6 mice received a single, daily dose of topical imiquimod cream (62.5mg) or TPA (100µM in 
100µL acetone) application to the shaved dorsal skin for three consecutive days. Simultaneously, 
other groups of mice received equivalent amounts of topical application of either aqueous cream or 
acetone application as controls for topical imiquimod cream and TPA application respectively. On 
day three of the model, other groups of mice received a single I.P. injection 100µL LPS or 100µL 
I.P. PBS injection as a control. On day 4, the mice were euthanized by CO2 asphyxiation, and 
peripheral blood was taken into EDTA anti-coagulation tubes, spun at >10,000xg for 10 minutes 
and plasma harvested for ELISA. Figure A is the calibration curve showing a good fit (R2=0.995) for 
the concentration of CCL2 and absorbance (optical density) and the detection limit of the assay. 
Figure B summarises the measured CCL2 concentration in the plasma of imiquimod cream (or 
aqueous cream) or TPA (or acetone) treated mice or LPS (or PBS controls) treated mice. Statistical 
significance was estimated for each treatment by using the 2-tailed, Mann-Whitney U test to 
compare the CCL2 concentration in the plasma of topical imiquimod cream or topical TPA treated 
mice or I.P. LPS treated mice with their respective controls. (N=5). 
5.3.3 Does disruption of the CCR2/CCL2 axis abrogate the 
systemic or peripheral inflammation-induced HSPC 
mobilisation? 
This question was addressed in two parts: firstly, by repeating the inflammation-
induced HSPC mobilisation models using CCR2 KO mice, and secondly, by 
neutralisation of CCL2 using anti-CCL2 antibodies in WT mice. 
5.3.3.1 Topical imiquimod cream application is unable to induce HSPC 
mobilisation in CCR2 KO mice. 
To begin to assess how disruption of the CCR2/CCL2 axis impacted the 
inflammation induced HSPC mobilisation, CCR2-/- KO mice were used. The caveat 
with the use of these mice is that these mice carry a complete CCR2 gene 
deletion; hence both haematopoietic and non-haematopoietic cells carry this 
deletion. Thus, the findings presented below should be interpreted in the 
context that the observations may be directly due to the absence of CCR2 in the 
haematopoietic cells, and/ or, an indirect effect due to the absence of CCR2 in 
the non-haematopoietic cells. Besides, others have also demonstrated 
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phenotypes such as monocytopenia and defective monocyte/macrophage 
recruitment in these mice (Boring et al., 1997).  
CCR2 KO mice received systemic LPS injection, or imiquimod cream/TPA 
treatment, exactly as described in the previous chapters. Peripheral blood was 
harvested from these mice to measure HSPC numbers using MethocultTM GF 
M3434 exactly as described in the previous chapters. After the incubation 
period, total colonies, representing haematopoietic progenitors mobilised in 
response to the various treatments, were enumerated using an inverted 
microscope. Figure 5-10 is a representative scatter plot summarising the total 
colonies counted from such cultures. 
In agreement with the data presented for WT mice in the previous chapters, I.P. 
LPS injection significantly mobilised increased haematopoietic progenitors to the 
circulation in CCR2 KO mice, in comparison to the I.P. PBS treated groups (figure 
5-10, p <0.0001; 2-tailed unpaired t-test). However, in direct contrast to the 
data presented for WT mice (see previous chapter), topical imiquimod cream 
application failed to mobilise increased numbers of haematopoietic progenitors 
into the circulation in CCR2 KO mice. Topical TPA application also induced 
significant mobilisation of increased haematopoietic progenitors into the 
circulation in CCR2 KO mice (p <0.0001; 2-tailed unpaired t-test). 
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Figure  5-10 Topical imiquimod cream application is unable to mobilise HPC in CCR2 KO 
mice. 
CCR2 KO mice received a single, daily dose of topical imiquimod cream (62.5mg) or TPA (100µM 
in 100µL acetone) application to the shaved dorsal skin for three consecutive days. 
Simultaneously, other groups of mice received equivalent amounts of topical application of either 
aqueous cream or acetone application as controls for topical imiquimod cream and TPA application 
respectively. On day three of the model, other groups of mice received a single I.P. injection of 
100µL LPS or 100µL I.P. PBS injection as a control. On day 4, the mice were euthanized by CO2 
asphyxiation, and peripheral blood was harvested into EDTA anti-coagulation tubes. After lysing 
red blood cells with Ammonium chloride solution, 1x105 peripheral blood leucocytes were seeded 
into 1.1mL of MethocultTM GF M3434 in duplicates, and incubated for 7-10 days at 37°C in a 
humidified incubator containing 5% CO2. After the incubation period, the total haematopoietic 
progenitor colonies were counted using an inverted microscope. Statistical significance was 
calculated using the unpaired t-test to compare the total colony count of each treatment group with 
its respective controls. [N=5; (3 independent experiments)]. 
Taken together, these data suggest that CCR2 may play an important role in 
HSPC mobilisation observed with the topical imiquimod cream application 
model. However, the HSPC mobilisation observed with either systemic LPS 
injection or topical TPA application would appear not to have any major 
dependence on the presence of CCR2. 
5.3.4 Does in vivo CCL2 neutralisation abrogate imiquimod 
cream-induced HSPC mobilisation in WT mice? 
The data presented thus far suggest that CCR2 may play a role in the topical 
imiquimod cream induced HSPC mobilisation. However, as stated earlier, the 
CCR2 KO mouse used in this assay was a complete gene knock-out in which the 
expression of CCR2 was absent in all tissues. To further clarify the role of the 
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CCR2/CCL2 axis in topical imiquimod cream-induced HSPC mobilisation in WT 
mice, in vivo CCL2 neutralisation with anti-CCL2 antibodies was carried out. 
To do this, WT mice received a single, daily topical application of 62.5mg 
imiquimod cream application for 3 consecutive days. However, on days 1 and 3 
during the model, one group received intravenous (I.V.) injection of 15µg anti-
mouse polyclonal CCL2 antibody (R&D Systems, Abingdon, UK) or I.V. injection of 
an equivalent amount of polyclonal goat IgG (R&D Systems, Abingdon, UK) as 
isotype-matched control. The dose of the anti-CCL2 neutralising antibody used 
was in agreement with previously published data (Fujimoto et al., 2009). On day 
4 of the model, mice were euthanized by CO2 asphyxiation and 1x10
5 peripheral 
blood leucocytes were cultured in MethocultTM GF M3434 medium exactly as 
described in the previous chapters. 
The scatter plot in figure 5-11 summarises the impact of CCL2 neutralisation on 
the topical imiquimod cream treatment-induced HSPC mobilisation. The 
comparison of the total haematopoietic colony counts showed that the 
neutralising anti-CCL2 antibody significantly reduced the number of 
haematopoietic progenitor cells mobilised to peripheral blood in WT mice 
compared to isotype-matched controls (p<0.0001, One-way ANOVA, with Tukey’s 
post-test). These data thus show that in vivo neutralisation of CCL2 in WT mice 
recapitulates the defective HSPC mobilisation seen in CCR2-/- mice in response 
to topical imiquimod cream treatment. 
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Figure  5-11 Anti-CCL2 neutralising antibody significantly reduces the HPC mobilised in 
response to topical imiquimod cream application. 
Two groups of C57BL/6 mice each received a single, daily application of topical 62.5mg imiquimod 
cream on the shaved dorsal skin for 3 consecutive days; of these, one group received 
simultaneous intravenous injection of anti-mouse CCL2 antibody, on days 1 and 3 of the model, 
whilst the other group received an equivalent volume of isotype-matched control. Another group of 
mice received topical aqueous cream application to provide estimate of peripheral blood basal HPC 
colony count. On day 4, the mice were euthanized by CO2 asphyxiation, and peripheral blood was 
harvested into EDTA microtainer tubes. After lysing red blood cells with Ammonium chloride 
solution, 1x105 peripheral blood leucocytes were seeded into 1.1mL of MethocultTM GF M3434 in 
duplicate, and incubated for 7-10 days at 37°C in a humidified incubator containing 5% CO2. After 
the incubation period, the total haematopoietic colonies were counted using an inverted 
microscope. Statistical significance was calculated using the One-Way ANOVA with Tukey multiple 
comparison to compare all treatment groups. [N = 4; 2-independent experiments)]. 
5.4 How does the peripheral inflammation model in CCR2 
KO mice compare to WT mice? 
5.4.1 Introduction 
After establishing that topical imiquimod cream failed to mobilise HSPC in CCR2 
KO mice, I next sought to investigate whether there were major differences in 
the cutaneous responses of WT mice and CCR2 KO mice to the peripheral 
inflammation models that might explain this phenomenon. The main questions I 
sought to answer in this part of the study were: 
(A) How different are the responses of the dorsal skins of WT and CCR2 KO mice 
to the imiquimod cream or TPA treatment? 
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(B) Which chemokines and cytokines were released into the circulation of CCR2 
KO mice in response to topical imiquimod cream treatment? 
In this way I sought to gain further insight into what could have been the 
underlying cause of the differences in response to topical imiquimod cream 
application in WT and CCR2 KO mice. 
5.4.2 How different are the responses of the dorsal skins of WT 
and CCR2 KO mice to the imiquimod cream treatment? 
5.4.2.1 Introduction 
Having found that topical imiquimod cream application was able to induce HSPC 
mobilisation in WT mice, but not in CCR2 KO mice, I next sought to understand 
the differential response to the topical imiquimod cream application in the two 
mouse strains. Firstly, as the imiquimod cream and TPA were directly applied to 
the dorsal skin, it was interesting to verify whether the dorsal skin of both 
mouse strains responded similarly to the peripheral inflammation-inducing 
agents. To do this, haematoxylin and eosin staining was employed to examine 
the morphology of the imiquimod cream/TPA treated skin. Although the primary 
focus in this section of the study was topical imiquimod cream treatment, TPA 
treatment model was also included as a comparator. 
WT mice or CCR2 KO mice received the imiquimod cream/TPA (or controls) 
application to shaved dorsal skin exactly as described in the previous chapters. 
The dorsal skin was then harvested into 10% neutral buffered formalin (10%NBF) 
and kept overnight at 4°C. The skin was next processed and embedded in 
paraffin (see materials and methods for details). Blocks were sectioned to 8µm, 
and then stained using haematoxylin and eosin. To enable a direct comparison of 
the effect of the peripheral inflammation-inducing agents on the dorsal skins of 
WT and CCR2 KO mice, the thickness of the epidermis was measured in each 
mouse strain as a quantitative index of the inflammatory response. 
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5.4.2.2 Topical imiquimod cream application induces a significantly greater 
inflammatory response in the dorsal skin of WT compared to CCR2 
KO mice 
Figures 5-12 A & B are the respective representative photomicrographs of the 
dorsal skins from topical aqueous cream (A) or imiquimod, IMQ cream (B) treated 
mice from WT mice; figures 5-12 C & D are also the respective representative 
micrographs of the dorsal skins from topical aqueous cream (C) or imiquimod 
cream (D) treated CCR2 KO mice. By comparing A & B, it was apparent that the 
topical imiquimod cream induced a severe inflammatory response in the dorsal 
skin as evidenced by the thickened epidermis in B compared to A. However, 
compared to the aqueous cream treated control (figure 5-12 C), topical 
imiquimod cream application (figure 5-12 D) induced only a moderate 
inflammatory response in the dorsal skin of the CCR2 KO mice. When the 
epidermal thickness was measured as a quantitative index of the inflammatory 
response (figure 5-12E), it was apparent that the topical imiquimod cream 
application induced a significant inflammatory response in the dorsal skin of WT 
mice compared to aqueous cream treated controls (p<0.0001; 2-tailed unpaired 
t-test). Also, the topical imiquimod cream application induced a significant 
inflammatory response in the dorsal skin of CCR2 KO mice when compared to 
aqueous cream treated controls (p<0.0001; 2-tailed unpaired t-test), although 
this was significantly less than that seen in WT mice (p=0.0001; 2-tailed unpaired 
t-test). This suggests that the CCR2 KO mice responded less well to the topical 
imiquimod cream treatment. 
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Figure  5-12 CCR2 KO mice have reduced cutaneous inflammation in response to topical 
imiquimod cream application. 
WT mice or CCR2 KO mice received a single, daily dose of topical imiquimod cream (62.5mg), or 
equivalent amount of topical aqueous cream application, to the shaved dorsal skin for three 
consecutive days. On day 4, the mice were euthanized by CO2 asphyxiation, and the dorsal skins 
that directly received the topical imiquimod cream were harvested into 10% neutral buffered 
formalin. 24-hours later, the skin tissues were paraffin embedded in a tissue processor, sectioned 
to 8µm and stained with haematoxylin and eosin for morphological examination. A and B are 
respective representative micrographs of dorsal skin of WT mice treated with either aqueous cream 
or topical imiquimod cream (20X magnification). C and D are the micrographs of the dorsal skin of 
CCR2 KO mice treated with either topical aqueous cream or topical imiquimod cream (20X 
magnification). In E, the epidermal thickness was measured using AxioVision software on Zeiss 
Axiostar Plus Microscope (Carl Zeiss, Welwyn, Garden City, UK) and compared between treatment 
groups, in the respective strains, by the unpaired t-test. [(N=8), DE, dermis; EP, epidermis; HF, hair 
follicle; SC, stratum corneum]. 
5.4.2.3 Topical TPA application induces comparable inflammatory response 
in both WT and CCR2 KO mice 
Figures 5-13 A & B are the respective representative photomicrographs of the 
dorsal skins from either topical acetone (A) or TPA (B) treated skin from WT 
mice; figure 5-13 C & D are also the respective representative micrographs of 
the dorsal skins from either topical acetone (C) or TPA (D) treated CCR2 KO 
mice. By comparing A & B, it was apparent that the topical TPA application 
induced a severe inflammatory response in the dorsal skin of WT mice as 
evidenced by the thickened epidermis in B, compared to A. Also, compared to 
the acetone treated control (figure 5-13 C), the topical TPA application (figure 
5-13 D) induced a severe inflammatory response in the dorsal skin of the CCR2 
KO mice. When the epidermal thickness was measured as a quantitative index of 
the inflammatory response (figure 5-13E), it was apparent that the topical TPA 
application induced a significant inflammatory response in the dorsal skin of WT 
mice (p<0.0001; 2-tailed unpaired t-test). The topical TPA application also 
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induced a significant inflammatory response in the dorsal skin of CCR2 KO mice 
(p<0.0001; 2-tailed unpaired t-test). Unlike the topical imiquimod cream model 
in which there was a significant difference in the inflammatory response 
between the WT and CCR2 KO mice, the topical TPA application induced 
comparable inflammatory responses in the two strains of mice.  
 
Figure  5-13 Topical TPA application induces comparable inflammatory responses in the 
epidermis of WT and CCR2 KO mice. 
WT mice or CCR2 KO mice received a single, daily dose of topical TPA (100µM in 100µL acetone), 
or topical application of 100µL acetone as a control, to the shaved dorsal skin for three consecutive 
days. On day 4, the mice were euthanized by CO2 asphyxiation, and the dorsal skins that directly 
received the topical acetone or TPA application were harvested into 10% neutral buffered formalin. 
24-hours later, the skin tissues were paraffin embedded in a tissue processor, sectioned to 8µm 
and stained with haematoxylin and eosin for morphological examination. A and B are the 
respective representative micrographs from dorsal skin of WT mice treated with either topical 
acetone or topical TPA (20X magnification). C and D are the respective micrographs from the 
dorsal skin of CCR2 KO mice treated with either topical acetone or topical TPA (20X 
magnification). In E, the epidermal thickness was measured using AxioVision software on Zeiss 
Axiostar Plus Microscope (Carl Zeiss, Welwyn, Garden City, UK) and compared between treatment 
groups, in the respective strains, by the unpaired t-test. [(N=8), DE, dermis; EP, epidermis; HF, hair 
follicle; SC, stratum corneum]. 
5.4.3 Which chemokines and cytokines are released into the 
circulation in response to topical imiquimod cream 
treatment? 
In the previous chapter, the plasma of mice treated with topical imiquimod 
cream was profiled for circulating cytokines and chemokines using the mouse 
cytokine array panel A (ARY006; R&D Systems). This same array kit was 
employed to characterise the plasma of CCR2 KO mice treated with the topical 
imiquimod cream model (see previous chapter for details). The objective was to 
compare the inflammatory proteome of the CCR2 KO mice with that of WT mice 
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to verify whether the differential response of the dorsal skin to the topical 
imiquimod cream was also reflected in the inflammatory mediators in the 
plasma. Ultimately, the aim was to probe for any candidate molecule(s) that 
could be explored as a potential ligand involved in the HSPC mobilisation seen in 
the topical imiquimod cream model in WT mice. The principle of the mouse 
cytokine array kit and the inflammatory mediators they detect, have been 
described in previous chapters. Just as explained in the previous chapters, 150µL 
of plasma, pooled from three mice, was used for the proteome array in order to 
obtain representative data. 
5.4.3.1 Quantifying the inflammatory mediators detected by the cytokine 
array. 
Figures 5-14 A & B show scanned images of the array blots from the topical 
aqueous cream and imiquimod cream treated CCR2 KO mice respectively. 
 
Figure  5-14 Array blots of plasma proteome detected by mouse cytokine proteome array 
A single, daily dose of topical imiquimod cream [IMQ (62.5mg)] or equivalent amount of aqueous 
cream was applied to the shaved dorsal skin of CCR2 KO mice for three consecutive days. On the 
fourth day, mice were euthanized by CO2 asphyxiation, and plasma was taken from the respective 
mice for cytokine proteome assay. In order to obtain a representative proteome profile for each 
treatment group, plasma from three mice was pooled together for each treatment group (i.e. topical 
imiquimod cream or aqueous cream). 150µL of the respective plasma samples was used for the 
proteome profiling using the Mouse cytokine array panel A kit (R&D systems). A & B are the 
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respective scanned images of the blots of the plasma from aqueous cream or imiquimod cream 
treated CCR2 KO mice. 
As explained previously, the signal intensities were estimated with ImageJ 1.48 
(NIH, USA) software. The fold changes in analyte expression levels were 
calculated using similar assumptions as outlined in the previous chapters. Only 
analytes demonstrating fold changes of 2 or more were considered to be 
sufficiently above background to merit further consideration.   
5.4.3.2 Estimating the plasma chemokines in CCR2 KO mice in response to 
topical imiquimod application. 
Figure 5-15 summarises the topical imiquimod cream-induced modulations in 
production of both CC- and CXC-chemokines in the plasma of CCR2 KO mice. For 
the CC-chemokines, the expression levels of CCL1, CCL2, CCL3 and CCL5 were all 
increased in the plasma of CCR2 KO mice compared to aqueous cream treated 
controls. Specifically, topical imiquimod cream application led to 2-fold, ~4-
fold, >12-fold or ~8-fold increases in the levels of circulating CCL1, CCL2, CCL3 
and CCL5 respectively. The increases in the expression levels of these 
chemokines compared favourably to the WT data (see section 4.5.2.3 of the 
previous chapter). However, there were some differences; whereas topical 
imiquimod cream treatment caused increased circulating CCL11 (6-fold 
increase), CCL12 (8-fold increase) and CCL17 (>2-fold increase) in WT mice, the 
circulating levels of these chemokines were below the threshold set to screen 
background noise. In addition, whereas CCL1 was ~2-fold more expressed in 
CCR2 KO plasma in response to topical imiquimod cream treatment, it was not 
expressed above background in WT mice.  
For CXC-chemokines, topical imiquimod cream application induced a >2-fold 
increase in circulating CXCL1 and CXCL13 in CCR2 KO mice when compared to 
aqueous cream treated controls. Although there were similarly increased CXCL13 
expression levels in WT mice in response to topical imiquimod cream treatment, 
there was no increased CXCL1 expression in WT mice. In addition, there was also 
a >2-fold reduced levels of CXCL2 and CXCL11 expression in the plasma of WT 
mice in response to topical imiquimod cream treatment; these reduced levels of 
CXCL2 and CXCL11 were not detected in CCR2 KO mice. 
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Figure  5-15 Topical imiquimod cream application modulates chemokine expression in the 
plasma of CCR2 KO mice. 
The signal intensities of each spot on the developed array blots (see section 5.4.3.1) were 
estimated with ImageJ 1.42 software (NIH, USA). As duplicate spots represent each chemokine, 
the mean of the pixel density of each chemokine was calculated, and the corrected signal 
intensities were next calculated by subtracting the mean signal intensity of the spots for the 
negative control, from the mean signal intensity of each chemokine. Next, the fold change in the 
corrected mean signal intensities was estimated for each analyte by dividing the corrected mean 
signal intensity of that analyte in the imiquimod cream treated sample by the corrected mean signal 
intensity of that same analyte in the aqueous cream treated group. Figure 5-15 is a bar graph 
showing the fold change in the plasma chemokines in response to the topical imiquimod cream 
application. Fold change >1, means increased production of the cytokine in response to topical 
imiquimod cream application. 
5.4.3.3 Topical imiquimod cream application modulates plasma cytokines in 
CCR2 KO mice 
The bar graph in figure 5-16 summarises the impact of the topical imiquimod 
cream application on circulating plasma cytokines in CCR2 KO mice. 
Interestingly, topical imiquimod cream application resulted in ~28-fold increase 
in triggering receptor expressed on myeloid cells 1 (TREM-1) levels in the 
circulation of CCR2 KO mice. This contrasts to the data from WT mice (see 
previous chapter), in which TREM-1 was not expressed above background. 
The plasma levels of interleukins (ILs) in CCR2 KO mice were also modulated by 
the topical imiquimod cream treatment. Specifically, topical imiquimod cream 
led to a >2-fold increase in circulating IL-1α levels in CCR2 KO mice. In addition, 
topical imiquimod cream treatment also led to >2-fold increase in the level of 
the natural antagonist for IL-1α, the IL-1rα, in the plasma of CCR2 KO mice. This 
increase in the levels of both IL-1α, and IL-1rα is understandable considering 
that a delicate balance is kept between IL-1α and IL-1rα to maintain cellular 
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homeostasis (Arend, 2002). Also, there was a strong increase (~28-fold) in the 
plasma levels of the anti-inflammatory cytokine, IL-10, in the circulation of 
CCR2 KO mice. Moreover, there were also increases in plasma levels of IL-16 (~8-
fold increase) and IL-17 (~4-fold increase) in CCR2 KO mice. These topical 
imiquimod cream treatment-induced increases in the IL-1rα, IL-10, IL-16 and IL-
17 were comparable to the imiquimod cream treatment-induced changes in WT 
mice (see previous chapter). However, there were many differences; whereas 
topical imiquimod cream treatment led to increased circulating levels of G-CSF 
(4-fold increase), TNF-1α (>2-fold increase), IL-23 (8-fold increase) and IL-27 (4-
fold increase) in WT mice, the expression of these cytokines was not above 
background in CCR2 KO mice.  
 
Figure  5-16 Topical imiquimod cream application modulates cytokine expression in the 
plasma of CCR2 KO mice. 
The signal intensity of each spot on the developed array blots (see figure 5-14) were estimated with 
ImageJ 1.42 software (NIH, USA). As duplicate spots represent each cytokine, the mean of the 
signal intensity of each cytokine was calculated, and the corrected mean signal intensities were 
next calculated by subtracting the mean signal intensity of the spots for the negative control, from 
the mean signal intensity of each cytokine. Next, the fold change in the corrected mean signal 
intensities was estimated for each analyte by dividing the corrected mean signal intensity of that 
analyte in the imiquimod cream treated sample by the corrected mean signal intensity of that same 
analyte in the aqueous cream treated group. Figure 5-16 is a bar graph showing the fold change in 
the plasma cytokines in response to the topical imiquimod cream application. Fold change >1, 
means increased production of the cytokine in response to topical imiquimod cream application.  
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5.4.4 HPC mobilisation is not just the result of soluble factors 
released from the skin 
To determine whether soluble factors from the skin was the cause of the HPC 
mobilisation action seen with the topical imiquimod cream or TPA painting, 
protein skin homogenates were administered I.P. to assess their ability to 
recapitulate the imiquimod cream- or TPA-induced HPC mobilisation. To do this, 
WT mice received the topical imiquimod cream/TPA treatment exactly as 
described in the previous chapters. After the treatment, mice were culled by 
CO2 asphyxiation and the dorsal skin was harvested into PBS. ~150mg of the skin 
from each mouse was minced with a scalpel, placed in 1.5mL microfuge tubes, 
two stainless steel beads were added and the mixture homogenised in 1mL PBS 
(see Materials and Methods for details). After centrifugation of the homogenate 
at 10,000xg for 10 minutes to get rid of hair and skin fragments, 150µL of the 
supernatant was injected I.P. per mouse. 60 minutes after the injection, mice 
were culled by CO2 asphyxiation, and peripheral blood harvested for 
myeloerythroid colony-forming assay in MethocultTM GF m3434 as described in 
previous sections. 60 minutes was chosen as the time point for this experiment 
in accordance with previous data showing that chemokine ligands are able to 
induce HSPC mobilisation within this time frame (Lord et al., 1992, Hunter et 
al., 1995). 
As shown in figure 5-17, skin homogenates from neither the imiquimod cream-
inflamed skin nor TPA-inflamed skin could induce mobilisation of HPC compared 
to controls. Thus, within the limits of the time frame used for this assay, the 
data suggest that although the inflammation initiated in the cutaneous skin was 
fundamental in the HSPC mobilisation seen in the peripheral inflammation 
models, other innate or adaptive cellular elements may be required to 
communicate these initial stimuli to the HSPC niche to mobilise HSPC. 
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Figure  5-17 Homogenates from digested skin of either topical imiquimod cream or TPA 
treated mice are unable to mobilise HSPC. 
C57BL/6 mice were either given a single dose of topical imiquimod cream (62.5mg) or TPA (100µM 
in 100µL acetone) application on the shaved dorsal skin for three consecutive days. 
Simultaneously, other groups of mice were given a topical application of equivalent amounts of 
either aqueous cream or acetone application on the shaved dorsal skin as controls for topical 
imiquimod cream and topical TPA application respectively. On the fourth day, the mice were 
euthanized by CO2 asphyxiation, and the shaved dorsal skin was harvested. 150mg of the skin 
from each mouse was homogenised in 1mL PBS, spun at 10,000xg and supernatants harvested in 
each case. 150µL of skin homogenates were injected I.P. per mouse per treatment group. 60 
minutes after the injection, the mice were euthanized by CO2 asphyxiation, and peripheral blood 
harvested for haematopoietic progenitor colony-forming assay. After lysing the red blood cells, 
1x105 peripheral blood leucocytes were seeded into 1.1mL of m3434 in duplicates, and colonies 
counted after 7-10 days culture at 37°C in 5% CO2 humidified chamber. (N=3, 2 independent 
experiments). 
In summary, the data presented in this section suggest that: 
1. CCR2 expression is required for the full spectrum of responses to topical 
imiquimod cream treatment. 
2. Topical imiquimod cream treatment is characterised by a strong IL-10 and 
TREM-1 expression in the plasma of CCR2-/- mice. 
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5.5 How do exogenously administered chemokines affect 
the HSPC numbers in peripheral blood? 
5.5.1 Introduction 
The chemokine receptor gene expression data presented in the previous chapter 
for both peripheral inflammation models (see also chapter 3 for similar findings 
in the LPS-induced systemic inflammation model) show that HSPC express 
chemokine receptors and that these receptors are modulated by inflammatory 
stimuli. Interestingly, prior reports have established that exogenous 
administration of some chemokines such as CXCL2, CXCL8, and CCL3 significantly 
mobilise HSPC to circulation. Given the number of chemokine receptors that 
were detectable by QPCR and the detection of their respective ligands in the 
plasma, I set out to test the hypothesis that in a non-inflamed context, HSPC 
may be mobilised in response to exogenously administered ligands of the 
chemokine receptors that were detected on the HSPC. Among the chemokine 
receptors that were highly modulated in the bone marrow HSPC were CCR2 (>16-
fold increase in both imiquimod and TPA-induced inflammation), CCR3 (>8-fold 
decrease in imiquimod cream-induced inflammation) and CCR5 (>4-fold increase 
in both imiquimod cream and TPA-induced inflammation). Surprisingly, of the 
CC-chemokine receptors, only CCR5 expression was ~8-fold upregulated in 
peripheral blood HSPC in imiquimod cream treated mice. 
5.5.2 Exogenously administered CCL2, CCL4 or CCL11 fail to 
mobilise HSPC in resting mice. 
The data presented in this chapter showed that HSPC express CCR2 and that this 
CCR2 expression was fundamental for imiquimod cream-induced HSPC 
mobilisation. However, one question that remains unanswered is whether the 
HSPC surface expression of CCR2 in resting mice was sufficient to allow these 
cells to respond to exogenously administered ligands. I therefore set out to use 
exogenous recombinant murine chemokines, namely CCL2 (CCR2 ligand), CCL4 
(CCR5 ligand) and CCL11 (CCR3 ligand) to assess their potential to induce HSPC 
mobilisation in a non-inflamed context. As the HSPC chemokine receptor gene 
profiling (see previous chapters) showed that these cells expressed CCR2, CCR3 
and CCR5, I surmised that with the relatively specific receptor affinities of CCL2, 
CCL4 and CCL11, the results of these mobilisation assays would provide insight as 
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to which chemokine receptor(s) was/were sufficiently expressed on the HSPC 
surface in the resting sate to impact on in vivo chemotactic response. 
Previously published data (Broxmeyer et al., 1998, Lord et al., 1995), showed 
that CC-chemokines could mobilise HSPC at a dose of 50µg/kg in 60 minutes. 
Therefore, a dosage of either 50µg/kg or 75µg/kg body weight given as a single 
S.C. injection for either 30 minutes or 60 minutes was employed to titrate the 
probable dose that could induce HPC mobilisation. However, as summarised in 
figures 5-18 A, B and C, irrespective of the dose (50µg/kg or 75µg/kg) or time 
(30 minutes or 60 minutes), none of the chemokines, CCL2, CCL4 or CCL11, 
could induce increased numbers of circulating HPC, although AMD3100 that was 
used as a positive control mobilised increased numbers of circulating HPC. 
 
Figure  5-18 Exogenously administered CCL2, CCL4, or CCL11 are unable to orchestrate 
HSPC mobilisation to the circulation. 
C57BL/6 mice received a single S.C. injection of 50µg/kg or 75µg/kg body weight of one of 
recombinant murine CCL2, CCL4, or CCL11. Simultaneously, other groups of mice received a 
single dose of either AMD3100 (5mg/kg body weight) or an equivalent volume of 0.1%w/v BSA as 
positive and negative controls respectively. 30 or 60 minutes after the injection, the mice were 
euthanized through CO2 asphyxiation and peripheral blood harvested for haematopoietic progenitor 
colony-forming assay. After lysing red blood cells, 1x105 peripheral blood leucocytes were seeded 
into 1.1mL of MethocultTM GF M3434 in duplicates, and colonies counted using an inverted 
microscope, after 7-10 days culture at 37°C in 5% CO2 in a humidified chamber. [(n = 3), three 
independent experiments]. 
Chapter 5: Topical imiquimod requires CCR2   239 
 
In summary, data presented in this section suggest that in the non-inflamed 
context, exogenously administered CCL2, CCL4 or CCL11 are unable to mobilise 
HSPC to the circulation suggesting the expression of their cognate receptors on 
the HSPC surface may not be sufficient to permit them to respond to these 
ligands. 
5.6 Discussion and summary 
This chapter sought to understand the roles played by the CCR2/CCL2 axis in the 
LPS-induced systemic inflammation or the topical imiquimod cream or topical 
TPA inflammation mediated egress of HSPC from the bone marrow. The 
objective was to begin to explore one of the candidates emerging from the 
chemokine receptor gene expression and chemokine ligand proteome array data 
presented in the previous chapters. The data presented herein show that 
myeloerythroid progenitors express functional CCR2 that is increased in response 
to inflammation. The data further argue that although HSPC may express 
chemokine receptors, the role of these chemokine receptors in HSPC biology 
may be context-dependent. For example, data shown in this chapter 
demonstrated that exogenously administered CCL2, or CCL4, or CCL11, failed to 
mobilise HSPC into the circulation in resting mice, i.e. in non-inflamed context. 
However, the CCR2 KO mice and CCL2 neutralisation experiments argue strongly 
that in an inflamed context, induced by topical imiquimod cream treatment, the 
CCR2/CCL2 axis was crucial in mediating HSPC egress from the bone marrow. 
Thus, an inflamed context may be required to induce the expression of 
inflammatory chemokine receptors on the HSPC that enable them to respond to 
chemotactic cues. 
5.6.1 CCR2 is required for the full spectrum of responses to the 
topical imiquimod cream. 
The expression of CCR2 appears to be a critical requirement in eliciting the full 
spectrum of responses to topical imiquimod cream. Firstly, although topical TPA 
application induced a comparable morphological change in the dorsal skin of WT 
mice and CCR2 KO mice, topical imiquimod cream could not induce comparable 
inflammatory responses in WT mice and CCR2 KO mice. Specifically, whereas the 
topical imiquimod cream caused exaggerated dorsal skin inflammatory response 
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noticeable by hyperkeratosis, and acanthosis, it only induced a modest 
inflammatory response in the dorsal skin of CCR2 KO mice. Previously, 
Vestergaard et al. showed that monocytes in peripheral blood of psoriatic and 
atopic dermatitis patients significantly up-regulate their CCR2 expression 
(Vestergaard et al., 2004). Others have also shown that keratinocytes from the 
skin of psoriatic patients produce increased levels of CCL2 (Giustizieri et al., 
2001, Deleuran et al., 1996, Kaburagi et al., 2001). As the topical imiquimod 
cream application model has been proposed to model human psoriatic diseases, 
it is reasonable to argue that the exaggerated inflammatory response observed 
in WT, but absent in CCR2 KO mice, was the result of a functional CCR2 that 
enabled the influx of inflammatory cells like monocytes into the cutaneous skin 
in response to CCL2 released from keratinocytes and mast cells (Drobits et al., 
2012).  
These differences in the response of WT and CCR2 KO mice to the topical 
imiquimod cream was also reflected in the circulating chemokine and cytokine in 
the plasma. In a paper published by van der Fits et al that established topical 
imiquimod application in mice as a model of human psoriasis, they implicated 
the IL-23/IL-17 axis as the critical determinant in the induction of the psoriasis 
phenotype (van der Fits et al., 2009). Interestingly, IL-23 was barely detectable 
in the CCR2 KO plasma, in contrast to its high expression in the plasma of WT 
mice (as reported in the previous chapter). In addition, IL-17 was also expressed 
at lower levels in CCR2 null mice in comparison to WT mice. This differential IL-
17 and IL-23 expression may, in part, mechanistically explain the reduced level 
of inflammation observed in CCR2 null mice seen with reduced epidermal 
inflammation. Interleukin-10 secretion was however, highly upregulated in both 
WT and CCR2 null mice perhaps as a negative feedback mechanism to modulate 
the inflamed state. Others have reported that direct TLR ligation (e.g. TLR-2, -3, 
-4 and -9) on immune cells like macrophages, and myeloid derived dendritic 
cells, leads to increased IL-10 secretion (Agrawal et al., 2003, Dillon et al., 
2004, Boonstra et al., 2006). Thus, it is possible that the massive increase in IL-
10 detected in the plasma may be the result of a direct TLR7 ligation on some of 
these immune cells. Whatever the exact source of the IL-10 production, it is 
clear that it was independent of CCR2 expression as both WT mice and CCR2 KO 
mice exhibited comparable levels of IL-10 in the plasma. 
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It is also interesting to note that there was high expression of TREM-1 in the 
plasma of CCR2 null mice (~28-fold increase above the baseline) treated with 
topical imiquimod cream application; this was in contrast to the very low level 
of TREM-1 in WT mice (i.e. not above background noise) reported in the previous 
chapter. Human neutrophils, monocytes and macrophages have been shown to 
express TREM-1 (Bouchon et al., 2000, Colonna and Facchetti, 2003). In 
granulocytes, it has been shown that TLR ligation leads to up-regulation of 
TREM-1 expression, which then acts to amplify the innate immune response by 
mediating the expression of pro-inflammatory chemokines such as CXCL8, CCL2, 
CCL3 and CCL7 (Bleharski et al., 2003). This TREM-1 mediated amplification of 
inflammatory chemokine expression has also been shown to be crucial in 
recruiting T helper 1 (TH1) cells and thus linking the innate and the adaptive 
immune systems (Bleharski et al., 2003). Therefore, the differential expression 
of TREM-1 in topical imiquimod cream-treated CCR2 null mice, compared to its 
expression in topical imiquimod cream-treated WT mice, offers some insights 
concerning the elevated CCL3 expression in CCR2 null mice compared to WT 
mice. Given that both WT and CCR2 null mice were given the same dose of 
topical imiquimod cream treatment for the same duration, and yet, gave 
different pattern of TREM-1 expression, it will be interesting to investigate the 
potential role that CCR2 plays in the induction of TREM-1 expression. It is also 
important to interpret these data in the light of other previous finding that 
TREM-1 was not upregulated in non-infectious inflammatory diseases like 
psoriasis and ulcerative colitis (Bouchon et al., 2001). Therefore, the fact that 
TREM-1 is highly upregulated in CCR2 null mice, but not WT mice, may be an 
indication that, in the absence of functional CCR2 receptor, topical imiquimod 
cream is unable to induce a psoriasis phenotype in the dorsal skin of mice. 
5.7 Chapter summary 
In this chapter, data has been presented to show that: 
1. HSPC particularly the myeloerythroid progenitors, i.e. GMP, PreGM, CFU-E and 
PreCFU-E, express CCR2. 
2. CCR2 expression is fundamental to the full spectrum of the inflammatory 
responses mediated by the topical imiquimod cream application. 
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3. CCR2/CCL2 axis is fundamental the topical imiquimod cream application-
induced HSPC mobilisation. 
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6.1 Introduction 
Anaemia of chronic disease has been known to complicate the prognosis of many 
inflammatory disease processes such as rheumatoid arthritis, systemic lupus 
erythematosus and inflammatory bowel diseases (Maury et al., 2003, Gasche et 
al., 2001, Weiss and Goodnough, 2005). Although the impact of inflammatory 
mediators on erythropoiesis has been extensively investigated, the same cannot 
be said of the HSPC compartment. Evidence is now emerging that many 
inflammatory processes mobilise increased numbers of haematopoietic 
progenitors into the circulation. However, the underlying mechanisms remain to 
be explored. In this study, I sought to use mouse models of systemic and 
peripheral inflammation to investigate the mechanisms driving the 
inflammation-induced HSPC mobilisation. As chemokines are one of the key 
players orchestrating in vivo cellular migration in multicellular organisms, I also 
sought to examine whether inflammation-driven HSPC mobilisation was the 
consequence of inducible expression of inflammatory chemokine receptors on 
HSPC, which would enable them to migrate in response to elaborated 
inflammatory chemokines. LPS (TLR4 ligand) injection and topical imiquimod 
cream treatment (TLR7 ligand) were employed to study the roles of TLR 
signalling in HSPC mobilisation, whereas the sterile inflammatory agent, TPA, 
was employed to investigate the role played by non-TLR-driven inflammatory 
responses to mobilise HSPC. Moreover, this study also sought to understand 
whether the mode of delivery of the inflammatory process, i.e. systemic via I.P., 
or peripheral via topical application, has a bearing on HSPC mobilisation from 
the bone marrow. 
In this chapter, the basic mechanistic concepts that emerged from the data 
presented in the previous chapters are discussed as well as conclusions and 
future directions presented.       
6.2 HSPC mobilisation with or without TLR signalling 
Using haematopoietic progenitor colony-forming assays as an indirect measure of 
the number of haematopoietic progenitors in circulation, data presented in this 
thesis show that LPS (TLR4 ligand), imiquimod cream (TLR7 ligand), or TPA (PKC 
stimulant with no TLR signalling effect), treatments each mobilise HSPC to the 
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circulation. This therefore demonstrates that TLR ligation was not obligatory for 
the HSPC mobilisation, but that the crucial component was the inflamed 
context. Although HSPC have not been traditionally proposed as directly involved 
in inflammation and infection resolution, recent evidence suggests otherwise. 
For example, not only have haematopoietic progenitors been shown to express 
TLRs, but also ligation of TLR4 in these progenitors was shown to lead to 
increased generation of common myeloid progenitor cells as well as 
differentiation of lymphoid progenitors into dendritic cells (Nagai et al., 2006, 
Rodriguez et al., 2009). The data presented in this thesis that showed that TPA-
driven sterile inflammation also mobilises increased HSPC numbers to the 
circulation therefore broaden our understanding and suggests that HSPC might 
play crucial roles in the resolution of both TLR-driven and non-TLR-driven 
inflammatory pathologies.  
Previously, others have reported that inflammatory models led to significant 
increases in Sca-1 expression in the HSPC compartment (Zhang et al., 2008, 
Melvan et al., 2011). Using LPS injection as a model of infection in TLR4 null 
mice, Shi et al. demonstrated that this increased Sca-1 expression was a TLR-
driven effect (Shi et al., 2013). The flow cytometric data presented in this thesis 
support that conclusion as both LPS and imiquimod cream treatment significantly 
increased Sca-1 expression in HSPC whereas TPA treatment did not. 
Interestingly, using various in vivo and in vitro infection models, Snapper et al. 
showed that increased Sca-1 expression in lymphocytes was dependent on the 
production of IFN-α/β and /or –γ (Snapper et al., 1991). Whilst a >2-fold 
increase in IFN-γ levels were detected in the plasma of LPS treated mice, the 
expression of IFN-γ in response to imiquimod cream treatment was not above 
the levels in control groups. As different time points were employed in the two 
models, i.e. 24 hours and 72 hours for LPS and imiquimod cream treatment 
respectively, it is possible that elevated IFN-γ levels were also responsible for 
the increased Sca-1 expression on HSPC, but that the window for detecting 
elevated IFN-γ plasma levels was missed in the imiquimod cream model. 
However, this does not rule out the possibility that different mechanisms might 
have been responsible for the increased Sca-1 expression in the LPS injection, 
and topical imiquimod cream, treatments. 
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The flow cytometry data presented in this thesis also showed that both TLR-
driven inflammatory processes [i.e. LPS injection (TLR4) or topical imiquimod 
cream treatment (TLR7)] significantly reduced the proportion of bone marrow 
LT-HSC population in contrast to the non-TLR driven inflammatory process, i.e. 
TPA treatment, which did not significantly alter the LT-HSC population. Although 
this study did not examine the long-term effects of these inflammation models 
on HSPC biology, it is reasonable to speculate that chronic TLR-driven 
inflammation could potentially lead to HSC exhaustion whereas chronic, non-TLR 
driven, inflammation may not have such a direct detrimental effect on the LT-
HSC. In this light, a population study in Sweden found an association between 
chronic infection/inflammation and haematopoietic malignancies in humans, 
suggesting that chronic exposure to inflammatory mediators may even trigger 
neoplastic transformation (Kristinsson et al., 2011). It was also reported that 
long term exposure of mice to low dose of LPS impaired HSC self-renewal and 
skewed HSC differentiation towards the myeloid lineage (Esplin et al., 2011). 
Others also showed that IFN-γ significantly impairs the self-renewal capacity of 
LT-HSC and ultimately led to bone marrow failure (de Bruin et al., 2013). 
Therefore, although the inflammation-induced HSPC mobilisation may be 
physiologically important for the survival of organisms in acute inflammatory 
situations, unresolved inflammation may overwhelm the ability of the 
haematopoietic system to restore homeostasis in the long-term and lead to 
pathology. 
6.3 Inflammation modulates the HSPC niche 
The bone marrow niche provides a safe haven that houses haematopoietic stem 
and progenitor cells. Within the niche, interactions between the HSPC, and 
cellular components as well as their secreted soluble products, ensure the 
maintenance of self-renewal, proliferation, differentiation and retention of 
HSPC. Many agents employed for mobilisation of HSPC for clinical use have been 
shown to disrupt one or more of these HSPC-niche interactions. Although LPS 
injection has been shown to mobilise HSPC to the circulation, the mechanism 
underlying this mobilising activity has not been fully elucidated. The data 
presented in this thesis show that both TLR-driven inflammation (LPS injection 
or imiquimod cream treatment), and non-TLR-driven inflammation, significantly 
reduce bone marrow CXCL12 concentration, suggesting a role for a perturbed 
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CXCR4/CXCL12 axis in the inflammation-induced HSPC mobilisation. However, 
flow cytometric data showed that whereas LPS injection led to significant 
reduction in HSPC surface CXCR4 expression, neither topical imiquimod cream, 
nor TPA, application significantly altered HSPC surface CXCR4 expression. Many 
previous reports have provided evidence indicating that cellular components of 
the bone marrow niche are being responsible for CXCL12 production in the 
niche. Amongst the prime candidates have been osteoblasts, endothelial cells 
and mesenchymal stromal cells (Ding et al., 2012, Mendez-Ferrer et al., 2010, 
Calvi et al., 2003, Jung et al., 2006). Through flow cytometry, evidence is 
provided in this thesis arguing for osteoblasts as the prime CXCL12 producing 
cells (at least amongst the three cellular niche components investigated in this 
study, i.e. osteoblast, endothelial cells and MSC). This conclusion stems from the 
fact that in spite of the reduced bone marrow CXCL12 concentration, both LPS 
injection and topical imiquimod cream treatment significantly increased bone 
marrow stromal MSC and endothelial cell fractions. The only stromal bone niche 
cellular element that was significantly reduced in each of the LPS injection and 
topical imiquimod cream/TPA treatment was osteoblasts, suggesting that 
osteoblast may be the major CXCL12 secreting cells. While this conclusion is 
contrary to other published data that implicates immature MSC and endothelial 
cells as the CXCL12 producing cells (Greenbaum et al., 2013, Sugiyama et al., 
2006), it is important to note that these studies were undertaken using 
conditional deletion of CXCL12 in different niche cell types in non-inflamed 
context. It is possible that processes regulating CXCL12 production in steady 
state may not necessarily be the same processes that pertain in stressed 
conditions.    
It is also interesting to note that both I.P. LPS and topical imiquimod cream 
treatment models led to high expression of G-CSF and significantly reduced bone 
marrow CD169+ macrophage cells. Previously, Levesque et al. proposed that G-
CSF mediated HSPC mobilisation was partly due to its activation of neutrophils to 
release proteolytic enzymes (Levesque et al., 2001). In addition, it has also been 
shown that CD169+ macrophages are fundamental niche cells that release 
soluble factors which stimulate nestin+ MSCs to release CXCL12 (Chow et al., 
2011). Therefore, the combined impact of a reduced CD169+ macrophage 
population, and increased circulating G-CSF levels, may have also significantly 
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contributed to the reduced bone marrow CXCL12 in both TLR-driven 
inflammations. However, in spite of the significant reduction in bone marrow 
CXCL12 in TPA treated mice, there were increased bone marrow CD169+ 
macrophage cell numbers as well as similar G-CSF levels in control and TPA 
treated groups. These suggest the possibility that different mechanisms may be 
involved in the TLR and non-TLR driven HSPC mobilisation. 
 
6.4 Identification of chemokine and cytokine expression 
in response to LPS injection, or topical imiquimod 
cream/TPA treatment. 
Using proteome array profiling of the plasma, the chemokines that were highly 
expressed in response to either LPS injection, or topical imiquimod cream 
treatment were CCL2, CCL5, CCL12 and CXCL13. However, of these chemokines, 
the only one that was also highly expressed in response to topical TPA treatment 
was CCL2, suggesting that if a common inflammatory chemokine expression 
played a role in orchestrating HSPC mobilisation, CCL2 could be such a 
candidate. The RT-QPCR data showed that inflammatory stimuli modulated the 
chemokine receptor expression on bone marrow HSPC, with CCR2 being the most 
highly expressed in the topical imiquimod cream/TPA treatment model. Using 
flow cytometry, data were also provided showing that haematopoietic 
progenitors expressed cell surface CCR2, which was upregulated, particularly in 
GMP and PreGM cells, in response to inflammatory stimuli. In testing the in vivo 
functional relevance of the inducible CCR2 expression in orchestrating the 
inflammation-induced HSPC mobilisation, CCR2 KO mice were used. These data 
showed that any role played by the inflammatory chemokine/chemokine 
receptor axis may be context dependent as each of LPS injection and topical TPA 
treatment, mobilised HSPC in these mice, whereas topical imiquimod cream 
could not. Targeted in vivo neutralisation of CCL2 using intravenous 
administration of anti-CCL2 neutralising antibodies during the imiquimod cream 
treatment abrogated the HSPC mobilisation suggesting the essential requirement 
for a functional CCR2/CCL2 axis in the topical imiquimod cream model. This is in 
agreement with previous data that demonstrated the requirement for the 
CCR2/CCL2 axis in inflammation-induced HSPC mobilisation (Si et al., 2010). 
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Additional evidence supporting the essential requirement for the expression of 
CCR2 in mediating the full spectrum of imiquimod cream treatment model also 
came from the cytokine proteome array and skin histology data. Whereas the 
topical imiquimod cream treatment induced a strong increase in the expression 
of the pro-inflammatory cytokines IL-17, IL-23 and IL-27 in WT mice, it induced 
increased expression of IL-17 (moderate) and very high TREM-1 levels in CCR2 KO 
mice. Van der fits et al. who established topical imiquimod cream application as 
a model of human psoriasis (van der Fits et al., 2009) implicated the IL-23/IL-17 
axis as the critical determinant of the psoriasis phenotype. However, in the 
absence of CCR2, topical imiquimod cream was unable to elicit a psoriasiform 
phenotype in CCR2 KO mice as evidenced by the significantly reduced epidermal 
thickening in CCR2 KO mice. Previously, Bouchon et al. showed that TREM-1 was 
not upregulated in non-infectious inflammatory diseases like psoriasis and 
ulcerative colitis (Bouchon et al., 2001). Therefore, the fact that TREM-1 is 
highly upregulated in CCR2 null mice, but not WT mice, may be an indication 
that, in the absence of functional CCR2 receptor, topical imiquimod cream is 
unable to induce a psoriasis phenotype in the dorsal skin of mice. 
 
6.5 Ability of inflammatory chemokine ligands to 
mobilise HSPC is context dependent.  
Haematopoietic stem cell mobilisation is an important component of the clinical 
therapy for treatment of malignancies. Although G-CSF has been the mainstay in 
the clinic for mobilising HSPC, due to the many drawbacks such as side effects, 
multiple dosing, as well as its inability to mobilise in some patients and healthy 
donors, the drive has been towards safer agents that mobilises HSPC faster with 
minimal inconvenience to the donor (Holm, 1998, Croop et al., 2001). 
Chemokine-based mobilising agents have shown immense promise in this area. 
For example AMD3100, a CXCR4 antagonist, mobilises HSPC within 60 minutes 
upon a single administration (Liles et al., 2003, Broxmeyer et al., 2005). Also 
CXCL2 and CXCL8 have also been shown to mobilise HSPC in a matter of hours 
(Pelus et al., 2004, Pruijt et al., 2002). The RT-QPCR data and proteome array 
data demonstrated chemokine/chemokine receptor axes may have significant 
impact on HSPC mobilisation during inflammation. In addition, the CCR2 KO 
mice, and in vivo CCL2 neutralisation, data demonstrated the importance of the 
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CCR2/CCL2 axis in imiquimod cream-induced HSPC mobilisation. As clinical HSPC 
mobilisation is conducted in the non-inflamed context, exogenous administration 
of chemokine ligands was tested to examine their abilities to mobilise HSPC in 
mice. However, administration of CCL2 (CCR2 ligand), or CCL4 (CCR5 ligand), or 
CCL11 (CCR3, & CCR5 ligand), showed that none of these chemokines was able 
to mobilise HSPC into the circulation in mice. Altogether, these data show that, 
in the non-inflamed context, the expression of inflammatory chemokine 
receptors on the cell surface of HSPC may be insufficient to enable them to 
respond to exogenously administered ligand. This is in contrast to CCL3 that was 
shown to mobilise HSPC in the non-inflamed context (Broxmeyer et al., 1999). 
Employing CCR1 null mice in a series of ligand-induced HSPC mobilisation assays, 
Broxmeyer et al. concluded that CCR1 may be the dominant receptor 
orchestrating the HPC mobilising effects that occur in response to exogenously 
administered CCL3. Interestingly, CCR1 was not detected on the HSPC.  
Taken together, the ability of chemokine ligands to mobilise HSPC into 
circulation differs in two ways: (1) In steady state some inflammatory 
chemokines mobilise HSPC into circulation through indirect action on terminal 
differentiated haematopoietic cells (Pruijt et al., 2002, Pelus et al., 2004, 
Broxmeyer et al., 1999); (2) In the inflamed context, HSPC inducibly express 
inflammatory chemokine receptors which enable them to migrate towards 
elaborated inflammatory chemokines in the circulation. Data presented in this 
thesis, particularly in the topical imiquimod cream treatment model, provide 
evidence for the second scenario. The long-term repercussion of this 
phenomenon of inflammation-induced chemokine receptor expression, and 
subsequent HSPC mobilisation, on the HSPC biology might be particularly 
important in chronic inflammatory diseases. Such inflammatory chemokine 
receptor expression on HSPC and subsequent egress from the bone marrow may 
ultimately lead to HSPC depletion in the bone marrow as well as bone marrow 
and peripheral blood cytopenia. This may be another contributory factor to the 
anaemia associated with chronic inflammatory diseases. 
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6.6 Proposed models for inflammation-induced HSPC 
mobilisation 
6.6.1 Proposed model for LPS-induced HSPC mobilisation 
Figure 6-1 summarises the proposed model of HSPC mobilisation occurring in 
response to I.P. LPS injection. As endothelial cells express TLR4, the circulating 
LPS stimulate these cells to produce G-CSF that enters the circulation (Boettcher 
et al., 2012). Both the elaborated G-CSF and LPS reaches the bone marrow niche 
through the circulation. As HSPC express TLR4 (Nagai et al., 2006) and G-CSFR 
(McKinstry et al., 1997), the presence of LPS and G-CSF stimulates emergency 
granulopoiesis that depletes GMP cell numbers (see appendix 2). In addition, 
there is a reduction in bone marrow CD169+ macrophage cells, perhaps as a 
result of mobilisation to other tissues. HSPC also reduce surface CXCR4 
expression in response to LPS probably as a result of interference with the re-
expression internalised CXCR4. The combined effects of a reduced osteoblast 
numbers and increased G-CSF lead to reduced bone marrow CXCL12, thereby 
creating a CXCL12 gradient in the circulation. Ultimately, this peripheral blood 
CXCL12 gradient mobilises neutrophils [resulting in peripheral blood Neutrophilia 
(see appendix 13B) and HSPC to the circulation. 
 
Figure  6-1 Proposed mechanism of I.P. LPS orchestrated HSPC mobilisation. 
1. Endothelial cells sense LPS and produce G-CSF that enters the circulation (Boettcher et al., 
2012): 2. Both G-CSF and LPS reaches the bone marrow niche through the circulation; As HSPC 
express TLR4 (Nagai et al., 2006) and G-CSFR (McKinstry et al., 1997), the presence of LPS and 
G-CSF stimulates emergency granulopoiesis; There is reduction in bone marrow CD169 
macrophage cells in addition to a concomitant downregulation of HSPC surface CXCR4 
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expression; Combined effect of reduced osteoblasts and increased G-CSF leads to reduced bone 
marrow CXCL12, thereby creating a CXCL12 gradient in the circulation: 3. This CXCL12 gradient 
mobilises neutrophils (peripheral blood neutrophilia) and HSPC to the circulation. [Arrow pointing 
down indicates reduction in cell population or receptor expression; Arrow pointing upwards 
indicates increased cell population; Double-headed horizontal arrow indicates no change in 
expression] 
 
6.6.2 Proposed model for imiquimod cream treatment-induced 
HSPC mobilisation 
Figure 6-2 summarises the proposed model for the topical imiquimod cream 
treatment-induced HSPC mobilisation. Resident skin cells like keratinocytes and 
mast cells perceive the imiquimod cream treatment and release CCL2 (Drobits et 
al., 2012). The CCL2, and G-CSF (most likely produced by skin endothelial cells 
as well as vascular endothelial cells), enter the circulation. In response to the 
circulating CCL2, HPC (and monocytes and neutrophils?) upregulates surface 
CCR2 expression resulting in mobilisation of HPC, monocytes and neutrophils to 
the periphery (see appendix 13 A & B). In addition, the increased G-CSF 
stimulates emergency granulopoiesis (see appendix 6) in bone marrow (leading 
to reduction in LMPP, CLP & LT-HSC) and reduction in CXCL12 levels. Significant 
reduction in bone marrow CD169+ macrophage numbers and increased osteoclast 
activity further reduce bone marrow CXCL12 levels and helps HPC to exit the 
bone marrow. Induction of a strong IL-10 secretion from innate immune cells is 
invoked to prevent dysregulated inflammatory reaction as a consequence of 
continual TLR7 ligation. 
 
Chapter 6: General discussion  253 
 
 
Figure  6-2 Proposed mechanism for topical imiquimod cream-induced HPC mobilisation 
1. Resident skin cells like keratinocytes and mast cells perceive the imiquimod cream treatment 
and release CCL2; The CCL2, and G-CSF (probably from skin endothelial cells as well as vascular 
endothelial cells), enter the circulation: 2. Upregulated surface CCR2 expression on MEP (and 
monocytes and neutrophils?) enable them to respond to the circulating CCL2 and results in 
mobilisation of HPC, monocytes and neutrophils; G-CSF causes emergency granulopoiesis in bone 
marrow (leading to reduction in LMPP, CLP & LT-HSC) and reduction in CXCL12: 3. Significant 
reduction in bone marrow CD169+ macrophages and increased osteoclast activity further helps 
HPC to exit the bone marrow: 4. Induction of a strong IL-10 secretion to prevent dysregulated 
inflammatory reaction. 
 
6.7 Future direction 
In this study I was able to define some mechanistic details explaining the 
inflammation-induced HSPC mobilisation. However, certain fundamental 
questions remain unanswered. These include: (1) what happens to the mobilised 
HSPC, i.e. do they home back to the bone marrow or do they migrate to the 
point of stimuli application, and if they do, what fate awaits them? (2) What 
epigenetic changes occur in these mobilised HSPC and are they reprogrammed 
after the infection? In future experiments, it will be interesting to explore these 
questions. Future studies using adoptive transfer of genetically marked or 
fluorescently labelled HSPC into congenic mouse strains, and subsequent 
harvesting of the skin tissues for analysis, will be critical in providing answers to 
these questions. The harvested skin tissues could be examined by a combination 
of techniques such as IVIS imaging and flow cytometry to shed light on whether 
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the mobilised HSPC reach the inflamed skin and whether they differentiate to 
specific haematopoietic lineages. 
In chapter 5, I showed that in the absence of CCR2 expression, topical imiquimod 
cream treatment significantly increased TREM-1 expression instead of IL-17/IL-23 
expression as occurred in WT mice. However, due to time constraints, I was not 
able to undertake an in-depth exploration of the role of CCR2 in the production 
of TREM-1. As upregulation in TREM-1 has been implicated in the 
pathophysiology of sepsis and other inflammatory disease conditions (Bouchon et 
al., 2001, Gibot et al., 2005, Buckland et al., 2011, Lagler et al., 2009, Wu et 
al., 2011), it would be interesting to examine how targeting CCR2 could be a 
means of modulating TREM-1 expression for therapeutic benefit to patients.   
Some previous data showed that increased osteoclast activity lead to the 
degradation of HSPC-niche factors resulting in HSPC mobilisation to the 
circulation (Kollet et al., 2006). However, other recent data have challenged 
this by showing that HSPC mobilisation was unaffected in osteoclast deficient 
mice and even reduced in mice with increased osteoclast activity (Miyamoto et 
al., 2011). Thus, the exact role of osteoclasts in HSPC biology remains an open 
question. In both systemic and peripheral inflammation models, I showed that 
there were significant increases in bone marrow Gr-1lowCD115+ monocytes. As 
osteoclasts are derived from the monocytic lineage, it would be interesting to 
investigate whether osteoclast formation and activity were affected by any of 
the inflammatory models and whether these contributed to the inflammation-
induced HSPC formation. 
Although data presented in this thesis show that TPA treatment also mobilises 
HSPC to the circulation, there were a lot of unknowns in mechanism driving the 
TPA-induced HSPC mobilisation. This might have been due the time points at 
which data were collected. It would be interesting to further explore the TPA 
treatment model using earlier time points to try to understand the processes 
that led to HSPC egress from the bone marrow.  
Lastly, in this thesis, snapshots were provided in connection with the impacts of 
inflammation on the bone marrow niche. It would be interesting to investigate 
how the inflammatory signals affected the distribution of the HSC in the niche. 
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For example, Kiel et al. used immunofluorescence technique to investigate the 
localisation of HSC in frozen bone sections of naïve/unmanipulated mice (Kiel et 
al., 2005). It would be interesting to use similar techniques to try to localise the 
HSC in relation to the endosteal and endothelial niches post inflammatory 
models to shed light on whether inflammation impacts the niche preference of 
HSC. 
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Appendix 1 
 
Appendix 1 LPS injection significantly increases the bone marrow MkP cell numbers 
The Kit+IL-7Rα- cell populations from the bone marrow of WT or CCR2 KO mice treated with either 
I.P. PBS or I.P. LPS were re-gated for the differential expression of CD41 and CD150 to elucidate 
MkP and MEP cell populations. A & B are the representative dot plots for MkP and MEP 
characterisation in the bone marrow of WT mice treated with I.P. PBS and I.P. LPS respectively. C 
& D are the representative dot plots for the MkP and MEP characterisation in the bone marrow of 
CCR2 KO mice treated with I.P. PBS and I.P. LPS respectively. E is a scatter plot summarising the 
impact of the I.P. PBS or I.P. LPS on the MkP population in both WT and CCR2 KO mice. 
Statistical significance was calculated using the Mann-Whitney U test (2-tailed) to compare the 
MkP population in I.P. PBS treated mice to the MkP population in I.P. LPS treated mice. [N= 4-5; 2-
independent experiments]. 
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Appendix 2 LPS injection significantly reduces the bone marrow GMP cell numbers. 
The MEP cell population from the bone marrow of WT or CCR2 KO mice treated with either I.P. 
PBS or I.P. LPS were re-gated for the differential expression of CD16/32 and CD150 antigens to 
characterise the GMP and non-GMP cell population. A & B are the representative dot plots for the 
GMP and non-GMP cell characterisation in the bone marrow of WT mice treated with I.P. PBS and 
I.P. LPS respectively. Similarly, C & D are the representative dot plots for the GMP and non-GMP 
cell characterisation in the bone marrow of CCR2 KO mice treated with either I.P. PBS (C) or I.P. 
LPS (D). E is a scatter plot summarising the impact of the I.P. PBS or I.P. LPS on the bone marrow 
GMP population in both C57B/L6 and CCR2 KO mice. Statistical significance was calculated using 
the Mann-Whitney U test (2-tailed) to compare the proportions of the GMP cells from I.P. PBS 
treated groups to that of I.P. LPS treated groups. [N= 4-5; 2-independent experiments]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix  260 
 
 
 
 
Appendix 3 
 
Appendix 3 LPS injection significantly reduces the bone marrow CFU-E cell population in 
WT mice. 
The bone marrow non-GMP cell populations of WT or CCR2 KO mice treated with either I.P. PBS 
or I.P. LPS were re-gated for the differential expression of CD105 and CD150 antigens to 
characterise the CFU-E, PreCFU-E, PreGM and the PreMegE cell populations. A & B are the 
representative dot plots showing the CFU-E, PreCFU-E, PreGM and the PreMegE cell 
characterisation in the bone marrow of WT mice treated with either I.P. PBS (A) or I.P. LPS (B). 
Similarly, C & D are the representative dot plots showing the CFU-E, PreCFU-E, PreGM and the 
PreMegE cell characterisation in the bone marrow of CCR2 KO mice treated with either I.P. PBS 
(D) or I.P. LPS (E). E is a scatter plot summarising the impact of the I.P. PBS or I.P. LPS on the 
CFU-E population in both WT and CCR2 KO mice. Statistical significance was calculated using the 
Mann-Whitney U test (2-tailed) to compare the proportions of the CFU-E cells from I.P. PBS treated 
groups to that of I.P. LPS treated groups. [N= 4-5; 2-independent experiments]. 
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Appendix 4 LPS injection significantly modulates the bone marrow PreCFU-E, PreGM, and 
PreMegE cell populations. 
The bone marrow non-GMP cell population in WT or CCR2 KO mice treated with either I.P. PBS or 
I.P. LPS were re-gated for the differential expression of CD105 and CD150 antigens to 
characterise the CFU-E, PreCFU-E, PreGM and the PreMegE cell population. A is a scatter plot 
summarising the impact of the I.P. PBS or I.P. LPS injection on bone marrow PreCFU-E cells in 
WT and CCR2 KO mice. B is a scatter plot summarising the impact of the I.P. PBS or I.P. LPS 
injection on the bone marrow PreGM cells in WT and CCR2 KO mice. C is a scatter plot 
summarising the impact of the I.P. PBS or I.P. LPS injection on bone marrow PreMegE cells in WT 
and CCR2 KO mice. [Statistical significances were calculated in all cases by using the Mann-
Whitney U test (2-tailed) to compare the proportions of the given progenitor population from the I.P. 
PBS treated groups to the respective population in the I.P. LPS treated groups. N= 4-5; (2-
independent experiments in all cases)]. 
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Appendix 5 Topical imiquimod cream application does not significantly change the bone 
marrow MkP cell numbers. 
The Kit+IL-7Rα- cell populations from the bone marrow of WT or CCR2 KO mice treated with either 
topical aqueous cream or topical imiquimod cream application were re-gated for the differential 
expression of CD41 and CD150 antigens to characterise the MkP and the MEP cell population. A & 
B are the representative dot plots for bone marrow MkP and MEP characterisation in WT mice 
treated with either topical aqueous cream (A) or topical imiquimod cream (B). C & D are the 
representative dot plots for bone marrow MkP and MEP characterisation in CCR2 KO mice treated 
with either topical aqueous cream (C) or topical imiquimod cream (D). E is a scatter plot 
summarising the impact of the topical aqueous cream or topical imiquimod cream application on 
the bone marrow MkP cells in both WT and CCR2 KO mice. Statistical significance was calculated 
by using the Mann-Whitney U test (2-tailed) to compare the proportions of the MkP cells in the 
aqueous cream treated groups to the proportion of MkP cells in the imiquimod cream treated 
groups. [N= 4-5; 2-independent experiments]. 
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Appendix 6 Topical imiquimod cream application significantly increases the bone marrow 
GMP cell numbers. 
The MEP cell population from the bone marrow of WT or CCR2 KO mice treated with either topical 
aqueous cream or topical imiquimod cream were re-gated for the differential expression of 
CD16/32 and CD150 antigens to characterise the GMP and the non-GMP cell population. A & B 
are the representative dot plots of bone marrow GMP and non-GMP cell characterisation in WT 
mice treated with either topical aqueous cream (B) or topical imiquimod cream (B). C & D are the 
representative dot plots for bone marrow GMP and non-GMP cell characterisation in CCR2 KO 
mice treated with either topical aqueous cream (C) or topical imiquimod cream (D). E is a scatter 
plot summarising the impact of the topical aqueous cream or topical imiquimod cream application 
on the bone marrow GMP population in both WT and CCR2 KO mice. Statistical significance was 
calculated using the Mann-Whitney U test (2-tailed) to compare the proportion of the GMP cells in 
the topical aqueous cream treated groups to the proportion of GMP cells in the topical imiquimod 
cream treated groups. [N= 4-5; 2-independent experiments]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix  264 
 
Appendix 7 
 
Appendix 7 Topical imiquimod cream application does not significantly change the bone 
marrow CFU-E cell numbers. 
The bone marrow non-GMP cell population in WT or CCR2 KO mice treated with either topical 
aqueous cream, or topical imiquimod cream, were re-gated for the differential expression of CD105 
and CD150 antigens to characterise the CFU-E, PreCFU-E, PreGM and the PreMegE cell 
populations. A & B are the representative dot plots for the CFU-E, PreCFU-E, PreGM and the 
PreMegE cell characterisation in WT mice treated with either topical aqueous cream (A) or 
imiquimod cream (B). C & D are the representative dot plots for the CFU-E, PreCFU-E, PreGM and 
the PreMegE cell characterisation in CCR2 KO mice treated with either topical aqueous cream (C) 
or imiquimod cream (D). E is a scatter plot summarising the impact of the topical aqueous cream or 
topical imiquimod cream application on the bone marrow CFU-E population in both WT and CCR2 
KO mice. Statistical significance was calculated using the Mann-Whitney U test (2-tailed) to 
compare the proportions of the CFU-E cells from topical aqueous cream treated groups to that of 
topical imiquimod cream treated groups. [N= 4-5; 2-independent experiments]. 
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Appendix 8 
 
Appendix 8 Topical imiquimod cream treatment modulates the bone marrow PreCFU-E, 
PreGM, and PreMegE cell numbers. 
The bone marrow non-GMP cell population in WT or CCR2 KO mice treated with either topical 
aqueous cream or topical imiquimod cream were re-gated for the differential expression of CD105 
and CD150 antigens to characterise the CFU-E, PreCFU-E, PreGM and the PreMegE cell 
populations. A is a scatter plot summarising the impact of the topical aqueous cream or topical 
imiquimod cream treatment on the bone marrow PreCFU-E in WT and CCR2 KO mice. B is a 
scatter plot summarising the impact of the topical aqueous cream or topical imiquimod cream 
treatment on bone marrow PreGM cells in WT and CCR2 KO mice. C is a scatter plot summarising 
the impact of the topical aqueous cream or topical imiquimod cream application on bone marrow 
PreMegE cells in WT and CCR2 KO mice. [Statistical significances were calculated in all cases by 
using the Mann-Whitney U test (2-tailed) to compare the proportions of the given progenitor 
population from topical aqueous cream treated groups to the respective population in the topical 
imiquimod cream treated groups. N= 4-5; (2-independent experiments in all cases)]. 
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Appendix 9 Topical TPA application significantly increases the bone marrow MkP cell 
numbers in WT mice. 
The Kit+IL-7Rα- cell populations from the bone marrow of WT or CCR2 KO mice treated with either 
topical acetone or TPA application were re-gated for the differential expression of CD41 and 
CD150 antigens to characterise the MkP and the MEP cell populations. A & B are the 
representative dot plots for the bone marrow MkP and MEP characterisation in WT mice treated 
with either topical acetone (A) or TPA (B). Similarly, C & D are the representative dot plots for the 
bone marrow MkP and MEP characterisation in CCR2 KO mice treated with either topical acetone 
(C) or TPA (D). E is a scatter plot summarising the impact of the topical acetone or TPA application 
on the MkP population in both WT and CCR2 KO mice. Statistical significance was calculated by 
using the Mann-Whitney U test (2-tailed) to compare the proportions of the MkP cells in the topical 
acetone treated groups to the proportion of the MkP cell from the topical TPA treated groups. [N= 
4-5; 2-independent experiments]. 
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Appendix 10 Topical TPA application significantly increases the bone marrow GMP cell 
numbers. 
The bone marrow MEP cell populations in WT or CCR2 KO mice treated with either topical 
acetone, or TPA, application were re-gated for the differential expression of CD16/32 and CD150 to 
characterise the GMP and the non-GMP cell populations. A & B are the representative dot plots 
showing the bone marrow GMP and non-GMP cell characterisation in WT mice treated with either 
topical acetone (A), or TPA (B). C & D are the representative dot plots for the bone marrow GMP 
and non-GMP cell characterisation in CCR2 KO mice treated with either topical acetone (C), or 
TPA (D). E is a scatter plot summarising the impact of the topical acetone, or TPA treatment on the 
GMP population in both WT and CCR2 KO mice. Statistical significance was calculated using the 
Mann-Whitney U test (2-tailed) to compare the proportion of the GMP cells from the bone marrow 
of topical acetone treated groups to the proportion of GMP cells from the bone marrow of topical 
TPA treated groups. [N= 4-5; 2-independent experiments]. 
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Appendix 11 
 
Appendix 11 Topical TPA application does not significantly change the bone marrow CFU-E 
cell numbers. 
The bone marrow non-GMP cell populations in WT or CCR2 KO mice treated with either topical 
acetone, or TPA were re-gated for the differential expression of CD105 and CD150 antigens to 
characterise the CFU-E, PreCFU-E, PreGM and the PreMegE cell populations. A & B are the 
representative dot plots for the CFU-E, PreCFU-E, PreGM and the PreMegE cell characterisation 
in the bone marrow of WT mice treated with either topical acetone (A), or TPA (B). C & D are the 
representative dot plots of the CFU-E, PreCFU-E, PreGM and the PreMegE cell characterisation in 
CCR2 KO mice treated with either topical acetone (C), or TPA (D). E is a scatter plot summarising 
the impact of the topical acetone, or TPA, treatment on the CFU-E population in both WT and 
CCR2 KO mice. Statistical significance was calculated using the Mann-Whitney U test (2-tailed) to 
compare the proportions of the CFU-E cells from topical acetone treated groups to that of topical 
TPA treated groups. [N= 4-5; 2-independent experiments]. 
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Appendix 12 
 
Appendix 12 Topical TPA application modulates the bone marrow PreCFU-E, PreGM, and 
PreMegE cell population. 
The bone marrow non-GMP cell populations in WT or CCR2 KO mice treated with either topical 
acetone, or TPA were re-gated for the differential expressions of CD105 and CD150 antigens to 
characterise the CFU-E, PreCFU-E, PreGM and the PreMegE cell populations. A is a scatter plot 
summarising the impact of the topical acetone, or TPA, application on the bone marrow PreCFU-E 
cells in WT and CCR2 KO mice. B is a scatter plot summarising the impact of the topical acetone, 
or TPA, application on the bone marrow PreGM cells in WT and CCR2 KO mice. C is a scatter plot 
summarising the impact of the topical acetone, or TPA, application on the bone marrow PreMegE 
cells in WT and CCR2 KO mice. [Statistical significances were calculated in all cases by using the 
Mann-Whitney U test (2-tailed) to compare the proportions of the given progenitor population from 
topical acetone treated groups to the respective population in the topical TPA treated groups. N= 4-
5; (2-independent experiments in all cases)]. 
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Appendix 13 
 
Appendix 13 Modulation of peripheral blood monocyte and neutrophil counts in WT mice 
treated with I.P. LPS or topical imiquimod cream/TPA. 
WT mice received a single, daily dose of topical imiquimod cream (62.5mg) or TPA (100µM in 
100µL acetone) application to shaved dorsal skin for three consecutive days. Simultaneously, other 
groups of mice received equivalent amounts of topical application of either aqueous cream or 
acetone application as controls for topical imiquimod cream and TPA application respectively. On 
day 3 of the model, other groups of mice received a single dose of I.P. LPS (100µg in 100µL PBS) 
or 100µL I.P. PBS as a control. On the fourth day, the mice were euthanized by CO2 asphyxiation, 
peripheral blood was taken into EDTA microtainer tubes and full blood counts assessed by the 
automated veterinary haematology analyser, HEMAVET 950FS (Drew Scientific Inc., USA). A & B 
are scatter plots summarising the peripheral blood monocyte and neutrophil counts respectively 
mice treated with I.P. LPS injection or topical imiquimod cream or TPA (or their respective 
controls). Each treatment group was compared to its respective control group using the unpaired t-
test (2-tailed) to determine the statistical significance. [n=8). 
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Appendix 14 
 
Appendix 14 Peripheral blood platelet, lymphocyte counts and haemoglobin concentration 
in mice treated with I.P. LPS or topical imiquimod cream/TPA. 
WT mice received a single, daily dose of topical imiquimod cream (62.5mg) or TPA (100µM in 
100µL acetone) application to the shaved dorsal skin for three consecutive days. Simultaneously, 
other groups of mice received equivalent amounts of topical application of either aqueous cream or 
acetone application as controls for topical imiquimod cream and TPA application respectively. On 
day 3 of the model, other groups of mice received a single dose of I.P. LPS (100µg in 100µL PBS) 
or 100µL I.P. PBS as a control. On the fourth day, the mice were euthanized by CO2 asphyxiation, 
peripheral blood was taken into EDTA microtainer tubes and full blood counts assessed by the 
automated veterinary hematology analyser, HEMAVET 950FS (Drew Scientific Inc., USA). A, B & 
C are scatter plots summarising the peripheral blood platelet counts, lymphocyte counts and 
haemoglobin concentration respectively in WT mice treated with I.P. LPS injection or topical 
imiquimod cream or TPA (or their respective controls). Each treatment group was compared to its 
respective control group using the unpaired t-test (2-tailed) to determine the statistical significance. 
[n=8).
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